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Abbreviations 
 
6-311G* Pople basis set 
[α]D specific rotation, sodium D line 
(589 nm) 
A1,3 1,3-allylic strain 
Ac acetyl 
Alloc allyloxycarbonyl 
ATR attenuated total reflection 
Ar aryl / aromatic 
Arg arginine 
b broad 
B3LYP Becke, 3-parameter, Lee-Yang-
Parr 
BMI 2-tert-butyl-3-methyl-4-
imidazolidinone 
Bn benzyl 
Boc tert-butyloxycarbonyl 
Bu Butyl 
c concentration 
CAM cerium ammonium molybdate 
cat catalyst /catalytic 
CH cyclohexane 
conc. concentrated 
COSY correlation spectroscopy 
δ chemical shift 
d doublet 
DAST N,N-diethylaminosulfur 
trifluoride 
dd doublet of doublets 
DEPT distortionless enhancement by 
polarisation transfer 
DFT density functional theory 
DIPEA N,N-diisopropylethylamine 
DMAP 4-(dimethyl)aminopyridine 
DMF N,N-dimethylformamide 
DMPU 1,3-dimethyltetrahydro-
pyrimidin-2(1H)-one 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
d.r. diastereomeric ratio 
E electrophilicity parameter / 
energy 
ee enantiomeric excess 
EI electron ionisation 
equiv./eq. equivalents 
e.r. enantiomeric ratio 
ESI electrospray ionisation 
ESP electrostatic potential 
II Abbreviations 
 
Et ethyl 
EWG electron withdrawing group 
FELIX free electron laser for infrared 
experiments 
FID flame ionisation detector 
FT-ICR Fourier transform ion cyclotron 
resonance 
GABA gamma-aminobutyric acid 
GC gas chromatography 
His Histidine 
HMBC heteronuclear multiple-bond 
correlation spectroscopy 
HMDS hexamethyldisilazane 
HOESY heteronuclear Overhauser effect 
spectroscopy 
HOMO highest occupied molecular 
orbital 
HPLC high performance liquid 
chromatography 
HR high resolution 
HSQC heteronuclear single-quantum 
correlation spectroscopy 
IR infrared spectroscopy 
IR-MPD infrared multiphoton 
dissociation 
J coupling constant  
k2 second-order rate constant 
kobs observed rate constant 
KPL ketopantolactone 
λ wavelength 
λi group electronegativity 
LDA lithium diisopropylethylamine 
LUMO lowest unoccupied molecular 
orbital 
Lys Lysine 
m multiplet / medium 
MBF methylbenzoylformate 
M.p. melting point 
Me methyl 
MM3 molecular mechanics force field 
MS molecular sieves / mass 
spectrometry 
MTO methyltrioxorhenium 
N nucleophilicity parameter 
NHC N-heterocyclic carbine 
NMR nuclear magnetic resonance 
NOESY nuclear Overhauser effect 
spectroscopy 
o/n overnight 
Ph phenyl 
Phe phenylalanine 
ppm parts per million 
Pr propyl 
q quartet 
Abbreviations III 
 
quant. quantitative 
Qzz traceless quadrupole moment 
tensor orthogonal to the 
aromatic ring 
rac. racemic 
Rf retardation factor 
RT room temperature 
σ bonding sigma orbital 
σ* anti-bonding sigma orbital 
σm Hammett constant, meta 
σp Hammett constant, para 
s singlet / strong 
SM starting material 
sN nucleophile-specific sensitivity 
parameter 
SN1 nucleophilic substitution, 
unimolecular 
SOMO singly occupied molecular 
orbital 
t triplet 
Tf triflate 
TFA trifluoroacetic acid 
TFAP trifluoroacetophenone 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMS trimethylsilyl 
Trp tryptophan 
Trt trityl 
Ts p-toluenesulfonyl 
Tyr tyrosine 
UHP urea hydrogen peroxide 
UV/VIS ultraviolet-visible spectroscopy 
w weak 
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Summary 
 
Since its renaissance in 2000, organocatalysis has established itself as the third pillar of 
contemporary catalysis together with enzymatic and metal mediated approaches. The field 
has rapidly developed and numerous prestigious laboratories have contributed to the 
identification of various powerful small-molecule catalysts ranging from biomolecules to 
thiourea catalysts and N-heterocyclic carbenes (NHCs). The underlying principles of 
asymmetric induction and mechanism are often not well understood and are yet to be 
unraveled. Most organocatalysts consist of the same building blocks as biomolecules and 
intermediates are often stabilised by the same structural features found in enzymes. In this 
thesis, one of the most renowned organocatalysts, the MacMillan imidazolidinone, was 
studied. It was proposed that stereoinduction is governed by non-covalent interactions in the 
transition state.  
 
MacMillan’s imidazolidinone organocatalysts have proven themselves to be highly effective 
in mediating various organic reactions involving enamine and iminium ion intermediates. 
The transient iminium ion formed by condensation of the 1st generation catalyst with an α,β-
unsaturated aldehyde (Scheme 1) is geometrically optimised to undergo stabilising CH-π and 
π-π interactions similar to those found in enzymes, providing an excellent playground to 
study these interactions in a small molecule. In this work, numerous catalyst sites were 
modified in a logical molecular editing study to identify the essential features and 
interactions for effective catalyst performance.  
From structural biology studies of large peptides and proteins it is known that non-bonding 
CH-π and π-π interactions are sensitive to electronic modulation. The iminium ion 
Scheme 1 Left: MacMillan 1st generation catalyst and the iminium ion intermediate. 
Right: Three possible staggered conformers of the intermediate. 
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intermediate of the phenylalanine-derived MacMillan catalyst can undergo the same 
interactions depending on the conformation (Scheme 1, right). The effect of electronic 
modifications of the phenyl-ring on conformational behaviour, reactivity and selectivity was 
investigated. For this purpose a library of new catalysts was synthesized with the aromatic 
group ranging from very electron-deficient (e.g., R = C6F5) to very electron-rich [e.g., 
R = C6H2(OMe)3]. The traceless quadrupole moment tensors perpendicular to the aromatic 
ring (Qzz) was calculated to reflect the electronic property of a given aryl group and ESP 
maps were computed to illustrate the electronic distribution (Figure 1, upper). Using 
spectroscopic ground-state conformational analysis in combination with kinetic and catalysis 
studies, it was possible to show that the conformational preferences can be biased by 
adjusting the electronic properties of the shielding group. Whereas iminium ions with 
shielding groups that have electronic properties similar to phenyl, predominantly populate 
conformer I, an increased population of conformer II was attained with more electron-rich 
derivatives. Electron-deficient systems on the other hand result in high population of 
conformer III. It was achieved to obtain X-ray structures of each of these three staggered 
conformers (Figure 1, lower). The conformational study was complemented and verified by 
a computational analysis of the lowest energy conformers.  
 
Figure 1 Upper: ESP maps and Qzz of the electronically modified shielding groups. Lower: X-ray structures of all three 
possible staggered conformers. 
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The importance of the electronic nature of the shielding group was highlighted by the 
observed direct linear correlation between the obtained enantioselectivity in the Friedel-
Crafts reaction of N-methyl pyrrole and (E)-cinnamaldehyde and the Qzz. Furthermore, an 
improved catalyst was developed [R = C6H2(OMe)3], enabling the reaction to be performed 
at RT within 3 h giving a selectivity of 94% ee [the MacMillan catalyst (R = Ph) gave 
93% ee after 42 h at –30 °C]. 
 
Further modifications of the catalyst were investigated as is summarised in Figure 2. It was 
found that the non-covalent interactions and consequently the observed enantioselectivities 
in the model reaction are not only sensitive to electronic modulations of the shielding group, 
but also to steric constraints of the shielding group (e.g., geometrical “fixation”, 
enlargement, introduction of a 2nd phenyl group, and displacement) or the geminal-dimethyl 
group (e.g., deletion, replacement by spiro-rings). Electronic modifications of the substrate 
on the other hand only resulted in minor changes in conformational behaviour. Because 
determination of the Qzz is not applicable to all compounds and the quantity requires 
computation, a spectroscopic quantity correlating with the observed ee was desired. The 
NMR shift-differences of the syn- and the anti-methyl groups of the geminal-dimethyl 
moiety (∆δ1Hsyn/anti) were identified to be an adequate, easily accessible quantity that 
correlates beautifully with the conformational behaviour of the iminium salt and the 
enantioselectivity of the model reaction.  
The accuracy of solid state and solution phase conformational analysis is bound to suffer 
from counterion, packing and/or solvent effects. Therefore, the conformational behaviour of 
a selection of isolated iminium ions was investigated by IR-MPD spectroscopy in the gas 
phase using the free electron laser FELIX at the Radboud University in Nijmegen. It should 
be noted that this is the first time this technique has been applied to the field of 
organocatalysis. It was demonstrated that the diagnostic conformations of these iminium 
Figure 2 Overview of MacMillan catalyst analogues. 
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ions, which are a consequence of non-covalent interactions, give rise to characteristic 
fingerprint C=O stretching frequencies which can be directly observed by IR-MPD 
spectroscopy. Thus, by comparing the experimental spectra with the computed spectra for 
each computed minium structure, theory and experiment validate our working hypothesis 
and provide guidelines for catalyst design.  
The organocatalytic Friedel-Crafts reaction of N-methyl indole and (E)-cinnamaldehyde was 
studied using the large imidazolidinone library. Trends observed for the reaction using  
N-methyl pyrrole were retained [correlation between obtained enantioselectivity and the Qzz 
of the shielding group and the spectroscopically dertermined (∆δ1Hsyn/anti)]. With catalysts 
proceeding via an iminium ion predominantly populating conformer III, reversal of 
selectivity was observed and a pincer-like model was proposed as explanation. This model 
also offers an explanation of the observed different behaviour of indoles as compared to 
pyrroles in the reaction. 
 
The structural resemblance of the MacMillan catalysts with cinchonidine (CD) led to the 
postulation that these species might be good chiral modifiers for heterogeneous 
hydrogenation reactions. The aromatic group of the molecule is expected to anchor to the 
metal surface, as is the case for CD, forming a chiral pocket in which the substrate is bound 
by the secondary amine moiety (Figure 3). It was anticipated that the catalysts equipped with 
a large, electron-rich aromatic groups (e.g., anthracene) would be especially promising. Even 
though in an initial screen these novel modifiers were not able to compete against the 
established CD, preliminary validation of the concept is presented. For example, application 
of the new modifiers in the reduction of ketopantolactone (KPL) on Pt/Al2O3 resulted in ees 
between 16%-21% as compared to CD giving 40% ee under the same reaction conditions. 
 
Figure 3 Comparison of cinchonidine (CD) with MacMillan derivatives for heterogeneous catalysis  
and proposed surface binding. 
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Zusammenfassung 
 
Seit ihrer Neuentdeckung im Jahr 2000 hat sich die Organokatalyse, neben enzymatischen 
und metallorganischen Strategien, als dritte Säule der gegenwärtigen homogenen Katalyse 
etabliert. Das Forschungsgebiet hat sich rasant entwickelt und zahlreiche angesehene 
Forschungsgruppen haben zu der Entwicklung von vielfältigen, leistungsfähigen 
Organokatalysatoren beigetragen. Diese reichen von Biomolekülen über Thioharnstoffe bis 
hin zu N-heterocyclischen Carbenen (NHCs). Die zugrundeliegenden Prinzipien der 
asymmetrischen Induktion und die Mechanismen sind oft nicht gut verstanden und benötigen 
Aufklärung. Die meisten Organokatalysatoren bestehen aus den gleichen Bildungsblöcken, 
aus denen auch Biomoleküle aufgebaut sind und die reaktiven Intermediate werden oft durch 
die gleichen strukturellen Besonderheiten stabilisiert, die man von Enzymen kennt. In dieser 
Doktorarbeit wurde das MacMillan Imidazolidinon, einer der renommiertesten 
Organokatalysatoren, untersucht. Es wurde postuliert, dass die Stereoinduktion von nicht 
kovalenten Wechselwirkungen im Übergangszustand bestimmt wird.  
 
Die Imidazolidinon-Organokatalysatoren, die von MacMillan entwickelt wurden, haben sich 
als sehr effektiv in vielzahligen organischen Reaktionen, die über ein Enamin oder ein 
Iminiumion ablaufen, erwiesen. Das, durch Kondensation des Katalysators erster Generation 
mit einem α,β-ungesättigten Aldehyd entstehende, kurzlebige Iminiumion (Schema 1, links) 
ist geometrisch dazu optimiert, stabilisierende CH-π und π-π Wechselwirkungen ähnlich 
denen in Enzymen einzugehen und bietet somit ein ideales Model für Untersuchungen dieser 
Wechselwirkungen in einem kleinen Molekül. Um die essentiellen Bestandteile und 
Interaktionen für eine effektive Katalyseleistung zu identifizieren, wurden verschiedene 
Komponenten des Katalysators in einer molekularen Editierungstudie modifiziert.  
Schema 1 Links: MacMillan’s Katalysator der ersten Generation und das Iminiumionen Intermediat. 
Rechts: Drei mögliche gestaffelte Konformere des Intermediats. 
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Von strukturellen Studien von Biomolekülen weiß man, dass nichtbindende CH-π und π-π 
Wechselwirkungen empfindlich gegenüber elektronischen Modulationen sind. Das 
Iminiumionen Intermediat des von Phenylalanin abgeleiteten MacMillan Katalysators kann, 
abhängig von der Konformation, diese Wechselwirkungen eingehen (Schema 1, rechts). Es 
wurde untersucht, welche Auswirkungen elektronische Modifikationen der abschirmenden 
Phenylgruppe auf die Konformation, die Reaktivität und die Selektivität haben. Hierfür 
wurde eine Bibliothek neuer Katalysatoren synthetisiert, deren aromatische Gruppen von 
sehr elektronenreich [z.B. R = C6H2(OMe)3] bis sehr elektronenarm (z.B., R = C6F5) 
spannen. Die spurlosen Quadrupolmomenttensoren senkrecht zum aromatischen Ring (Qzz) 
wurden berechnet, um die elektronischen Eigenschaften der aromatischen Gruppen zu 
beschreiben und die ESP Abbildungen wurden berechnet, um die Elektronenverteilung 
widerzuspiegeln (Abbildung 1, oben). Mittels spektroskopischen Untersuchungen des 
Grundzustandes zusammen mit kinetischen und Katalysestudien, war es möglich zu zeigen, 
dass das konformelle Verhalten durch elektronische Modulation der Abschirmungsgruppe 
beeinflusst werden kann. Während Iminiumionen mit Abschirmungsgruppen die Phenyl 
elektronisch ähnlich sind bevorzugt Konformer I populieren, weisen elektronenreichere 
Derivate eine erhöhte Population von Konformer II auf. Dagegen resultieren elektronenarme 
Systeme in hoher Population von Konformer III. Erfreulicherweise wurde es errreicht von 
jedem der drei gestaffelten Konformere eine Kristallstruktur zu erhalten (Abbildung 1, 
Abbildung 1 Oben: ESP Abbildungen und Qzz der elektronisch modifizierten Abschirmungsgruppen.  
Unten: Kristallstrukturen der drei gestaffelten Konformere. 
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unten). Die Konformationsstudie wurde durch eine theoretische Analyse der energetisch 
niedrigsten Konformere ergänzt und verifiziert.  
Eine beobachtete direkt-lineare Abhängigkeit zwischen den erhaltenen Enantioselektivitäten 
in der Friedel-Crafts Reaktion von N-Methyl Pyrrol und (E)-Zimtaldehyd und den Qzz hebt 
die Bedeutung der elektronischen Eigenschaften der Abschirmungsgruppe hervor. Zudem 
wurde ein verbesserter Katalysator entwickelt [R = C6H2(OMe)3], der es möglich macht, die 
Reaktion in 3 h bei RT mit einer Selektivität von 94% ee durchzuführen [der MacMillan 
Katalystor (R = Ph) führte zu 93% ee nach 42 h bei –30 °C]. 
 
Es wurden weitere Modifikationen des Katalysators untersucht (Abbildung 2). Dabei wurde 
entdeckt, dass die nichtbindenden Wechselwirkungen und somit die beobachteten 
Enantioselektivitäten nicht nur empfindlich gegenüber elektronischen Modifikationen der 
Abschirmungsgruppe sind, sondern auch gegenüber sterischen Einschränkungen der 
Abschirmungsgruppe (z.B. durch geometrische Fixierung, Vergrößerung, Einführung einer 
zweiten Phenylgruppe, Erhöung der Distanz) oder der geminalen-Dimethylgruppe (z.B. 
durch Entfernung oder Einführung von Spiroringen). Dagegen scheinen elektronische 
Modifikationen des Substrates nur geringen Einfluss auf das konformelle Verhalten zu 
haben. Da nicht für alle Verbinungen ein Qzz bestimmt werden kann und diese Größe von 
theoretischen Berechnungen abhängig ist, wurde nach einer spektroskopischen Größe, die 
mit dem erhaltenen ee korreliert, gesucht. Die Unterschiede in der chemischen Verschiebung 
(NMR) der syn- und anti-Methylgruppen der geminalen-Dimethylgruppe (∆δ1Hsyn/anti) wurde 
als hierfür geeignete, einfach zugängliche Größe identifiziert, die sehr gut mit dem 
konformellen Verhalten des Iminiumsalzes und der erhaltenen Enantioselektivität in der 
Testreaktion korreliert. Analysen von Festkörpern oder von Lösungen haben den Nachteil, 
dass Einflüsse von Gegenionen und/oder vom Lösungsmittel sowie Packungseffekte, nicht 
ausgeschloßen werden können. Deswegen wurde das Konformationsverhalten von einer 
Selektion von isolierten Iminiumionen in der Gasphase mit Hilfe von IR-MPD 
Abbildung 2 Überblick über MacMillan Katalysatorderivate. 
XII Zusammenfassung 
 
Spektroskopie unter Verwendung des Freie-Elektronen-Lasers FELIX an der Radboud 
Universität in Nijmegen untersucht. Es sollte beachtet werden, dass dies die erste 
Verwendung dieser Analysemethode im Forschungsgebiet der Organokatalyse ist. Es wurde 
gezeigt, dass die spezifische Konformation eines Iminiumions, die eine Konsequenz der 
nichtbindenden Wechselwirkungen ist, charakteristische C=O Streckschwingungsfrequenzen 
im Fingerprintbereich bewirkt, die mit Hilfe von IR-MPD Spektroskopie beobachtet werden 
können. Durch Vergleich der experimentellen Spektren mit den theoretischen Spektren ein 
jeder Energieminimumsstruktur, war es möglich, Theorie und Experiment zu validieren und 
hilfreiche Richtlinien für zukünftiges Katalysatordesign zu liefern. Die organokatalytische 
Friedel-Crafts Reaktion von N-Methyl Indol und (E)-Zimtaldehyd wurde mittels der 
entwickelten Katalysatorbibliothek untersucht. Die Tendenzen, die in der Reaktion unter 
Verwendung von N-Methyl Pyrrol beobachtet wurden, konnten reproduziert werden 
[Korrelation zwischen der erhaltenen Enantioselektivität und dem Qzz der 
Abschirmungsgruppe und der spektroskopisch bestimmten (∆δ1Hsyn/anti)]. Mit Katalysatoren, 
die ein Iminiumion bilden, das bevorzugt Konformer III populiert, wurde eine Umkehr der 
Selektivität beobachtet und ein Pincer-artiges Model wurde zur Erklärung vorgeschlagen. 
Dieses Model liefert auch eine Erklärung für das beobachtete unterschiedliche Verhalten von 
Indolen und Pyrrolen in dieser Reaktion. 
 
Die strukturelle Ähnlichkeit der MacMillan Katalysatoren mit Cinchonidin (CD) führte zu 
dem Vorschlag, dass diese Strukturen gute chirale Modifikatoren für heterogene 
Hydrierungen sein könnten. Der Aromat des Moleküls könnte als Anker zur 
Metalloberfläche dienen, wie es für CD der Fall ist, und so eine chirale Tasche formen, in 
der das Substrat von dem sekundären Amin gebunden wird (Abbildung 3). Es wurde 
erwartet, dass Katalysatoren mit großen Aromaten (z.B. Anthracen) priviligiert sind. Obwohl 
die Imidazolidinone in einem ersten Screening nicht gegen CD konkurrieren konnten, wurde 
eine erste Validation der Idee präsentiert.  
Abbildung 3 Vergleich von Cinchonidine (CD) mit MacMillan Derivaten für heterogene Katalyse. 
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1.1 Asymmetric Organocatalysis and Reaction Deconstruction  
1.1.1 History and Overview 
The field of asymmetric catalysis has traditionally been dominated by enzyme and 
organometallic catalysis. However, in 2000, two independent publications by List, Barbas, 
and Lerner and by Ahrendt, Borths, and MacMillan triggered enormous interest in the field 
of organocatalysis leading to the vast amount of methods available today.[8] It is surprising 
that organocatalysis did not emerge earlier when considering, that the first organocatalytic 
transformation (benzoin condensation catalysed by cyanide) was reported almost 170 years 
earlier by Wöhler and Liebig.[9] The term “organische Katalysatoren” however, has been 
proposed many years later by Langenbeck in 1928.[10] A selection of early, important 
contributions is summarised in Figure 4.[11] 
 
 
• 1832 Wöhler & Liebig: Benzoin condensation.[9] 
• 1860 Liebig: Acetaldehyde as catalyst in synthesis of 
oxamide.[12]  
• 1894/1896 Knoevenagel: First iminium catalysed 
reaction.[13]  
• 1886 Dennstedt/Zimmermann: Isolation of acylated 
pyridine.[14] 
• 1901 Verley/Bölsing: Catalytic use of pyridine in 
acylation of alcohols.[15]  
• 1909 Dakin: Catalytic action of amino acids.[16]  
• 1912 Bredik/Fiske: First asymmetric reaction using 
cinchona base.[17] 
• 1929/1937 Langenbeck: Explanation of Liebig’s 1860 
observations / iminium ion catalysed conjugate 
addition.[1b;18] 
• 1943/1958 Ukai/Breslow: Structural and reactivity work 
on the mechanism of thiamine.[19]  
• 1954 Prelog/Wilhelm: Mechanism of asymmetric 
cyanohydrin synthesis.[20]  
• 1960/1964 Pracejus: First high levels of selectivity with 
cinchona alkaloids.[21]  
• 1962 Cordes/Jencks: Iminium catalysed transimination.[22]  
• 1967/1969 Litvinenko/Kirichenko & Steglich/Höfle: 
Discovery of DMAP as an acylation catalyst.[23]  
• 1969 Yamada/Otani: Proline-catalysed (stoichiometric) 
asymmetric Robinson annulations.[24]  
• 1971 Eder/Sauer/Wiechert/Hajos/Parrish: Catalytic, 
asymmetric aldol reaction using proline.[25]  
• 1981 Woodward: Total synthesis of erythromycin.[26]  
• 1989 Jung: Asymmetric Diels-Alder reactions of chiral 
alkoxy iminium salts.[27]  
 
Figure 4 Upper: Timeline highlighting the late emerge of organocatalysis, the y-axis refers to number of Sci-Finder hits for 
the term ‘organocat’. Lower: Selected important, early contributions to the field of organocatalysis. 
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2 1 Introduction 
 
A notable feature of organocatalysts is their bio-mimetic nature. The catalysts can activate 
the substrate covalently or by non-bonding interactions similar to the way in which enzymes 
bind substrates. Many organocatalysts are derived from the same building blocks as enzymes 
(i.e., amino acids), thus, it is hardly surprising that similar types of interactions are 
observed.[28] During intramolecularisation, a conformational change of the catalyst scaffold 
is often observed, leading to stabilisation of the reactive intermediate. An instructive 
comparison highlighting the parallels between enzyme and organocatalysis is the way in 
which proline binds carbonyl compounds reflecting the activation mode of type I aldolases, 
both forming reactive enamines (Figure 5).[29]  
 
Highly enantioselective organocatalysts for various activation pathways have been 
developed and the major classes will be discussed herein. In Figure 6, catalysts engaging the 
substrate (generally a carbonyl compound) in a covalent manner are summarised. L-proline 
derived catalysts and MacMillan type catalysts are both secondary amines and have proven 
to be effective for the activation of carbonyl compounds for subsequent reaction with an 
electrophile, by forming an enamine (HOMO raising).[30] Alternatively, the secondary 
amines can condense with an α,β-unsaturated carbonyl system to give an iminium salt, 
activated for condensation with a nucleophile or a diene (LUMO lowering).[31] Furthermore, 
MacMillan type catalysts have recently been shown to successfully activate meso-
cyclopropane carbaldehydes towards attack of a nucleophile.[32] Cinchona alkaloids carrying 
a primary amine are useful for stereoselective reactions proceeding via an enamine or an 
iminium salt.[33] Chiral dimethyl amino pyridine (DMAP)-analogues are especially valuable 
Figure 5 Upper: General activation mode common to enzyme and organocatalysis. 
Middle: Activation mode of type I aldolase. Lower: Activation mode of L-proline. 
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for acyl-transfer and related reactions and function by activating the corresponding 
electrophile.[34] Finally, N-heterocyclic carbenes complement the library through an 
Umpolung-activation mode, activating formerly electrophilic carbonyl-moieties towards 
reactions with nucleophiles.[19b;35] 
 
Figure 6 Overview over the major classes of organocatalysts working via covalent activation modes  
and the corresponding reactive intermediates. 
 
Complementing covalent catalysis, a number of scaffolds for non-covalent catalysis have 
been developed (Figure 7). These include chiral thioureas introduced by Schreiner and co-
workers and Jacobsen,[36] Brønsted acids pioneered by Akiyama and Terada[37] and chiral 
quaternary ammonium salts used as phase transfer catalysts.[38] Furthermore, carbohydrate 
derived organocatalysts such as the Shi epoxidation catalyst[39] and peptide derivatives[40] 
enrich this toolbox. 
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Figure 7 Major classes of organocatalysts activating the substrate by non-covalent interactions. 
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With the plethora of organocatalytic methods available today, research interests are now 
beginning to focus on mechanistic understanding of these processes. In contrast to the non-
covalent processes, the organocatalytic reactions proceeding via a covalently bound catalyst-
substrate complex form intermediates that are feasible to isolate. This allows for isolation 
and investigation of these structures by spectroscopic, crystallographic and kinetic 
techniques. By studying these important intermediates, organocatalytic reactions can be 
deconstructed and valuable insights into their conformational and reaction behaviour can be 
gained, ultimately leading to guidelines for rational reaction design. As the conformations of 
these intermediates are often governed by non-covalent interactions, an understanding of 
these interactions is crucial for reaction deconstruction. A short overview of the interactions 
important for the context of this thesis is therefore given in chapter 1.2. In the following 
section, mechanistic work on reactions proceeding via iminium salts derived from secondary 
amines and α,β-unsaturated aldehydes/ketones is discussed. 
 
1.1.2 Deconstruction of Organocatalytic Reactions Proceeding via an Iminium Ion 
Derived from Secondary Amines and α,β-Unsaturated Aldehydes/Ketones 
Intramolecularisation involving a secondary amine and an α,β-unsaturated aldehyde or 
ketone leads to the formation of an iminium salt, with concomitant lowering of the lowest 
unoccupied molecular orbital (LUMO, Figure 8, upper).[1c;41] This intermediate can readily 
interact with a number of different nucleophiles or dienophiles.[31] In the case of initial 
nucleophilic attack in the β-position, the transient enamine can be trapped, thus allowing for 
fast construction of molecular complexity by organo-cascade catalysis (Figure 8, lower).[42] 
Figure 8 Upper: Activation mode in α,β-unsaturated iminium ions. 
Lower: General sequence of an organocatalytic cascade reaction catalysed by a secondary amine 
Organocatalytic cascade reaction catalysed by a secondary amine
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A number of secondary amine catalysts have been developed in the recent years. The most 
prominent examples are all related to L-proline or the L-phenylalanine derived MacMillan 
catalyst (Figure 9), rendering most of these catalysts readily available. 
 
Studies of iminium salts derived from L-diarylprolinol analogues: 
L-diarylprolinol-derivatives have been introduced independently by Jørgensen and Hayashi 
in 2005 and since then found numerous applications in asymmetric organic synthesis.[43] 
Experimental structural insights into the corresponding iminium ion formed by condensation 
with (E)-cinnamaldehyde have been reported by Seebach and co-workers.[5;44] X-ray 
crystallographic analysis (Figure 10, left) and NMR studies suggested, that the conformation 
around the C=N+-bond is predominantly (E) and that the facial shielding is provided by the 
silyl-group and one of the phenyl groups.[5] Recent mechanistic studies on the prominent 
diarylprolinol-catalysed (R = OTMS) Jørgensen epoxidation of α,β-unsaturated aldehydes by 
hydrogen peroxide have revealed that a secondary intermediate (peroxyhydrate) plays a 
crucial role in accelerating the reaction (Figure 10, centre).[6] Gilmour et al. developed 
diarylprolinol organocatalysts with a fluorine substituent instead of the silylether-moiety in 
the benzylic position.[7;45] In the corresponding β-fluoroiminium salt a stabilising fluorine-
iminium ion gauche effect (σCH→σCF* and N+· · ·Fδ-) places the fluorine substituent in the 
synclinal-endo arrangement, thus directing one of the phenyl groups in the molecular space 
over the iminium chain. This working hypothesis was supported by crystallographic and 
spectroscopic analysis of several fluorine bearing iminium ions (Figure 10, right). 
Furthermore, the diphenylfluoroprolinol derivative was shown to be highly effective in 
enantioselective epoxidations and aziridinations.[45-46] 
 
 
Figure 9 Common secondary amine catalysts for iminium catalysis. 
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Figure 11 1st generation MacMillan organocatalyst and the corresponding iminium ion generated by  
condensation with (E)-cinnamaldehyde. 
 
 
Studies of iminium salts derived from MacMillan catalysts: 
 
 
 
 
The 1st generation MacMillan catalyst (Figure 11) was originally reported in 2000 as catalyst 
for “the first highly effective organocatalytic Diels-Alder reaction”.[8a] The seminal report by 
MacMillan et al. included a computational investigation of the corresponding α,β-
unsaturated iminium ion using MM3-9 and proposed that the stereoinduction originated from 
selective formation of the (E)-conformation around the C=N+-bond and selective positioning 
of the aryl shielding group over the iminium chain (conformer II, Figure 12, right). In 
general, the iminium ion formed from the imidazolidinone and, for example,  
(E)-cinnamaldehyde is a well-defined intermediate with a rigid geometry and only few 
degrees of freedom. The core five-membered ring is virtually flat as a consequence of the 
three sp2-hybridised atoms, and the pendant iminium chain is fixed in the same plane. The 
geminal-dimethyl group is perpendicular to this plane, leaving the benzyl-moiety solely 
Figure 10 Left: X-ray structure of the iminium salt of diphenylprolinol trimethylsilylether and (E)-cinnamaldehyde.[5] 
Centre: Proposed catalytic cycle for the Jørgensen-epoxidation.[6]  
Right: Application of the fluorine-iminium ion gauche effect for molecular pre-organisation.[7] 
1 Introduction 7 
responsible for discriminating the two faces. Of the three staggered conformers resulting by 
rotation around the benzylic bond, conformer II is presumably stabilised by a π-π interaction 
and conformer I was postulated to be stabilised by a CH-π interaction. In addition to the 
three possible staggered conformers, a fourth staggered conformer (IV) has been identified 
to be relevant (Figure 12, right).[47] The geometry around the N=C+ was found to be (E)-
selective (>95%, NMR studies), which was attributed to minimisation of A1,3-type 
interactions.[1d;44a;48] These features are beautifully illustrated in the first reported X-ray 
structure of this iminium salt (Figure 12, left).[49] In the crystal structure, conformer I is 
adopted, in contrast to the conformation postulated by MacMillan, but consistent with higher 
level theoretical investigations and experimental studies. 
 
In a detailed theoretical conformational study by Houk, the global energy minimum of the 
MacMillan iminium ion derived from (E)-crotonaldehyde was found to be a structure 
stabilised by a CH-π interaction (conformer I), whilst conformer II was found to be 
0.3 kcal/mol higher in energy. Conformers IV and III were found at +1.3 and +5.5 kcal/mol, 
respectively.[47] Tomkinson and co-workers also identified conformer I to be the global 
minimum of the (E)-cinnamaldehyde and reported an even larger energetic difference 
between conformer I and II (∆E = 1.2 kcal/mol). Furthermore, they found that in the 
1H NMR spectrum the syn-methyl group of the geminal-dimethyl moiety is significantly 
shifted up field as compared to the anti-methyl group and attributed this to predominant 
population of conformer I, in which the phenyl group is shielding the syn-methyl group.[49] 
Further experimental and theoretical proof came from Seebach and a collaborative work by 
Seebach and Grimme, validating conformer I to be the global minimum structure.[50] 
Figure 12 Left: X-ray structure of the 1st generation MacMillan catalyst-derived iminium salt, counterion omitted for 
clarity. Right: Conformational diversity in the iminium salt. 
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To probe the influence of the two low lying conformers I and II, this laboratory has 
developed geometrically fixed analogues by virtue of the fluorine-iminium ion gauche 
effect.[4] By introduction of a configurationally defined fluorine substituent in the benzylic 
position, two diastereoisomers were generated, functioning as so-called “conformer 
equivalents” (Figure 13). Addition of nucleophiles to these systems independently suggested 
that interplay of both conformers is important for high levels of selectivity. It was postulated, 
that conformation II is responsible for high levels of (E)/(Z) geometric control, while 
conformer I assures high levels of enantioinduction. 
 
This laboratory has also extended the concept of iminium catalysis to cyclopropyl iminium 
activation.[51] Key to this reaction design are the parallels that exist between cyclopropanes 
and olefins as a consequence of the Walsh orbitals and the reminiscence of the resulting 
cyclopropyl iminium ion to the cyclopropyl carbonyl cation. Enantioselective 1,3-
dichlorination was achieved, thus extending the substrate scope of unsaturated carbonyl 
compounds through formal Umpolung of the γ-position (Figure 14). 
Figure 13 Iminium ions of “conformer equivalents”. 
Figure 14 Cyclopropyl iminium activation for the preparation α,γ-chlorinated aldehydes. 
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In the 2nd generation MacMillan catalyst, the geminal-dimethyl group is replaced by a syn-
tert-butyl group (Figure 15). While the 1st generation catalyst proved to be highly 
stereoselective in the Friedel-Crafts reaction of N-methyl pyrrole and α,β-unsaturated 
aldehydes, it only gave low levels of enantioinduction in addition reactions using less 
reactive N-methyl indole. For this transformation, the 2nd generation catalyst resulted in 
faster conversion and higher levels of enantioselectivity.[52] The increased reaction rates 
were attributed to the more exposed nitrogen lone pair, due to removal of the anti-methyl 
group. Furthermore, Mayr et al. reported in 2011, that the (E)-cinnamaldehyde derived 
iminium ion of the 2nd generation catalyst (Figure 15) is about 102 times more reactive than 
that of the 1st generation catalyst.[53] 
 
Computational conformational analysis of the iminium ion by Houk[47] as well as by Seebach 
and Grimme[50b] indicated that conformer II is the global minimum, while conformer I is 
much higher in energy for this compound presumably due to steric repulsion between the 
aryl shielding group and the tert-butyl group. A second low lying conformer identified was 
conformer IV. Furthermore, Seebach and Grimme proposed conformers II and IV to be 
connected by an energetic plateau in their “windshield-wiper” model.  
While the increased reaction rates when employing the 2nd generation MacMillan catalyst 
are well understood, the differences in stereoselectivity when changing from N-methyl 
pyrrole to N-methyl indole require clarification. 
These small molecules present themselves as excellent platforms to study non-covalent 
interactions and these interactions have proven to play a significant role in catalysis. 
  
Figure 15 2nd generation MacMillan organocatalyst and the corresponding iminium ion generated 
by condensation with (E)-cinnamaldehyde. 
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1.2 Non-Covalent Aromatic Interactions 
1.2.1 Overview of Chemical Bonding in Organic Chemistry 
The existence of non-covalent interactions was first postulated by Van der Waals during his 
PhD studies in the 1870s.[54] He observed that attracting forces between gas molecules/atoms 
are responsible for the deviations in behaviour of real gases as compared to ideal gases. His 
studies revolutionised several fields of physics and chemistry and he was rewarded with the 
Nobel Prize in Physics 1910 “for his work on the equation of state for gases and liquids”.[55] 
Non-covalent interactions, next to covalent bonds, are now accepted as the second most 
important form of chemical bonding in organic chemistry. These interactions are especially 
common and important in biology[56] and supramolecular chemistry,[57] as they are 
predominantly responsible for the secondary and tertiary structure of macromolecules and 
chemical recognition processes. The importance of stabilising non-covalent interactions to 
every other aspect of organic chemistry is also increasingly recognised. In organocatalysis 
for example, they have been exploited for hydrogen bonding catalysis.[28b;58] A common 
feature of non-covalent interactions is that they are less directional and have smaller bond 
energies than their covalent counterparts.[59] Even though individual contributions might be 
small, the cooperativity and additivity of several non-bonding interactions can accumulate, 
resulting in significant interactions. There are four categories of non-covalent interactions 
(Figure 16): Electrostatic interactions, Van der Waals forces, hydrophobic effects, and 
Figure 16 Types of chemical bonding in organic chemistry. Left Box: Typical bond strength for a selection of interactions. 
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aromatic interactions. Herein, only the aromatic interactions relevant for the content of this 
thesis will be discussed (Figure 16, red). 
Aromatic interactions are attractive forces involving π-electron-rich systems and have been 
proposed to consist of all other three non-covalent interactions, i.e., electrostatic interactions, 
Van der Waals forces (dispersion and repulsion), and hydrophobic effects.[60] This 
complexity renders their investigation difficult, and the contribution of each force is still 
under debate.[61] Generally, the electrostatic component, which arises from the interaction of 
the quadrupolar moment, provides a good, simplified quantity for qualitative analyses of 
these interactions. The quadrupolar moment component perpendicular to the aromatic plane 
Qzz describes the charge distribution resulting from the π-system above and below the plane 
(Figure 17). The Qzz is discussed in greater detail in chapter 2.2.2. Benzene has an electron-
rich π-cloud above the ring (negative Qzz), which can undergo stabilising interactions with 
electron-deficient moieties (e.g., cations). By introducing electron-donating or electron-
withdrawing substituents, the electron-density can be increased or decreased, respectively. 
Introduction of highly electron-withdrawing groups or several electron-withdrawing groups 
leads to inversion of the polarity, resulting in a positive Qzz. Interestingly, the magnitude of 
the Qzz of hexafluorobenzene is similar to that of benzene, but with opposite polarity.[60] 
 
The importance of non-covalent interactions has triggered research in this area, and 
numerous reports investigating individual aromatic interactions by rational design of small 
molecules have enriched the field.[62] Furthermore, many of these interactions have been 
studied computationally. Herein, exemplary highlights from both, experimental and 
theoretical, approaches will be described and examples of applications discussed.  
 
 
Figure 17 Schematic representation of the charge distribution 
in benzene and benzene-derivatives  
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1.2.2 Arene-Arene (π-π)-Interactions 
Arene-arene interactions are of upmost importance in biology. The stacking interactions 
between the nucleotides in DNA are largely responsible for the formation of the double 
helix.[63] Furthermore, about 60% of the aromatic side chains in proteins have been reported 
to participate in arene-arene interactions.[64] The simplest and probably most studied π-π-
interaction is the stacking between two benzene rings. It should be noted, that the term 
stacking is highly misleading since it has been demonstrated, that the face-to-face orientation 
is not the preferred situation for a benzene-dimer.[65] The three interaction geometries that 
have been computationally identified as energetic minima, are termed parallel-displaced, T-
shaped edge-to-face, and eclipsed face-to-face (Figure 18): The first two are energetically 
more favourable. The face-to-face interaction was found to be 0.7–1.5 kcal/mol higher in 
energy, which is attributed to the repulsive interaction between the two negatively charged 
π-clouds. The interactions between benzene-dimers have been calculated to result in a 
stabilisation of –1.6 to –2.4 kcal/mol in the gas phase.[62a]  
 
Similar observations were made for hexafluorobenzene dimers. However, the picture 
changes when looking at 1:1 mixtures of benzene and hexafluorobenzene. Instead of the 
parallel-displaced interaction observed for the two separate compounds, in the mixture an 
alternating eclipsed face-to-face orientation has been reported. The resulting crystalline 
mixture has a significantly higher melting point than either benzene or hexafluorobenzene 
(297 K as compared to 278 K for both).[66] This is a consequence of optimised interaction of 
the two opposing quadrupolar moments and C–H···F–C interactions.[67] The binding energy 
of one dimer has been calculated to be in the range of –3.7 to –5.6 kcal/mol.[68] Recently, the 
Figure 18 Left: Interaction geometries of benzene dimers. Right: Interaction geometry of benzene with hexafluorobenzene. 
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heterodimer of indole and hexafluorobenzene has been calculated to also adopt the eclipsed 
face-to-face orientation.[69] 
Several rationally designed synthetic receptors for the quantification of substituent effects 
and solvent dependencies have been reported in the literature. Examples include molecular 
balances[70], e.g., the molecular torsion balance developed by Diederich et al. for the 
investigation of edge-to-face interactions (Figure 19).[71] It was found that for the compound 
with R1 = H the folding preference was essentially independent of R2, while for the balance 
with R1 = CF3 a strong dependence on R2 was observed and a clear correlation between the 
free enthalpy of folding (∆Gfold) and the Hammett constant σm was observed. This 
observation was consistent in C6D6 and CDCl3. 
 
A clear correlation between the Hammett constant σm and barrier of rotation (∆Grot) has also 
been observed by Siegel and co-workers in their studies of parallel displaced interactions in 
substituted benzophenanthrenes (Figure 20).[72] They found that the rotation barrier increased 
with increasingly electron-withdrawing groups. 
 
Another type of receptor developed for studying aromatic stacking interactions are molecular 
tweezers and clips for guest complexation.[73] The host-guest complexation only takes place, 
if stabilising non-covalent interactions occur. Among the most successful receptors are the 
tweezers developed by Kärner et al. (Figure 21)[74]. The electron-rich pre-organised 
structures were found to effectively bind electron-deficient aromatic systems and cations, 
while electron-rich arenes were not complexated. 
Figure 19 Molecular balance reported by Diederich et al. for the quantification of arene-arene interactions. 
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Figure 20 Benzophenanthrene system developed by Siegel et al. for the investigation of parallel-displaced interactions. 
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Hunter and co-workers have developed a multitude of thermodynamic, synthetic double 
mutant cycles for the quantification of free energy changes due to π-π-stacking and other 
non-covalent interactions.[75] Using the double mutant cycle shown in Figure 22, the group 
determined the magnitude of stabilisation resulting from one terminal edge-to-face π-π-
interaction to be –0.3 kcal/mol. Free energies of π-π-interactions employing various 
substituted aryl moieties and heterocycles were quantified using this method.[75] A general 
trend observed is that the magnitude of interaction increases with increasing electron-density 
difference of the two interacting aromatics. This method has also been applied for the 
quantification of other non-covalent interactions including cation-π,[76] halogen-π,[77] and 
carbohydrate-π interactions.[78] 
OAc
AcO
CNNC
NO2O2N
NO2
Figure 21 Example of a host-guest system reported by Kärner et al. 
Figure 22 Double mutant cycle for the quantificcation of two terminal edge-to-face π-π-interactions. 
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Substituent effects have also been extensively studied by computational methods. For the 
face-to-face geometry monosubstituted dimers were found to be generally more stable than 
the parent benzene-benzene dimer independent of the electronic nature of the substituent.[79] 
In the face-to-edge orientation, para-substitution of the edge-component led to stabilisation 
only in the case of electron-withdrawing substituents, while electron-donating substituents 
resulted in the opposite effect.[80] Houk and co-workers have reported, that direct 
electrostatic interactions between the substituents on one arene with the other arene govern 
how the substituents influence the electron density and, thus, the π-π-stacking interaction. 
The strength of these direct interactions was also found to correlate with the Hammett 
constant σm.
[81]
  
Understanding π-π-stacking interactions is not only important for unravelling biological 
processes, but also for protein design[82] and development of novel materials,[83] and highly 
selective organic synthesis protocols.[84] One of the best studied systems for stereoselective 
synthesis utilising a π-π-stacking interaction is the chiral auxiliary 8-phenylmenthol 
developed by Corey and co-workers.[85] The auxiliary has proven powerful among other 
transformation for the asymmetric Diels-Alder reaction of its acrylate esters as has 
beautifully been shown in the Coreys synthesis of prostaglandins. The asymmetric induction 
has been shown to be due to π-π-stacking interactions between the arene and the enoate by 
computational,[86] crystallographic[87] and spectroscopic analyses.[88] 
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1.2.3 CH-π Interactions 
First postulated in 1952 by Tamres et al.[89], the CH-π interaction is ubiquitous in organic 
molecules. A crystallographic database study revealed that >29% of organic compounds[90] 
and >42% of the peptide structures[91] bearing at least one aryl ring exhibit at least one CH-π 
interaction and that this interaction is crucial for numerous supramolecular host-guest 
complexes.[92] Evidence for this interaction has also come from spectroscopic, 
thermodynamic, and bond critical point analysis.[93] Much debate is found in the literature on 
the classification of this weak interaction. Originally described as soft base-soft acid 
hydrogen bond,[94] it has been suggested that the CH-π interaction should not be classified as 
a hydrogen bond since electrostatic components are less important and dispersion 
components are more important than for XH-π interactions.[62b;95] However, the electrostatic 
component (dipole/quadrupole and charge-transfer interactions) is important for the 
directionality of the interaction and numerous reports support the hydrogen bond nature of 
the interaction.[94;96] Thus, herein the CH-π interaction will be treated as special form of 
hydrogen bond. 
A special feature of the CH-π interaction is that it is operational in polar as well as in 
nonpolar solvents, which is a consequence of the large contribution of the dispersion 
energy.[94] As mentioned, the directionality of the interaction is crucial and is dominated by 
electrostatic interactions, thus differentiating the CH-π interaction from London dispersion 
forces. The simplest example, the methane-benzene dimer has been studied by Sakaki et 
al.[97] In the preferred conformation the methane is positioned on the axis perpendicular to 
the centre of the benzene ring with one C–H bond oriented towards the arene (Figure 23, a). 
The stabilisation for this conformation was calculated to be –0.57 kcal/mol. The second 
lowest conformation was found to be only slightly less stabilising (–0.49 kcal/mol, b). 
Figure 23 Selection of possible conformers for methane-benzene dimers. 
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In a recent publication by Tsuzuki using a different level of theory and a larger basis set, the 
same conformational preferences were found, but larger interaction energies were postulated  
(–1.45 and –1.23 kcal/mol for a and b, respectively).[98] The optimal distance between the 
hydrogen donor carbon and the hydrogen acceptor aryl was found to be 3.8 Å. Furthermore, 
the interaction energy with benzene was found to increase with increasing acidity of the 
hydrogen in the series of ethane, ethylene, and acetylene. Similar trends have been observed 
in other computational analyses[96a;96c;99] and as a rule of thumb it can be concluded that the 
stronger the proton donating ability of the CH group, the larger the stabilising effect of CH-π 
interactions.  
As a consequence of the weak and poorly directional nature of the CH-π interactions, they 
have primarily been studied by computational analyses and in crystal structures. Recently, 
Carroll and co-workers have reported a series of molecular balances for quantification of 
CH-π interactions by solution phase NMR analyses (Figure 24).[100] This report highlights 
how delicate these interactions are and how difficult experimental quantification is. 
 
A second molecular switch based on proline containing peptides has been reported by 
Zondlo (Figure 25).[101] The authors found that the population-ratio of cis and trans-
configured amide bond is tunable by electronic-modification of the aryl moiety, and that 
systems containing more electron-rich aromatic groups show a higher population of the cis-
conformer. When employing para-substituted phenylalanines, a correlation between the 
Hammett constant σm and the cis/trans-ratio was observed. This report supports the notion 
that CH-π interaction strength are not only dependent on the acidity of the CH-donor, but 
also on the electron-density of the aromatic hydrogen-acceptor. 
 
 
Figure 24 Molecular balance developed by Carroll et al. for the quantification of CH-π interactions. 
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Carbohydrate recognition is one of the most important applications of the CH-π 
interaction.[102] Another beautiful application has been reported by Martín and co-workers. 
The authors achieved chiral recognition of amino acid derivatives with a synthetic receptor. 
Analysis using a double mutant cycle proposed that 70% of the enantioselectivity is caused 
by a single CH-π interaction.[103] In the last decade, several reports have suggested the 
importance of a CH-π interaction for facial discrimination in reactions catalysed by the 1st 
generation MacMillan catalyst (see chapter 1.1.2). 
 
1.2.4 Cation-π Interactions 
Cation-π interactions are stabilising interactions between the face of an electron-rich π-
system and an adjacent cation.[104] First experimental support for these interactions came 
from mass spectrometry and ion cyclotron resonance studies in 1981 and the following 
years.[105] These studies postulated strong interactions between cations like K+ and NH4+ 
with simple aromatics. Furthermore, it was established that several of these interactions are 
of similar strength as the corresponding cation-water interactions (e.g., K+–H2O was found 
to have an interaction energy of 18 kcal/mol, while the one for K+–benzene was found to be 
19 kcal/mol). It is now widely established that cation-π interactions are ubiquitous in nature 
and play important roles in protein-DNA binding and protein-protein interactions.[106] 
Especially prevalent are interactions between the aromatic amino acids Phe, Tyr, and Trp 
and protonated amino acid side chains (i.e., Arg, His+, Lys) and neurotransmitters 
(Acetylcholine, GABA, and serotonin).[106b] The geometry of the interaction has been 
studied computationally and it has been shown that the cation is placed over the centroid of 
the aromatic ring (Figure 26).[104a] It has been postulated, that the dominating force in cation-
π interactions is the electrostatic component (cation-quadrupole interaction). One of the 
trends supporting this notion is that smaller ions exhibit stronger affinity (Figure 26).[106d] 
Thus, a good qualitative evaluation of these interactions can be achieved by studying the 
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Figure 25 Peptide structure developed by Zondlo exhibiting tunable CH-π interactions. 
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electron surface potential maps (ESP) of the aromatic moiety. The cation affinity is strongest 
at the most electron-rich position of the π-system. Another important feature of these 
interactions is that they are generally much stronger than other non-covalent interactions. 
Recent work by Houk and co-workers postulated, that effects of substituents to the aromatic 
part of the interacting dimer arises due to through-space effects of the substituent and not 
due to polarisation of the π-system.[81;107]  
 
Cation-π interactions have extensively been studied by Doughtery and co-workers.[104a] The 
group has developed a series of cyclophane hosts which were able to complex numerous 
cations in aqueous media, thus demonstrating the strength of the interaction. An example of 
such a cyclophane and complexed cations is shown in Figure 27. 
 
Valuable contributions to the development of artificial receptors for cation complexation 
have also come from the groups of Schneider[108], Lehn[109], and others,[104a] but will not be 
discussed further. 
Several examples of cation-π interactions in organocatalysis have been reported in the 
literature. Jacobsen and co-workers have developed several hydrogen-bond donor catalysis 
protocols, for which the enantioselectivity of the transition state is achieved by cation-π 
Figure 26 Orientation of the Cation-π interaction and selection of gas phase binding energies. 
Figure 27 Cyclophane hosts developed by Doughtery and examples of guests. 
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interactions.[28b;110] Recently, ab initio calculations of the α,β-unsaturated iminium ion 
derived from the 2nd generation MacMillan catalyst by Yamada et al.[111] suggested, that a 
cation-π interaction stabilises the lowest energy conformer. Furthermore, this study reported 
that introducing an electron-donating para-substituent to the shielding aryl group leads to 
increase of the interaction strength, while electron-withdrawing substituents exhibit the 
opposite effect.  
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2 Molecular Editing of the MacMillan Catalyst 
Derived Iminium Ion Intermediate 
2.1 Introduction 
2.1.1 The MacMillan Catalyst 
The L-phenylalanine-derived imidazolidinone catalyst 1 (Figure 28) developed by 
MacMillan et al. was introduced in 2000 as the first highly enantioselective organocatalyst 
for the enantioselective Diels-Alder reaction.[8a] More importantly, this publication 
formalised the notion of iminium ion catalysis, an activation mode that is used frequently in 
the rapidly evolving field of organocatalysis. Although the seminal example of what is now 
termed iminium ion catalysis was reported as early as 1894 by Knoevenagel[13] (see 
chapter 1.1.1), MacMillan was the first to describe iminium ion activation in more general 
terms as a LUMO-lowering phenomenon, thus making parallels to Lewis acid catalysis. The 
introduction of this seminal report has let to considerable increased interest in this field and a 
large number of related transformations have since been developed.[31] Consequently, not 
only various reactions proceeding via an iminium ion have been developed,[52;112] but also 
several transformations proceeding via the enamine,[113] and SOMO[114] activation have been 
described. The mode of activation, along with previous work on structural and mechanistic 
aspects of the MacMillan catalyst, is discussed in the introductory part of this thesis (see 
chapter 1.1.2).  
 
2.1.2 Conformational Diversity in the MacMillan Catalyst Derived Iminium Salts 
Organocatalysts operate by similar mechanisms as have been formalised for general enzyme 
catalysis (Figure 28).[115] The catalyst, in this case the imidazolidinone 1, binds the substrate, 
in this case condensation with (E)-cinnamaldehyde 2, causing a conformational change. In a 
second step, the bond forming process takes place, and then the product is released (by 
hydrolysis). The catalyst is hereon available for the next cycle. For reactions proceeding via 
a reactive intermediate, the transition-state can be assumed to closely resemble this 
intermediate (Hammond-Leffler postulate).[116] Consequently, the origin of selectivity can be 
explored by studying the isolatable iminium ion 1a. 
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The iminium ion intermediate 1a is rigid with only few degrees of conformational 
freedom.[4;8a] The core imidazolidinone ring is virtually planar due to three sp2-hybridized 
atoms in the five-membered ring. The bound substrate also lies flat in this same plane with 
the geminal-dimethyl group being perpendicular. Only the aryl shielding group discriminates 
between the two faces of the planar electrophile. These features are beautifully illustrated by 
the crystal structure of the iminium ion 1a derived from the 1st generation MacMillan 
catalyst 1 and trans-cinnamaldehyde 2 by Tomkinson et al. (Figure 29, left).[49] For effective 
catalyst performance, the (E)/(Z)-geometry of the C=N+ iminium bond must be controlled. It 
was reported in a computational study by Houk, and in experimental studies by Mayr, 
Seebach, and Gilmour, that the (E)-isomer is selectively formed to avoid A1,3-type allylic 
strain between the pendant iminium chain and the geminal-dimethyl group (Figure 29, 
right).[1a;1c;1d;117]  
 
 
 
 
 
 
Figure 28 Parallels in the mechanisms of enzyme and iminium ion catalysis. 
Figure 29 Left: X-ray structure of 1a as the PF6- salt. The counter ion has been omitted 
for clarity. Right: Selective formation of the (E)-isomer due to A1,3-allylic strain.[1] 
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The facial selectivity of the MacMillan-catalyst promoted reactions proceeding through an 
iminium ion intermediate must largely be induced by the aryl shielding group. Rotation 
around the benzylic C–C bond leads to three possible staggered conformers (Figure 30).  
 
Conformer I is predisposed to undergo a stabilizing CH-π interaction with the syn-methyl 
group and has been reported to be the global energy minimum.[1a;47;50b] This is consistent 
with the solid state structure identified by X-ray crystallographic analysis (see Figure 29). 
Conformer II, which was originally reported by MacMillan to be the predominantly 
populated conformation,[8a] is presumably stabilised by a π-π interaction between the aryl 
shielding group and the iminium chain. The third staggered conformation with the aryl group 
pointing away from the reaction centre (conformer III), was found to not be an energetic 
minimum by Houk[47] as well as Seebach and Grimme.[50b] A third conformer that has been 
proposed by computational analysis is conformer IV, in which the shielding group eclipses 
with the adjacent hydrogen. A more detailed discussion on previous studies can be found in 
chapter 1.1.2. 
 
2.1.3 Project Overview 
Whilst the MacMillan catalyst 1 is now widely established as a highly efficient and broadly 
applicable catalyst for iminium activation, the mode of enantioinduction remains to be 
clarified. Iminium salts are attractive candidates for reaction deconstruction as their covalent 
nature allows for isolation and analysis. It was envisaged that a detailed, logical molecular 
Figure 30 Four possible low-energy conformers of the MacMillan catalyst derived α,β-unsaturated iminium ion 1a. 
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editing study of the intermediate iminium ion 1a would assist in identifying which features 
and interactions are essential for effective catalyst performance, and ultimately lead to a 
better understanding of the catalytic behaviour. Moreover, the postulated stabilising non-
bonding CH-π and π-π interactions associated with the MacMillan catalyst derived iminium 
ions (Figure 30)[1a;3;44a;47;49-50;111;118] mirror those found in many biomolecules,[28b;106b;106e;119] 
providing an excellent platform to study these important interactions in a small molecule. 
Conversely, one can exploit advances in structural biology and supramolecular chemistry 
regarding intra- and intermolecular interactions and employ them in the design of highly 
selective organocatalysts. It was of particular interest in this work to investigate how the 
modifications would influence conformational and kinetic behaviour and to find general 
guidelines for catalyst design derived from our findings. The sites of the catalyst, which 
were investigated are summarised in Figure 31. Experimental designs and results are 
discussed separately for each site in the following chapters. In chapter 2.2 the consequence 
of electronically modulating the shielding aryl group by substituent variation is discussed in 
detail. It is known that CH-π and π-π interactions are sensitive to electron-density, thus it 
was expected that the polarity of the aryl group is determinant for conformational behaviour.  
 
In the following chapter 2.3, additional modifications of the aryl group are discussed. The 
necessity of an aromatic shielding group was envisaged to be proven by studying the 
saturated cyclohexyl analogue. Furthermore, it was investigated how extension of the 
aromatic system and employment of heterocycles would influence catalyst behaviour. Next, 
the benzylic position was investigated (chapter 2.4). To explore the influence of steric bulk, 
the number of aryl shielding groups was varied. The flexibility of the system was enhanced 
by increasing the distance between the shielding group and the imidazolidine moiety. Also 
the results of introducing fluorine in the benzylic position to generate "conformer 
equivalents" are addressed.[4] In chapter 2.6, differently sized spiro rings were introduced in 
Figure 31 An overview of the molecular editing study of the MacMillan catalyst derived iminium salt 1a. 
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place of the geminal-dimethyl group to study the influence of geometric control on the 
ability of the system to undergo CH-π interactions. Additionally, the dimethyl group was 
removed, which was expected to be destructive on the control of iminium ion bond 
geometry. Subsequently, a series of second generation catalysts with a tert-butyl group 
instead of the geminal-dimethyl group is looked at (chapter 2.7). In chapter 2.8, the 
electronic modification of the substrate´s aryl ring by substituent variation is studied. It was 
expected that the kinetic behaviour of the iminium ions will be especially sensitive to 
electronic modulation of the bound substrate. This has also been verified by Mayr et al. 
during the course of the herein reported study.[120]  
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2.2 Electronic Modulation of the Shielding Group 
In recent years, evidence implicating that CH-π and π-π interactions stabilise conformers I 
and II, respectively, (Figure 32, upper) of the transient iminium ion formed by condensation 
of the MacMillan catalyst with an α,β-unsaturated aldehyde, has been reported.[1a;3;44a;47;49-
50;111;118]
 From structural biology studies it is established that these interactions are sensitive 
to electronic alterations of the π-system or in its vicinity.[82;106a;106c;121] For a detailed 
discussion of non-covalent aromatic interactions see chapter 1.2. It was envisaged, that by 
introducing electron-donating or electron-withdrawing groups to the shielding aryl group, 
the conformational preferences and consequently catalytic performance could be modulated. 
For this purpose, a library of electronically modified MacMillan-type imidazolidinones was 
synthesised, ranging from highly electron-rich (3) to highly electron-deficient (10) aromatic 
systems (Figure 32, lower). 
 
As measurement of the charge distribution of the aryl shielding group, the quadrupole 
moment tensor orthogonal to the aryl group (Qzz) was calculated in collaboration with Dr. 
Mück-Lichtenfeld (Westfälische Wilhelms-Universität Münster). Moreover, the electronic 
surface potential (ESP) maps were computed to assist in visualising electronic properties. 
Subsequently, the effect of these structural changes on solid state and solution phase 
Figure 32 Upper: Possible staggered conformers. Lower: Catalyst library with electronically modified aromatic groups. 
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conformational behaviour of the corresponding iminium salts, as well as on reactivity and 
efficiency in catalysis were studied. 
 
2.2.1 Syntheses of Imidazolidinones with Electronically Modified Shielding Groups 
The preparation of the catalysts with electronically modified shielding aryl substituents can 
be divided into two groups: Catalysts derived from natural amino acids (1 and 6) or 
commercially available unnatural amino acids (4 and 9), and catalysts derived from 
unavailable unnatural amino acids (3, 5, 7, 8, and 10).  
Catalysts derived from natural amino acids or available unnatural amino acids: 
The synthesis of imidazolidinones 1, 4, 6, and 9 followed the same procedure reported by 
MacMillan for the preparation of 1 in a three step sequence.[8a] The commercially available 
amino acids (11-14) were converted into the corresponding methyl esters by treatment with 
thionyl chloride in MeOH. Next, the methyl amides (15-18) were prepared from the crude 
methyl esters by addition of an excess of methylamine in EtOH. In the final step, cyclisation 
with acetone in MeOH gave the desired imidazolidinones in good to excellent yields. 
Depending on the substrate, the yields of the cyclisation could be improved by addition of 
catalytic amounts of base (Et3N) or acid (TsOH). 
 
Catalysts derived from unavailable unnatural amino acids: 
The imidazolidinones derived from non-commercial amino acid derivatives (3, 5, 7, 8, and 
10) were prepared following Seebach´s procedure for the selective α-functionalisation of 
amino acids.[122] This methodology was optimised for the unbranched glycine derivative 
BMI 19 as a general route to chiral α-amino acids. Herein, the method has been exploited 
using L-α-amino acids. The key intermediate BMI 19 can be prepared by cyclisation of 
Scheme 2 General procedure for the syntheses of catalysts derived from natural amino acids or available unnatural amino 
acids (1, 4, 6, and 9). 
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glycine methyl amide 20 with pivaldehyde 21 followed by chiral resolution of the resulting 
enantiomers using (S)-mandelic acid 22 (Scheme 3).[122b] 
  
Boc-protection gives the key intermediate (S)-tert-butyl-2-(tert-butyl)-3-methyl-4-oxo-1-
imidazolidinonecarboxylate [(S)-Boc-BMI, 23)] which is also commercially available (CAS: 
119838-38-9). Deprotonation of (S)-Boc-BMI generates a chiral enolate which can then be 
selectively alkylated to form the trans-product. Finally, hydrolysis of the imidazolidinone 
gives the L-α-amino acid or methyl amide, depending on conditions. In this work, the 
BMI·TFA salt 19·TFA was used as an economical starting point which was neutralised and 
Boc-protected in a two step procedure (81% yield; Scheme 4).  
 
For optimisation studies of the alkylation reaction, racemic Boc-BMI was prepared on large 
scale (Scheme 5) in a simple three step procedure. Amidation of glycine methyl ester 
hydrochloride 24 followed by cyclisation with pivaldehyde 21 gave BMI in good yield 
(74%). Subsequent Boc-protection using catalytic DMAP furnished the product 23 in 64% 
overall yield. 
Scheme 3 Synthesis and chiral resolution of BMI 19 as described by Seebach. 
Scheme 5 Synthesis of racemic Boc-BMI 23 for optimisation studies. 
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Scheme 4 Synthesis of (S)-Boc-BMI 23 from (R)-BMI·TFA. 
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With Boc-BMI 23 in hand, optimisation studies for the alkylation step were performed. In all 
cases, the substituted arylbromides were used as the electrophile; these were either 
commercially available or prepared from the corresponding alcohol using PBr3. It was 
observed that the fluorinated arylbromides gave good yields using LDA as base (27-29) as 
originally reported by Seebach.[122b] In the case of the less reactive methoxy-substituted 
arylbromides the use of LiHMDS and addition of 1,3-dimethyltetrahydropyrimidin-2(1H)-
one (DMPU) seemed to be beneficial due to increased solubility of the alkylating agent (25, 
26). The optimised conditions were then applied with (S)-Boc-BMI followed by cleavage of 
the Boc-group and hydrolysis to obtain optically pure L-phenylalanine N-methyl amide 
derivatives (30-34). Ring closure with acetone under basic conditions gave the target 
imidazolidinones in good overall yields (Scheme 6, 65%–77%).  
 
Syntheses of the iminium salts: 
Having completed the preparation of catalysts 1 and 3-10, the corresponding iminium salts 
(1a and 4a-10a) were synthesised for structural analysis. These materials were successfully 
prepared as the perchlorate salts by condensation with (E)-cinnamaldehyde 2 (Scheme 7). 
Despite repeated attempts, the iminium salt of catalyst 3 (Ar = C6H4NH2) and 7 (Ar = 
C6H4F) could not be isolated. 
 
Scheme 6 Syntheses of catalysts derived from unavailable unnatural amino acids 3, 5, 7, 8, and 10. 
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Scheme 7 Synthesis of the iminium perchlorate salts 1a and 4a-10a. 
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2.2.2 The Quadrupole Moment Qzz 
The charge distribution in a molecule can be conveniently expressed by multipoles. 
Topologically, monopoles look like s-orbitals, whilst dipoles look like p-orbitals and 
quadrupoles look like d-orbitals (Figure 33).[123] Chemists are familiar with describing point 
charges as monopoles. Furthermore, the term bond dipole is frequently used to express the 
charge distribution in polarised covalent bonds, and small molecules like CH3CN or H2O are 
known to exhibit molecular dipoles.[123] These concepts are helpful in understanding and 
predicting chemical reactivity and non-covalent interactions. Just as the dipole is a 
combination of two monopoles of equal and opposite charge, the quadrupole moment 
consists of two or more identical dipoles aligned anti-parallel such that there is no net dipole. 
Whereas higher multipoles become increasingly complicated for illustrative descriptions of 
molecular properties, the quadrupole moment is important in describing charge distribution 
in aryl rings. Aromatic interactions are of outmost importance for non-covalent interactions 
in molecular recognition and pre-organisation.[104a;121a;124] Although it must be kept in mind 
that other inherent properties like the electrostatic potential surface contribute to these 
phenomena, quadrupolar interactions are central to these phenomena and provide a good, 
simplified picture for qualitative investigations.[104a;125]  
 
Of particular interest for describing the properties of a benzene ring is the large permanent 
dz² quadrupole moment which is the sum of six sp²–CH dipoles.[126] The permanent 
perfluorobenzene quadrupole moment is similar in magnitude but has the opposite polarity. 
The magnitude of dz² is represented by the traceless quadrupole moment tensor component 
perpendicular to the aromatic ring (Qzz).[127] 
In collaboration with Dr. Mück-Lichtenfeld (Westfälische Wilhelms-Universität Münster), 
the Qzz for the toluene analogues of the electronically modified aryl rings and, for visual 
illustration, the electronic surface potential maps were computed (Figure 34). The DFT 
calculations were performed using TURBOMOLE.[128] 
Figure 33 Schematics of multipoles and the dz2 quadrupole 
moment of benzene and perfluorobenzene. 
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Figure 34 Electron surface potential (ESP) maps and quadrupole moment tensor components perpendicular to the 
aromatic ring (Qzz) of the toluene derivatives of the modified benzyl group given in Debeye·Ångstrom. Colour range of the 
electrostatic potential: −0.06 (red) to + 0.06 (blue). 
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2.2.3 X-Ray Crystallographic Analysis of Imidazolidinone Hydrochloride Salts and 
Iminium Salts 
X-ray structures of the hydrochloride salts of the imidazolidinones 1, 3, and 8-10: 
For most of the catalysts it was possible to obtain crystals suitable for X-ray crystallographic 
analysis as the hydrochloride salts (Figure 35). The crystal structure of 1 is taken from 
Burley and Gilmour,[3] in which the first solid state and computational study of this 
imidazolidinone is reported. For catalysts 3 and 10 the racemic analogues were used. The 
nitrogen of the amine function of all the imidazolidinones was found to be pyramidalised 
such that the resulting envelope allows for the benzylic substituent to be in quasi-equatorial 
position. Except for the trimethoxyphenyl-derived catalyst 3, all other structures were found 
to adopt the staggered conformation with the aryl group rotated in proximity of the 
protonated amine (ΦNCCC = –72.0° (1), –82.6° (8), –74.5° (9), and –83.0° (10)). The 
trimethoxy catalyst 3 on the other hand adopts the staggered conformer in which the aryl 
ring is rotated into proximity of the carbonyl moiety (ΦNCCC = –170.0°). 
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Figure 35 X-ray structures of the hydrochloride salts of catalysts 1[3], 3, and 8-10. 
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X-ray structures of the catalysts derived iminium ions: 
For most of the iminium salts derived from the imidazolidinones, it proved very difficult to 
obtain crystals suitable for X-ray analysis, due to poor stability in solution and tendencies to 
form an oil. Gratifyingly, crystallisation of one electron-rich (6a) and one electron-deficient 
(10a) example was achieved by vapour diffusion with Et2O from a solution in CH3CN or 
MeOH/CH3CN (2:1), respectively. For both, the racemic analogues were used. The severe 
effect of electronic modulation on conformation is beautifully represented in the crystal 
structures. As expected, due to their similar Qzz, the tyrosine-derived catalyst iminium salt 6a 
adopts the same conformation (conformer I, Figure 30) as the parent phenylalanine-derived 
structure (Figure 29)[49] allowing for a stabilising CH-π contact. In contrast, the pentafluoro-
analogue 10a (Qzz = +3.01) adopts a conformation with the aromatic group rotated away 
from the core five-membered ring (ΦNCCC = –176.7°; conformer III, Figure 30). To the best 
of our knowledge, this is the first structural report of this conformation. Moreover, Houk and 
co-workers have calculated that conformer III is electronically disfavoured for the parent 
iminium salt 1a, derived from crotonaldehyde (Me instead of Ph on substrate).[47] Similarly, 
Seebach and Grimme reported that this conformation is not an energetic minimum of 1a in 
their "windshield-wiper" model.[50b] Also clearly visible from the crystal structures is the 
ideal planarity of the core ring-iminium chain moiety with the aromatic group solely 
discriminating the two faces.  
Figure 36 X-ray structures of iminium perchlorate salts of 6a and 10a. The ClO4- counterions are omitted for clarity. 
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2.2.4 NMR Analysis of the Electronically Modified Iminium Salts 
Chemical shifts of the geminal-dimethyl group: 
As reported by Tomkinson et al.[49] the CH-π interaction in conformer I of the iminium salts 
between the shielding group and the syn-methyl group of the geminal-dimethyl functionality 
is clearly visible by solution phase NMR (Figure 37). The interaction leads to a significant 
upfield shift of the syn-methyl as compared to the anti-methyl (benzyl:  
∆δ1Hsyn/anti = –0.89 ppm; ∆δ13Csyn/anti = –2.77 ppm). It was therefore envisaged, that the 
conformational preferences of the modified iminium salts would be qualitatively represented 
by the ∆δsyn/anti of the chemical shifts, because the magnitude of the differences should 
directly be connected to the population in conformer I. Therefore the chemical shifts (1H and 
13C NMR) of the geminal-dimethyl group for all iminium salts were deduced from their 
NMR spectra (Table 1 and Figure 37). The large difference of the shifts of the two methyl 
groups [∆δ(syn/anti)] observed for electron-rich systems 1a, 3a, 5a, and 6a is a result of 
shielding of the syn-methyl group in conformer I due to the CH-π interaction. Smaller 
∆δ(syn/anti) in the spectra of 8a and 10a suggest lower population of this conformer. 
Notably, the nitro derivative 9a exhibits a much larger shift-difference than the other 
electron-poor compounds, suggesting different conformational behaviour. 
Table 1 Differences of the chemical shifts of the geminal-dimethyl group observed by 1H and 13C NMR spectroscopy. 
Iminium Salt (Ar) Qzz [D·Ǻ] 
∆δ(syn/anti)1H 
[ppm] 
∆δ(syn/anti)13C 
[ppm] 
3a (C6H2(OMe)3) –5.68 –0.62 –1.87 
5a (C6H3(OMe)2) –4.72 –0.62 
 
6a (C6H4OH) –3.71 –0.78 –2.48 
1a (C6H5) –3.46 –0.89 –2.77 
8a (C6H2F3) +0.26 –0.18 +0.06 
9a (C6H4NO2) +2.46 –0.74 –1.79 
10a (C6F5) +3.01 –0.13 +0.36 
 
2 Molecular Editing of the MacMillan Catalyst 35 
 
Figure 37 Upper: The three staggered conformers of the imidazolidinone derived iminium salts. The CH-π interaction in 
conformer I results in an upfield shift of the syn-methyl group in the 1H and 13C NMR spectra. Lower: 1H-NMR spectra.  
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Figure 38 Me-indole 
imidazolidione 35. 
Conformer population analysis of iminium salts 1a, 3a, 6a, 8a, 10a, and 35a: 
Together with Dr. K. Bergander from the NMR department at the 
Westfälische Wilhelms-Universität Münster, a detailed solution phase 
conformer population analysis was performed for a selection of catalysts 
(1a, 3a, 6a, 8a, 10a, and additionally the Me-indole derivative 35a, Figure 
38, discussed in greater detail in chapter 2.2.8). It was assumed that only 
the three staggered conformers I-III (Figure 37) should be significantly populated and 
therefore contribute to 3J couplings. The mole fractions XI, XII, and XIII corresponding to the 
three conformers can be determined by solving a system of three linear equations: 
 
  60° +  300° +   180° =  
  60° +  180° +   300° =  
 +  +  = 1 
 
A solution to the system is given by: 
 
 =   − 60°

300° − 60° −
 − 60°
180° − 60°  
180° − 60°
300° − 60° −
300° − 60°
180° − 60°   
 =  − 60° −  180° − 60°
 
300° − 60°  
 = 1 −  −  
 
The expected 3J values for the distinct rotamers [3J(60°), 3J(180°), and 3J(300°)] were 
determined for each iminium salt using the Diez-Altona Donders equation with the aid of 
MestReJ (v1.1).[129] For this, the two diastereotopic benzylic protons were assigned via  
1D-NOESY and HF-HOESY experiments and the experimental 3J coupling constants 
(ArCH2 to 5-H) were determined. The substituent parameters (group electronegativities) λi 
of all substituents attached to benzylic C-C bond were taken from Altona et al. or deduced 
from the corresponding ethane derivatives.[130] With the 3J values for the distinct rotamers in 
hand, the mole fractions were calculated. The results for the iminium salts 1a, 3a, 6a, 8a, 
10a, and 35a are summarised in Table 2.  
N
N
H
Me
Me
MeO
N
Me 35
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Iminium Salt Qzz [D·Å] XI XII XIII 
8a (C6H2F3) +0.26 0.39 0.21 0.40 
10a (C6F5) +3.01 0.37 0.16 0.47 
1a (C6H5) –3.46 0.75 0.03 0.23 
6a (C6H4OH) –3.71 0.76 0.04 0.20 
3a (C6H2(OMe)3) –5.68 0.57 0.28 0.15 
35a (Me-Indole) –5.40 0.65 0.17 0.18 
 
 
For the electron-rich species 1a, 3a, 6a, and 35a, conformer I, stabilized by a CH-π 
interaction, is predominantly populated. In contrast to the phenylalanine 1a and tyrosine 6a 
derived catalysts, the more electron-rich systems 3a and 35a significantly populate 
conformer II, stabilised by π-π-type interactions. The electron-deficient systems 8a and 10a 
showed very different mole fraction distributions. Unlike the other iminium salts, these 
systems do not predominantly populate conformer I (<40%), but exhibit a more diverse 
distribution. These observations are consistent with the trends deduced from the chemical 
shift-differences (∆δ(syn/anti)1H and 13C NMR) of the geminal-dimethyl group (Table 1).  
 
2.2.5 Kinetic Analysis of two Iminium Salts by Photometric Monitoring 
The rate constants of the reactions of the iminium salts from the most electron-rich 3a (R = 
C6H2(OMe)3) and most electron-deficient 10a (R = C6F5) catalysts with silyl ketene acetals 
36 and 37 were studied to quantify the influence of electronic modulation on electrophilic 
reactivity and to determine the electrophilicity parameter for these iminium salts (Scheme 8). 
The kinetic analysis described in this chapter was performed in collaboration with S. Paul, 
Dr. S. Lakhdar, and Prof. H. Mayr at the Ludwig-Maximilians-Universität München.  
Table 2 Mole fractions XI, XII and XIII determined by NMR conformer population analysis 
at RT in CD3CN. 
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Mayr and co-workers have elegantly demonstrated that reactions of various Michael 
acceptors with σ, n, and π nucleophiles can be described by Equation 1 (sN = nucleophile-
specific sensitivity parameter, E = electrophilicity parameter, N = nucleophilicity 
parameter).[131] Recently, it has been shown that electrophilicities of the 1st and the 2nd 
generation MacMillan catalyst-derived iminium salts fit this equation well.[53;117;132]  
 
The reaction kinetics were followed photometrically by measuring the decay of absorbance 
of the iminium salts using UV/VIS spectroscopy (374/376 nm, CH2Cl2, 20 °C). Large 
excesses of the silyl ketene acetals were employed to ensure pseudo-first-order kinetics 
[kobs (s-1)]. Furthermore, to obtain the second-order rate constants k2 (M-1s-1), kobs was 
determined for different concentrations of the nucleophile ([Nuc]). Plotting kobs versus [Nuc] 
gave a linear relationship with k2 as the slope. The second-order rate constants k2 and 
electrophilicity parameter E obtained are shown in Table 3, and were compared to the results 
of iminium salt 1a from previous studies.[117] Whereas 2a exhibited comparable reactivity to 
1a, the pentafluoro-system 10a proved to be about 9 times more reactive, thereby 
approaching the reactivity of MacMillan’s 2nd generation catalyst (Figure 39).[53]  
 
 
)()20(log 2 NEsCk N +=°
Equation 1 Correlation between the rate constant of a reaction 
and the electrophilicity/nucleophilicity of the reaction partners. 
Scheme 8 Determination of the electrophilicity of iminium salts 3 and 10. 
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2.2.6 Catalysis Screening: Organocatalytic Friedel-Crafts Reaction of N-Me-Pyrrole 
Finally, to test the performance of the electronically modified imidazolidinones in catalysis, 
the Friedel-Crafts reaction of N-methyl pyrrole (38) with (E)-cinnamaldehyde (2) was 
investigated. This reaction was selected due to the high effectiveness reported for the parent 
catalyst 1 by MacMillan et al. with enantioselectivities up to 93% ee.[112b] However, reaction 
temperatures of –30 °C led to long reaction times of 42 h. The aldehyde 2 was added in 
excess (3 eq.) and catalysts were used as TFA salts with catalyst loadings being 20 mol%. 
Enantioselectivities of the corresponding alcohols after in situ reduction with NaBH4 were 
measured using chiral HPLC. The results of the first catalyst screen at RT are given in Table 
4, left (blue) columns. When employing catalyst 4 (R = C6H4NH2) no reaction occurred. 
This is consistent with the previous failure to isolate the iminium salt of this catalyst, likely 
due to the aniline function. All other catalysts proved to be competent with reactions 
reaching full conversion within 3 h. Interestingly, a clear relation between the electron-
density of the aryl shielding group, expressed as the Qzz, and the level of enantioinduction 
was observed. The more electron-rich the aromatic group, the higher the observed 
selectivity. An exception to this observation was found in the nitro derivative 9, which may 
be explained by the different conformational behaviour observed in the NMR studies (2.2.4). 
Also catalyst 7 performed slightly better than expected.  
 
 
k2 (36)  
[M–1 s–1] 
k2 (37)  
[M–1 s–1] E 
1a 9.06 × 103 5.23 × 102 -7.2[a] 
3a 8.13 × 104 3.43 × 103 -6.0 
10a 1.49 × 104 5.78 × 102 -7.0 
 
The E parameter for 3a and 10a were determined from 
a least-squares minimisation of ∆2 =Σ(logk2– sN(E + 
N))2 which uses k2 (this table) and the nucleophile 
parameter N and sN (for 36: N = 12.56, sN = 0.70; for 
37: N = 10.61, sN = 0.86). [a] taken from [117]. 
Table 3 Second-order rate constants k2 for the reactions 
of iminium salts 1a, 3a and 10a with ketene acetals 36 
and 37 (20 °C, CH2Cl2, counterion: 3a, 10a = ClO4–, 1a 
= OTf -). 
 
Figure 39 Comparison of k2 for the reactions of the 
iminium ions 1a, 3a, and 10a with ketene acetal 36. 
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OMe
OMeMeO
3
 
 
ee [%] e.r. Qzz [D·Å] Catalyst ∆δ
1Hsyn/anti 
[ppm] ee [%] e.r. 
94 97:3 –5.68 
 
–0.62 76 88:12 
– – –5.50 
 
– – – 
88 94:6 –4.72 
 
–0.62   
90 95:5 –3.71 
 
–0.78 67 83.5:16.5 
85 92.5:7.5 –3.46 
 
–0.89 70 85:15 
87 93.5:6.5 –1.62 
 
–   
70 85:15 +0.26 
 
–0.18 43 71.5:28.5 
91 95.5:4.5 +2.46 
 
–0.74   
66 83:17 +3.01 
 
–0.13 39 69.5:30.5 
Table 4 Screening of the electronically modified catalysts in the Friedel-Crafts reaction of N-Me-pyrrole 38 to 
(E)-cinnamaldehyde 2. 
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When plotting the observed ee values (or e.r. values) against the quadrupolar moment tensor 
perpendicular to the aromatic system (Qzz) of catalysts 1, 3, 5-8, and 10, a direct linear 
relationship between the level of enantioinduction and the electron-density of the aryl group 
as function of the quadrupole moment tensor Qzz was observed. While the electron-deficient 
catalysts 8 and 10 gave moderate selectivities (65% and 70% ee, respectively), the 
phenylalanine and tyrosine derived catalysts 1 and 6 gave improved selectivities of 84% and 
90% ee, respectively. With the electron-rich trimethoxy imidazolidinone 3, it was possible to 
achieve remarkable selectivity (94% ee), reaching similar levels of enantioselectivity as 
reported for the parent catalyst 1 (93% ee), while being able to perform the reaction at room 
temperature instead of –30 °C thus reducing reaction times from 42 h to 3 h. To further 
enhance the selectivities, the reaction was repeated at –55 °C using the two electronic 
extremes 3 and 10, and the parent catalyst 1. The selectivity of 10 was improved to 83% ee, 
while both 1 and 3 gave >99% ee. 
Purification of the product 39 proved difficult because it exhibits the same retention time on 
TLC as cinnamyl alcohol (reduced 2 which was used in excess). To ease purification, a 
selection of reactions were repeated using an excess of N-methyl pyrrole (38, 3 eq.). Even 
though the plot of ee against Qzz gives the same trend (Figure 40), reactions were marginally 
less selective (Table 4, right (red) columns).  
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Figure 40 Plot of the component of the traceless quadrupole moment tensor orthogonal to the aromatic ring of the Ar-CH3 derivatives 
(Qzz) with enantiomeric excess (ee), and enantiomeric ratio (e.r.). 
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2.2.7 Computational Analysis of Lowest Energy Conformers of Iminium Ions 
To complement the experimental structural analysis of the imidazolidinone iminium salts 
used in this study, calculation of the lowest energy conformers were performed at the DFT 
level in a collaborative work with Dr. Anthony Meijer from the University of Sheffield 
(UK). For this computational analysis, the parent catalyst (1a), the two electronic extremes 
(3a, and 10a) and two additional catalysts (5a and 8a) were chosen. In Figure 41, the three 
staggered conformers and an eclipsed conformer (IV), which has previously been reported 
by Houk,[47] are illustrated. 
 
First generation MacMillan catalyst derived iminium ion 1a: 
The iminium ion derived from condensation of the 1st generation MacMillan catalyst with 
crotonaldehyde (R = Me) has previously been studied using DFT computations by Houk[47] 
and with (E)-cinnamaldehyde (R = Ph) by Tomkinson[49] and Seebach.[50b] Houk reported 
three energy minima after optimisation for the rotation of the shielding group around the C–
C-bond. The global minimum was found to be conformer I followed by conformer II 
(1.3 kJ/mol). A third minimum was found with the C–C bond to the phenyl ring almost 
eclipsing the adjacent C–H bond (conformer IV, 5.4 kJ/mol). Conformer III was not located 
as a minimum structure which was rationalised by a repulsive electrostatic interaction 
between the carbonyl group and the phenyl ring. In the calculations by Seebach as well as by 
Tomkinson the staggered conformer IV was unfortunately not considered. However, both 
groups reported very similar energetic differences between conformers I and II (5.5 kJ/mol 
and 5.0 kJ/mol, respectively) for the (E)-cinnamaldehyde derived iminium ions, which are 
considerably larger than those reported by Houk for crotonaldehyde. Interestingly, for the 2nd 
Figure 41 Possible low-energy conformers of imidazolidinone derived α,β-unsaturated iminium salts Xa.  
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generation MacMillan catalyst, Seebach et al. reported the potential-energy profile for the 
rotation around the PhCH2–CH bond. It was shown, that there is an energetic plateau 
between conformation II and the staggered conformer IV whereas conformer III was again 
not identified as an energetic minimum. Moreover, the group reported relatively low 
rotational barriers, suggesting that at ambient temperature, the benzyl group rotates almost 
freely. This phenomenon was termed the “windshield-wiper” effect.[50b] 
In this work, the iminium ion derived from the condensation with (E)-cinnamaldehyde was 
investigated by DFT studies (Figure 42, left). Consistent with the other reports, the CH-π 
conformer was found to be the global energy minimum (ΦNCCC = 52.2°). A second energy 
minimum is one in which the previously discussed staggered conformation IV is adopted 
(+4.7 kJ/mol, ΦNCCC = –134.0°). The reason that conformer II was not found to be a global 
minimum might be explained by a situation like the one described by Seebach et al. with an 
energetic plateau in which the shielding group oscillates.[50b]  
 
Tyrosine-derived imidazolidinone iminium ion 6a: 
Next, the electronically similar tyrosine-derived imidazolidinone iminium ion 6a was 
investigated (Figure 42, right). As expected, similar energy minima as for 1a were identified, 
but the energetic difference was found to be smaller (∆E = 2.7 kJ/mol). The higher 
population of the staggered conformer IV, which is believed to be connected by an energetic 
plateau with conformer II, could explain the slightly improved enantioselectivity of the 
tyrosine derived catalyst as compared to the phenylalanine derived catalyst (see 2.2.6). 
 
Figure 42 Optimised geometries and relative energies for iminium ions 1a (left) and 6a (right).  
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Figure 43 Optimised geometries and relative energies for iminium ion 3a. 
Electron-rich extreme: The trimethoxy-derivative 3a: 
The most electron-rich system of the series gave the highest levels of enantiocontrol in the 
Friedel-Crafts alkylation (94% ee). From the solution phase studies, it was suggested, that 
conformer II is significantly populated at RT (see 2.2.4). Moreover, DFT studies point 
towards a different global energy minimum as for 1a and 6a. Whereas for the previously 
discussed iminium ions 1a and 6a this is conformer I, for 3a there are two low lying 
structures, the global minima corresponds to conformer II and the staggered conformer IV 
was found at +0.08 kJ/mol (ΦNCCC = –78.2° and –132.2°, respectively), presumably 
connected by an energetic plateau. Conformer I was found to be slightly higher in energy 
(+0.5 kJ/mol). Another low-lying conformer resembling conformer II, was identified 
(+3.3 kJ/mol). From this computational analysis, it seems likely that the molecular space 
over substrate from ΦNCCC = –132.2° to +51.7° is shielded by the oscillating aryl group, 
consistent with the high levels of enantioinduction observed. This constitutes an extension of 
the “windshield-wiper' effect. 
 
 
 
Electron-deficient extreme: The pentafluoro-derivative 10a: 
For the electron-deficient extreme of the series 10a (Qzz = 3.01, Figure 44), the global 
energetic minimum was found to be conformer III (ΦNCCC = – 168.8°) which is in perfect 
agreement with the crystal structure and the other experimental findings. This constitutes, to 
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the best of our knowledge, the first theoretical description of this conformer. Moreover, the 
global minimum is the only conformer that is significantly populated. The other two 
identified minima corresponding to the π-π conformer II and a distorted conformer I in 
which a stabilising interaction between one hydrogen of the syn-methyl group with a carbon 
of the aromatic ring seems to occurs, lie much higher in energy (+7.1 kJ/mol and 
+11.8 kJ/mol, respectively). The predominant population of conformer III provides an 
explanation for the poor selectivity of the pentafluorophenyl-catalyst (65% ee). 
 
 
 
 
 
 
Trifluorophenyl-derived imidazolidinone iminium ion 8a: 
As expected, the electron-poor iminium ion 8a was computed to preferentially adopt the 
same conformation as compound 10a (conformer III, ΦNCCC = –168.3°). Also, a similar 
distorted conformer I was found to be an energy minimum (+10.7 kJ/mol). Surprisingly, 
conformer II, which was the second lowest energy minimum for iminium ion 10a, was not 
identified.  
Figure 44 Optimised geometries and relative energies for iminium ion 10a. 
Figure 45 Optimised geometries and relative energies for iminium ion 8a. 
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2.2.8 Conformational Analysis of the Transition State for the Friedel-Crafts 
Alkylation of N-Methyl Pyrrole to Iminium Ion 1a 
It was assumed, that the transition-state of the Friedel-Crafts reaction proceeding via the 
discussed intermediate iminium ion, closely resembles this reactive intermediate according 
to the Hammond-Leffler postulate.[116] To verify this hypothesis, a conformational analysis 
of the transition state for the Friedel-Crafts reaction of N-methyl indole 38 and iminium salt 
1a was performed in collaboration with Dr. Mück-Lichtenfeld (Figure 46). The CH-π 
conformer I was identified as the global minimum in agreement with the conformational 
analysis of iminium salt 1a (see page 42). Two other energy minima corresponding to 
conformers II and IV were both found to be +2.4 kcal/mol higher in energy. Thus, it is 
proposed, that the assumption that the transition state resembles the reactive intermediate is a 
good working model for the studied Friedel-Crafts reaction. 
 
  
Figure 46 Conformational analysis of the transition state for the addition of N-Me pyrrole to iminium ion 1a. 
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2.3 Additional Modifications of the Shielding Group 
In the previous chapter 2.2, electronic modifications of the shielding group of MacMillan 
type catalysts have been described. It was established that decreasing the electron-density of 
the aromatic ring by introducing electron-withdrawing groups errodes the stereocontrol 
whilst substituting with electron-donating moieties improves the stereoselectivity. The next 
questions to be addressed in this study were: Can the enantioselectivity be improved further 
by extending the aryl group? Are the postulated CH–π and π–π interactions really crucial for 
governing stereoselectivity? How will other natural amino acid-derived catalysts bearing 
heterocyclic, aromatic rings perform in the reaction? To answer the first question, two 
extended aromatic systems were envisaged (Figure 47, left). The electron-rich para-pyrrolo-
phenyl derivative 40 was postulated to show enhanced selectivity due to better shielding of 
the distant electrophilic reaction center. The highly electron-rich anthracene derivative 41 on 
the other hand, might be more effective in shielding based on simple steric arguments. To 
explore whether or not the non-covalent interactions between the aryl shielding group and 
the iminium π-system and syn-Me group are really necessary for effective catalytic 
performance, the reduced cyclohexyl-derivative 42 was also prepared (Figure 47, middle). 
To explore the performance of heteroaromatic amino acid derivatives, compounds 35, 43, 
and 44 were synthesised (Figure 47, right). Catalyst 43 has previously been reported to give 
good selectivity in the Diels-Alder reaction of trans-cinnamaldehyde 2 and 
cyclopentadiene[133] and in the addition of organoboronic acids to ortho-
hydroxycinnamaldehyde.[134] Catalyst 44 has also already been identified as a competent 
catalyst for the enantioselective Diels-Alder reaction and conjugate addition of nitroalkanes 
to trans-cinnamaldehyde.[135]  
Figure 47 Additional modifications of the shielding group. 
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2.3.1 Syntheses of Catalysts 40-43 
Imidazolidinones 40 and 41 were synthesised from (S)-Boc-BMI 23 following the procedure 
described in chapter 2.2.1. As for the other electron-rich benzyl bromide derivatives, a set of 
optimised conditions using LiHMDS and DMPU were employed (Scheme 9).  
 
The four other derivatives (35 and 42-44) were prepared from the corresponding amino acids 
(49-51) or histidine methyl ester dihydrochloride (52) in a 2-3 step procedure previously 
described in chapter 2.2.1.  
 
Scheme 10: Syntheses of imidazolidinones derived from tryptophan (35 and 43), 3-cyclohexyl-L-alanine (42),  
and histidine methyl ester dihydrochloride (44). 
 
After successful preparation of the desired catalyst structures, the syntheses of the 
corresponding iminium salts were attempted by condensation with (E)-cinnamaldehyde 2. 
Whilst it was not possible to isolate the iminium salts derived from catalyst 44 and 40, the 
other targets were successfully isolated as the perchlorate salts (35a, 41a-43a, Scheme 11).  
Scheme 9 Syntheses of imidazolidinones with extended shielding groups 40 and 41. 
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Scheme 11 Syntheses of iminium salts 35a and 41a-43a. 
 
2.3.2 The Quadrupolar Moment (Qzz) of the Toluene Analogues of the Shielding 
Groups 
The quadrupolar moment is described in detail in chapter 2.2.2. As for the electronically 
modified catalysts, the quadrupolar moments and ESP maps for the toluene analogues of the 
extended aromatic systems, the heteroaromatic groups and methyl-CH were computed.  
 
Whereas the anthracene derivative 41 has an even lower Qzz than the most electron-rich 
example of the study thus far (trimethoxy analogue 3, Qzz = –5.68), the Qzz of the two indole 
derivatives are of similar magnitude (35 and 43, Qzz = –5.40 and –6.12, respectively). The 
quadrupolar moment tensors perpendicular to the aromatic plane of the toluene analogues of 
40 and 44 (Qzz = –3.21 and –4.29, respectively) are in the same range as the ones for 
derivative 6 and 1 (Qzz = –3.71 and –3.46, respectively). The Qzz of the cyclohexyl derivative 
was also calculated, even though it is not directly comparable to the other compounds, and 
was found to be slightly positive (Qzz = 0.54). 
 
Figure 48 Quadrupolar moment tensor components perpendicular to the aromatic plane in D·Å (Qzz) 
and electron surface potential (ESP) of the toluene derivatives of imidazolidinones 35, and 40-44. 
Colour range of the electrostatic potential: −0.06 (red) to + 0.06 (blue). 
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2.3.3 X-Ray Crystallographic Analysis of Imidazolidinone Salts 42-44 and Iminium 
Salt 43a 
 
Gratifyingly, single crystals suitable for X-ray crystallographic analysis of the cyclohexyl 
and the histidine derived catalyst were obtained as the hydrochloride salts (Figure 49). 
Catalyst 44 crystallised as the dihydrochloride salt. For catalyst 43 it was possible to obtain 
crystals of the perchlorate salts. Analogous to previous observations in the crystal structures 
of the electronically modified catalyst series (chapter 2.2.3), the shielding groups reside in a 
quasi-equatorial orientation. Moreover, the shielding group is in proximity of the protonated 
amine [ΦNCCC = –69.7° (42), –67.7° (44), and –67.2 (43)]; this torsional preference was also 
found in structures 1, 8, 9, and 10. 
A racemic sample of the indole-derived iminium salt 43a was successfully crystallised as the 
hexafluorophosphate salt. Interestingly, the compound adopts a tilted form of conformer II, 
which is postulated to be stabilised by a π-π interaction (Figure 50, ΦNCCC = –74.1°). In 
chapter 2.2.3, iminium salts adopting conformer I (6a, R = C6H4OH) and, for the first time, 
Figure 49 X-ray structures of the hydrochloride salts of catalysts 42 and 44, and of the perchlorate salt of 43. The ClO4- 
counterion has been omitted for clarity. 
Figure 50 X-ray structure of iminium hexafluorophosphate salt 43. The PF6- 
counterion has been omitted for clarity. 
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conformer III (10a, R = C6F5) have already been discussed. Thus, a crystal structure for each 
three staggered conformers partitioned by 120° is presented in this work. 
 
2.3.4 NMR Analysis of the Iminium Salts 35a, 41a, 42a, and 43a 
The solution phase NMR spectroscopic analysis of the library of electronically modified 
phenyl analogues indicates that the shift-difference of the two methyl groups of the geminal-
dimethyl moiety (chapter 2.2.4, ∆δ1Hsyn/anti and ∆δ13Csyn/anti) already gives good insights into 
the preferred conformational behaviour of the iminium salts. Furthermore, in the cases for 
which a significant ∆δ1Hsyn/anti was observed, the enantioselectivity of the corresponding 
catalyst in the studied Friedel-Crafts reaction was generally good. To probe whether or not 
this observation could be generalised as an easy method for predicting the level of 
stereoinduction for a given catalyst, the ∆δ1Hsyn/anti and ∆δ13Csyn/anti values for the iminium 
salts 35a and 41a-43a were determined (Table 5 and Figure 51). The indole derivatives 35a 
and 43a exhibit a similar magnitude of shift-differences as the trimethoxy catalyst 3a 
(∆δ1Hsyn/anti = –0.58, –0.64, and –0.62 ppm, respectively). This is in agreement with the 
quadrupolar moment tensors, which were found to be in the same range (Qzz = –5.40, –6.12, 
and –5.68, respectively). The iminium salt of 35 was also included in the conformer 
population analysis described in chapter 2.2.4 and was found to show similar conformational 
behaviour as the iminium salt derived from 3. Therefore analogues 35 and 43 were predicted 
to give similar enantioselectivities as compound 3. This hypothesis will be tested in 
chapter 2.3.5. The anthracene iminium salt 41a, which was computed to have the highest 
electron-density over the aromatic ring (Qzz = –7.62) of all studied structures, revealed a 
surprisingly small shift-difference of the dimethyl group (∆δ1Hsyn/anti = –0.26 ppm). This 
suggests that the anthracene moiety is likely positioned away from the geminal-dimethyl 
group probably due to unfavourable non-bonding interactions. This could possibly indicate a 
critical size effect of the shielding group on the selectivity of the reaction. Again, this will be 
investigated in the next chapter. The cyclohexyl bearing compound 42a also exhibits a small 
shift-difference, which is consistent with the positive Qzz. Consequently, the cyclohexyl 
analogue is expected to give low levels of enantioinduction. 
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Table 5 Chemical shift-differences of the geminal-dimethyl group observed by 1H and 13C NMR spectroscopy. 
Iminium Salt (Ar) Qzz [D·Å] 
∆δ(syn/anti)1H 
[ppm] 
∆δ(syn/anti)13C 
[ppm] 
41a (anthracene) –7.62 –0.26 +0.10 
42a (C6H11) +0.54 –0.03 +0.85 
35a (Me-Indole) –5.40 –0.58 –1.68 
43a (Indole) –6.12 –0.64 –1.83 
 
 
 
 
 
Figure 51 Upper: The three staggered conformers of the imidazolidinone derived iminium salts. The CH-π interaction in 
conformer I results in an upfield shift of the syn-methyl group in the 1H and 13C NMR spectra. Lower: 1H-NMR spectra. 
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2.3.5 Catalysis Screening: Organocatalytic Friedel-Crafts Reaction of N-Me-Pyrrole  
The performance of MacMillan catalyst analogues 35 and 40-44 were tested in the Friedel-
Crafts reaction of N-methyl pyrrole 38 to (E)-cinnamaldehyde 2 (excess, 3 eq.). The 
enantioselectivities observed (determined using chiral HPLC after in situ reduction to the 
corresponding alcohols) were generally in very good agreement with the predictions made 
from the NMR analysis. The two catalysts 41 and 42 for which the corresponding iminium 
salts showed very small chemical shift-differences for the geminal-dimethyl group 
(∆δ1Hsyn/anti = –0.26 and –0.03 ppm, respectively) resulted in lower enantioselectivities in the 
studied reaction (ee = 55% and 38%, respectively) as expected. Steric congestion in the 
iminium salt is believed to account for the low enantioselectivity using the anthracene 
system. Conversely, in the para position extended phenyl-pyrrolo system 40 gave an 
acceptable enantiomeric excess of 87%. This is consistent with what would be expected 
from the Qzz (–4.29), suggesting that extension of the aryl group into this direction is 
tolerated, but not beneficial in this reaction. The two indole derivatives 35 and 43 which 
displayed Qzz values and chemical shift-differences in the same range as the trimethoxy-
derivative 3, showed enantioselectivities that are lower than expected (80% and 83%, 
respectively). Again, this might be a consequence of increased steric congestion. It is also 
important to note that for these derivatives the position of the quadrupolar moment tensor 
perpendicular to the aromatic ring is positioned differently due to the larger aromatic system 
and, thus direct comparison is not always valid. The histidine derived catalyst 44 showed the 
lowest level of enantioselectivity of all the catalysts tested so far (ee = 36%). This might at 
first be surprising considering the Qzz of –3.21. But it must be kept in mind, that the 
imidazole moiety will be protonated under the reaction conditions which will inverse the 
polarity of the heterocycle.[136] Thus, the imidazole group will likely rotate away from the 
iminium chain, resembling conformer III. 
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Catalyst Qzz [D·Å] ∆δ
1Hsyn/anti 
[ppm] ee [%] e.r. 
 
–4.29 – 87 93.5:6.5 
 
–7.62 –0.26 55 77.5:22.5 
 
0.54 –0.03 38 69:31 
 
–6.12 –0.58 83 91.5:8.5 
 
–5.40 –0.64 80 90:10 
 
–3.21 – 36 68:32 
 
 
 
Table 6 Screening of the catalysts with modified shielding groups in the Friedel-Crafts reaction of N-Me-
pyrrole 38 and (E)-cinnamaldehyde 2. 
HN
N
44
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2.3.6 Computational Analysis of Lowest Energy Conformers of Iminium Ions 35a, 
41a, and 42a 
To support the working hypothesis that the conformational preferences of the anthracene and 
indole derivatives are governed by steric repulsion, the ground-state energy minimum 
conformations of the iminium salts of 41a and 35a were computationally predicted. 
Additionally, the conformational behaviour of the CH analogue derived iminium ion 42a 
was investigated. The calculations at the DFT level of theory were performed by Dr. 
Anthony Meijer at Sheffield University (UK). 
 
Anthracene-derived imidazolidinone iminium ion 41a: 
 
For the iminium ion derived from the anthracene catalyst 41a, only one conformer was 
found to be significantly populated at RT (Figure 52). This conformer corresponds to 
conformer II stabilized by a π–π interaction (ΦNCCC = –77.2°). The anthracene moiety is 
significantly twisted out of plane presumably allowing for an edge-on interaction to the 
positively charged conjugated iminium chain (Figure 52, right). Consequently, shielding of 
the top face is insufficient. The other two identified minima corresponding to conformer I 
and III lie much higher in energy (+13.2 and +18.2 kJ/mol, respectively). 
 
 
Figure 52 Optimised geometries and relative energies for iminium ion 41a. 
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Tryptophan-derived imidazolidinone iminium ion 35a: 
 
Computational analysis of the Me-indole iminium ion 35a resulted in the identification of 
four energy minimum conformations. In the global minimum conformer the aromatic 
substituent was found to be positioned away from the reactive centre (ΦNCCC = –149.0°, 
between conformers III and IV). Two conformations resembling conformer I were 
identified at +2.5 kJ/mol and +5.9 kJ/mol. In both cases the stabilising CH-π interaction with 
the syn-methyl group was found to be directed to the centre of the five-membered ring of the 
indole moiety, but the heteroaromatic system was found to be flipped by 180° in the 
energetically higher lying conformer I as compared to the other one at +2.5 kJ/mol. A fourth 
low lying conformer resembling conformer II was found at +4.2 kJ/mol (ΦNCCC = –71.7°). 
The smaller energetic differences between the conformers explains the higher selectivity 
(∆ee = 25%) of 35a as compared to 41a. Surprisingly, the obtained X-ray structure of the 
other indole iminium salt 43a corresponds to the π-π conformer at +4.2 kJ/mol, suggesting 
that either 43a exhibits a different conformational behaviour than the methylated-analogue 
35a or that packing effects govern the solid state conformation.  
 
Figure 53 Optimised geometries and relative energies for iminium ion 35a. 
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Cyclohexyl-derived imidazolidinone iminium ion 42a: 
For the saturated-cyclohexyl derivative 42a, four energy minima were identified (Figure 54). 
By far the lowest lying conformation corresponds to conformer III (ΦNCCC = –168.0°), 
where the substituent is rotated away from the core ring, thus providing insufficient 
shielding. This is in agreement with the low enantioselectivity obtained with this catalyst 
(ee = 38%). In two additional energy minima identified, the group is also rotated away 
resembling conformer III (+7.1 kJ/mol and +10.5 kJ/mol). A structure resembling 
conformer I was found at 12.0 kJ/mol. 
 
Figure 54 Optimised geometries and relative energies for iminium ion 42a. 
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2.4 Modifications of the Benzylic Position 
In the last two chapters 2.2 and 2.2.8, it was discussed how modifications of the aromatic 
shielding group influence the behaviour of the MacMillan catalyst and by extension the 
corresponding α,β-unsaturated iminium salt. In this chapter, a molecular editing study is 
described to investigate the benzylic site in α-position to the shielding group. The 
development of so-called "conformer equivalents" by the stereoselective introduction of 
fluorine in the benzylic position has been previously reported by this laboratory.[4] The 
iminium salts of the two diastereomers are postulated to be fixed in conformation I (57a, S) 
or in conformation II (58a, R), due to an interplay of a stabilising fluorine-iminium ion 
gauche effect and a CH–π or π–π interaction, respectively (Figure 55). Herein, the two 
diastereomers 57 and 58 are studied further, and a computational conformation analysis is 
enclosed.  
 
Furthermore, the ramifications of increasing the distance between the central 
imidazolidinone core and the aryl shielding group by introducing a CH2-moiety (59) were 
studied. It was expected, that the phenyl group would no longer be able to undergo a CH–π 
interaction with the syn-methyl group. Likewise, it was predicted, that the increased 
flexibility would disfavour the population of conformer II due to increased rotational 
freedom. Additionally, it was planned to gradually increase the steric bulk by varying the 
number of shielding phenyl groups from zero (60) via monophenyl 1 and diphenyl 61 all the 
way to the trityl group (62). The modulations of the benzylic position discussed in this 
chapter are summarised in Figure 56. 
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Figure 55 Conformer equivalents 57a and 58a and mode of conformational control.[4] 
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2.4.1 Syntheses of the MacMillan Analogues Modified in the Benzylic Position 
"Conformer Equivalents" 57 and 58: 
The syntheses of the two diastereomers 57 and 58 bearing a configurationally defined 
fluorine in the benzylic position were carried out by Patrick Bentler in course of his Master 
thesis following the procedures developed by this laboratory.[4] Therefore, the synthesis will 
not be discussed in detail, but the key features are summarised below. Both catalysts can be 
constructed from a common precursor, L-threo-phenylserine 63 (Scheme 12).  
 
The key challenge in these protocols is the stereoselective deoxyfluorination of the benzylic 
position. To achieve this transformation a method described by Bach was modified and 
utilised.[137] The Bach model describes that facial selectivity of nucleophilic attack to chiral 
benzylic cations can be achieved by exploiting A1,3-strain (Figure 57). The hydrogen 
substituent is positioned in plane with the aromatic ring to minimize A1,3-strain. The 
nucleophile then attacks from the less hindered face in which the smaller substituent is 
placed. It should be noted, that because deoxyfluorinations in benzylic positions using 
DAST likely proceed via a SN1 mechanism, this method is believed to be valid for the 
Me
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Figure 56 Modulations of the MacMillan catalyst in the benzylic position. 
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Scheme 12 Retrosynthetic analysis of 57 and 58. 
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described fluorination. The facial selectivity of the reaction can be controlled by adjusting 
the size of the amino and the carboxy function. The optimised structures were found to be L-
phenylserine methyl amide 64 and compound 65 for the preparation of the (R,R)-
diastereomer 66 and the (S,R)-diastereomer 67, respectively. A possible rationalisation of the 
selectivity for these two structures is illustrated in Figure 57. 
 
 
 
 
 
Analogue with increased distance of the shielding group 59: 
Compound 59 was obtained from (S)-Boc-BMI 23 and (2-bromoethyl)benzene in a three 
step procedure in 26% overall yield (Scheme 13) following the procedure described in 2.2.1.  
 
Synthesis of catalyst series with varied numbers of shielding groups: 
The synthesis of the 1st generation MacMillan catalyst 1 is described in 2.2.1. The methyl-
analogue 60 without an aryl shielding group was obtained from L-alanine ethyl ester 
hydrochloride 68 in a two step procedure in very good yield (Scheme 14).  
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Scheme 13 Synthesis of the MacMillan imidazolidinone analogue 59. 
Scheme 14 Synthesis of the alanine derived catalyst 60. 
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Figure 57 The Bach model and application for the fluorination of L-threo-
phenylserine derivatives 66 and 67. 
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Similarly, the diphenyl catalyst 61 was synthesised from the corresponding commercially 
available amino acid (Scheme 15). Formation of the methyl amide 71 proceeded in good 
yield (87% over 2 steps). The product imidazolidinone 61 was isolated in only moderate 
yield (52%). 
 
The synthesis of the trityl-derivative 62 was initially attempted via alkylation of Boc-BMI 23 
using the Seebach procedure (see chapter 2.2.1). However, despite trying numerous reaction 
conditions, formation of the product was never observed (Scheme 16).  
 
 
 
 
 
Subsequently, a strategy was envisaged that has been reported for the synthesis of 2-
tritylpyrrolidine (72, Scheme 17). The key step of this transformation is the nucleophilic 
attack of lithium triarylmethide (prepared in situ) to nitrone 73.  
 
 
 
By employing the nitrone of BMI (74) it was envisaged that the trans product might be 
formed selectively. This proposal was supported by a report by Long et al. who used the 
chiral 74 in highly stereoselective cycloaddition reactions.[138] However, unfortunately this 
strategy proved unsuccessful for the synthesis of compound 62 (Scheme 18).  
Scheme 15 Synthesis of the diphenyl-derivative 61. 
Scheme 16 Attempted synthesis of 62. 
Scheme 17 Synthesis of triarylpyrrolidine 72. 
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A third attempt following a procedure by Klumpp et al. was investigated, using 
aminoalcohol 75, benzene and CF3SO3H (Scheme 19). Compound 75 was prepared from 
commercially available methyl-(S)-3-Boc-2,2-dimethyl-4-oxazolidinecarboxylate (76) by 
Grignard addition of PhMgBr in 88% yield. The product was then treated with CF3SO3H in 
benzene at RT. The desired compound could not be isolated, but instead a mixture of 
products was formed. Finally, deprotection of the amine prior to the build-up of the trityl 
moiety was explored, but the protocols tested led to formation of the open-chain compound 
77. The preparation of 62 was not further investigated.  
 
Syntheses of the iminium salts:  
With the catalyst structures 57-61 in hand, the corresponding iminium salts 57a-61a were 
prepared by formation of the perchlorate salts and subsequent condensation with trans-
cinnamaldehyde 2 (Scheme 20). Despite repeated attempts, the iminium salt of 59 could not 
be isolated. 
 
Scheme 18 Attempted synthesis of 62 via nitrone 74. 
Scheme 19 Attempted synthesis of 62 by reaction of aminoalcohol 75 with benzene and CF3SO3H. 
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2.4.2 X-Ray Crystallographic Analysis of Imidazolidinone and Iminium Salts 
The crystal structures of the hydrochloride salt of 58 and of the hexafluorophosphate salt of 
57 (Figure 58) have been reported previously.[4] Both compounds were crystallised from the 
racemic mixture. For 57 the other enantiomer is shown (R,S). As expected, in both 
imidazolidinone salts, the fluorine is positioned gauche to the protonated amine. For 58 the 
fluorine is in synclinal-exo arrangement (ΦNCCF = 53.4°), whilst for 57 the fluorine is 
synclinal-endo (ΦNCCF = –73.0°). Thus, in both structures the benzyl is rotated away from the 
core ring. In 58 the amine is pyramidalised to a similar extend as was observed for the 
previously discussed imidazolidinone salts placing the benzyl in quasi-equatorial position 
(chapter 2.2.3 and 2.3.3). However, in 57 the nitrogen is almost flat in plane. 
 
 
 
 
 
 
Additionally, single crystals suitable for X-ray crystallographic analysis of the methyl 
analogue 60 were isolated (Figure 58). The nitrogen is pyramidalised such that the methyl is 
in a quasi-equatorial position. 
Scheme 20 Syntheses of iminium perchlorate salts 57a, 58a, 60a, and 61a. 
Figure 58 X-ray structures of 58·HCl, 57·HPF6 and 60·HCl. For 57 and 58 the counterions have been 
omitted for clarity. 
64 2 Molecular Editing of the MacMillan Catalyst 
Gilmour and Sparr also reported the crystal structure of the iminium salt derived from 
imidazolidinone 58 and (E)-cinnamaldehyde 2. The crystal structure beautifully 
demonstrates that the stereoselective introduction of fluorine in the benzylic position to give 
the R,R diastereomer forces the shielding group into conformer II (as opposed to conformer 
I for the parent structure described in 2.2.3). The fluorine substituent is positioned synclinal-
endo to the nitrogen of the iminium moiety (ΦNCCF = 64.6°).  
 
2.4.3 NMR Analysis of the Iminium Salts 57a-61a 
In chapter 2.3.4 it was shown that the NMR shift-differences observed for the two geminal-
methyl groups in the imidazolidinone derived iminium salts already give a qualitative 
evaluation of the efficiency of the corresponding catalyst in the organocatalytic addition of 
N-methyl pyrrole to (E)-cinnamaldehyde. The upfield-shift of the syn-methyl group was 
attributed to a CH-π interaction with the aryl shielding group that occurs in conformer I. To 
test whether this prediction only holds true for the series of catalysts with modified aryl 
shielding groups, the ∆δ1Hsyn/anti and ∆δ13Csyn/anti of iminium salts 20a-24a were determined 
(Table 7). As expected, the conformer equivalent fixed in the CH-π position (57a) shows the 
largest differences in shifts of all the studied iminium salts. This is not surprising, because 
this compound is believed to almost solely populate conformer I. Similarly, the other 
conformer equivalent, which is believed to predominantly populate conformer II, shows 
very small shift-differences of the two methyl groups. (∆δ1Hsyn/anti = –0.06 ppm). Also 
anticipated was the small ∆δ1Hsyn/anti observed for the methyl derived iminium salt 60a. The 
negligible shift-difference of the methyl analogue also serves as a proof for the shift 
occurring due to an interaction with the shielding group. The diphenyl analogue 61a gave 
surprisingly low shift-differences (∆δ1Hsyn/anti = –0.57 ppm) suggesting that the shielding of 
this moiety might not be as good as for a single phenyl group. This seemed surprising, but 
might be explained by the fact that the phenyl groups are probably forced to rotate out of 
Figure 59 X-ray structure of the hexafluoroantimonat salt of 58a. The SbF6- counterion is omitted for clarity. 
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plane and are therefore unable to undergo nonbonding CH-π or π-π interactions. Thus, it is 
proposed from the NMR analysis, that the diphenyl catalyst 61 gives decreased levels of 
enantioselectivity as compared to the parent catalyst 1. This is tested in the following 
chapter.
 
Table 7 Differences of the chemical shifts of the geminal-dimethyl group observed by 1H and 
13C NMR spectroscopy. [a] SbF6- salt.[4] 
Iminium Salt (R) ∆δ(syn/anti)
1H 
[ppm] 
∆δ(syn/anti)13C 
[ppm] 
1a (CH2C6H5) –0.89 –2.77 
57a (S-CHFC6H5)[a] –1.08 –3.60 
58a (R-CHFC6H5)[a] –0.06 +0.60 
60a (CH3) +0.03 +1.40 
61a (CH(C6H5)2) –0.57 
 
 
2.4.4 Catalysis Screening: Organocatalytic Friedel-Crafts Reaction of N-Me-Pyrrole 
To test the organocatalytic performance of the imidazolidinones modified in the benzylic 
position in a model reaction, and compare the results to predictions made from the NMR 
analysis, 57-61 were employed in the Friedel-Crafts reaction of N-methyl pyrrole 38 and 
(E)-cinnamaldehyde 2 (Table 8). All catalysts proved to be competent and completion of the 
reaction was observed within three hours at RT. The CH-π conformer equivalent 57 resulted 
in slightly improved enantioselectivity compared to the parent catalyst 1 (90% and 85% ee, 
respectively). The π-π conformer equivalent 57 on the other hand showed significantly 
decreased levels of enantioinduction (63% ee). This is consistent with the small ∆δ1Hsyn/anti 
observed for 57. Despite this agreement, the low stereoselectivity is surprising given that this 
iminium salt is predicted to predominantly populate conformer II, and in this conformer 
shielding should be effective. This finding requires clarification. Employment of the 
imidazolidinone with increased distance between the shielding group and the reaction centre 
59 resulted in very low levels of enantioinduction (38% ee). This may suggest as predicted, 
that the aryl shielding group of this catalyst is not ideally positioned to undergo non-covalent 
interactions with the syn-methyl group and the iminium chain. As expected, the Me-
analogue 60 gave the lowest levels of enantioinduction of all the structures studied so far 
(27% ee). The enantioselectivity obtained for the diphenyl-catalyst 61 was also low (51% ee) 
consistent with the small ∆δ1Hsyn/anti observed. 
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Catalyst ∆δ(syn/anti)
1H 
[ppm] ee [%] e.r. 
 
–0.89 85 92.5:7.5 
 
–1.08[a] 90 95:5 
 
–0.06[a] 63 81.5:18.5 
 
– 38 69:31 
 
+0.03 27 63.5:36.5 
 
–0.57 51 75.5:24.5 
 
 
 
Table 8 Screening of the modified catalysts in the Friedel-Crafts reaction of N-
Me-pyrrole 38 to (E)-cinnamaldehyde 2. [a] SbF6- salts.[4] 
N
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N
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2
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2.4.5 Computational Analysis of Lowest Energy Conformers of Iminium Ions 57a, 
58a, 61a, and 60a 
To gain a more detailed insight into the conformational behaviour of the two conformer 
equivalents 57a and 58a, and of the iminium ion derived from the diphenyl-imidazolidinone 
61, a computational analysis of the lowest energy conformers was performed in 
collaboration with Dr. Anthony Meijer from the University of Sheffield (UK). Additionally, 
the methyl-analogue 60a was investigated for completeness. 
CH-π conformer equivalent 57a: 
 For the iminium ion 57a predicted to be “fixed” in conformer I, three energy minima were 
identified (Figure 61). As expected, the global minimum structure was found to be the CH-π 
conformer with the fluorine positioned synclinal exo to the nitrogen, thus satisfying the 
fluorine-iminium ion gauche preference (ΦNCCF = –79°). The second minimum identified is 
8.8 kJ/mol higher in energy. In this conformer, the positions of the aryl shielding group and 
the fluorine are practically preserved, but the geometry of the N+=C iminium bond is 
changed to the (Z)-isomer. Even higher in energy (+13.3 kJ/mol) is a third conformer in 
which the other gauche-conformation is engaged. Consequently, it can be concluded, that 
almost solely the anticipated conformer I is populated at RT. 
Figure 61 Optimised geometries and relative energies for iminium ion 57a. 
Figure 60 Possible low-energy conformers of imidazolidinone derived iminium salts Xa.  
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π-π conformer equivalent 58a: 
The compound that was designed as the conformer II equivalent was also identified to have 
three energy minima (Figure 62). Again, the global energetic minimum verifies the predicted 
conformation. The fluorine nitrogen relationship is synclinal endo. This is consistent with 
the crystal structure described in chapter 2.4.2, though the calculated conformation is slightly 
distorted as compared to the X-ray structure (ΦNCCF = 48.8° and 64.6°, respectively). A 
second energy minimum was found to be conformer IV in which the bond to the shielding 
aryl group eclipses with the neighbouring C–H bond and the C–F bond eclipses with C–N+ 
bond. In this conformation, which is only 1.3 kJ/mol higher in energy than the global 
minimum, the reaction centre is not very well shielded. These findings partially rationalise 
the reduced selectivity observed (63% ee). Much higher in energy at +18.8 kJ/mol is a 
conformation in which the fluorine is positioned anti to the iminium nitrogen, highlighting 
the power of the fluorine-iminium ion gauche effect. 
  
Iminium ion derived from the diphenyl imidazolidinone (61a): 
For the diphenyl analogue 61a, three energy minimum conformations were identified 
(Figure 63). However, only one conformer was found to be significantly populated at RT. In 
this conformer, both phenyl groups are positioned far away from the reaction centre 
approximately populating conformer III (Figure 56), thus almost eclipsing the neighbouring 
C–H and C–C bonds (ΦNCCC = 82.3° and –145.9°). The conformer is shown with the view 
along the CC–CN benzylic bond in Figure 63 for clarification. The other two energy minima 
identified, in which the shielding groups are placed in the space corresponding to conformer 
Figure 62 Optimised geometries and relative energies for iminium ion 58a. 
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II/III and conformer I/II lie much higher in energy (+16.2 and +22.3 kJ/mol, respectively). 
These findings correspond well to the small shift-differences (∆δ1Hsyn/anti = –0.57 ppm) 
observed for the two geminal-methyl groups by NMR analysis and the low levels of 
stereocontrol (51% ee) in the Friedel-Crafts addition of N-methyl pyrrole 38 to  
(E)-cinnamaldehyde 2. 
 
Figure 63 Optimised geometries and relative energies for iminium ion 61a. 
 
Iminium ion derived from the alanine-derived imidazolidinone (60a): 
For the α,β-unsaturated iminium ion 60a of the alanine derived imidazolidinone, only one 
energy minimum was identified with the iminium chain in the (E)-conformation (Figure 64). 
Figure 64 Optimised geometry of the global 
energy minimum for iminium ion 60a. 
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2.5 Correlation between Conformational Preferences, Enantioselectivity 
and 1H NMR-Shift of the syn-Methyl-Group 
In chapters 2.2–1.1, a clear correlation between the shift-differences of the syn- and the anti-
methyl groups of the geminal-dimethyl moiety (∆δ1Hsyn/anti) in the iminium salts and the 
observed enantioselectivity in the addition of N-methyl pyrrole 38 and (E)-cinnamaldehyde 
2, was observed. The coherence was so general, that in several cases the enantioselectivity 
achieved with a given catalyst was well predicted based on the ∆δ1Hsyn/anti of the 
corresponding iminium salt. This observation was not overly surprising, as both the 
∆δ1Hsyn/anti and the level of enantioinduction are direct consequences of the conformational 
behaviour of the iminium ion (Figure 65). To test the generality of this correlation, the 
∆δ1Hsyn/anti deduced from the NMR spectra of the α,β-unsaturated iminium ions were plotted 
against the enantioselectivity of the corresponding organocatalysts in the Friedel-Crafts 
reactions of N-methyl pyrrole 38 and (E)-cinnamaldehyde 2 (Figure 66). The diphenyl-
derivative 61 was omitted from this analysis, since the influence of the diphenyl-moiety on 
the syn-methyl NMR-shift is not comparable to the other compounds. 
 
In
flu
e
n
ce
s Influences
Figure 65 Correlation between conformational behaviour of the iminium ion, the observed ∆δ1Hsyn/anti and the 
enantioselectivity of the corresponding catalyst in the addition of N-methyl pyrrole 38 to (E)-cinnamaldehyde 2. 
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Figure 66 Plot of the observed ∆δ1Hsyn/anti of the MacMillan catalyst-derived iminium salts against the observed 
enantioselectivity of the corresponding catalyst in the Friedel-Crafts addition of N-methyl pyrrole 38 to  
(E)-cinnamaldehyde 2. The coloured regions group iminium salts according to their conformational behaviour. 
 
The plot shows a clear correlation between ∆δ1Hsyn/anti and the obtained selectivities, which 
is conveniently represented by a polynomial fit. Furthermore, the different regions of the 
graph can be attributed to distinct conformational preferences: The red region includes the 
catalysts giving poor enantioselectivities, with iminium salts displaying small differences in 
the chemical shifts of the geminal-dimethyl groups, and corresponds to the iminium salts 
predominantly populating conformer III and/or a distorted conformer II. The green region 
represents the iminium salts that are postulated to populate conformer I and conformer II 
with a slight preference for conformer II. The blue region includes the iminium ions with a 
similar conformational behaviour, but with a slight preference for conformer I. The 
‘conformer equivalent’ fixed in conformer I resulted in the largest ∆δ1Hsyn/anti (–1.08 ppm) 
and lies in the yellow region of the plot. This clearly illustrates, that the 1H NMR spectra of 
these imidazolidinone-derived iminium ions give reliably predictions for the catalytic 
performance of the corresponding imidazolidinone-catalysts. Furthermore, it is believed, that 
this holds true for structural analogues and, thus, may prove useful for future catalyst design. 
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2.6 Modification of the geminal-Dimethyl group 
Having investigated the consequences of altering the shielding group and the benzylic 
position in chapters 2.2–2.5, it was envisaged that a study of the effects of changing the 
geminal-dimethyl group of the MacMillan catalyst would be insightful. Therefore, as a first 
stage, the analogue with the dimethyl group removed (78) and a series with differently sized 
spiro rings 79-81 were planned (Figure 67).  
 
It was expected that in the iminium salt of imidazolidinone 78 not only the conformational 
behaviour of the phenyl ring will be altered, but also that the (E)/(Z)–selectivity (for the 
conformational diversity of the iminium ions see Figure 68). Since conformer I is 
presumably no longer stabilised by a CH-π interaction, the phenyl group will likely be 
positioned in conformers II and IV in iminium salt 78a. Additionally, the (E)/(Z)-ratio, 
which is believed to be controlled by A1,3-allylic strain, could be profoundly influenced. For 
the geometrically controlled spiro-compounds, decreased abilities to undergo stabilising  
CH-π interactions with the aryl shielding group were expected, and it was predicted that this 
effect will be the more pronounced, the smaller the spiro ring. Oxetane was chosen as 
smallest spiro system. The properties and synthesis of this moiety has been extensively 
studied by Carreira and co-workers[139] and found valuable applications, especially in drug 
design. Carreira et al. reported, that the oxetanyl group occupies essentially the same van der 
Waals volume as a geminal-dimethyl group,[139a] thus, it is proposed, that substitution of the 
geminal-dimethyl group by oxetane should have negligible effects on the (E)/(Z)-ratio. But 
the geometry of the CH2 group will be drastically changed as compared to the CH3-groups. 
The geminal-dimethyl moiety was found to be in perfect tetrahedral arrangement with the 
angle between the two methyl groups being 111.5° and 112.3° for the iminium salt 1a and 
the hydrochloride salt of imidazolidinone 1, respectively. However, the C–C–C bond angle 
for 3,3-disubstituted oxetanes was reported to be 84.1±0.7°.[139d] Furthermore, the oxetane 
Figure 67 Modification of the geminal-dimethyl group. 
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was found to be essentially planar, unlike the structurally similar cyclobutane. The planarity 
renders the oxetanyl group particularly interesting for this study, because the hydrogen 
substituents that could undergo a stabilising CH-π interaction with the aryl shielding group 
are virtually fixed in the molecular space. The neighbouring oxygen further activates the 
hydrogen substituents towards a CH-π interaction, thus, inability to undergo this interaction 
can likely be solely attributed to geometric control. In extension to this study, the 
cyclopentane 80 and CH 81 spiro compounds were studied. These compounds have 
previously been tested on their efficiency as organocatalysts in the enantioselective Michael 
addition of aldehydes to enones by Gellman et al.[140] While the cyclopentane catalyst 80 
gave good levels of enantioselectivity (up to 92% ee), the employment of catalyst 81 lead to 
racemic products. It was envisaged to study how these compounds would behave in a 
reaction proceeding via an iminium ion instead of an enamine. 
Figure 68 Conformational diversity of the iminium salts derived from the imidazolidinones with substitution of the 
geminal-dimethyl group. 
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2.6.1 Syntheses of the MacMillan Catalyst Analogues 78 to 81 
The four compounds 78-81 were synthesised in one step by ring closure of L-phenylalanine 
methyl amide 15 with the corresponding ketone (Scheme 21). Oxetan-3-on for the synthesis 
of 79 was generously provided by Prof. Carreira (ETH Zurich). Compounds 79-81 were 
prepared using the same procedure used for the preparation of the geminal-dimethyl 
compound (chapter 2.2.1, Scheme 21 right). For the preparation of 78, a procedure reported 
by Poloński was applied (Scheme 21 left).[141] 
 
 
 
 
The syntheses of the corresponding iminium salts proved to be difficult. It was not possible 
to form the iminium salts of 78 and 79, while the iminium salt of 81 could not be isolated 
from a mixture of 81a·PF6-, 81, and (E)-cinnamaldehyde 2 (1:1.4:0.06). Only iminium salt 
80a was isolated cleanly as the hexafluorophosphate salt (Scheme 22). 
 
 
 
 
2.6.2 X-Ray Crystallographic Analysis of Imidazolidinone Hydrochloride Salts 80 
and 81 and Iminium Salt 80a 
It was possible to obtain single crystals suitable for X-ray crystallographic analysis of the 
hydrochloride salts of 80 and 81 (Figure 69). In both salts the nitrogen is pyramidalised such 
that the benzyl group is placed in quasi-equatorial position consistent with the previously 
identified crystal structures (see chapters 2.2.3, 2.3.3, and 2.4.2). In both structures the 
phenyl ring is positioned anti to the amine function [ΦNCCC = –165.6°(80) and –170.2°(81)], 
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Scheme 21 Syntheses of imidazolidinones 78-81. 
Scheme 22 Synthesis of α,β-unsaturated iminium salt 80a. 
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a conformation that was so far only found in the crystal structure of the trimethoxy 
imidazolidinone salt 3 (chapter 2.2.3). The C–C–C bond angles around the spirocentre are 
perfectly tetrahedral [(106.8°(80) and 112.2° (81)]. For the CH-derivative 81, one hydrogen 
substituent in the α-position to the spirocentre is oriented such that it could undergo a 
stabilising CH-π interaction with the aryl shielding group in the iminium salt. This 
interaction might be geometrically difficult in 80a. 
 
Nevertheless, in the crystal structure (Figure 70) of the hexafluorophosphate salt of 80a 
reported by Mayr et al.,[53] it can be clearly seen that in the solid state the compound does 
adopt conformer I (ΦNCCC = +51.9°), presumably stabilised by the aforementioned CH-π 
interaction. The C–C–C bond angle of 106.0° corresponds to a tetrahedral arrangement. The 
distance (3.54 Å) of the syn-α-carbon to the centroid of the shielding group also supports the 
existence of a CH-π interaction. 
 
 
 
N
H2N
Me
O
Cl-
N
H2N
Me
O
Cl-
80 81
could undergo
CH-π interaction
Figure 69 X-ray structures of the hydrochloride salts of catalyst 80 and 81. 
Figure 70 X-ray structure of the hexafluorophosphate salt 
of 80a. The PF6- counterion has been omitted for clarity. 
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2.6.3 NMR Analysis of Iminium Salt 80a 
For the imidazolidinone-derived iminium salts studied so far, an upfield-shift of the syn-
methyl, as compared to the anti-methyl of the geminal-dimethyl group, could be observed. 
The magnitude of this difference was found to directly correlate with the predicted 
preference of CH-π conformer I. Furthermore, catalysts with significant differences were 
found to give higher enantioselectivities when employed in the Friedel-Crafts reactions of  
N-methyl-pyrrole and (E)-cinnamaldehyde. A similar observation was made for the iminium 
salt derived from the cyclopentane spirocompound 80. The two CH2 groups in α-position to 
the spiroatom showed hugely different NMR shifts in the 1H (Figure 71) and 13C NMR 
spectra of 80a (∆δ1Hsyn/anti = –1.11 ppm; ∆δ13Csyn/anti = –1.56 ppm). This is consistent with 
the crystal structure discussed in chapter 2.6.2. Shift-differences of similar magnitude were 
found for the cyclohexyl-derivative 81a (∆δ1Hsyn/anti = –1.10 ppm; ∆δ13Csyn/anti = –1.77 ppm). 
 
 
Figure 71 1H NMR spectrum of iminium salt 80a displaying the large shift-differences of the two indicated CH2-groups. 
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2.6.4 Catalysis Screening: Organocatalytic Friedel-Crafts Reaction of N-Me-Pyrrole 
Finally, the MacMillan catalysts modified in the position of the geminal-dimethyl group  
78-81 were tested on in the Friedel-Crafts reaction of N-methyl-pyrrole 38 with  
(E)-cinnamaldehyde 2. The catalyst 78 in which the geminal-dimethyl group was removed, 
and the oxetanyl-derivative 79 gave very low levels of enantioselectivity (20% and 22% ee, 
respectively). The low levels of enantioinduction of the second are a further verification for 
the importance of the CH-π interaction. Because the same enantiomer is obtained in excess, 
it is believed that even in 78a the (E)-conformer is predominantly populated. The 
cyclopentane spiro-compound 80 also gave low levels of stereoselectivity, even though 
considerably higher than 78 and 79. This finding is currently not well understood, since  
X-ray and solution phase NMR analyses of 80a suggested significant population of 
conformer I and high levels of (E)/(Z)-control. Also the CH spirocompound 81 resulted in 
lower levels of enantioselectivity (72% ee) than expected.  
  
Catalyst ee [%] e.r. 
 
20 60:40 
 
22 61:39 
 
35 67.5:32.5 
 
72 86:14 
Table 9 Screening of the modified catalysts in the Friedel-Crafts reaction of N-
Me-pyrrole 38 to (E)-cinnamaldehyde 2. 
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2.7 2nd Generation MacMillan Catalyst Derivatives 
Whilst the 1st generation MacMillan catalyst was successfully applied in enantioselective 
Diels-Alder reactions,[8a] 1,3-dipolar cycloadditions with nitrones,[112a] the Friedel-Crafts 
alkylation using pyrroles[112b] and other reactions, diminished reactivity and enantioinduction 
were observed when using indoles or furans as π-nucleophiles. To overcome these 
constraints, MacMillan and co-workers introduced a 2nd generation catalyst (82, Figure 72, 
left) carrying a tert-butyl group instead of the geminal-dimethyl group in 2002.[52] The 
increased reaction rates and higher levels of enantiocontrol of this catalyst in the Friedel 
Crafts reaction of indoles was rationalised by the more exposed nitrogen and the decreased 
steric hinderance of the attack (see chapter 1.1.2). It was demonstrated in chapter 2.2 that 
increase of the electron-density of the aryl shielding group of the 1st generation MacMillan 
catalyst leads to enhanced enantioselectivities in the Friedel-Crafts reaction. Decreasing the 
electron-density on the other hand, lead to diminished selectivities. To probe whether a 
similar trend can be observed for the 2nd generation catalyst, the trimethoxy (84)- and the 
pentafluoro-derivative (86) were prepared (Figure 72). Additionally, for the parent catalyst 
and for these two analogues, the corresponding anti-diastereomers were prepared (83, 85, 
and 87). The so-called 3rd generation MacMillan catalyst (19)[112d] was also included in this 
study to test the enantiocontrol induced by solely the tert-butyl group in the Friedel-Crafts 
addition using N-methyl pyrrole (38). 
 
 
Figure 72 Left: Mode of stereocontrol in the transition state proposed for the 2nd generation MacMillan catalyst 82.  
Right: Libary of 2nd generation MacMillan catalyst derivatives and the 3rd generation MacMillan catalyst 19. 
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2.7.1 Syntheses of syn and anti 2nd Generation MacMillan Cataylst Derivatives 
The 2nd generation imidazolidinones were prepared following a procedure reported by 
Tomkinson et al. from the corresponding aldehydes and pivaldehyde using catalytic amounts 
of Yb(OTf)3.[142] A mixture of both diastereomers was obtained in all cases which could be 
separated by column chromatography (Figure 73).  
 
It was possible to obtain crystals suitable for X-ray crystallographic analysis of the  
syn-pentafluoro-derivative as the hydrochloride salt (86·HCl, Figure 74). It was found that 
the compound adopts a very similar conformation as it was found for the 1st generation 
analogue (10·HCl, chapter 2.2.3), placing the aromatic group away from the core 
imidazolidinone ring (ΦNCCC = –159.8°) and with the nitrogen pyramidalised such that the 
benzylic substituent and the tert-butyl group are in quasi-equatorial position.  
  
H2N
H
N
O
Me
Yb(OTf)3, CHCl3
reflux, 8 h
N
H
N
O
H
Me
N
H
N
O
H
Me
O
syn anti
OMe
OMe
OMe
F F
F
FF
82: 11% 83: 58%
84: 33% 85: 41%
86: 49% 87: 30%
Figure 73 Syntheses of 2nd generation MacMillan catalyst derivatives (syn and anti). 
N
N
H2
MeO
Me
Me
Me
F
F
F
F
F
86•HCl
Cl-
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2.7.2 Catalysis Screening: Organocatalytic Friedel-Crafts Reaction of N-Me-Pyrrole 
 
Catalyst ee [%] e.r. 
 
85 92.5:7.5 
 
8 54:46 
 
84 92:8 
 
36 68:32 
 
52 76:24 
 
34 67:33 
 
–34 33:67 
Table 10 Screening of the 2nd generation catalysts in the Friedel-Crafts reaction of  
N-Me-pyrrole 38 and (E)-cinnamaldehyde 2. 
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The imidazolidinone catalysts were tested on their catalytic performance in the Friedel-
Crafts addition of N-methyl pyrrole 2 and (E)-cinnamaldehyde 38 (Table 10). All reactions 
went to completion within 3 h. When using the parent catalyst 82 the same enantioselectivity 
as for the 1st generation benzyl catalyst 1 were obtained (both 85% ee, see chapter 2.2.6). 
But in contrast to what was achieved for the 1st generation system, the level of 
enantioinduction could not be increased by introduction of electron-donating substituents to 
the aryl shielding group (84% for the trimethoxy-system 84 as compared to 94% for the 
trimethoxy 1st generation catalyst 3). Implementation of electron-withdrawing groups 
however, resulted in loss of enantioselectivity (R = C6F5, 86, 52% ee) and in fact the 
selectivity was lower then the one obtained with the 1st generation analogue (R = C6F5, 10, 
66% ee). Unsurprisingly, employing the anti-imidazolidinones generally resulted in 
diminished enantioselectivities. Whilst the anti-benzyl derivative 83 led to almost complete 
loss of facial selectivity (8% ee), the anti-trimethoxy derivative 85 and the anti-pentafluoro 
system 87 both resulted in moderate selectivities of 36% and 34% ee, respectively. The level 
of stereocontrol obtained with the tert-butyl catalyst without a shielding group (19) was in 
the same range at 34% ee. 
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2.8 Electronic Modification of the Substrate (E)-Cinnamaldehyde 
In chapter 2.2, it was established that the conformational behaviour of the reaction 
intermediates generated from condensation of MacMillan catalyst derivatives and  
(E)-cinnamaldehyde can be affected by introduction of electron-rich or electron-deficient 
substituents on the aryl shielding group. Furthemore, it was shown, that the level of 
stereocontrol is directly linked to the conformational behaviour. This immediately raises the 
question, what consequences would arise from electronic modifications of the π-system of 
the (E)-cinnamaldehyde substrate. Therefore a series of para-substituted  
(E)-cinnamaldehydes 88-91 were condensed with the parent MacMillan catalyst 1 (Figure 
75) and the resulting iminium salts 92-95 studied via NMR spectroscopic analysis. 
 
It was observed, that para-substitution of the condensed iminium leads to subtle changes in 
the shift-differences of the syn- and the anti-methyl groups of the geminal-dimethyl moiety 
(∆δ1Hsyn/anti and ∆δ13Csyn/anti, Table 11 and Figure 76). The changes are delicate but follow a 
clear trend: The more electron-donating the substituent is the larger are ∆δ1Hsyn/anti and 
∆δ13Csyn/anti. 
Table 11 Differences of the chemical shifts of the geminal-dimethyl group observed by 1H and 13C NMR spectroscopy. 
Iminium Salt (Ar) Hammett Constant σpara[143] 
∆δ(syn/anti)1H 
[ppm] 
∆δ(syn/anti)13C 
[ppm] 
92 (para-Cl) +0.23 –0.89 –2.72 
93 (para-F) +0.06 –0.90 –2.75 
1a (para-H) +0.00 –0.89 –2.77 
94 (para-OMe) –0.27 –0.92 –2.82 
95 (para-NMe2) –0.83 –0.94 –2.84 
 
Figure 75 Electronic modification of the π-system of the substrate. 
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Figure 76 Upper: The three staggered conformers of the imidazolidinone derived iminium salts. The CH-π interaction in 
conformer I results in an upfield shift of the syn-methyl group in the 1H and 13C NMR spectra. Lower: 1H-NMR spectra. 
 
This suggests, that introduction of a para-substituent to the substrate (E)-cinnamaldehyde 
does not significantly influence the CH-π interaction between the syn-methyl group of the 
imidazolidinone moiety and the aryl-shielding group. It was possible to obtain single crystals 
suitable for X-ray crystalographic analysis of the para-chloro derivative 92 (Figure 77). The 
compound adopts conformer I stabilised by the discussed CH-π interaction 
(ΦNCCC = +50.4°), thus, supporting this notion. Further spectroscopic and crystallographic 
evidence supporting this hypothesis can be found in a recent publication by Lakhdar and 
Mayr.[120]  
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2.9 Conclusions and Outlook 
A thorough molecular editing study of the MacMillan catalyst-derived iminium salt has been 
performed. By logical investigation of the different catalyst sites, the contributions of the 
different moieties and the importance of intramolecular interactions have been enlightened. 
A large number of α,β-unsaturated imidazolidinone iminium salts was prepared and 
conformational behaviour was experimentally investigated by solution phase NMR analyses 
and X-ray crystallographic studies. These results were complemented by computational 
analyses of lowest energy conformers. Consequently, performance of this MacMillan 
organocatalysts in the Friedel-Crafts reaction of N-methyl pyrrole to (E)-cinnamaldehyde 
was tested. Observed enantioselectivities were correlated to the postulated conformational 
behaviour. Besides identification of an improved catalyst structure leading to higher 
enantioselectivities, a clear correlation between preferred conformational behaviour has been 
unravelled. It was demonstrated, that high enantioselectivities in the Friedel-Crafts addition 
of N-methyl pyrrole to (E)-cinnamaldehyde can only be achieved when in the intermediate 
iminium only the aryl shielding group is predominantly placed in conformers I (CH-π) and 
II (π-π) and that a low energetic barrier between these two conformations is benefical.  
Figure 77 X-ray structure of 92·HClO4-, conformer I is adopted. 
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3 Conformational Analysis of Organocatalytic 
Intermediates using IR-MPD Spectroscopy 
 
The iminium ions generated by condensation of MacMillan catalyst-derived 
imidazolidinones with (E)-cinnamaldehyde were studied in the gas phase using Infrared 
Multiple Photon Dissociation (IR-MPD) spectroscopic analysis. It was envisaged that 
conformational behaviour would be directly reflected by characteristic shifts of the 
absorption bands of the typical fingerprint IR-chromophore C=O. By performing this 
analysis in the gas phase, influences from counterions or solvent molecules can be excluded. 
The combination of a free electron laser (FEL) with an ion trapping mass spectrometer 
makes it possible to record IR spectra in the gas phase over a wide wavelength range (500–
2000 cm-1). Currently, only a handful of free electron lasers for IR-measurements are 
available for external users, making beam time extremely valuable and competitive. 
Fortunately, it was possible to secure three days of beam time for the proposed project at the 
FELIX (Free-Electron Lasers for Infrared eXperiments) facility at Radboud University 
(Nijmegen) and experiments were performed in late December 2013.  
3.1 Introduction: IR-MPD Experiments using FELIX 
The experiments at the FELIX facility were performed in collaboration with Mathias Schäfer 
from the University of Cologne and the FELIX team in Nijmegen. I am particularly grateful 
to Prof. Jos Oomens and Dr. Giel Berden for their contribution to this work.  
Figure 78 Schematic representation of the instrumentation used to obtain gas phase IRMPD spectra over a wide 
wavelength-range. Figure taken from N. Polfer and J. Oomens, Phys. Chem. Chem. Phys. 2007, 9, 3804. 
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Figure 79 FELIX facilities at Radboud University 
Nijmegen. Left: FT-ICR mass spectrometer and Right: 
Free electron laser used for the study of gas phase IR 
spectra of imidazolidinone derived iminium ions. 
The iminium salts of interest were transferred into the gas phase from a solution in CH3CN 
by electrospray ionization delivering very abundant, intact molecular ions. These ions were 
subsequently trapped in a Fourier transform ion cyclotron resonance (FT-ICR) mass 
spectrometer.[144] Due to the low abundance of ions in the mass spectrometer, direct IR 
absorption measurements are not possible.[145] Instead an “action spectroscopy” method was 
used, infrared multiple photon dissociation (IR-MPD).[146] The trapped ion was irradiated 
with a laser and, if the frequency of the laser is resonant to a vibrational mode in the 
molecule, photons were absorbed.[147] Tens to hundreds of photons must be absorbed to 
cause dissociation of the molecule, which can then be detected as loss of the parent ion mass 
and occurrence of fragment ions.[148] By using a widely tunable and powerful free electron 
laser, the molecular ion was irradiated at each wavelength over a wide range (3-250 µm) 
with relatively consistent irradiation times, while monitoring the extent of dissociation. The 
spectrum was then normalized with the relative laser power for each frequency. One of the 
biggest challenges is to create a stable, tunable free electron laser.[149] The experimental 
spectra were then compared to the theoretical spectra computed by Dr. A. Meijer from the 
University of Sheffield (UK) for each identified low-energy conformer. 
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3.2 Project Outline 
Experimental analysis of the conformational behaviour of MacMillan catalyst-derived 
iminium ions has so far heavily relied on solution phase NMR analyses and X-ray 
crystallographic analyses. Whilst these are valuable methods, potential limitations have to be 
considered. Crystallography suffers from the drawback that packing effects might influence 
conformation. Similarly, solution phase analyses comes with the caveat that counterions may 
be influential, and in the context of organocatalysis using MacMillan catalysts, have been 
shown to be far from innocent.[150] To reconcile the clear requirement for methods to study 
iminium salt intermediates in the absence of counterions and solvents, infrared multiple 
photon dissociation (IR-MPD) spectroscopy has been explored as unique method for probing 
gas phase conformations of iminium ions derived from MacMillan’s 1st generation catalyst 
(1). It was envisaged that the characteristic fingerprint C=O chromophore of the 
imidazolidinone ring moiety would be an excellent diagnostic signal. It was envisaged that 
the stretching frequency of the carbonyl group would be delicately influenced by the various 
conformations resulting from rotation around the C–C(Ph) bond (Figure 80, right). By 
comparing the recorded spectra to the computed spectra for each low-energy conformer 
identified that was significantly populated, it would be possible to verify previously 
postulated conformational behaviour. It should be noted, that this work constitutes the first 
application of IR-MPD spectroscopy to organocatalysis. So far, IR-MPD spectroscopy of 
organic molecules has predominantly been used to study small biologically relevant 
structures, e.g., amino acids and small peptides.[148a;151] Only recently, this method has been 
applied to study intermediates in the Diels-Alder reaction catalysed by cobalt-complexes.[152] 
Furthermore, a theoretical study by Sigman and co-workers has recently appeared in the 
literature demonstrating that selectivity in catalysis can be correlated to shifts in the 
theoretical IR spectrum.[153] To validate the utility of IR-MPD spectroscopy, eleven iminium 
ions were studied. For each of these compounds, the lowest energy conformers have been 
calculated using the B3LYP[154] functional of DFT with 6-311G**[155] basis set used on all 
atoms (see chapters 2.2.7, 2.3.6, and 2.4.5). For this study, the theoretical gas phase IR-
spectra for each conformer significantly populated at RT were computationally predicted in 
collaboration with Dr. Anthony Meijer from the University of Sheffield .  
To achieve pronounced electronic changes, five iminium ions with significantly differing 
quadrupole moments of the aryl shielding group (1a, 3a, 6a, 8a, and 10a, Qzz = –5.68 D·Å to 
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+3.01 D·Å) were studied (Figure 80, top). Furthermore, two systems with extended shielding 
groups (35a and 41a) and the saturated CH-derivative 42a were also investigated (Figure 80, 
middle). Additionally, the conformational equivalents (57a and 58a) frozen by virtue of the 
fluorine-iminium ion gauche effect were studied and, as a control compound, the methyl-
derivative 60a was investigated (Figure 80, lower). For all compounds, an  
IR-MPD spectrum was successfully recorded at FELIX. To ensure reliable detection of the 
minimal shift-differences in the range of 3–5 cm-1, some analytes were measured as pairs, in 
doing so, they function as internal standard for each other. The prerequisite for this method 
is that the analytes and products differ in ion mass. 
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Figure 80 Overview of the iminium ions studied by IR-MPD spectroscopy at the FELIX facilities (Radboud University 
Nijmegen) and of possible low-energy conformers. Bottom: Working hypothesis.  
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3.3 Results of the IR-MPD Analysis 
3.3.1 IR-MPD Analyses of Iminium Ions with Electronically Modulated Shielding 
Groups 
The iminium ion derived from the parent 1st generation MacMillan catalyst: 
As described in chapter 2.2, experimental analysis of the L-phenylalanine derived 
imidazolidinone iminium ion 1a indicates that conformer I is predominantly populated. 
Computational conformer analysis supported this notion by identifying conformer I as the 
global minimum. A second significantly populated conformer was found to be conformer IV 
(+4.7 kJ/mol). The theoretical gas phase IR spectra of these two conformers were computed 
and compared to the experimentally obtained IR-MPD spectrum of 1a. Unfortunately, for 
this compound the C=O stretching modes for the two energy minima proved to be almost 
identical (I:1753 cm-1 and IV:1752 cm-1), thus, it was not possible to differentiate the two 
conformers based on this (Figure 81). However, by inspection of the region between 1200-
1400 cm-1 and the intense band at 1500-1700 cm-1, the experimental spectrum was found to 
show better agreement with the theoretical spectrum of conformer I, suggesting predominant 
population of this conformer, which is in agreement with theory. 
 
The iminium ion derived from the trimethoxy analogue 3a: 
The most electron-rich example of the catalysts with electronically modified aryl shielding 
groups (3) gave the best enantioselectivities in the Friedel-Crafts reaction of N-methyl-
pyrrole to (E)-cinnamaldehyde (94%, chapter 2.3.5). The conformational behaviour of the 
corresponding iminium ion was studied by experimental and computational analysis and the 
existence of two global minimum structures was discovered, i.e., conformers II and IV. 
However, conformer I was found to be only slightly higher in energy (+0.5 kJ/mol), and 
thus, is expected to be populated to a similar extend as II and IV at RT. A fourth conformer 
resembling conformer II was found at +3.3 kJ/mol. The theoretical IR-MPD spectra of those 
four conformers were computed and compared to the measured spectrum. The C=O 
stretching bands of the four conformers were found to be: 1747 cm-1 (0.0 kJ/mol, II), 
1758 cm-1 (0.0 kJ/mol, IV), 1749 cm-1 (0.5 kJ/mol, I), and 1761 cm-1 (3.3 kJ/mol, II). The 
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measured C=O IR-band was found in between the theoretically predicted bands, thus, 
illustrating the distributed conformer population of 3a (Figure 81). 
 
The iminium ion derived from the tyrosine-derived analogue 6a: 
Because of their similar electronic properties, it was unsurprising that the iminium salt 6a 
derived from tyrosine resembled the iminium salt of the parent catalyst (1a). Conformer I 
was found to be the global minimum of this system. However, the energy difference between 
conformer I and the energetically second lowest conformer IV was found to be smaller for 
6a than for 1a (∆E = 2.7 kJ/mol versus +4.7 kJ/mol). Accordingly, also the measured and 
calculated IR-MPD spectra closely resemble those for 1a. While the C=O stretching 
frequencies are too close together to allow for conformer-assignment (1751 cm-1 and 
1753 cm-1), the region between 1200-1400 cm-1 again more closely resembles the calculated 
spectrum of the global minimum structure (Figure 81). 
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Figure 81 IR-MPD-spectra of 1a (left, upper), 3a (left, middle), and 6a (left, lower) overlaid with the theoretical spectra of 
the computationally identified energy minimum conformations (right). The torsion angles around the benzylic bonds 
(ΦNCCC) and the wavelength of the C=O stretching modes are also indicated. 
92 3 Conformational Analysis using IR-MPD Spectroscopy 
The iminium ion derived from the trifluorophenyl-derivative 8a: 
For the α,β-unsaturated iminium ion 8a only one significantly populated conformer 
corresponding to conformer III was identified. The measured C=O frequency at 1761 cm-1 
fits perfectly to the theoretical value, whilst the second calculated energy minimum was 
much higher in energy (+10.7 kJ/mol, distorted conformer I) and is slightly blue-shifted 
(1764 cm-1, Figure 82). 
 
The iminium ion derived from the pentafluorophenyl-analogue 10a: 
Last of this series, the pentafluorophenyl-analogue 10a was studied as the electron-deficient 
extreme (Figure 82). From the X-ray structure and other structural data it was concluded that 
this iminium ion preferentially adopts conformer III with the aromatic shielding group 
rotated away from the imidazolidinone core.[156] This conformer was also computationally 
identified as the global minimum structure. Two additional conformers were found: A 
structure resembling conformer II at +7.1 kJ/mol and a distorted conformer I at 
+11.8 kJ/mol were identified. Whilst the C=O stretching frequency computed for the global 
minimum structure (1760 cm-1) and the measured frequency are in good agreement, the C=O 
stretching frequencies of the other two identified minima are slightly blue-shifted (1763 cm-1 
and 1764 cm-1, respectively).  
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Figure 82 IR-MPD-spectra of 8a (left, upper) and 10a (left, lower) overlaid with the theoretical spectra of the 
computationally identified energy minimum conformations (right). The torsion angles around the benzylic bonds (ΦNCCC) 
and the wavelength of the C=O stretching modes are also indicated. 
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3.3.2 IR-MPD Analyses of Iminium Ions with Extended Shielding Groups and of an 
Iminium Ion with a Saturated Shielding Group 
The iminium ion derived from the Me-indole-analogue 35a: 
For the tryptophan-derived iminium ion 35a, four low-lying conformers where identified. 
The global energy minimum was found correspond to conformer II. Furthermore, two 
minima adopting conformer I were found at +2.5 kJ/mol and +5.9 kJ/mol, and a further 
conformer reminiscent of conformer IV at +4.2 kJ/mol. Compared to the C=O stretching 
modes of the other conformers, the signature for the global minimum was computed to be 
considerably blue-shifted [1760 cm-1 as compared to 1751 cm-1
 
(+2.5 kJ/mol), 1748 cm-1
 
(+4.2 kJ/mol) and 1750 cm-1
 
(+5.9 kJ/mol)]. The C=O bond measured was found to fit best 
to the global minimum (Figure 83), but is considerably red-shifted likely due to significant 
population of the other conformers.  
 
The iminium ion derived from the anthracene-analogue 41a: 
The iminium ion with the anthracene-moiety 41a most beautifully illustrates the potential of 
IR-MPD spectroscopy in studying conformational behaviour. For each of the three possible 
conformers I, II, and III an energy minimum was computationally identified (13.2 kJ/mol, 
0.0 kJ/mol, and 18.2 kJ/mol, respectively), but only conformer II is predicted to be 
significantly populated. Moreover, the corresponding C=O frequency shifts were found to 
clearly differ from each other (1751 cm-1, 1755 cm-1, and 1764 cm-1, respectively). The IR-
MPD carbonyl stretching frequency perfectly fits to the computed spectrum for conformer 
II, thus, validating the predominant population of this conformer (Figure 83).  
 
The iminium ion derived from the cyclohexyl-analogue 42a: 
For the cyclohexyl-derivative 42a, only one significantly populated conformation was 
computed (conformer III), with a carbonyl stretching frequency of 1753 cm-1. Additionally, 
three higher lying conformations were identified, all with corresponding theoretical carbonyl 
stretching modes blue-shifted compared to the one for the global minimum (III, 7.1 kJ/mol, 
1756 cm-1 and IV, 10.5 kJ/mol, 1761 cm-1 and I, 12.0 kJ/mol, 1759 cm-1). The measured 
spectrum fits well to the predicted spectrum of the global minimum (Figure 83). 
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Figure 83 IR-MPD-spectra of 35a (left, upper), 41a (left, middle) and 42a (left, lower) overlaid with the theoretical spectra 
of the computationally identified energy minimum conformations (right). The torsion angles around the benzylic bonds 
(ΦNCCC) and the wavelength of the C=O stretching modes are also indicated. 
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3.3.3 IR-MPD Analyses of Iminium Ions with Modifications in the Benzylic Position 
The CH-π “conformer equivalent” 57a: 
Unsurprisingly, the only significantly populated conformer for this iminium ion was found 
to be one corresponding to conformer I. Another energetically low lying conformation was 
identified to be a conformer also stabilised by an interaction with the syn-methyl group, but 
with the (Z)-conformation around the C=N+ iminium bond (+8.8 kJ/mol). Higher in energy 
(+13.3 kJ/mol) is the other gauche-conformation directing the phenyl-ring away from the 
core ring. The computed IR spectra of the two CH-π conformations are very similar and the 
C=O stretching frequencies are too close together to make differentiation possible (Figure 
84). However, for the (Z)-conformer, a band at around 1410 cm-1 was predicted, that could 
not found in the measured spectrum nor the theoretical spectrum of the global minimum 
conformation. The computed C=O stretching frequency of the other gauche-conformer is 
considerably blue-shifted compared to the other conformers and the measured frequency. 
 
The π-π “conformer equivalent” 58a: 
For the π-π ‘conformer equivalent, not only the predicted conformer II but a second 
significantly populated conformation corresponding to conformer IV was identified 
(+1.3 kJ/mol). The computed spectra of these two conformers show significantly different 
C=O stretching frequencies (1762 cm-1 and 1751 cm-1, respectively). The experimental C=O 
band was found to have a stretching frequency in between those found computed for 
conformers II and IV, thus, supporting the notion that both conformers are significantly 
populated. 
 
The iminium ion derived from the methyl-analogue 60a: 
Finally, the iminium ion derived from the methyl-derivative was investigated. 
Unsurprisingly, computational analysis predicted only one energetic minimum 
conformation. The predicted IR spectrum and the measured IR-MPD spectrum correspond 
well.  
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Figure 84 IR-MPD-spectra of 57a (left, upper), 58a (left, middle) and 60a (left, lower) overlaid with the theoretical spectra 
of the computationally identified energy minimum conformations (right). The torsion angles around the benzylic bonds 
(ΦNCCC) and the wavelength of the C=O stretching modes are also indicated. 
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3.4 Conclusions and Outlook 
Herein, a preliminary validation of gas phase IR-MPD-spectroscopy for probing the 
conformational behaviour of low molecular weight organocatalytic intermediates is 
presented. The carbonyl stretching frequency was shown to depend on the position of the 
shielding substituent as a consequence of rotation around the central C–C bond. By 
comparison of the computed spectra for each energetic minimum conformation with the 
experimental gas phase IR-spectrum of a given compound, the conformational preferences 
could successfully be assigned in many cases, thus providing valuable structural insights. 
Unfortunately, in other cases, the frequency-differences were at the boundaries of reliable 
assignment. Thus, the current limitations of this method were illustrated. In future, with 
improved theoretical methods and more stable laser radiation, these limitations may be 
overcome. The current development of low-temperature gas phase IR spectroscopy will 
likely bring additional advances to the field. In conclusions, a preliminary validation of the 
potential of IR-MPD spectroscopy for investigating reaction intermediates and enlightening 
mechanistic subtleties is presented.  
4 The Organocatalytic Friedel-Crafts Reaction of N-Me-Indole: Inversed Selectivity 99 
4 The Organocatalytic Friedel-Crafts Reaction of N-
Me-Indole: An Unusual Selectivity Reversal 
 
In the previous chapters of this thesis, the conformational behaviour of the α,β-unsaturated 
iminium salts of various MacMillan catalyst-derivatives was studied and correlated to trends 
observed in the Friedel-Crafts addition of N-methyl pyrrole 38 to (E)-cinnamaldehyde 2. To 
investigate whether or not these trends are also found in the addition of other charge neutral 
nucleophiles to (E)-cinnamaldehyde, the Friedel-Crafts reaction of N-methyl indole 96 was 
studied using the catalysts discussed in chapter 2. MacMillan and co-workers reported that 
selectivities and reactions rates of this reaction are significantly improved when using the 2nd 
generation MacMillan catalyst 82 (88% ee, 98% yield at –40 °C, 4 h for crotonaldehyde) 
instead of the 1st generation catalyst 1 (56% ee, 85% yield at –40 °C, 48 h for 
crotonaldehyde).[52] These observations were attributed to the lower reactivity of indole-
derivatives as compared to pyrrole-derivatives (see also chapter 1.1.2). While this 
explanation likely accounts for the increased reaction rate, it was proposed that additional 
effects must be responsible for the significant differences in selectivity. Particularly curious 
was the observation, that for N-methyl pyrrole both the 1st and the 2nd generation MacMillan 
catalysts gave virtually the same enantioselectivity of 85% ee (chapters 2.2.6 and 2.7.2). 
Furthermore, a recent publication by Seebach et al. reported on the reversal of the 
stereochemical outcome of the reaction when a fluorine substituent was introduced to the 
syn-methyl group, but not when it was introduced to the trans-methyl group (Scheme 
23).[157] 
 
Scheme 23 Reversal of selectivity in the Friedel-Crafts addition of  
N-methyl indole 96 and (E)-cinnamaldehyde 2 observed by Seebach et al. 
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4.1 Catalysis Screening 
4.1.1 Catalysts with Electronically Modulated Shielding Groups 
 
Initially, the 2nd generation MacMillan catalyst 82 was employed in the addition reaction of 
N-methyl indole 96 under the same conditions used throughout this study resulting in 
76% ee at RT and 89% ee at –55 °C. Subsequently, the series of electronically modulated 
MacMillan-derivatives was tested (Figure 85). For these compounds, a clear correlation 
between the electron densities represented by the component of the quadrupolar moment 
tensors Qzz perpendicular to the aryl shielding groups, and the obtained stereoselectivities 
was observed in the addition reaction of N-methyl pyrrole. Furthermore, the electron-rich 
extreme [3, R = C6H2(OMe)3] resulted in the best stereoselectivities (94% ee) of the series. 
Both observations were repeated in the addition reaction using N-methyl indole. Even 
though selectivities were generally lower, a clear correlation between the Qzz and the ee (or 
e.r.) obtained was observed (Figure 86, Table 12). The best selectivity was reached using 
catalyst 3 (44% ee). 
Figure 85 Catalyst library with electronically modified shielding aryl groups. 
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Figure 86 Plot of the component of the traceless quadrupole moment tensor orthogonal to the aromatic ring of the Ar-CH3 
derivatives (Qzz) with enantiomeric excess (ee), and enantiomeric ratio (e.r.). Nitro-analogue 9 was left out from this study 
due to different conformational behaviour that requires clarification. 
4 The Organocatalytic Friedel-Crafts Reaction of N-Me-Indole: Inversed Selectivity 101 
OMe
OMeMeO
3
 
Catalyst Qzz [D·Å] ∆δ
1Hsyn/anti 
[ppm] 
Postulated 
Conformer ee [%] e.r. 
 
–5.68 –0.62 II/I 44 72:28 
 
–5.50 – 
 
– – 
 
–4.72 –0.62 II/I 32 66:34 
 
–3.71 –0.78 I 30 65:35 
 
–3.46 –0.89 I 31 65.5:34.5 
 
–1.62 – 
 
36 68:32 
 
+0.26 –0.18 III –20 40:60 
 
+2.46 –0.74 I 31 65.5:34.5 
 
+3.01 –0.13 III –20 40:60 
 
Table 12 Screening of the electronically modified catalysts in the Friedel-Crafts reaction of N-methyl indole 96 to  
(E)-cinnamaldehyde 2. 
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Consistent with previous findings, no reaction was observed when employing catalyst 4 
(R = C6H4NH2), potentially due to imine formation with the substrate. Furthermore, also in 
this reaction, the nitro-substituted analogue 9 gave much higher selectivities than would be 
expected from the Qzz, but consistant with the large ∆δ1Hsyn/anti (–0.74 ppm). This is 
consistent with the findings described for the addition of N-methyl pyrrole (Chapter 2.2.6). 
Surprisingly, changing the nucleophile from N-methyl pyrrole 38 to N-methyl indole 96, led 
to reversal of selectivity when using the perfluorinated-catalyst 10 or the trifluorophenyl-
derivative 8 (–20% ee for both). This indicates that the difference in behaviour, already 
observed by MacMillan and Seebach, most likely cannot solely be attributed to reactivity 
differences. Interestingly, for the two corresponding α,β-unsaturated iminium ions 8a and 
10a, it was postulated that no CH-π interactions between the aryl-shielding group and the 
syn-methyl group occur, and, thus, conformer I is essentially unpopulated. This might also 
be the key for the reversed stereoselectivity observed by Seebach et al. upon introduction of 
a fluorine-substituent on the syn-methyl group. The fluorine probably averts the CH-π 
interaction which stabilises conformer I.[157] To test whether selectivities could be improved 
by decreasing the reaction temperature, the reactions were repeated at 0 °C and –55 °C with 
the parent catalyst 1 and the two electronic extremes 3 [R = C6H2(OMe)3] and 10 (R = C6F5) 
(Table 13). While no significant improvements were achieved for the electron-rich catalyst 
3, the stereoselectivity of the 1st generation MacMillan catalyst 1 increased to the same 
levels at –55 °C (44% ee as compared to 45% ee for 3). Remarkably, the electron-deficient 
catalyst 10 gave almost the same enantiomeric excess, i.e. –40% ee, of the other enantiomer 
at –55 °C. Thus, solely by modifying the electron-density of the aryl shielding group by 
introducing electron-withdrawing or electron-donating groups, differences in 
enantioselectivity of 85% ee were obtained, highlighting the importance of non-covalent 
interactions in these low molecular weight organocatalysts. The reversal of selectivity is 
believed to be due to intermolecular interactions between the nucleophile and the iminium 
ion intermediate, which direct the nucleophile to attack from the top-face. This attack is 
supposedly only possible, when the shielding group is rotated away from the reaction centre 
as a consequence of prevention of the CH-π (and π-π) interaction. Since the only moiety 
discriminating the two faces of the iminium ion is the substituent in the 5-position (i.e. in the 
parent catalyst the benzyl group), the directing interaction must occur between this moiety 
and the nucleophile. In the case of the fluorinated-derivatives, one could invoke a π,π-
stacking interaction between the electron-deficient aryl ring and the electron-rich π-system 
of the nucleophile, or of a CH-π interaction of the latter with the benzylic protons. The 
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OMeMeO
3
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OMeMeO
3
indole-containing amino acid tryptophan is known to undergo various non-bonding 
interactions important for controlling protein-structures[106b;106e;158] and indole itself has 
recently been reported to undergo a π,π-stacking interaction with hexafluorobenzene,[69] 
thus, both directing effects seem reasonable. Naturally, the question arises, why this 
phenomenon was not observed for the nucleophile N-methyl pyrrole. Reasons for this might 
be the more electron-rich nature of indole as compared to pyrrole and the larger aromatic 
system. To gain a better understanding of the underlying mechanisms more imidazolidinone 
catalysts were studied. 
Table 13 Screening of catalysts 1, 3, and 10 in the Friedel-Crafts reaction of N-methyl indole 96 to (E)-cinnamaldehyde 2 
at 0 °C and -55 °C. 
 
 
Catalyst Qzz [D·Å] ∆δ
1Hsyn/anti 
[ppm] 
Postulated 
Conformer T [°C] ee [%] e.r. 
 
–5.68 –0.62 II/I 0 44 72:28 
 
–3.46 –0.89 I 0 36 68:32 
 
+3.01 –0.13 III 0 –28 36:64 
 
–5.68 –0.62 II/I –55 45 72.5:27.5 
 
–3.46 –0.89 I –55 44 72:28 
 
+3.01 –0.13 III –55 –40 30:70 
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4.1.2 Catalysts with Additionally Modified Shielding Groups 
Next, the remaining imidazolidinones with modified shielding groups (35 and 40-44, chapter 
2.2.8) were tested on their catalytic behaviour in the discussed reaction (Table 14). 
Table 14 Screening of the imidazolidinone catalysts 35 and 40-44 in the Friedel-Crafts reaction of N-methyl indole 96 to 
(E)-cinnamaldehyde 2. 
Catalyst Qzz [D Å] ∆δ
1Hsyn/anti 
[ppm] 
Postulated 
Conformer ee [%] e.r. 
 
–4.29 – I 33 66.5:33.5 
 
–7.62 –0.26 II 5 52.5:47.5 
 
0.54 –0.03 III –22 39:61 
 
–6.12 –0.58 II 36 68:32 
 
–5.40 –0.64 II 41 70.5:29.5 
 
–3.21 – 
 
–4 48:52 
 
HN
N
44
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The selectivities obtained were generally in good agreement with the predictions made based 
on the proposed conformational behaviour, and the previous results from the addition of  
N-methyl pyrrole 38 to (E)-cinnamaldehyde 2. The extended electron-rich system 40 gave 
similar levels of enantioinduction as the parent compound (33% ee). Both, the anthracene 
and the imidazole-derivatives 41 and 44 gave very low levels of selectivity (5% and –4% ee, 
respectively) as it was also observed for the addition of N-methyl pyrrole. The indole 
derivatives 35 and 43 gave moderate stereoselectivities only slightly lower than obtained 
with the trimethoxy-analogue 3 (36% and 41%, respectively, as compared to 44%,). With the 
cyclohexyl-catalyst 42, which was postulated to predominantly populate conformer III, the 
reversed selectivity was again observed (–22% ee). Lowering the reaction temperature to  
–55 °C, while increasing the reaction time to 142 h led to –52% ee for 42. This might 
implicate that a CH-π interaction between the indole substrate and the iminium ion as being 
responsible for the reversal of selectivity observed with catalysts which populate 
conformer III. 
 
4.1.3 Catalysts with Modulations in the Benzylic Position 
The next catalysts tested in the Friedel-Crafts reaction of N-methyl indole 96 to  
(E)-cinnamaldehyde 2 were the MacMillan-derivatives with modifications in the benzylic 
position (Table 15). The selectivities obtained with the two “conformer equivalents” 57 and 
58 were surprising: While the diastereomer 58 with the corresponding iminium ion 
predominantly populating conformer II gave 20% ee of the expected enantiomer, 57 with the 
iminium ion fixed in conformer I exhibited reversal of selectivity. This was unexpected as it 
was previously believed that catalysts in which the corresponding iminium ions 
predominantly populate conformer I and/or II do not result in this inversed selectivity. The 
results obtained for 57 suggest, that this only holds true for conformer I when a certain 
degree of flexibility is ensured. For the other structures mainly populating conformer I, a 
non-diminishable population of conformer II was identified whereas for 57a conformer I 
was found to be the only minimum structure (chapter 2.4.5). The diphenyl-catalyst 61 
resulted in relatively low selectivities (21% ee), which is consistent with the previous 
observations. Reversal of selectivity was observed for both catalysts 59 and 60 (–27% and  
–32% ee). The iminium ion of catalyst 59, in which the distance between the aryl shielding 
group and the reaction centre is extended by an additional CH2-group, was proposed to 
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predominantly populate conformer III. Consequently, the reversal of selectivity for this 
catalyst was expected. The methyl-derivative 60 gave the highest levels of enantiomeric 
excess of the imidazolidinones resulting in reversed selectivity (–32% ee). Moreover, 
lowering the reaction temperature to –55 °C resulted in the highest selectivity observed for 
all 1st generation-derived catalysts so far, i.e. –58% ee. Therefore, it was assumed that a  
CH–π interaction between the methyl-group (or CH2R-group in the other catalysts) and the 
N-methyl indole nucleophile functions as a directing effect.  
Table 15 Screening of MacMillan catalyst-derivatives modified in the benzylic position in the Friedel-Crafts 
reaction of N-methyl indole 96 to (E)-cinnamaldehyde 2. 
Catalyst ∆δ(syn/anti)
1H 
[ppm] 
Postulated 
Conformer ee [%] e.r. 
 
–0.89 I 31 65.5:34.5 
 
–1.08[a] I –13 43.5:56.5 
 
–0.06[a] II 20 60:40 
 
 III –27 36.5:63.5 
 
+0.03  –32 34:66 
 
–0.57  21 60.5:39.5 
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Figure 87 Working hypothesis for the use of experimental ∆δ1Hsyn/anti as tools for predicting the stereochemical outcome 
of Friedel-Crafts additions of N-methyl indole 96 to (E)-cinnamaldehyde 2 catalysed by MacMillan catalyst-analogues 
4.2 Correlation between Conformational Preferences, Enantioselectivity 
and 1H NMR-Shift of the syn-Methyl-Group Revisited 
In chapter 2.5, it was shown that the conformational preferences of the isolable, intermediate 
iminium salts derived from the imidazolidinone catalysts, are reflected in the observed 
NMR-shift differences of the two signals obtained for the geminal-dimethyl group 
(∆δ1Hsyn/anti). Since the conformational behaviour of the intermediate is also believed to 
govern the stereoselective outcome of the addition of a charge-neutral nucleophile, the utility 
of the experimental ∆δ1Hsyn/anti value as a predictive tool was investigated. In chapter 2.5 the 
value of this approach was illustrated by plotting the ∆δ1Hsyn/anti against the obtained 
enantiomeric excess and ascribing the different regions of the plot to distinct conformational 
behaviour. To test the generality of this correlation, a similar plot was created from the 
results of the catalyst screen in the addition of N-methyl indole 96 to (E)-cinnamaldehyde 2 
Figure 87 and Figure 88). 
In
flu
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s Influences
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Gratifyingly, the correlation was even more pronounced for this particular reaction, probably 
due to a greater selectivity range from –32% ee to +44% ee. The trend is again well 
represented by a polynomial fit. The catalysts, for which the corresponding iminium salts 
exhibited only small ∆δ1Hsyn/anti, gave either very low selectivities (41, distorted conformer 
II) or resulted in reversal of selectivity (8, 10, 42, and 60, conformer III). The only 
exception to these observations was found in “conformer equivalent” 58. A probable 
explanation is that the spacial arrangement of the phenyl group in conformer II prevents the 
proposed directing effect. The catalysts with iminium ions populating conformer III or a 
rigid conformer II are combined in the red-coded region of the plot. The best selectivities 
were observed for the catalysts in the green region of the plot, which all contain a very 
electron-rich aromatic shielding group. The corresponding iminium salts were found to have 
a higher population in conformer II than in conformer I. The opposite behaviour was found 
for the catalysts highlighted in the blue region, which were proposed to have a (slight) 
preference of conformer I over conformer II. While these catalysts show a larger ∆δ1Hsyn/anti, 
the enantioselectivity is slightly diminished. In the yellow region the “conformer equivalent” 
fixed in conformer I is shown. As a consequence of the fixation in the CH-π stabilised 
conformation, the deduced ∆δ1Hsyn/anti of this iminium salt is the largest of all compounds. 
Employing the corresponding catalyst in the studied reaction led to reversal of selectivity. 
Thus, it was shown that qualitative predictions of the enantioinduction of a MacMillan-type 
catalyst can be made from the experimental ∆δ1Hsyn/anti of the corresponding iminium salt. 
 
Figure 88 Plot of the observed ∆δ1Hsyn/anti of the MacMillan catalyst-derived iminium ions against the observed 
enantioselectivity of the corresponding catalyst in the Friedel-Crafts addition of N-methyl indole 96 to (E)-cinnamaldehyde 
2. The coloured regions group iminium ions according to their conformational behaviour.  
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4.3 Catalysis Screening with Catalysts Modified at the geminal-
Dimethyl Moiety 
In the Friedel-Crafts addition of N-methyl pyrrole 2 to (E)-cinnamaldehyde 38 it was 
observed that removal of the geminal-dimethyl group leads to a drastic drop of 
enantioinduction. Furthermore, the spiro-compounds 79-81 gave lower levels of 
enantiocontrol than the parent catalyst and it was found that the enantioselectivity increases 
with increasing spiro-ring size (chapter 2.6.4). Similarly, employing catalyst 78 in the 
reaction using N-methyl indole 96 as the π-nucleophile resulted in very low selectivity of 
8% ee. In contrast to the previous findings, for this reaction the cyclopentane-derivative 80 
gave the best selectivity (better than the cyclohexyl-compound 81) which was found to be in 
the same range as for the parent catalyst (34% as compared to 36% for 1).  
 
Catalyst ee [%] e.r. 
 
8 54:46 
 
13 56.5:43.5 
 
34 67:33 
 
24 62:38 
  
Table 16 Screening of the modified catalysts in the Friedel-Crafts reaction 
of N-Me-indole 96 to (E)-cinnamaldehyde 2. 
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4.4 Catalysis Screening with 2nd Generation Catalysts  
 
Catalyst ee [%] e.r. 
 
76 88:12 
 
0 50:50 
 
49 74.5:25.5 
 
18 59:41 
 
70 85:15 
 
35 67.5:32.5 
 
–53 23.5:76.5 
Table 17 Screening of the 2nd generation catalysts in the Friedel-Crafts reaction of 
 N-Me-indole 96 and (E)-cinnamaldehyde 2. 
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The 2nd generation catalysts were tested on their performance in the organocatalytic Friedel-
Crafts reaction of N-methyl indole 96 and (E)-cinnamaldehyde 2. The highest selectivities 
were obtained with the parent 2nd generation MacMillan catalyst 82 (76% ee). The electron-
deficient imidazolidinone 86 resulted in only slightly diminished enantiomeric excess of 
70%, whilst surprisingly, the electron-rich catalyst 84 only gave 49% ee. The anti-analogues 
generally led to considerably decreased selectivities. The anti-benzyl catalyst 83 even 
resulted in racemic product, 85 [R = C6H2(OMe)3] and 87 (R = C6F5) gave 18% and 35% ee, 
respectively. Interestingly, in the reaction using the 3rd generation catalyst 19 without an aryl 
shielding group the attack appears from the face opposite the tert-butyl group (53% ee).  
 
4.5 Proposed Rationalisation for the Reversal of Selectivity  
In Figure 89, the imidazolidinones for which the attack of the indole in the Friedel-Crafts 
addition of N-methyl indole 96 and (E)-cinnamaldehyde 2 was observed to occur from the 
same face of the intermediate, in which the substituent is positioned, are summarised. 
Common to all of these structures is that in the corresponding iminium salt conformer II is 
postulated to be virtually unpopulated. Moreover, with exception of “conformer equivalent” 
57, conformer I was also postulated not to be populated to a significant extent. 57 was the 
catalyst of this series giving the lowest level of facial discrimination. 
Figure 89 Catalysts for which a ‘reversal of selectivity’ was observed in the Friedel-Crafts addition of N-Me-indole 
96 and (E)-cinnamaldehyde 2. 
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It seems likely that a directing interaction must be key to the observed reversal of the 
stereochemical outcome in the Friedel-Crafts addition when using N-methyl-indole as the 
nucleophile. Since the substituent in the 5-position of the imidazolidinone ring is the only 
moiety discriminating the two faces of the iminium ion, a directing interaction must occur 
between this moiety and the nucleophile. It is proposed, that the hydrogen substituents in α-
position undergo a CH-π interaction with the indole. An additional CH-π interaction could 
occur between the nucleophile and the syn-methyl group, leading to a pincer-like interaction 
(Figure 90, left). CH-π interactions of indole moieties (especially of tryptophan) are very 
common and well studied. Computational analysis by Macias and MacKerell has shown that 
CH-π interactions to the six-membered ring of tryptophan are the strongest of all for 
aromatic amino acid side chains.[158b] Similarly, Sherrill et al. computed the interaction 
between methane and the six-membered ring of indole to be more stable than the one 
between methane and the five-membered ring of indole.[159] A protein database study 
identified three quarters of all tryptophan moieties to be involved in a CH-π interaction, 
making it the most abundant CH-π interaction in proteins. Furthermore, interactions with the 
six-membered ring of tryptophan dominate over those with the five-membered ring.[119a] In 
the pincer hydrogen bond system proposed in this study, a CH-π interaction with the six-
membered ring of N-methyl indole would allow the reacting π-bond of the nucleophile to be 
in proximity to the reaction center of the iminium chain. There could be an additional 
stabilising CH-π interaction between the hydrogen pointing towards the iminium chain and 
the five-membred ring of the indole. This pincer model would also offer a possible 
explanation for why reversal of the stereochemical outcome in the Friedel-Crafts addition 
was not observed for the nucleophile N-methyl pyrrole. Besides the fact that the five-
membered ring of N-methyl pyrrole undergoes weaker CH-π interactions than the six-
membered ring of N-methyl indole (Qzz = –4.10 and –5.10, respectively, Figure 90, right), 
the pincer interaction proposed would not bring the pyrrole nucleophile in close enough 
proximity to the reaction center for an effective directing effect. 
 
  
Figure 90 Left: Proposed pincer-like interaction involving two CH-π interactions between indole and the iminium salt. 
Right: ESP maps and Qzz of N-Me indole 96 and N-Me pyrrole 38.  
Colour range of the electrostatic potential: −0.06 (red) to + 0.06 (blue). 
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In addition, this model provides an explanation for why it was found beneficial to employ 
the 2nd generation MacMillan catalyst instead of the 1st generation MacMillan catalyst in the 
addition reaction of indoles but not of pyrroles: The introduction of a tert-butyl group in 
place of the geminal-dimethyl group prevents a directing CH-π interaction, thus, ensuring 
higher selectivity from the other face. This is presumably not required for the addition of 
pyrrole since, as proposed above, a directing effect is not functional. For “conformer 
equivalent” 57 a different interaction must be responsible for the observed reversal of the 
stereochemical outcome. A possible explanation is a directing CF-π interaction between the 
fluorine substituent positioned in proximity of the pendant iminium chain by virtue of a 
stabilising fluorine-iminium ion gauche effect and the indole. A similar CF-π interaction 
could also account for the increased selectivity of the MacMillan catalyst carrying a fluorine 
substituent on the anti-methyl group as compared to the parent catalyst 1 observed by 
Seebach et al. (62% as compared to 44% ee, see page 99 and Figure 91).[157]  
 
4.6 Conclusions and Outlook 
In this chapter, the organocatalytic Friedel-Crafts addition of N-methyl indole 96 to  
(E)-cinnamaldehyde 2 was studied using a large library of MacMillan catalyst derived 
imidazolidinones. Trends observed for the addition of N-methyl pyrrole (e.g., clear 
correlations between the obtained ee and the Qzz and the NMR ∆δ1Hsyn/anti, respectively) 
were retained. Furthermore, an explanation for the observed reversal of the stereochemical 
outcome when using specific imidazolidinone catalysts in the addition reaction of indoles is 
presented. The working hypothesis also offers an explanation for the observation that 
enatioselectivities can be improved by using the 2nd generation MacMillan catalyst instead of 
the 1st generation MacMillan catalyst when indoles are used as the nucleophile in the 
Friedel-Crafts addition, but not when pyrroles are used. Experimental proof for the 
hypothesis presented in here is required. NMR studies to detect the proposed CH-π 
interactions are ongoing. For the purpose of these, a relatively unreactive iminium salt 98 
Figure 91 Left: Parent catalyst 1. Middle and right: Fluorinated derivatives suggested to undergo a directing CF-π 
interaction with the substrate in the Friedel-Crafts reaction of N-Me indole and (E)-cinnamaldehyde. 
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was prepared by condensation of the alanine-derived imidazolidinone 60 and  
(E)-(para-dimethylamino)cinnamaldehyde 91. Due to the strong π-donor-character of the 
dimethylamino-substituent, the cation is stabilised by delocalisation. Mayr and Lakhdar 
found that the iminium ion derived from the benzyl catalyst 1 and (E)-(para-
dimethylamino)cinnamaldehyde 91 is almost two orders of magnitude less reactive than the 
iminium ion of 1 and (E)-cinnamaldehyde 3 in the reaction with silyl ketene acetals 36 and 
37 (Figure 92).[120]  
 
Thus, it is proposed that a mixture of 98 and N-methyl indole would be inert enough to 
observe CH-π interactions by low-temperature NMR spectroscopy (Figure 93). 
 
 
 
k2 (36)  
[M–1 s–1] 
k2 (37)  
[M–1 s–1] 
1a 9.06 × 103 5.23 × 102 
95 2.07 × 101 1.31 × 100 
Figure 92 By two orders of magnitude decreased reactivity of 95 as compared to 1a reported by Mayr and Lakhdar. 
Figure 93 Proposed model structure for NMR studies to verify CH-π interactions 
between the iminum salt and the substrate. 
5 Partial Cationic Character of the Non-Covalent Interactions 115 
5 Partial Cationic Character of the CH-π and the π-π 
Interactions in the MacMillan Catalyst Derived 
Iminium Ion 
 
In the MacMillan catalyst derived α,β-unsaturated iminium ions, two stabilising non-
covalent interactions involving the shielding aryl group have been identified to be important 
for high levels of enantioinduction: A CH-π interaction with the syn-methyl group and a π-π 
interaction with the pendant iminium chain (see Chapter 2.1.2). These interactions control 
the spacial arrangement of the shielding aryl group. Herein, it has been shown that disrupting 
these interactions by either electronic modifications or by geometric constraints, leads to 
diminished enantioselectivities in the Friedel-Crafts reaction using N-methyl pyrrole 
(Chapter 2) or N-methyl indole (Chapter 4). The interactions are predominantly treated as  
π-π and CH-π interactions in the literature. But the iminium cation can be delocalised into 
iminium chain (Figure 94), thus, raising the question whether the π-π interaction should not 
partially be treated as a cation-π interaction. A recent study by Mori and Yamada has 
suggested, that a cation-π interaction is operative in the iminium ion of the 2nd generation 
MacMillan catalyst and (E)-crotonaldehyde.[111] Furthermore, polarisation of the syn-methyl 
group through an inductive electron-withdrawing effect from the iminium ion might cause a 
partial positive charge on the hydrogen participating in the CH-π interaction. Thus, the CH-π 
interaction might also have a partial cationic character (Figure 94).  
 
To probe this hypothesis, a Mulliken population analysis of iminium ion 1a in the CH-π 
conformation (global minimum, see chapter 2.2.7) and of 10a forced into this conformation 
(not found to be a global minium, see chapter 2.2.7) was performed in collaboration with Dr. 
Mück-Lichtenfeld from WWU Münster (Figure 95). 
Figure 94 Proposed charge delocalisation in iminium ion 1a. 
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Figure 95 Group electronegativities obtained from Mulliken population analyses of iminium salt 1a and 10a constrained in 
the CH-π conformation. 
 
It was found that only a small fraction of the positive charge is located on the iminium 
nitrogen (14.4% and 12.3% for 1a and 10a, respectively). A large portion of the charge is 
delocalised in the pendant aromatic system (47.0% and 50.8%, respectively). But also the 
methyl groups of the geminal-dimethyl moiety carry a significant partial positive charge. 
This is particularly pronounced for the syn-methyl group of the benzyl iminium ion 1a 
(15.0%), whilst the anti-methyl group of 1a only carries 12.2% of the positive charge. The 
same partial charge was found for the anti-methyl group of 10a, but in contrast to the parent 
structure 1a, the syn-methyl group of the pentafluoro-system 10a is less positively charged 
than the anti-group (11.3%). The difference of partial charge in the syn-methyl group of 
3.7% corresponds well to the difference of partial charge in the pendant aromatic system 
(3.8%). This suggest that in the CH-π conformation of 1a the positive charge is located on 
the syn-methyl group to a greater extent, thus, stabilising this favourable interaction, while 
the opposite is observed when the electron-deficient pentafluorophenyl-ring is forced into 
proximity of the syn-methyl group. The difference might be even more obvious when 
comparing the partial charge of the interacting hydrogen-substituents. Whereas all the other 
hydrogen-substituents have similar partial charges for both iminium ions, the interacting 
hydrogen of the benzyl-iminium ion 1a is 1.4 times as positively charged as the 
corresponding one in the fluorinated derivative 10a. 
To quantify the CH-π interaction, the two interacting moieties of the molecule (i.e., the 
aromatic ring and the rest of the molecule) were fragmented and the electronic distributions 
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calculated. The electron distribution changes resulting from bringing the two fragments into 
the CH-π contact are illustrated in Figure 96 for iminium ions 1a (left) and 10a (right). 
Green clouds correspond to increased electron-density, whilst orange clouds correspond to 
decreased electron-density. It was found that the two aryl rings are both polarised to a 
similar extent with increased electron-density towards the methyl-group. But the influence 
on the interacting methyl-group was found to be very different for the two systems. Whereas 
the syn-methyl group of the iminium fragment shows hardly any electronic redistribution 
when placed into close contact with the pentafluorophenyl, a strong redistribution is 
observed when the same fragment is put into contact with the electron-rich phenyl ring. Not 
only the interacting hydrogen-substituent, but also the iminium nitrogen show decreased 
electron-density, suggesting a strongly stabilising interaction. These differences are also 
reflected in the stabilisation energies resulting from combination of the fragments: The CH-π 
interaction of the iminium fragment with the phenyl-ring was computed to result in a 
stabilisation of 7.2 kcal/mol, while the interaction with the pentafluoro-ring only leads to a 
stabilisation of 3.4 kcal/mol. 
 
 
Figure 96 Quantification of the stabilisation resulting from the combination of the two components of the CH-π interaction 
and illustration of the consequent redistribution of electron-density for iminium salts 1a and 10a.  
Isodensity value: 0.0005 a.u.  
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6 Chiral Modifiers for Asymmetric Heterogeneous 
Catalysis 
6.1 Introduction 
Asymmetric heterogeneous catalysis is considerably less well established as a working horse 
for asymmetric synthesis compared to its homogeneous counterpart.[160] This is largely due 
to challenges in creating stable, active and highly enantioselective reaction sites on a solid 
surface.[160a] Nevertheless, the development of effective heterogeneous asymmetric catalysis 
processes is highly sought after because of their inherent advantages, i.e., easy separation 
and efficient recycling of the catalyst, very low catalyst loadings, and ease of transfer to 
continuous mode operation.[160c] Furthermore, the ever-growing demand for enantiopure 
compounds promotes research in this field and impressive progress has been reported in 
recent years. There are a number of strategies for the creation of asymmetric heterogeneous 
catalysts:[161]  
The first, maybe most obvious, is the immobilisation of homogenous catalysts.[162] Examples 
for this include covalent tethering of the catalyst (e.g., on silica[163] and polymeric resins[164]), 
copolymerisation of monomers carrying the catalytic moiety,[165] encapsulation of the 
catalyst,[166] and fixation by electrostatic interactions.[160c]  
Another strategy focuses on the use of chiral solids, which can e.g. be obtained by depositing 
the catalytically active particles (i.e., metals or metal oxides) on intrinsically chiral support 
materials, such as quartz and cellulose, or by developing enantiopure zeolites.[167] An 
additional research area in this category is the development of metal organic frameworks 
(MOFs) for heterogeneous asymmetric catalysis.[168] 
Today, arguably the most successful strategy for the creation of an enantioselective 
heterogeneous catalyst is to chirally modify an achiral catalytic metal surface by adsorption 
of a chiral organic molecule, the so-called chiral modifier.[160a;169] Three general 
requirements for the chiral modifier have been identified to achieve efficient chiral 
modification of a metal catalyst: A strongly adsorbing anchor to rivet the modifier to the 
catalyst, a “chiral pocket” with specific stereochemical information to induce the desired 
facial discrimination, and an interacting moiety to guide the reactant to the chiral surface 
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site.[170] The three most successful systems so far have been the Pd/ and Pt/cinchona 
alkaloids[171] (especially cinchonidine) and Ni/tartaric acid.[172] Both systems have primarily 
been used in hydrogenation reactions. There are many critical parameters that have to be 
adjusted in order to develop a highly selective system for a specific substrate. The 
concentration and adsorption strength of the modifier are important. On the one hand, the 
modifier coverage should be sufficient to avoid background (stereounselective) reduction of 
the substrate. On the other hand, the substrate and hydrogen also require access to the metal 
surface, and so excess modifier molecules might block active hydrogenation surface sites. 
Furthermore, it has been reported, that some mobility is beneficial for formation of the 
modifier-substrate complex.[173] The adsorption strength is obviously strongly dependent on 
the anchoring unit, but also on the solvent and the hydrogen surface concentration as well as 
efficient mass transfer and the reaction temperature.[160a] In addition, the stereoselective 
surface reaction was found to be highly specific with regard to the molecular structures of 
the reactant and the chiral modifier. Pioneering work on the Pt/cinchona system for the 
reduction of alkyl pyruvates has been reported as early as 1979.[174] Nevertheless, continuous 
research efforts aimed at the elucidation of the surface phenomena (mechanistic studies) and 
at the optimisation of the catalytic performance (catalytic studies) have been reported in the 
literature, highlighting the complexity of the system and the great interest in achieving 
efficient asymmetric catalysis on chirally-modified metals. 
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6.2 MacMillan Catalyst-derived Imidazolidinones as Chiral Modifiers 
It was envisaged, that due to common structural features in both imidazolidinones and 
cinchonidine (Figure 97), these species could be potentially good chiral modifiers for 
heterogeneous hydrogenation reactions. The imidazolidinones display all features which are 
essential for a chiral modifier: An anchoring moiety, a chiral centre, and, most importantly, a 
moiety that can interact with the substrate. The aromatic ring system of the molecule is 
expected to function as the anchoring unit, strongly adsorbing to the metal surface, as is the 
case for cinchonidine. Consequently, an asymmetric surface site could be formed by 
imidazolidinones in the heterogeneous hydrogenation of activated ketones. The 
enantioselectivity is proposed to originate from an N–H–O-type hydrogen bond involving 
the secondary amine moiety (Figure 97) or a covalent fixation. 
 
The heterogeneous catalysis experiments reported in this thesis were carried out in 
collaboration with Prof. Alfons Baiker and Fabian Meemken at the ETH Zurich. For an 
initial structure-activity/enantioselectivity screening, a library of 20 different 
imidazolidinones (Figure 98) was tested in the reduction of ketopantolactone (KPL), which 
is the best-studied reaction for the chiral modification with cinchonidine. Afterwards, the 
modifiers were tested in the reduction of methylbenzoylformate (MBF) and 
trifluoroacetophenone (TFAP). 
 
 
 
 
Figure 97 Structural resemblance of cinchonidine with imidazolidinones (41 shown as example). Left: Binding mode of 
cinchonidine and ketopantolactone (KPL) on Pt/Al2O3 as reported by Baiker et al.[2] Right: Proposed binding mode of 41. 
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6.2.1 Reduction of Ketopantolactone (KPL) 
The modifiers were initially tested in the reduction of ketopantolactone (dihydro-4,4-
dimethyl-2,3-furandione, Scheme 24) to complete a preliminary structure-
activity/enantioselectivity screening (Table 18). The hydrogenations were performed in 
10 mL of toluene at RT for 2 h with 50 mg pre-reduced Pt/Al2O3-catalyst (1 h under H2-flow 
at 400 °C), 0.2 M substrate and 1 mM modifier under constant H2-flow at atmospheric 
pressure with stirring of 500 rpm. The enantioselectivity and conversion were determined by 
chiral GC. First, as a reference, the performance of cinchonidine under the given reaction 
conditions was established, resulting in 40% enantiomeric excess (R). 
Figure 98 Library of imidazolidinones tested for their efficiency as chiral surface modifiers of Pt/Al2O3 for the reduction 
of different ketones. 
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Table 18 Structure-activity screen of 20 different imidazolidinones as modifiers for the asymmetric reduction of 
ketopantolactone on Pt/Al2O3. 
Modifier ee [%] e.r. Conversion [%] 
Cinchonidine 40 (R) 70:30 Full 
1 racemic racemic Full 
3 11 (R) 55.5:44.5 Full 
4 5 (R) 52.5:47.5 Full 
6 9 (R) 54.5:45.5 Full 
8 racemic racemic 97 
9 5 (R) 52.5:47.5 Full 
10 7 (R) 53.5:46.5 Full 
35 17 (R) 58.5:41.5 Full 
41 21 (R) 60.5:39.5 Full 
42 13 (R) 56.5:43.5 Full 
43 16 (R) 58:42 Full 
44 5 (R) 52.5:47.5 73 
57 racemic racemic 97 
58 racemic racemic 95 
60 11 (R) 55.5:44.5 Full 
80 racemic racemic 98 
81 racemic racemic 99 
82 racemic racemic 97 
83 racemic racemic 97 
99 5 (R) 52.5:47.5 62 
 
Almost all reactions showed full conversion within the 2 h reaction time. Six 
imidazolidinones resulted in enantioselectivities over 10% [all (R)]. As expected, the best 
results were achieved with the modifiers carrying larger aromatic systems, namely the two 
indole-derivatives (35 and 43 with 17% and 16% ee, respectively) and the anthracene 
Scheme 24 Reduction of ketopantolactone. 
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derivative (41, 21% ee). To our great surprise, modifier 60 without an anchoring group gave 
a small but notable ee of 11%, an observation that is currently not well understood and 
requires clarification. It was also surprising that the 1st generation MacMillan 
imidazolidinone 1 did not yield any selectivity, but the corresponding reduced modifier 42 
gave an enantiomeric excess as high as 13%. For the lead compound 41, a solvent screening 
with commonly used solvents for this kind of transformation was conducted (Table 19). All 
other reaction parameters were kept constant. Whereas employing acetic acid or iPrOH led to 
a drastic decrease of enantioselectivity, in THF comparable levels of stereocontrol as for 
toluene were reached. 
Table 19 Solvent screen in the asymmetric reduction of ketopantolactone on Pt/Al2O3 using 41 as chiral modifier. 
Modifier Solvent ee [%] e.r. Conversion [%] 
41 Toluene 21 (R) 60.5:39.5 Full 
41 Acetic acid 5 (R) 52.5:47.5 Full 
41 THF 21 (R) 60.5:39.5 Full 
41 iPrOH 7 (R) 53.5:46.5 Full 
 
6.2.2 Reduction of Methylbenzoylformate (MBF) 
Next, a selection of imidazolidinone-derived modifiers was tested in the reduction of 
methylbenzoylformate (MBF, Scheme 25, Table 20). The reactions were performed using 
the same reaction parameters as for the reduction of KPL. The reaction, which already 
displayed low conversion when using cinchonidine (41% after 2 h), was even slower when 
using the imidazolidinones (8% after 2 h when using anthracene-derivative 41). Again, the 
anthracene derivative 41 showed the highest levels of stereoselectivity (20% ee after 2 h) of 
the imidazolidinones tested, which is consistent with the observations discussed in 
chapter 6.2.1. However, the levels of enantioselectivity obtained are considerably worse 
compared to those obtained with cinchonidine (82% ee). To study the linearity of the 
reaction, the performance of three modifiers were monitored over several hours (GC-
analysis after 2, 3, 4, and 5 h), showing an increase of both conversion and selectivity over 
time. Thus, the results for modifier 41 could be improved to 24% ee and 18% conversion 
after 5 h. Furthermore, to exclude problems with the reaction setup or the purity of the 
substrate, the reductions were run without addition of a modifier. In this control experiment, 
the MBF used in the discussed reactions (68% conversion) and freshly purified 
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methylbenzoylformate (85% conversion) were tested, showing that the quality of the 
substrate does influence the conversion but does not explain the very low conversion with 
the tested modifiers.  
 
Table 20 Screen of different imidazolidinones as modifiers for the asymmetric reduction of methylbenzoylformate on 
Pt/Al2O3. (a) Freshly opened methylbenzoylformate was used. 
Modifier Time [h] ee [%] e.r. Conversion [%] 
without 2 - - 68 
without(a) 2 - - 85 
Cinchonidine 2 82 (R) 91:9 41 
3 2 2 (R) 51:49 57 
6 2 2 (R) 51:49 44 
6(a) 2 2 (R) 51:49 44 
41 2 20 (R) 60:40 8 
 
3 22 (R) 61:39 11 
 
4 23 (R) 61.5:38.5 14 
 
5 24 (R) 62:38 18 
43 2 7.1 (R) 53.5:46.5 11 
 
3 7.1 (R) 53.5:46.5 15 
 
4 7.2 (R) 53.6:46.4 18 
 
5 7.4 (R) 53.7:46.3 21 
99 2 racemic racemic 23 
 
3 racemic racemic 31 
 
4 racemic racemic 38 
 
5 racemic racemic 45 
 
In order to improve conversions and selectivities, a number of reactions were repeated at 
higher pressure (10 bar). Enantioselectivity of the Pt/cinchona-system for the hydrogenation 
of activated ketones is generally improved at higher hydrogen pressure. 
Scheme 25 Reduction of methylbenzoylformate. 
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Modifier ee [%] e.r. Conversion [%] 
without - - 99 
without(a) - - 99 
1 racemic racemic 73 
35 11 (R) 55.5:44.5 27 
41 47 (R) 73.5:26.5 39 
43 21 (R) 60.5:39.5 28 
44 racemic racemic 62 
 
This strategy proved successful and the results using the anthracene-derivative 41 could be 
improved to 47% ee and 39% conversion. The only other two imidazolidinones giving 
mentionable selectivities were the two indole-derivatives 35 and 43. However, 
enantioselectivity and conversion were both much lower than for 41. Interestingly, when 
employing either 1 (phenyl) or 44 (imidazole), the conversion was much better, but no 
selectivity was observed. The deterioration of enantioselectivity found for these two 
modifiers might be linked to their weaker adsorption, which might be expected for the 
phenyl- or imidazole-group due to the smaller size of the aromatic system as compared to the 
other compounds tested. 
 
 
Table 21 Screen of different imidazolidinones as modifiers for the asymmetric reduction of MBF on 
Pt/Al2O3 using 10 bar H2. (a) Freshly purified methylbenzoylformate was used. 
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6.3 L-Proline-derived Chiral Modifiers 
The L-proline-derived structures 100, 101, and 102 have previously been studied by Tungler 
and co-workers as chiral modifiers in the reduction of the C=C double bond of isophorone 
on Pd-catalysts (Scheme 26).[175] These structures feature all the prerequisites needed for a 
chiral modifier: A chiral centre, an anchoring moiety and a secondary amine as interacting 
group. For this reaction, the best results were achieved with 100 yielding enantioselectivities 
up to 42% ee and full conversion.  
 
 
 
 
Motivated by this study, we envisaged to test 100 and a number of L-proline-derivatives 
103-110 (Figure 99), previously synthesised in the group or commercially available, as 
modifiers in the reduction of different ketones. 
Scheme 26 L-Proline-derivatives as modifiers in the asymmetric reduction of isophorone reported by Tungler et al. 
Figure 99 Library of L-proline-derivatives investigated in the heterogeneous asymmetric reduction of various ketones. 
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6.3.1 Reduction of Ketopantolactone (KPL) 
First, the reduction of ketopantolactone, which gave promising results in the study using 
chiral imidazolidinones as modifiers (chapter 6.2.1), was investigated. The same reaction 
parameters were used as a starting point. Cinchonidine was used as reference compound 
which gave an enantiomeric excess of 40% and full conversion. 
 
 
 
 
Modifier ee [%] e.r. Conversion [%] 
Cinchonidine 40 (R) 30:70 Full 
100 racemic racemic Full 
103 23 (S) 61.5:38.5 Full 
104 2 (R) 49:51 Full 
105 9 (S) 54.5:45.5 Full 
106 22 (S) 61:39 Full 
107 racemic racemic 92 
108 13 (S) 56.5:43.5 Full 
109 racemic racemic Full 
110 5 (S) 52.5:47.5 Full 
 
Almost all reactions reached completion within two hours. The compound 100, reported by 
Tungler et al., did not give any stereoselectivity in this reaction. Interestingly, when 
substituting the hydroxyl group by fluorine, the selectivity went up to 23% ee. The same 
trend was preserved for the di-biphenyl-compounds: While 105 gave low levels of 
enantioselectivity (9% ee), the selectivity went up to 22% ee when using the fluorinated 
analogue 106. Using the third fluorinated compound 108 as chiral modifier resulted in a 
lower selectivity of 13% ee, which is probably due to the large tert-butyl groups hindering 
successful anchoring. Results for the most successful compound 100 were tried to be 
improved by increasing the hydrogen pressure to 10 bar and increasing the stirring to 
750 rpm, but no improvement could be achieved (22% ee, full conversion). 
Table 22 Structure-activity screen of L-proline-derivatives as modifiers for the asymmetric 
hydrogenation of ketopantolactone on Pt/Al2O3. 
6 Chiral Modifiers for Asymmetric Heterogeneous Catalysis 129 
6.3.2 Reduction of Methylbenzoylformate (MBF) 
The most promising L-proline-derived modifiers for the reduction of ketopantolactone 
proved to be the fluorinated compounds 103, 106, and 108. Therefore, these structures and 
their non-fluorinated counterparts 100 and 105 were tested in the hydrogenation of MBF 
(Table 23). The reduction was found to be very slow when using this class of modifiers with 
conversions being between 16%-35% after two hours, indicating a competitive adsorption 
between these modifiers and the substrate on the same surface site.[176] The best selectivity 
was observed for 103 (17% ee), again much higher than the non-fluorinated counterpart (5% 
ee). Unfortunately, when increasing the reaction time to obtain higher conversion, the 
selectivity decreased (13% ee and 81% conversion after 13.5 h). The fluorinated biphenyl 
modifier 106 gave the best results after 13.5 h (14% ee and 99% conversion). Only 
marginally less effective was the non-fluorinated counterpart 105 (11% ee and 96% 
conversion).  
  
Modifier Time [h] ee [%] e.r. Conversion [%] 
Cinchonidine 2 82 (R) 9:91 41 
100 2 5 (S) 52.5:47.5 24 
 
13.5 4 (S) 52:48 99 
103 2 17 (S) 58.5:41.5 16 
 
13.5 13 (S) 56.6:43.5 81 
105 2 12 (S) 56:44 23 
 
13.5 11 (S) 55.5:44.5 96 
106 2 12 (S) 56:44 23 
 
13.5 14 (S) 57:43 99 
108 2 10 (S) 55:45 35 
 
Increasing the hydrogen pressure (10 bar) and stirring rate (750 rpm) led to slightly 
increased performance of 19% ee and 34% conversion after 2 h. 
Table 23 Screening of several fluorinated and non-fluorinated L-proline-derivatives as modifiers for the asymmetric 
hydrogenation of methylbenzoylformate on Pt/Al2O3. 
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6.3.3 Reduction of Trifluoroacetophenone (TFAP) 
As a third reaction for investigation, the hydrogenation of TFAP was studied, again using the 
fluorinated L-proline-derivatives and their hydroxyl-counterparts (Table 24). The reference 
compound cinchonidine was found to give 36% ee and 90% conversion in this reaction after 
2 h when employing the same reaction conditions as used in the reductions of KPL and 
MBF. 
 
 
Modifier Time [h] ee [%] e.r. Conversion [%] 
Cinchonidine 2 36 (R) 32:68 90 
100 2 11 (S) 55.5:44.5 89 
 
3 10 (S) 55:45 97 
 
4 9 (S) 54.5:45.5 98 
 
5 9 (S) 54.5:45.5 99 
103 2 13 (S) 56.6:43.5 35 
 
3 11 (S) 55.5:44.5 42 
 
4 11 (S) 55.5:44.5 47 
 
5 10 (S) 55:45 47 
105 2 17 (S) 58.5:41.5 32 
 
3 14 (S) 57:43 44 
 
4 12 (S) 56:44 52 
 
5 11 (S) 55.5:44.5 59 
106 2 20 (S) 60:40 37 
 
3 18 (S) 59:41 53 
 
4 17 (S) 58.5:41.5 68 
 
5 16 (S) 58:42 78 
108 2 2 (S) 51:49 32 
 
3 1 (S) 50.5:49.5 50 
 
4 1 (S) 50.5:49.5 65 
Table 24 Screen of several fluorinated and non-fluorinated proline-derivatives as modifiers for the asymmetric 
hydrogenation of trifluoroacetophenone on Pt/Al2O3. 
6 Chiral Modifiers for Asymmetric Heterogeneous Catalysis 131 
Consistent with previous findings, better results were found for the fluorinated modifiers 
than for the hydroxyl-analogues, even though the difference was less pronounced (100 and 
103 resulted in 11% ee and 13% ee, respectively, and 105 and 106 resulted in 17% ee and 
20% ee, respectively). The fluorinated compound carrying a tert-butyl group on the 
anchoring moieties (108) was not an effective modifier in this reaction. The best results were 
obtained with modifier 106 (20% ee, 37% conversion). Unfortunately, increasing the 
reaction times to achieve higher conversion led to a loss of selectivity. Similarly, increasing 
the hydrogen pressure to 4 bar and stirring to 750 rpm resulted in deterioration of 
enantioselectivity to 12% ee while increasing conversion to 55% after 2 h. 
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6.4 Conclusions and Outlook 
The performances of two classes of low molecular weight organic molecules as chiral 
modifiers in asymmetric heterogeneous hydrogenations of several activated ketones were 
tested. The first class of substances, which has so far not been tested on the performance as 
chiral modifier, included different imidazolidinones (Page 121, Figure 98). The second class 
of compounds represents L-proline-derivatives, mostly carrying aromatic moieties which can 
act as anchoring units on the metal catalyst (Page 127, Figure 99). In the context of 
heterogeneous catalysis, this type of compound has been subject to studies by Tungler et al. 
as modifiers for C=C bond reductions on Pd,[175c] but, to the best of our knowledge, have not 
been tested as chiral modifiers for C=O bond hydrogenations. At this early stage of 
exploring the potential of these compounds as novel chiral modifiers, these were not able to 
compete with the established cinchonidine. Nevertheless, a preliminary validation of their 
potential is presented. For example, application of the new modifiers in the reduction of KPL 
on Pt/Al2O3 resulted in stereoselectivities of 21% ee for the imidazolidinone carrying an 
anthracene anchor (41) and 23% ee for the fluorinated L-proline-derived modifier 103, while 
the benchmark modifier cinchonidine provides 40% ee under the same reaction conditions. 
Furthermore, it was observed that the fluorinated L-proline-derivatives performed generally 
better than their hydroxyl-analogues, the most prominent example being 23% difference in 
the enantiomeric excess using 100 and 103 in the hydrogenation of MBF. It is believed that 
further optimisation studies will likely enhance the performance of these modifiers to a 
synthetically useful level. It is important to note that the optimisation of cinchonidine as a 
chiral modifier took decades to achieve and is still ongoing. Moreover, studies on the 
observed beneficial effect of fluorine in modifier design may assist in designing improved 
modifiers. 
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7 Conclusions and Outlook 
 
In this thesis, the importance of non-covalent interactions for molecular pre-organisation in 
MacMillan catalyst-derived iminium ions were studied. In this intermediate, two of the three 
possible staggered conformations around the C–CPh bond are postulated to be stabilised by 
non-covalent interactions, and predominant population of these two conformers is believed 
to be crucial for high levels of enantioinduction. It is proposed that conformer I is stabilised 
by a partially cationic CH-π interaction with the syn-methyl group, and conformer II by a π-
π interaction with the iminium chain (Figure 100, centre).[8a;47;49]  
 
Figure 100 Overview of the studies on non-covalent interactions in the MacMillan catalyst-derived reactive intermediate. 
 
A large library of imidazolidinones was prepared in an elaborate molecular editing study. 
Iminium salts of many of these catalysts were obtained by condensation with  
(E)-cinnamaldehyde, and studied by solution phase NMR. A conformer population analysis 
of a selection of iminium salts with electronically modified aryl shielding moieties (R) 
demonstrated that those with shielding group electron-densities similar to those of the parent 
phenyl structure predominantly populate conformer I. Increasing the electron-density of the 
shielding group by introduction of electron-donating substituents led to an increased 
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population of conformer II, while electron-deficient analogues preferentially populate 
conformer III, presumably due to destabilisation of the non-covalent interactions. The 
electron-densities were represented by the computed traceless quadrupole moment tensor 
component perpendicular to the aromatic ring (Qzz). Gratifyingly, it was possible to obtain 
X-ray structures of one electron-rich (R = indole, Qzz = –5.10, conformer II), one electron-
deficient (R = C6F5, Qzz = +2.33, conformer III), and one electronically intermediate 
iminium ion (R = C6H4OH, Qzz = –3.78, conformer I) verifying the conformational diversity 
proposed by NMR studies. Moreover, it was observed that for the geminal-dimethyl moiety, 
the shift-differences of the syn- and the anti-methyl groups (∆δ1Hsyn/anti) in the iminium salts 
vary greatly. This is likely directly related to the population of conformer I. Whilst a high 
population of conformer I was believed to lead to large ∆δ1Hsyn/anti due to strong shielding of 
the syn-methyl group, the opposite effect was attributed to decreased population of 
conformer I. A computational lowest energy conformer analysis supported this supposition. 
In the molecular editing study it was also observed that the non-covalent interactions 
controlling the conformational behaviour of the iminium salts are not only sensitive towards 
electronic modifications of the aryl shielding group, but also to steric modifications and 
modifications in the benzylic position. The catalyst library was tested in the organocatalytic 
Friedel-Crafts reaction of N-methyl pyrrole and (E)-cinnamaldehyde. The electron-rich 
trimethoxyphenyl imidazolidinone was identified as an improved catalyst as compared to the 
parent MacMillan catalyst (94% as compared to 85% ee at RT after 3 h). Furthermore, a 
direct linear relationship between the enantioselectivities obtained and the Qzz of the 
shielding group of a given imidazolidinone was observed for most of the catalysts. Because 
comparison of the Qzz value was not always convenient for all imidazolidinones, and 
additionally because this analysis requires computation, the ∆δ1Hsyn/anti was found to be a 
more amenanable quantity for all imidazolidinones. Fortunately, a clear correlation between 
the enantioselectivity obtained and the ∆δ1Hsyn/anti was identified, providing a useful tool for 
future catalyst design. Due to the exothermicity of this reaction, it was assumed that the 
transition state resembles the iminium ion intermediate, thus observed enantioselectivity was 
rationalised based on the conformational behaviour of the iminium ion. To validate this 
working hypothesis, a computational lowest energy conformation analysis of the transition 
state was performed. Consistent with the results for the iminium ion, conformer I was 
identified as the global minimum structure. Subsequent application of the catalyst library in 
the organocatalytic Friedel-Crafts reaction of N-methyl indole and (E)-cinnamaldehyde 
replicated the trends observed for the reaction using N-methyl pyrrole. Interestingly, using 
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N-methyl indole, a reversal of selectivity was observed for catalysts predominantly 
populating conformer III. A pincer type model directing the indole nucleophile by the action 
of two CH-π interactions was proposed. Consequently, an explanation is offered for the 
observation that in the Friedel-Crafts reaction of indoles the 2nd generation MacMillan 
catalysts was found to be privileged, while when using pyrroles, the 1st and 2nd generation 
catalysts gave virtually the same enantioselectivities. Furthermore, it was suggested that the 
discussed CH-π and π-π interactions have a considerable cationic character due to 
delocalisation of the positive charge into not only the iminium chain, but also in the geminal-
dimethyl group. Indeed, a Mulliken population analysis of the iminium ion derived from the 
1st generation MacMillan catalyst showed that only 14.4% of the positive charge is localised 
on the nitrogen and that the rest of the charge is not only delocalised into the aromatic 
system but also into the geminal-dimethyl group. In an additional theoretical study, the 
molecule was partitioned into the two interacting fragments and the stabilisation energy 
resulting from bringing the two fragments into CH-π contact was found to be –7.2 kcal/mol. 
Comparison of this result to the interaction energy of NMe4+ and benzene (–9 kcal/mol)[104a] 
and of CH4 and benzene (–1.45 kcal/mol)[98] supports the notion of a considerable cationic 
character of the CH-π interaction. A selection of iminium ions were studied by gas phase  
IR-MPD spectroscopy using the free electron laser FELIX at Radboud University in 
Nijmegen. It was proposed that conformational preferences in the gas phase could be 
detected by delicate characteristic shifts of fingerprint IR bands. A preliminary validation of 
this method is presented. Moreover, the efficiency of the studied imidazolidinones as chiral 
modifiers for asymmetric heterogeneous catalysis was examined and first promising results 
were obtained. 
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8.1 Materials and Methods 
All chemicals were purchased as reagent grade and used without further purification. 
Solvents for purification (extraction and chromatography) were purchased as technical grade 
and distilled on the rotary evaporator prior to use. All reactions using air or moisture 
sensitive compounds were carried out in flame-dried and evacuated glassware under an 
atmosphere of argon. Solvents for these reactions were dried according to standard 
procedures or were taken from the solvent drying system. For column chromatography 
SiO2–60 (230–400 mesh ASTM; Fluka) was used as stationary phase. Analytical thin layer 
chromatography (TLC) was performed on glass plates pre-coated with SiO2–60 F254 (Merck) 
and visualized with a UV-lamp (254 nm) or by dipping in cerium ammonium molybdate 
(CAM) stain, KMnO4 stain, or ninhydrine stain, followed by heating. Flash column 
chromatography was carried out on Fluka silica gel 60 (230-400 mesh). Concentration in 
vacuo was performed at ~10 mbar and 40 °C, drying at ~10-2 mbar and RT. NMR spectra 
were measured at ETH Zurich on a Varian AVANCE 300 MHz, a Bruker ARX 300 MHz, a 
Bruker DRX 400 MHz or a Bruker AV 400 MHz spectrometer at ambient temperature or by 
the Laboratory for Organic Chemistry (ETH) NMR service on a Bruker AV 600 MHz, DRX 
600 MHz or DRX 500 MHz spectrometer at ambient temperature. Or NMR spectra were 
measured by the NMR service of the Organisch-Chemisches Institut, Westfälische 
Wilhelms-Universität Münster on a Bruker AV300 or an Agilent DD2 600 spectrometer at 
ambient temperature. 1H NMR spectra are reported as follows: chemical shift δ in ppm 
(multiplicity, number of protons, coupling constant J in Hz, assignment of proton). The 
deuterated solvent residual peak was used as internal reference: CHCl3 (δH 7.260), CD2HOD 
(δH 3.310), C2D5HOS (δH 2.500) and CD2HCN (δH 1.940). 13C NMR spectra are reported as 
follows: chemical shift δ in ppm (multiplicity if different from s due to heteronuclear 
couplings to fluorine, number of carbons if different from 1, coupling constant xJCF in Hz, 
assignment of carbon). The solvent peak was used as internal reference: CDCl3 (δC 77.16), 
CD3OD (δC 49.000), C2D6OS (δH 2.500) and CD3CN (δC 1.32). 19F NMR spectra are 
reported as follows: chemical shift δ in ppm (multiplicity, number of fluorines, coupling 
constant xJYF in Hz, assignment of fluorine). The resonance multiplicity is abbreviated as: s 
(singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet) and b (broad). Assignments of 
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unknown compounds are based on DEPT, COSY (HH and FF), HMBC, HSQC, HOESY 
and/or NOESY spectra if required for assignment. Melting points were measured on a Büchi 
B-545 melting-point apparatus in open capillaries and are uncorrected. IR spectra were 
recorded on a Perkin-Elmer 100 FT-IR spectrometer, selected adsorption bands are reported 
in wavenumbers (cm–1) and intensities are reported as: w (weak), m (medium), s (strong) and 
b (broad). Optical rotations were measured on a JASCO P-2000 polarimeter or a Perkin-
Elmer 341 polarimeter with 1 dm cell length and λ = 589 nm (Na D-line), concentrations are 
given as mg mL-1. HPLC spectra were recorded on an Agilent 1100 series (DAD, Agilent 
technologies 1200 series) using a Chiralcel OJ-H (5 µm, 250·4.6 mm) or a Reprosil Chiral-
OM (5 µm, 250·4.6 mm) column and n-hexane/iso-propanol as eluent. GC spectra were 
recorded on an Agilent 7890A chromatograph equipped with a flame ionization detector 
(FID) operated at 300 °C using hydrogen as fuel gas (30 mL/min) and air as oxidant 
(400 mL/min). Nitrogen was used as a make-up gas (25 mL/min) and helium as a carrier gas 
(1.623 mL/min), the injections with a split ratio of 20:1 were performed at 250 °C . 
Separation was achieved using a CP-Chirasil-Dex CB (0.25 µm, 25 m·0.25 mm) chiral 
capillary column. High-resolution mass spectra (HR ESI and EI MS) were measured by the 
MS service of the Laboratory for Organic Chemistry, ETH Zurich and by the MS service of 
the Organisch-Chemisches Institut, Westfälische Wilhelms-Universität Münster. Elemental 
analyses were performed at the Laboratory for Organic Chemistry, ETH Zurich on a LECO 
CHN/900 instrument. 
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8.2 Synthetic Procedures 
8.2.1 Synthesis of 1-Boc-2-(tert-butyl)-3-methyl-4-imidazolidinone (racemic and 
chiral) 
 
2-(tert-Butyl)-3-methyl-4-imidazolidinone (BMI) (19)[177] 
 
To glycine methyl ester hydrochloride (12.5 g, 99.6 mmol, 1.0 equiv.) was added MeNH2 
(8 N in EtOH, 50.0 mL, 398 mmol, 4.0 equiv.) at RT and the resulting solution was heated to 
50 °C until complete conversion was observed on TLC after 2.25 h. The reaction was 
allowed to come to RT and evaporated in vacuo to give glycine methyl amide hydrochloride 
as a white solid. The product was dissolved in MeOH (150 mL) and pivalaldehyde (75% in 
tBuOH, 31.4 mL, 199 mmol, 2.0 equiv.) and Et3N (11.1 mL, 79.7 mmol, 0.8 equiv.) were 
added at RT. The resulting solution was heated to reflux for 20 h. The mixture was 
concentrated in vacuo, CH2Cl2 was added to the residue and the insoluble white solid 
(Et3N·HCl) filtered off. The filtrate was concentrated in vacuo and purified by CC (SiO2; 
CH2Cl2/MeOH/NH3 (25% in H2O) 20:1:0.1) to give imidazolidinone 19 as a yellow oil 
(11.4 g, 74%).  
Rf = 0.74 (SiO2; CH2Cl2/MeOH 10:1); 1H NMR (400 MHz, CDCl3): δ = 4.04 (d, 1H, J = 1.2, 
H–C2), 3.41 (d, J = 16.0, 1H, H–C5), 3.34 (d, J = 16.0, 1H, H–C5), 2.86 (s, 3H, H–C8), 2.32 
(b, 1H, H–N), and 0.88 (s, 9H, H–C7) ppm; 13C NMR (100 MHz, CDCl3): δ = 174.7 (C4), 
85.0 (C2), 49.1 (C5), 37.5 (C6), 31.1 (C8), and 25.5 (3C, C7) ppm; IR (ATR):  = 3295m, 
2962m, 2908w, 2868w, 1666s, 1485m, 1433m, 1405s, 1389m, 1363w, 1353w, 1319s, 
ν~
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1260m, 1210m, 1123w, 1105s, 1028m, 1003w, 957w, 886s, 825s, 747m, 681s, and 
654w cm-1; HR-ESI-MS: m/z: 157.1333 ([M+H]+, calcd for C8H17N2O+: 157.1335); 
analytical data in agreement with the literature.[142;177] 
 
1-Boc-2-(tert-butyl)-3-methyl-4-imidazolidinone (Boc-BMI, racemic) (23) 
 
To a solution of imidazolidinone 19 (2.75 g, 17.6 mmol, 1.00 equiv.) in acetone (35.0 mL) 
were added Boc2O (5.32 g, 24.3 mmol, 1.38 equiv.) and DMAP (0.24 g, 1.9 mmol, 
0.11 equiv.) under Ar at 0 °C. The solution was allowed to come to RT and stirred for 14.5 h 
during which time it turned from yellow to an intense orange color. Et3N (2.5 mL, 
17.6 mmol, 1.0 equiv.) and, after another 7 h, H2O (1.5 mL) were added. After stirring for an 
additional 1.0 h, the organic solvent was evaporated in vacuo. Et2O (20 mL) and an aqueous 
solution of HCl (1 N, 20 mL) were added to the residue, the layers were separated and the 
organic layer was washed with an aqueous solution of HCl (1 N, 20 mL) and with a saturated 
aqueous solution of NaHCO3 (20 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. The resulting oil was purified by CC (SiO2; CH2Cl2/MeOH/NH3 
(25% in H2O) 20:1:0.1) to give Boc-BMI (23) as an off-white solid (3.88 g, 86%). 
Rf = 0.67 (SiO2; CH2Cl2/MeOH 10:1); M.p. = 71.3–72.2 °C; 1H NMR (400 MHz, CDCl3): 
δ = 4.89 (bs, 1H, H–C2), 4.05 (bs, 1H, H–C5), 3.66 (bd, 1H, J = 16.0, H–C5), 2.93 (s, 3H, 
H–C8), 1.40 (s, 9H, H–C4'), and 0.91 (s, 9H, H–C7) ppm; 13C NMR (100 MHz, CDCl3): 
δ = 170.5 (C4), 154.6 (b, C1'), 82.3 (b, C2), 81.1 (b, C3'), 50.0 (b, C5), 39.5 (C6), 31.5 (C8), 
28.2 (3C, C4'), and 25.9 (3C, C7) ppm; IR (ATR):  = 3373w, 3344w, 3291w, 2940w, 
2915w, 2877w, 1644s, 1524s, 1495m, 1455m, 1439w, 1399m, 1343w, 1322w, 1267w, 
1230w, 1153m, 1109m, 1031w, 979w, 927m, 914m, 877m, 858m, 745s, 699s, and 661w cm-
1; HR-ESI-MS: m/z: 279.1678 ([M+Na]+, calcd for C13H24N2O3Na+: 279.1685); analytical 
data in agreement with the literature.[122b]  
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(2S)-1-Boc-2-(tert-butyl)-3-methyl-4-imidazolidinone (S-Boc-BMI) (23, chiral)[122b] 
 
To a solution of (R)-BMI trifluoroacetic acid (2.00 g, 7.40 mmol, 1.00 equiv.) in CH2Cl2 
(5.00 mL) was added aqueous NaOH (2 N, approx. 7 mL) to adjust the pH to approx. 8. The 
layers were separated and the aqueous phase extracted three times with CH2Cl2. The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue 
was dissolved in acetone (14.0 mL) and Boc2O (2.21 mL, 9.62 mmol, 1.3 equiv.) and DMAP 
(90.4 mg, 0.74 mmol, 0.1 equiv.) were added under Ar at 0 °C. The solution was allowed to 
come to RT and stirred for 19 h. Et3N (1.0 mL, 7.4 mmol, 1.0 equiv.) and after another 2 h 
H2O (0.7 mL) were added. After stirring for an additional 2 h, the organic solvent was 
evaporated in vacuo. Et2O (10 mL) and an aqueous solution of HCl (1 N, 10 mL) were added 
to the residue, the layers were separated and the organic layer was washed with an aqueous 
solution of HCl (1 N, 10 mL) and with a saturated aqueous solution of NaHCO3 (10 mL). 
The organic layer was dried over MgSO4 and concentrated in vacuo give (S)-Boc-BMI (23) 
as a white solid (1.53 g, 81%). 
Rf = 0.69 (SiO2; CH2Cl2/MeOH 10:1); M.p. = 65.0–65.7 °C; [α]D20: –11.6 (c = 1.05, 
CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 4.88 (bd, 1H, J = 55.0, H–C2), 4.08 (bd, 1H, 
J = 14.1, H–C5), 3.73 (bd, 1H, J = 16.0, H–C5), 2.98 (s, 3H, H–C8), 1.46 (s, 9H, H–C4'), 
and 0.96 (s, 9H, H–C7) ppm; 13C NMR (100 MHz, CDCl3): δ = 170.6 (C4), 154.7 (b, C1'), 
82.3 (b, C2), 81.0 (b, C3'), 59.5 (b, C5), 39.5 (C6), 31.5 (C8), 28.2 (3C, C4'), and 25.9 (3C, 
C7) ppm; IR (ATR):  = 2968w, 2951w, 1694s, 1480w, 1450w, 1434w, 1400m, 1362s, 
1301s, 1288m, 1252s, 1162s, 1118m, 1104s, 1035w, 1007w, 939m, 928m, 877m, 868m, 
776m, 762w, 728w, and 664w cm-1; HR-ESI-MS: m/z: 257.1861 ([M+H]+, calcd for 
C13H25N2O3+: 257.1860); analytical data in agreement with the literature.[122b] 
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8.2.2 Syntheses of (5S)-5-Benzyl-2,2,3-trimethyl-4-imidazolidinone (1) and (5S)-5-
Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium salt 
(1a) 
 
L-Phenylalanine methyl amide (15)[178] 
 
To a suspension of L-phenylalanine (6.98 g, 42.3 mmol, 1.0 equiv.) in MeOH (17.1 mL, 
423 mmol, 10 equiv.) was added thionyl chloride (3.70 mL, 50.7 mmol, 1.2 equiv.) over 
15 min at 0 °C and the resulting solution was allowed to come to RT before it was heated to 
reflux for 22 h. The solution was allowed to come to RT and evaporated in vacuo to give the 
L-phenylalanine methyl ester hydrochloride as a white solid. To the ester was added MeNH2 
(8 N in EtOH, 21.0 mL, 169 mmol, 4.0 equiv.) at RT and the solution stirred for 23 h. The 
reaction was concentrated in vacuo and a saturated aqueous solution of NaHCO3 (45 mL) 
was added. The aqueous layer was extracted with CH2Cl2 (3 x 55 mL). The combined 
organic layers were dried over MgSO4, filtrated and concentrated in vacuo to give amide 15 
as a yellowish solid (6.44 g, 86%). 
Rf = 0.37 (CH2Cl2/MeOH 10:1); M.p. = 58.5–59.6 °C; [α]D20: –66.1 (c = 1.07, CH2Cl2); 
1H NMR (300 MHz, CDCl3): δ = 7.32 (2H, t, J = 7.2, H–C4'), 7.28–7.19 (4H, m, H–C3', H–
C5', H–Namide), 3.61 (1H, dd, J = 9.4, 3.9, H–C2), 3.29 (1H, dd, J = 13.7, 3.9, H–C1'), 2.82 
(3H, d, J = 5.0, H–C3), 2.68 (1H, dd, J = 13.7, 9.4, H–C1'), and 1.38 (2H, b, H–Namine) ppm; 
13C NMR (75 MHz, CDCl3): δ = 174.9 (C1), 138.2 (C2'), 129.4 (2C, C3'), 128.8 (2C, C4'), 
126.9 (C5'), 56.6 (C2), 41.2 (C1'), and 26.0 (C3) ppm; IR (ATR):  = 3343w, 3291w, 
3033w, 2940w, 2915w, 2877w, 1644s, 1524s, 1455m, 1439m, 1399m, 1342w, 1322w, 
1268w, 1229w, 1152w, 1109m, 978w, 927w, 913w, 877m, 858m, 834w, 745s, and  
ν~
8 Experimental Section 143 
699s cm-1, HR-ESI-MS: m/z: 179.1186 ([M+H]+, calcd for C10H15N2O+: 179.1179); 
analytical data in agreement with the literature.[178] 
 
(5S)-5-Benzyl-2,2,3-trimethyl-4-imidazolidinone (1)[179] 
 
To a solution of amide 15 (1.00 g, 5.6 mmol, 1 equiv.) in MeOH (12.0 mL) was added 
acetone (2.1 mL, 28.1 mmol, 5.0 equiv.) and NEt3 (0.6 mL, 4.5 mmol, 0.8 equiv.) at RT 
under an atmosphere of argon and the yellow solution was heated to reflux overnight. The 
reaction was allowed to come to RT and concentrated in vacuo to give 1 as a yellow oil 
(1.22 g, quant.). 
Rf = 0.79 (CH2Cl2/MeOH 10:1); [α]D20: –33.2 (c = 0.94, CH3OH); 1H NMR (400 MHz, 
CDCl3): δ = 7.36–7.18 (5H, m, H–C2', H–C3', and H–C4'), 3.80 (1H, dd, J = 6.8, 4.5, H–
C5), 3.15 (1H, dd, J = 14.2, 4.5, H–C8), 3.01 (1H, dd, J = 14.2, 6.8, H–C8), 2.76 (3H, s, H–
C7), 1.70 (1H, b, H–Namine), 1.27 (3H, s, H–C6), and 1.16 (3H, s, H–C6) ppm; 13C NMR 
(101 MHz, CDCl3): δ = 173.5 (C4), 137.3 (C1'), 129.7 (2C, C2'), 128.7 (2C, C3'), 126.9 
(C4'), 75.7 (C2), 59.4 (C5), 37.4 (C8), 27.4 (C6), 25.5 (C6), and 25.4 (C7) ppm; IR (ATR): 
 = 3317b, 2979w, 2931w, 1745w, 1680s, 1602w, 1496w, 1424s, 1398s, 1367m, 1269m, 
1148m, 1089w, 1030w, 922w, 904w, 748s, 701s, and 673w cm-1; HR-ESI-MS: m/z: 
219.1492 ([M+H]+, calcd for C13H19N2O+: 219.1492); analytical data in agreement with the 
literature.[179] 
 
  
ν~
144 8 Experimental Section 
(5S)-5-Benzyl-2,2,3-trimethyl-4-imidazolidinone hydrochloride (1·HCl) 
 
Imidazolidinone 1 (7.0 mg, 32 µmol, 1.0 equiv.) was dissolved in HCl in MeOH (1.25 N, 
0.1 mL, 125 µmol, 3.9 equiv.) and stirred for 30 min at RT. The solution was concentrated in 
vacuo to give 1·HCl as a white solid (8.2 mg, quant.). 
1H NMR (400 MHz, CD3OD): δ = 7.47–7.29 (5H, m, H–C2', H–C3', and H–C4'), 4.66 (1H, 
dd, J = 10.7, 3.4, H–C5), 3.54 (1H, dd, J = 15.2, 3.4, H–C8), 3.07 (1H, dd, J = 15.2, 10.7, 
H–C8), 2.92 (3H, s, H–C7), 1.75 (3H, s, H–C6), and 1.60 (3H, s, H–C6) ppm; 13C NMR 
(101 MHz, CD3OD): δ = 167.7 (C4), 136.5 (C1'), 130.22 and 130.19 (2·2C, C2' and C3'), 
128.8 (C4'), 79.0 (C2), 59.7 (C5), 35.0 (C8), 25.7 (C6), 24.3 (C6), and 22.1 (C7) ppm; 
analytical data in agreement with the literature.[3] 
 
(5S)-5-Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium 
perchlorate (1a·ClO4-): 
 
To imidazolidinone 1 (34.9 mg, 0.16 mmol, 1 equiv.) in Et2O (0.20 mL) was added 
perchloric acid (60% in H2O, 26.80 mg, 0.16 mmol, 1 equiv.) in EtOH/Et2O (1:1, 0.40 mL) 
at RT and the resulting mixture stirred for 15 min before it was evaporated in vacuo to give 
the imidazolidinone salt. The salt was redissolved in MeOH (0.40 mL) and heated to 35 °C. 
(E)-cinnamaldehyde (40.2 µL, 0.32 mmol, 2 equiv.) was added and the yellow solution 
stirred for 1 h. The solvent was removed in vacuo and the residue dissolved in a minimum 
amount of MeOH. From this solution the iminium salt was crashed out with Et2O and the 
supernatant solution taken off. The washing procedure was repeated and the iminium salt 
isolated as a yellow solid (31.9 mg, 46%). 
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M.p. = 189.9–191.9 °C; [α]D20.5: +2.5 (c = 0.45, CH3CN); 1H NMR (300 MHz, CD3CN): 
δH = 8.73 (1H, dd, J = 10.7, 1.9, H–C1''), 8.18 (1H, d, J = 15.0, H–C3''), 7.93 (2H, d, J = 7.3, 
H–C5''), 7.77–7.68 (1H, m, H–C7''), 7.62 (2H, t, J = 7.6, H–C6''), 7.38–7.20 (4H, m, H–C3', 
H–C4', H–C2''), 7.09 (2H, dd, J = 7.9, 1.7, H–C2'), 5.20 (1H, s, H–C5), 3.57 (1H, dd, 
J = 14.7, 5.7, H–C8), 3.47 (1H, dd, J = 14.7, 3.7, H–C8), 2.78 (3H, s, H–C7), 1.70 (3H, s, 
H–C6anti), and 0.79 (3H, s, H–C6syn) ppm; 13C NMR (151 MHz, CD3CN): δC = 168.2 
(C1''), 166.7 (C3''), 165.2 (C4), 136.1 (C7''), 134.8 (C1'), 134.4 (C4''), 132.5 (2C, C5''), 
131.1 (2C, C2'), 130.7 (2C, C6''), 130.1 (2C, C3'), 129.2 (C4'), 118.4 (C2''), 86.5 (C2), 65.2 
(C5), 37.2 (C8), 27.5 (C6anti), 26.1 (C7), and 24.8 (C6syn) ppm; IR (ATR):  = 2938b, 
1712s, 1620s, 1601s, 1587s, 1455m, 1438m, 1420m, 1043m, 1335w, 1311w, 1281m, 
1235w, 1197m, 1179m, 1151w, 1115m, 1081m, 1051w, 1012m, 999m, 955w, 933w, 872w, 
756m, 750m, 705m, 684w, 642w, and 622s cm-1; HR-ESI-MS: m/z: 333.19602 ([M-ClO4-]+, 
calcd for C22H25N2O+: 333.19614); analytical data in agreement with the literature.[49] 
 
(5S)-5-Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium 
hexafluoroantimonat (1a·SbF6-): 
 
To imidazolidinone 1 (50.0 mg, 0.23 mmol, 1.0 equiv.) in MeOH (1.0 mL) was added 
fluoroantimonic acid (65% in H2O, 135.0 mg, 0.25 mmol, 1.1 equiv.) in MeOH (1.0 mL) at 
RT and the resulting mixture stirred for 15 min before (E)-cinnamaldehyde (29.0 µL, 
0.23 mmol, 1 equiv.) was added. The yellow solution was stirred overnight. The solvent was 
removed in vacuo and the residue dissolved in a minimum amount of MeOH. From this 
solution the iminium salt was crashed out with Et2O and the supernatant solution taken off. 
This purification procedure was repeated two additional times to give 1a·SbF6- as a red 
solid.  
M.p. = 172.0–173.3 °C; [α]D20 = +506.7 (c = 1.06 in MeOH); 1H NMR (600 MHz, CD3CN): 
δH = 8.73 (1H, dd, J = 10.7, 1.9, H–C1''), 8.20 (1H, d, J = 15.0, H–C3''), 7.93 (2H, dd, 
J = 8.4, 1.0, H–C5''), 7.74–7.69 (1H, m, H–C7''), 7.62 (2H, t, J = 7.8, H–C6''), 7.33–7.25 
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(4H, m, H–C3', H–C4', H–C2''), 7.11–7.07 (2H, m, H–C2'), 5.19 (1H, t, J = 5.4, H–C5), 3.57 
(1H, dd, J = 14.8, 5.8, H–C8), 3.47 (1H, dd, J = 14.8, 3.6, H–C8), 2.79 (3H, d, J = 0.4, H–
C7), 1.70 (3H, s, H–C6anti), and 0.81 (3H, s, H–C6syn) ppm; 13C NMR (151 MHz, CD3CN): 
δC = 168.2 (C1''), 166.8 (C3''), 165.2 (C4), 136.1 (C7''), 134.8 (C1'), 134.4 (C4''), 132.5 (2C, 
C5''), 131.2 (2C, C2'), 130.7 (2C, C6''), 130.1 (2C, C3'), 129.2 (C4'), 118.4 (C2''), 86.5 (C2), 
65.2 (C5), 37.3 (C8), 27.6 (C6anti), 26.1 (C7), and 24.8 (C6syn) ppm; IR (ATR):  = 3064b, 
1712s, 1622s, 1603s, 1588s, 1455m, 1437m, 1402m, 1392m, 1309w, 1291m, 1235w, 
1198m, 1179m, 1151m, 1118w, 1081w, 1050w, 1013w, 1000w, 935w, 862w, 755m, 703m, 
687w, 655m, and 640s cm-1; HR-ESI-MS: m/z: 333.19588 ([M-SbF6-]+, calcd for 
C22H25N2O+: 333.19614). 
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8.2.3 Syntheses of (5S)-2,2,3-Trimethyl-5-(3,4,5-trimethoxybenzyl)imidazolidin-4-one 
(3) and 5-(3',3',4'-Trimethoxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-
phenylallylidene]-imidazolidin-1-ium salt (3a) 
 
1-Bromomethyl-3,4,5-trimethoxybenzene[180] 
 
To a solution of 3,4,5-trimethoxybenzyl alcohol (4.00 g, 20.2 mmol, 1.00 equiv.) in Et2O 
(1.00 L) were added successively PBr3 (5.46 g, 20.2 mmol, 1.00 equiv.) and pyridine 
(79.8 mg, 1.01 mmol, 0.05 equiv.) slowly at RT. The mixture was heated to 40 °C and after 
completion was detected by TLC (3 h), it was allowed to cool to RT. H2O was added and the 
aqueous layer extracted twice with Et2O. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo to give 1-bromomethyl-3,4,5-trimethoxybenzene as a 
white solid (5.27 g, quant.), which should be kept in the freezer (turns first orange then 
brown at RT). 
Rf = 0.76 (CH/EtOAc 1:1); M.p. = 72.3–73.4 °C (Lit. 74–75 ºC); 1H NMR (300 MHz, 
CDCl3): δ = 6.62 (2H, s, H–C3), 4.47 (2H, s, H–C1), 3.88 (6H, d, J = 0.7, H-C6), and 3.85 
(3H, d, J = 0.8 Hz, H-C7) ppm; 13C NMR (101 MHz, CDCl3): δ = 153.5 (2C, C4), 138.3 
(C5), 133.3 (C2), 106.3 (2C, C3), 61.0 (C7), 56.3 (2C, C6), and 34.4 (C1) ppm; HR-EI-MS: 
m/z: 181.0866 ([M-Br-]+, calcd for C10H13O3+: 181.0859); analytical data in agreement with 
the literature.[181]  
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(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-(3,4,5-trimethoxybenzyl)-4-imidazolidinone 
(25)[122b] 
 
A solution of HMDS (1.28 mL, 6.16 mmol, 1.2 equiv.) in dry THF (4.00 mL) in a flame-
dried Schlenck under an atmosphere of argon was cooled to 0 °C. nBuLi (1.6 N in nhexane, 
3.85 mL, 6.16 mmol, 1.2 equiv.) was added dropwise and the solution stirred for 15 min 
before it was cooled to –78 °C. DMPU (1.86 mL, 15.4 mmol, 3.0 equiv.) and then (S)-Boc-
BMI (23) (1.30 g, 5.13 mmol, 1.0 equiv.) in THF (4.00 mL) was added dropwise to the 
orange solution that turned darker upon addition. After 30 min, 1-bromomethyl-3,4,5-
trimethoxybenzene (1.34 g, 5.13 mmol, 1.0 equiv.) in THF (4.00 mL) was added slowly and 
the resulting mixture stirred for 3 h during which time a brown solid formed. The reaction 
was quenched by addition of a saturated aqueous solution of NH4Cl and extracted three 
times with CH2Cl2. The combined organic layers were dried over MgSO4 and concentrated 
in vacuo. Purification by CC (SiO2; CH/EtOAc 3:1) gave 25 as a white solid (1.93 g, 86%). 
Rf = 0.40 (CH/EtOAc 1:1); M.p. = 69.6–71.2 °C; [α]D23: +34.4 (c = 0.83, CH3OH); 1H NMR 
(300 MHz, CDCl3): δ = 6.38 (2H, s, H–C3'), 4.65 (1H, d, J = 1.5, H–C2), 4.28 (1H, dd, 
J = 4.4, 2.2, H–C5), 3.80 (6H, s, H–C6'), 3.79 (3H, s, H–C7'), 3.65 (1H, bs, H–C1'), 3.13 
(1H, bd, J = 12.8, H–C1'), 2.80 (s, 3H, H–C8), 1.47 (s, 9H, H–C4'), and 0.93 (s, 9H, H–C7) 
ppm; 13C NMR (100 MHz, CDCl3, racemic compound, C4 and C1'' not visible): δ = 152.8 
(C4'), 136.9 (C2'), 131.7 (b, C5'), 107.4 (2C, C3'), 81.1 (C2), 77.4 (C3''), 61.0 (C7'), 60.9 
(C5), 56.4 (2C, C6'), 41.1 (C6), 32.0 (C1'), 28.4 (3C, C4''), 26.8 (3C, C7), and 25.9 
(C8) ppm; IR (ATR): = 2966w, 2931w, 2840w, 1693s, 1588w, 1509w, 1456w, 1433w, ν~
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1407w, 1380m, 1363m, 1339w, 1325w, 1302w, 1254m, 1239m, 1165m, 1126s, 1112s, 
1050w, 1019m, 966w, 956w, 930w, 889w, 859w, 835w, 787w, 764m, 713w, and 668w cm-1; 
HR-ESI-MS: m/z: 459.2464 ([M+Na]+, calcd for C23H36N2O6Na+: 459.2466). 
 
L-3,4,5-Trimethoxyphenylalanine N-methyl amide (30)[182] 
 
To a solution of 25 (1.75 g, 4.01 mmol, 1.0 equiv.) in MeOH (45.0 mL) was added an 
aqueous solution of HCl (1 N, 45.0 mL) at RT and the mixture heated to reflux for 11 h. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N) and extracted three times with CH2Cl2. The combined organic layers were dried 
over MgSO4 and concentrated in vacuo to give amide 30 as an off-white solid (812 mg, 
75%). 
Rf = 0.26 (CH2Cl2/MeOH 10:1); M.p. = 127.8–128.6 °C; [α]D20: +16.6 (c = 0.98, CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 7.30 (1H, b, H–Namide), 6.43 (2H, s, H–C3'), 3.83 (6H, s, 
H–C6'), 3.81 (3H, s, H–C7'), 3.59 (1H, dd, J = 9.4, 3.9, H–C2), 3.19 (1H, dd, J = 13.6, 3.9, 
H–C1'), 2.82 (3H, d, J = 5.0, H–C3), 2.61 (1H, dd, J = 13.6, 9.4, H–C1'), and 1.48 (2H, bs, 
H–Namine) ppm; 13C NMR (101 MHz, CDCl3): δ = 174.8 (C1), 153.3 (2C, C4´), 136.7 (C2'), 
133.6 (C5'), 106.0 (2C, C3'), 60.8 (C7'), 56.6 (C2), 56.1 (2C, C6'), 41.4 (C1'), and 25.9 
(C3) ppm; IR (ATR):  = 3390w, 3311w, 2998w, 2945w, 2841w, 1648m, 1589m, 1507m, 
1454m, 1420w, 1402w, 1328m, 1232s, 1185w, 1149w, 1123s, 1040w, 1002m, 972w, 920w, 
857w, 812s, 783w, 760m, 739m, and 686w cm-1; HR-ESI-MS: m/z: 269.1497 ([M+H]+, 
calculated for C13H21N2O4+: 269.1496).  
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(5S)-2,2,3-Trimethyl-5-(3,4,5-trimethoxybenzyl)imidazolidin-4-one (3)  
 
To a solution of amide 30 (300 mg, 1.12 mmol, 1.0 equiv.) in MeOH (5.0 mL) were added 
aceton (0.62 mL, 8.40 mmol, 7.5 equiv.) and NEt3 (0.12 mL, 0.90 mmol, 0.8 equiv.) at RT 
under an atmosphere argon and the solution heated to reflux for 7 h. The reaction was 
allowed to come to RT and concentrated in vacuo to give imidazolidinone 3 as an off-white 
solid (345 mg, quant.).  
Rf = 0.73 (CH2Cl2/MeOH 10:1); M.p. = 116.8–118.2 °C; [α]D20: –37.2 (c = 0.94, CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 6.44 (2H, s, H–C3'), 3.81 (6H, s, H–C6'), 3.80 (3H, s, H–
C7'), 3.75 (1H, t, J = 5.3, H–C5), 3.02 (2H, d, J = 5.3, H–C1'), 2.74 (3H, s, H–C7), 1.26 (3H, 
s, H–C6), and 1.16 (3H, s, H–C6) ppm; 13C NMR (75 MHz, CDCl3): δ = 173.5 (C4), 153.3 
(2C, C4'), 136.9 (C2'), 132.8 (C5'), 106.5 (2C, C3'), 75.7 (C2), 61.0 (C7'), 59.4 (C5), 56.2 
(2C, C6'), 37.4 (C1'), 27.3 (C6), 25.4 (C6), and 25.4 (C7) ppm; IR (ATR):  = 3291w, 
2920w, 2686w, 2565w, 2432w, 1702s, 1673w, 1590m, 1508w, 1459m, 1424s, 1396s, 
1385m, 1328m, 1315w, 1234m, 1154w, 1113s, 1064w, 1000m, 967w, 875w, 831w, 789w, 
and 771w cm-1; HR-ESI-MS: m/z: 309.1814 ([M+H]+, calcd for C16H25N2O4+: 309.1809); 
elemental analysis calcd (%, racemic compound) for C16H24N2O4 (308.2): C 62.32, H 7.84, 
N 9.08, O 20.75; found: C 62.02, H 7.68, N 8.96, O 20.82.  
 
2,2,3-Trimethyl-5-(3,4,5-trimethoxybenzyl)imidazolidin-4-one hydrochloride (3·HCl) 
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Imidazolidinone 3 (30.0 mg, 97 µmol, 1.0 equiv.) was dissolved in HCl in MeOH (1.25 N, 
0.31 mL, 388 µmol, 4.0 equiv.) and stirred for 30 min at RT. The solution was concentrated 
in vacuo to give the hydrochloride salt 3·HCl as a white powder (33 mg, quant.).  
Crystals suitable for X-ray crystallographic analysis were achieved by vapour exchange of a 
methanolic solution of 3·HCl with Et2O. 
M.p. = 85.2–86.0 °C; 1H NMR (600 MHz, CD3OD): δ = 6.77 (2H, s, H–C3'), 4.69 (1H, dd, 
J = 11.0, 3.0, H–C5), 3.87 (6H, s, H–C6'), 3.74 (3H, s, H–C7'), 3.50 (1H, dd, J = 15.1, 3.0, 
H–C1'), 2.97 (1H, dd, J = 15.1, 11.0, H–C1'), 2.93 (3H, s, H–C7), 1.77 (3H, s, H–C6), and 
1.60 (3H, s, H–C6) ppm; 13C NMR (151 MHz, CD3OD): δ = 167.6 (C4), 155.0 (2C, C4'), 
138.4 (C2'), 132.4 (C5'), 107.3 (2C, C3'), 78.9 (C2), 61.0 (C7'), 59.9 (C5), 56.7 (2C, C6'), 
35.2 (C1'), 25.7 (C7), 24.2 (C6), and 21.9 (C6) ppm; IR (ATR):  = 3309w, 2920w, 2684w, 
2517w, 2431w, 1702s, 1614w, 1591m, 1507w, 1457m, 1425m, 1397m, 1385m, 1327w, 
1315w, 1241m, 1181w, 1155w, 1111s, 1064w, 1034w, 999m, 968w, 875w, 831w, 789w, 
and 667m cm-1. 
 
1H NMR counterion-effect study of 3·X in CD3OD at RT 
 
Imidazolidinone 3 (rac, 25.0 mg, 81 µmol, 1.0 equiv.) was dissolved in EtOH (0.5 mL), the 
corresponding acid was added (81 µmol, 1.0 equiv.) in Et2O (0.5 mL) and the solution stirred 
for 30 min at RT. The solution was concentrated in vacuo to give the salt as a white solid in 
quant. yield.  
3·HPF6: HPF6 (60% in H2O, 20 mg)  
1H NMR (300 MHz, CD3OD): δ = 6.74 (2H, s, H–C3'), 4.63 (1H, dd, J = 10.5, 3.5, H–C5), 
3.87 (6H, s, H–C6'), 3.74 (3H, s, H–C7'), 3.47 (1H, dd, J = 15.0, 3.5, H–C1'), 3.01–2.89 (4H, 
m, H–C1', H–C7), 1.74 (3H, s, H–C6), and 1.60 (3H, s, H–C6) ppm.  
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3·HClO4: HClO4 (70% in H2O, 12 mg) 
1H NMR (300 MHz, CD3OD): δ = 6.73 (2H, s, H–C3'), 4.68 (1H, ddd, J = 10.8, 3.5, 0.5, H–
C5), 3.87 (6H, s, H–C6'), 3.74 (3H, s, H–C7'), 3.51 (1H, dd, J = 15.1, 3.5, H–C1'), 2.92 (3H, 
d, J = 0.6, H–C7), 2.90 (1H, dd, J = 15.2, 10.9, H–C1'), 1.76 (3H, s, H–C6), and 1.61 (3H, s, 
H–C6) ppm. 
3·HSbF6: HSbF6 (65% in H2O, 43 mg) 
1H NMR (300 MHz, CD3OD): δ = 6.72 (2H, s, H–C3'), 4.64 (1H, ddd, J = 10.8, 3.5, 0.6, H–
C5), 3.87 (6H, s, H–C6'), 3.74 (3H, s, H–C7'), 3.51 (1H, dd, J = 15.2, 3.5, H–C1'), 2.94–2.83 
(4H, m, H–C1', H–C7), 1.74 (3H, s, H–C6), and 1.60 (3H, s, H–C6) ppm. 
 
5-(3',3',4'-Trimethoxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium perchlorate (3a·ClO4-): 
 
To racemic imidazolidinone 3 (49.6 mg, 0.16 mmol, 1.0 equiv.) in Et2O (0.2 mL) was added 
HClO4 (60% in H2O, 26.8 mg, 0.16 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.4 mL) at RT and 
stirred for 10 min, before the yellow solution was evaporated in vacuo to give the off-white 
HClO4 salt as a solid. The solid was dissolved in MeOH (0.4 mL) and E-cinnamaldehyde 
(40.2 µL, 0.32 mmol, 2.0 equiv.) was added at 35 °C and the yellow solution stirred for 1 h. 
The solvent was evaporated in vacuo. The residue was dissolved in a minimum amount of 
MeOH, the iminium salt was crashed out with Et2O and the supernatant solution taken off. 
This purification procedure was repeated two additional times to give iminium salt 3a·ClO4- 
as a yellow solid.  
M.p. = 116.1 °C decomp.; 1H NMR (600 MHz, CD3CN): δH = 8.77 (1H, dd, J = 10.7, 1.9, 
H–C1''), 8.13 (1H, d, J = 15.0, H–C3''), 7.87–7.83 (2H, m, H–C5''), 7.71–7.67 (1H, m, H–
C7''), 7.59 (2H, t, J = 7.9, H–C6''), 7.11 (1H, dd, J = 15.0, 10.7, H–C2''), 6.38 (2H, s, H–
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C2'), 5.17 (1H, td, J = 5.3, 1.6, H–C5), 3.73 (6H, s, H–C5'), 3.52 (1H, dd, J = 14.7, 5.4, H–
C8), 3.47 (3H, s, H–C6'), 3.31 (1H, dd, J = 14.7, 5.2, H–C8), 2.86 (3H, d, J = 0.5, H–C7), 
1.75 (3H, s, H–C6anti), and 1.13 (3H, s, H–C6syn) ppm; 13C NMR (151 MHz, CD3CN): 
δC = 168.2 (C1''), 165.9 (C4), 165.4 (C3''), 154.8 (2C, C3'), 139.0 (C4'), 136.0 (C7''), 134.4 
(C4''), 132.4 (2C, C5''), 130.6 (2C, C6''), 130.3 (C1'), 118.6 (C2''), 108.2 (2C, C2'), 86.6 
(C2), 65.1 (C5), 60.7 (C6'), 56.8 (2C, C5'), 38.2 (C8), 27.3 (C6anti), 26.2 (C7), and 25.5 
(C6syn) ppm; IR (ATR):  = 3382br, 3068w, 2984w, 1704s, 1622s, 1588s, 1517m, 1441m, 
1403m, 1392m, 1325w, 1277w, 1233w, 1198m, 1178m, 1153w, 1073s, 999s, 931m, 852w, 
813w, 756m, 726w, 684m, and 621s cm-1; HR-ESI-MS: m/z: 423.22755 ([M-ClO4-]+, calcd 
for C25H31N2O4+: 423.22838).  
 
1H NMR counterion-effect study of 3a·X in CD3CN at RT 
 
5-(3',3',4'-Trimethoxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium hexafluoroantimonat (3a·SbF6-) 
To imidazolidinone 3 (rac, 9.6 mg, 31 µmol, 1.0 equiv.) in MeOH (0.5 mL) was added 
fluoroantimonic acid (65% in H2O, 11.5 mg, 33 µmol, 1.1 equiv.) RT and the resulting 
mixture stirred for 30 min before (E)-cinnamaldehyde (4 µL, 31 µmol, 1.0 equiv.) was 
added. The yellow solution was stirred for 3 h. The solvent was removed in vacuo and the 
residue dissolved in a minimum amount of MeOH. From this solution the iminium salt was 
crashed out with Et2O and the supernatant solution taken off. This purification procedure 
was repeated two additional times to give iminium salt 3a·SbF6- as a yellow solid.  
1H NMR (400 MHz, CD3CN): δH = 8.71 (1H, dd, J = 10.7, 1.8, H–C1''), 8.09 (1H, d, 
J = 15.0, H–C3''), 7.84 (2H, dd, J = 8.2, 1.0, H–C5''), 7.70 (1H, tt, J = 7.4, 1.9, H–C7''), 7.59 
(2H, t, J = 7.6, H–C6''), 7.10 (1H, dd, J = 15.0, 10.7, H–C2''), 6.38 (2H, s, H–C2'), 5.15 (1H, 
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td, J = 4.9, 0.9, H–C5), 3.73 (6H, s, H–C5'), 3.52 (1H, dd, J = 14.6, 5.4, H–C8), 3.48 (3H, s, 
H–C6'), 3.31 (1H, dd, J = 14.6, 5.2, H–C8), 2.86 (3H, d, J = 0.4, H–C7), 1.74 (3H, s, H–
C6anti), and 1.12 (3H, s, H–C6syn) ppm. 
 
5-(3',3',4'-Trimethoxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium hexafluorophosphat (3a·PF6-) 
To imidazolidinone 3 (rac, 25 mg, 81 µmol, 1.0 equiv.) was added fluorophosphoric acid 
(60% in H2O, 19.7 mg, 81 µmol, 1.0 equiv.) in EtOH (0.5 mL) at RT and the resulting 
mixture stirred for 10 min before it was concentrated in vacuo. The salt was dissolved in 
EtOH (0.3 mL) and (E)-cinnamaldehyde (11.2 µL, 89 µmol, 1.1 equiv.) was added. The 
yellow solution was stirred overnight during which time the product precipitated from the 
solution as a yellow solid. The supernatant solution was taken off and the solid washed with 
EtOH to give iminium salt 3a·PF6- as a yellow solid.  
1H NMR (300 MHz, CD3CN): δH = 8.72 (1H, dd, J = 10.7, 1.8, H–C1''), 8.08 (1H, d, 
J = 15.1, H–C3''), 7.86 (2H, d, J = 7.3, H–C5''), 7.76–7.67 (1H, m, H–C7''), 7.61 (2H, t, 
J = 7.5, H–C6''), 7.12 (1H, dd, J = 15.0, 10.7, H–C2''), 6.40 (2H, s, H–C2'), 5.17 (1H, t, 
J = 4.7, H–C5), 3.75 (6H, s, H–C5'), 3.54 (1H, dd, J = 14.6, 5.3, H–C8), 3.50 (3H, s, H–C6'), 
3.33 (1H, dd, J = 14.6, 5.2, H–C8), 2.88 (3H, s, H–C7), 1.76 (3H, s, H–C6anti), and 1.14 (3H, 
s, H–C6syn) ppm. 
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8.2.4 Syntheses of (5S)-5-para-Aminobenzyl-2,2,3-trimethyl-4-imidazolidinone (4) and 
5-(4'-Aminobenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium salt (4a) 
 
(5S)-5-para-Aminobenzyl-2,2,3-trimethyl-4-imidazolidinone (4) 
To 4-amino-L-phenylalanine hydrochloride (12) (500 mg, 2.31 mmol, 1.0 equiv.) in MeOH 
(2.5 mL, 61.7 mmol, 26.7 equiv.) was added thionyl chloride (0.2 mL, 2.77 mmol, 
1.2 equiv.) over 5 min at 0 °C and the resulting solution was allowed to come to RT before it 
was heated to reflux for 10 h. The solution was allowed to come to RT and evaporated in 
vacuo to give the L-tyrosine methyl ester hydrochloride as a white powder. To the ester was 
added MeNH2 (8 N in EtOH, 1.20 mL, 9.24 mmol, 4.0 equiv.) at RT and the solution stirred 
overnight. After evaporation in vacuo, the residue was dissolved in MeOH (5.0 mL), acetone 
(0.85 mL, 11.6 mmol, 5.0 equiv.) was added at RT under an atmosphere of argon and the 
yellow solution was heated to reflux overnight. The reaction was allowed to come to RT and 
concentrated in vacuo. Purification by CC (SiO2; CH2Cl2/MeOH/NH3 (33% aqueous) 
10:1:0.1) gave imidazolidinone 6 as a brown oil (458 mg, 85%). 
Rf = 0.41 (CH2Cl2/MeOH 10:1); [α]D23: –55.6 (c = 0.78, CH3OH); 1H NMR (300 MHz, 
CDCl3): δ = 6.98 (2H, d, J = 8.3, H–C2'), 6.60 (2H, d, J = 8.3, H–C3'), 3.70 (1H, t, J = 5.3, 
H–C5), 2.97 (2H, dd, J = 5.2, 1.8, H–C8), 2.72 (3H, s, H–C7), 1.23 (3H, s, H–C6), and 1.13 
(3H, s, H–C6) ppm; 13C NMR (75 MHz, CDCl3): δ = 173.7 (C4), 145.3 (C4'), 130.5 (2C, 
C2'), 126.4 (C1'), 115.4 (2C, C3'), 75.6 (C2), 59.4 (C5), 35.9 (C8), 27.1 (C7), and 25.3 (2C, 
C6) ppm; IR (ATR):  %ν  = 3343w, 2973w, 2925w, 1673s, 1516s, 1428m, 1399s, 1319w, 
1274m, 1206w, 1180m, 1147m, 1089w, 1018w, 921w, 805m, and 728w cm-1; HR-ESI-MS: 
m/z: 234.1611 ([M+H]+, calcd for C14H19N3O+: 234.1601).  
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8.2.5 Syntheses of (5S)-2,2,3-Trimethyl-5-(3,5-dimethoxybenzyl)imidazolidin-4-one 
(5) and 5-(3',3'-Dimethoxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-
phenylallylidene]-imidazolidin-1-ium salt (5a) 
 
1-Bromomethyl-3,5-dimethoxybenzene[180] 
 
To a solution of 3,5-dimethoxybenzyl alcohol (500m g, 2.97 mmol, 1.00 equiv.) in Et2O 
(14 mL) were added successively PBr3 (0.28 mL, 2.97 mmol, 1.00 equiv.) and pyridine 
(12 µL, 0.15 mmol, 0.05 equiv.) slowly at RT. The mixture was heated to 40 °C and after 
completion was detected by TLC (2 h), it was allowed to cool to RT. H2O (20 mL) was 
added slowly and the aqueous layer extracted Et2O (3·15 mL). The combined organic layers 
were washed with H2O and brine and dried over MgSO4. Concentration in vacuo gave 1-
bromomethyl-3,5-dimethoxybenzene as a white crystalline solid (625 mg, 91%), which 
should be kept in the freezer (turns first orange then brown at RT). 
Rf = 0.88 (CH/EtOAc 1:1); M.p. = 71.2–71.8 °C; 1H NMR (400 MHz, CDCl3): δ = 6.55 (2H, 
d, J = 2.3, H–C3), 6.41 (1H, d, J = 2.3, H–C5), 4.42 (2H, s, H–C1), and 3.79 (6H, s, H-
C6) ppm; 13C NMR (101 MHz, CDCl3): δ = 161.0 (2C, C4), 139.8 (C2), 107.0 (2C, C3), 
100.6 (C5), 55.4 (2C, C6), and 33.7 (C1) ppm; HR-EI-MS: m/z: 151.0758 ([M-Br-]+, calcd 
for C9H11O2+: 151.0759); analytical data in agreement with the literature.[180] 
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(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-(3,5-dimethoxybenzyl)-4-imidazolidinone 
(26)[122b] 
 
A solution of HMDS (0.3 mL, 1.42 mmol, 1.2 equiv.) in dry THF (1.00 mL) in a flame-dried 
Schlenck under an atmosphere of argon was cooled to 0 °C. nBuLi (1.6 N in nhexane, 0.9 mL, 
1.42 mmol, 1.2 equiv.) was added dropwise and the solution stirred for 15 min before it was 
cooled to -78 °C. DMPU (0.43 mL, 3.54 mmol, 3.0 equiv.) and then (S)-Boc-BMI (23) 
(300 g, 1.18 mmol, 1.0 equiv.) in THF (1.00 mL) was added dropwise, the solution turned 
yellow during the addition. After 30 min, 1-bromomethyl-3,5-dimethoxybenzene (273 g, 
1.18 mmol, 1.0 equiv.) in THF (1.00 mL) was added slowly and the resulting mixture stirred 
for 5 h. The reaction was quenched by addition of a saturated aqueous solution of NaHCO3 
(4 mL) and extracted with CH2Cl2 (3·5 mL). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. Purification by CC (SiO2; CH/EtOAc 3:1) gave 26 as a 
colourless oil (352 mg, 73%). 
Rf = 0.53 (CH/EtOAc 1:1); [α]D20: +40.0 (c = 1.00, CH3OH); 1H NMR (400 MHz, CDCl3): 
δ = 6.31 (2H, s, H–C3'), 6.27 (1H, bt, J = 2.1, H–C5'), 4.63 (1H, bs, H–C2), 4.27 (1H, bs, H–
C5), 3.71 (6H, s, H–C6'), 3.66 (1H, bs, H–C1'), 3.13 (1H, dd, J = 14.2, 1.2, H–C1'), 2.81 (s, 
3H, H–C8), 1.47 (s, 9H, H–C4'), and 0.91 (s, 9H, H–C7) ppm; 13C NMR (101 MHz, CDCl3): 
δ = 171.5 (C4), 160.3 (2C, C4'), 152.8 (C1''), 138.0 (C2'), 108.0 (b, 2C, C3'), 99.0 (b, C5'), 
81.0 (C2), 81.0 (C3''), 60.5 (C5), 55.3 (2C, C6'), 40.9 (C6), 34.4 (b, C1'), 31.9 (C8), 28.3 
(3C, C4'), and 26.6 (3C, C7) ppm; IR (ATR): = 2966w, 2838w, 1698s, 1595s, 1457m, 
1431m, 1407m, 1397s, 1366s, 1312w, 1251m, 1204m, 1151s, 1127s, 1067m, 1033w, 960w, 
887w, 862w, 774w, 755w, 736w, and 696w cm-1; HR-ESI-MS: m/z: 407.2542 ([M+H]+, 
calcd for C22H35N2O5+: 407.2540). 
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L-3,5-Dimethoxyphenylalanine N-methyl amide (31)[182] 
 
To a solution of 26 (300 mg, 0.74 mmol, 1.0 equiv.) in MeOH (7.0 mL) was added an 
aqueous solution of HCl (1 N, 7.0 mL) at RT and the mixture heated to reflux for 8 h. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N, circa 4 mL) and extracted three times with CH2Cl2. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo to give amide 31 as a white solid 
(175 mg, 99%). 
M.p. = 61.7–63.6 °C; [α]D23: +15.1 (c = 0.60, CH3OH); 1H NMR (400 MHz, CDCl3): 
δ = 7.33 (1H, bd, J = 5.5, H–Namide), 6.34 (2H, s, H–C3'), 6.31 (1H, s, H–C5'), 3.74 (6H, d, 
J = 1.2, H–C6'), 3.56 (1H, dd, J = 9.7, 3.9, H–C2), 3.19 (1H, dd, J = 13.6, 3.9, H–C1'), 2.79 
(3H, d, J = 5.0, H–C3), 2.56 (1H, dd, J = 13.6, 9.6, H–C1'), and 1.45 (2H, bs, H–
Namine) ppm; 13C NMR (101 MHz, CDCl3): δ = 174.9 (C1), 161.0 (2C, C4´), 140.4 (C2'), 
107.2 (2C, C3'), 98.8 (C5'), 56.4 (C2), 55.4 (2C, C6'), 41.4 (C1'), and 25.9 (C3) ppm; 
IR (ATR):  = 3379w, 3314w, 2958w, 2935w, 2865w, 1636m, 1595s, 1524m, 1463m, 
1446m, 1428m, 1400m, 1346m, 1332w, 1291m, 1205s, 1147s, 1147s, 1097w, 1081w, 
1057s, 994w, 955w, 907w, 877w, 838w, 822m, 786w, 742m, 690m, and 657w cm-1;  
HR-ESI-MS: m/z: 239.1397 ([M+H]+, calcd for C12H19N2O3+: 239.1390).  
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(5S)-2,2,3-Trimethyl-5-(3,4,5-trimethoxybenzyl)imidazolidin-4-one (5)  
 
To a solution of amide 31 (100 mg, 0.42 mmol, 1.0 equiv.) in MeOH (2.0 mL) were added 
aceton (0.23 mL, 3.15 mmol, 7.5 equiv.) and NEt3 (47 µL, 0.34 mmol, 0.8 equiv.) at RT 
under an atmosphere argon and the solution heated to reflux for 6 h. The reaction was 
allowed to come to RT and concentrated in vacuo to give imidazolidinone 5 as a yellow oil 
(122 mg, quant.).  
[α]D23: –39.3 (c = 1.02, CH3OH); 1H NMR (400 MHz, CDCl3): δ = 6.37 (2H, d, J = 2.3, H–
C3'), 6.31 (1H, d, J = 2.3, H–C5'), 3.73 (7H, m, H–C5, H–C6'), 3.06 (1H, dd, J = 14.1, 4.5, 
H–C1'), 2.91 (1H, dd, J = 14.0, 6.9, H–C1'), 2.74 (3H, s, H–C7), 1.24 (3H, s, H–C6), and 
1.18 (3H, s, H–C6) ppm; 13C NMR (101 MHz, CDCl3): δ = 173.5 (C4), 160.9 (2C, C4'), 
139.6 (C2'), 107.4 (2C, C3'), 99.0 (C5'), 75.6 (C2), 59.2 (C5), 55.4 (2C, C6'), 37.7 (C1'), 
27.4 (C6), 25.4 (C6), and 25.3 (C7) ppm; IR (ATR):  = 2933w, 2839w, 1684s, 1595s, 
1461m, 1429s, 1398m, 1368w, 1315w, 1294w, 1205s, 1151s, 1066m, 931w, 832w, and 
698w cm-1; HR-ESI-MS: m/z: 279.1708 ([M+H]+, calcd for C15H23N2O3+: 279.1703). 
 
5-(3',3'-Dimethoxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium perchlorate (5a·ClO4-): 
 
To racemic imidazolidinone 5 (3.3 mg, 12 µmol, 1.0 equiv.) in Et2O (20 µL) was added 
HClO4 (70% in H2O, 1.7 mg, 12 µmol, 1.0 equiv.) in EtOH/Et2O (1:1, 40 µL) at RT and 
stirred for 10 min, before the yellow solution was evaporated in vacuo to give the off-white 
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HClO4 salt as a solid. The solid was dissolved in MeOH (20 µL) and (E)-cinnamaldehyde 
(3.0 µL, 24 µmol, 2.0 equiv.) was added at 35 °C and the yellow solution stirred for 1 h. The 
solvent was evaporated in vacuo. The residue was dissolved in a minimum amount of 
MeOH, the iminium salt was crashed out with Et2O and the supernatant solution taken off. 
The iminium salt 5a·ClO4- was isolated as a yellowish solid contaminated with (E)-
cinnamaldehyde (P/(E)-cinnamaldehyde 1:1.3).  
1H NMR (300 MHz, CD3CN): δH = 8.73 (1H, dd, J = 10.7, 1.7, H–C1''), 8.10 (1H, d, 
J = 14.8, H–C3''), 7.88–7.82 (2H, m, H–C5''), 7.72–7.58 (3H, m, H–C7'', H–C6''), 7.11 (1H, 
dd, J = 15.1, 10.6, H–C2''), 6.34–6.27 (3H, m, H–C2', H–C4'), 5.16 (1H, b, H–C5), 3.67 
(6H, s, H–C5'), 3.50 (1H, dd, J = 14.5, 5.3, H–C8), 3.30 (1H, dd, J = 14.5, 5.1, H–C8), 2.84 
(3H, d, J = 0.7, H–C7), 1.74 (3H, s, H–C6anti), and 1.13 (3H, s, H–C6syn) ppm; HR-ESI-MS: 
m/z: 393.2170 ([M–ClO4-]+, calcd for C24H29N2O3+: 393.2173). 
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8.2.6 Syntheses of (5S)-5-para-Hydroxybenzyl-2,2,3-trimethyl-4-imidazolidinone (6) 
and 5-(4'-Hydroxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium salt (6a) 
 
L-Tyrosine methyl amide (17) 
 
To L-tyrosine (1.00 g, 5.52 mmol, 1.0 equiv.) in EtOH (3.4 mL, 82.8 mmol, 15 equiv.) was 
added thionyl chloride (0.6 mL, 8.28 mmol, 1.5 equiv.) over 5 min at 0 °C and the resulting 
solution was allowed to come to RT before it was heated to reflux for 8 h. The solution was 
allowed to come to RT and evaporated in vacuo to give the L-tyrosine ethyl ester 
hydrochloride as a white powder. To the ester was added MeNH2 (8 N in EtOH, 2.80 mL, 
22.1 mmol, 4.0 equiv.) at RT and the solution stirred overnight. After evaporation in vacuo, 
THF was added and the remaining white solid filtered off (MeNH2·HCl). The filtrate was 
concentrated in vacuo to give amide 17 as an orange oil (1.09 g, quant.). 
Rf = 0.21 (CH2Cl2/MeOH 10:1); [α]D20: +23.2 (c = 1.02, CH3OH); 1H NMR (300 MHz, 
CD3OD): δ = 7.00 (2H, d, J = 8.5, H–C3'), 6.71 (2H, d, J = 8.6, H–C4'), 3.44 (1H, t, J = 6.8, 
H–C2), 2.87 (1H, dd, J = 13.4, 6.5, H–C1'), 2.71 (1H, dd, J = 13.4, 7.1, H–C1'), and 2.67 
(3H, s, H–C3) ppm; 13C NMR (75 MHz, CD3OD): δ = 177.1 (C1), 157.4 (C5'), 131.3 (2C, 
C3'), 129.3 (C2'), 116.3 (2C, C4'), 57.9 (C2), 41.6 (C1'), and 26.1 (C3) ppm; IR (ATR): 
 = 3275b, 2939w, 1644s, 1612s, 1592s, 1540m, 1513s, 1447m, 1410m, 1309w, 1234s, 
1170m, 1105w, 1022w, 942w, 821s, and 696w cm-1; HR-ESI-MS: m/z: 195.1133 ([M+H]+, 
calculated for C10H15N2O2+: 195.1128); analytical data in agreement with the literature.[183] 
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(5S)-5-para-hydroxybenzyl-2,2,3-trimethyl-4-imidazolidinone (6) 
 
To a solution of amide 17 (985 mg, 5.07 mmol, 1.0 equiv.) in MeOH (10.0 mL) was added 
acetone (1.9 mL, 25.4 mmol, 5.0 equiv.) at RT under an atmosphere of argon and the yellow 
solution was heated to reflux overnight. The reaction was allowed to come to RT and 
concentrated in vacuo to give imidazolidinone 6 as an off-white solid (1.15 g, 97%). 
Rf = 0.64 (CH2Cl2/MeOH 10:1); M.p. = 94.5–95.8 °C; [α]D20.5: –57.0 (c = 1.00, CH3OH); 
1H NMR (300 MHz, CD3OD): δ = 7.06 (2H, d, J = 8.5, H–C2'), 6.72 (2H, d, J = 8.6, H–C3'), 
3.73 (1H, dd, J = 6.8, 4.4, H–C5), 3.00 (1H, dd, J = 14.3, 4.3, H–C8), 2.85 (1H, dd, J = 14.3, 
7.1, H–C8), 2.75 (3H, d, J = 0.4, H–C7), 1.26 (3H, s, H–C6), and 1.20 (3H, s, H–C6) ppm; 
13C NMR (101 MHz, CD3OD): δ = 175.5 (C4), 157.4 (C4'), 131.5 (2C, C2'), 129.0 (C1'), 
116.3 (2C, C3'), 77.4 (C2), 60.9 (C5), 37.0 (C8), 26.8 (C6), 25.6 (C7), and 24.8 (C6) ppm; 
IR (ATR):  %ν  = 3276w, 2974w, 2939w, 1661s, 1479w, 1447m, 1427m, 1400s, 1384s, 1370s, 
1331w, 1262m, 1243m, 1210w, 1147s, 1076m, 1037m, 1004w, 993w, 936s, 916m, 847s, 
and 757s cm-1; HR-ESI-MS: m/z (%): 235.1444 ([M+H]+, calculated for C13H19N2O2+: 
235.1441); analytical data in agreement with the literature.[184] 
 
5-para-hydroxybenzyl-2,2,3-trimethyl-4-imidazolidinone hydrochloride (6·HCl, 
racemic) 
 
Imidazolidinone 6 (18.7 mg, 80 µmol, 1.0 equiv.) was dissolved in HCl in MeOH (1.25 N, 
0.25 mL, 313 µmol, 3.9 equiv.) and stirred for 30 min at RT. The solution was concentrated 
in vacuo to give 6·HCl as a white solid (19 mg, quant.). 
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M.p. = 84.7–85.6 °C; 1H NMR (400 MHz, CD3OD): δ = 7.21 (2H, d, J = 8.5, H–C2'), 6.81 
(2H, d, J = 8.6, H–C3'), 4.57 (1H, dd, J = 10.7, 3.5, H–C5), 3.45 (1H, dd, J = 15.3, 3.5, H–
C8), 2.91 (3H, s, H–C7), 2.95–2.85 (1H, m, H–C8), 1.70 (3H, s, H–C6), and 1.58 (3H, s, H–
C6) ppm; 13C NMR (101 MHz, CD3OD): δ = 167.8 (C4), 158.4 (C4'), 131.2 (2C, C2'), 126.6 
(C1'), 116.9 (2C, C3'), 78.9 (C2), 60.0 (C5), 34.3 (C8), 25.6 (C7), 24.2 (C6), and 22.0 
(C6) ppm; IR (ATR):  = 2924w, 2702m, 2493w, 1696s, 1614w, 1594m, 1516m, 1423s, 
1394s, 1309w, 1264m, 1217s, 1174m, 1160m, 1101w, 1038w, 938w, 826m, 794w, 732w, 
and 668m cm-1. 
 
1H NMR counterion-effect study of 6·X in CD3OD at RT 
 
Imidazolidinone 6 (10.0 mg, 43 µmol, 1.0 equiv.) was dissolved in MeOH (0.5 mL), the 
corresponding acid was added (47 µmol, 1.1 equiv.) and the solution stirred for 30 min at 
RT. The solution was concentrated in vacuo to give the corresponding salt as a white solid in 
quant. yield.  
6·HClO4: HClO4 (70% in H2O, 6.7 mg) 
1H NMR (300 MHz, CD3OD): δ = 7.22 (2H, d, J = 8.5, H–C2'), 6.81 (2H, d, J = 8.6, H–C3'), 
4.57 (1H, ddd, J = 10.7, 3.3, 0.5, H–C5), 3.44 (1H, dd, J = 15.3, 3.5, H–C8), 2.91 (3H, d, 
J = 0.5, H–C7), 2.89 (1H, dd, J = 15.4, 10.6, H–C8), 1.71 (3H, s, H–C6), and 1.59 (3H, s, H–
C6) ppm. 
6·HBF4: HBF4 (50% in H2O, 8.2 mg) 
1H NMR (300 MHz, CD3OD): δ = 7.21 (2H, d, J = 8.5, H–C2'), 6.81 (2H, d, J = 8.6, H–C3'), 
4.56 (1H, dd, J = 10.6, 3.4, H–C5), 3.44 (1H, dd, J = 15.4, 3.5, H–C8), 2.91 (3H, s, H–C7), 
2.88 (1H, dd, J = 15.3, 10.6, H–C8), 1.70 (3H, s, H–C6), and 1.58 (3H, s, H–C6) ppm. 
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6·HSbF6: HSbF6 (65% in H2O, 24.9 mg) 
1H NMR (300 MHz, CD3OD): δ = 7.21 (2H, d, J = 8.5, H–C2'), 6.81 (2H, d, J = 8.6, H–C3'), 
4.55 (1H, dd, J = 10.7, 3.6, H–C5), 3.43 (1H, dd, J = 15.2, 3.6, H–C8), 2.90 (3H, d, J = 0.6, 
H–C7), 2.88 (1H, dd, J = 15.3, 10.6, H–C8), 1.70 (3H, s, H–C6), and 1.58 (3H, s, H–
C6) ppm. 
 
5-(4'-Hydroxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-
ium perchlorate (6a·ClO4-) 
 
To imidazolidinone 6 (37.5 mg, 0.16 mmol, 1 equiv.) in Et2O (0.20 mL) was added 
perchloric acid (60% in H2O, 26.80  mg, 0.16 mmol, 1 equiv.) in EtOH/Et2O (1:1, 0.40 mL) 
at RT and the resulting mixture stirred for 10 min before it was evaporated in vacuo to give 
the imidazolidinone salt. The salt was dissolved in MeOH (0.40 mL) and heated to 35 °C. 
(E)-cinnamaldehyde (40.2 µL, 0.32 mmol, 2 equiv.) was added and the yellow solution 
stirred for 1 h. The solvent was removed in vacuo and the residue dissolved in a minimum 
amount of MeOH. From this solution the iminium salt was crashed out with Et2O and the 
supernatant solution taken off. The washing procedure was repeated and the iminium salt 
6a·ClO4- isolated as a yellow solid (50.3 mg, 70%). 
Crystals suitable for X-ray crystallographic analysis were obtained from a solution in 
CH3CN by vapor diffusion with Et2O. 
M.p. = 117.3 °C decomp.; 1H NMR (600 MHz, CD3CN): δH = 8.71 (1H, dd, J = 10.7, 1.9, 
H–C1''), 8.14 (1H, d, J = 15.0, H–C3''), 7.90 (2H, dd, J = 8.4, 1.1, H–C5''), 7.73–7.69 (1H, 
m, H–C7''), 7.63–7.59 (2H, m, H–C6''), 7.23 (1H, dd, J = 15.0, 10.7, H–C2''), 6.92 (2H, d, 
J = 8.5, H–C2'), 6.72 (2H, d, J = 8.6, H–C3'), 5.13 (1H, t, J = 4.8, H–C5), 3.49 (1H, dd, 
J = 14.9, 5.6, H–C8), 3.36 (1H, dd, J = 14.9, 4.0, H–C8), 2.80 (3H, d, J = 0.5, H–C7), 1.71 
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(3H, s, H–C6anti), and 0.93 (3H, s, H–C6syn) ppm; 13C NMR (151 MHz, CD3CN): 
δC = 168.0 (C1''), 166.3 (C3''), 165.4 (C4), 158.0 (C4'), 136.0 (C7''), 134.4 (C4''), 132.4 (2C, 
C5''), 132.4 (2C, C2'), 130.7 (2C, C6''), 125.6 (C1'), 118.5 (C2''), 116.8 (2C, C3'), 86.6 (C2), 
65.4 (C5), 36.7 (C8), 27.5 (C6anti), 26.1 (C7), and 25.1 (C6anti) ppm; IR (ATR): 
 = 3370br, 3070w, 2985w, 1704s, 1603s, 1588s, 1517m, 1441m, 1403m, 1392m, 1325w, 
1276w, 1233w, 1199m, 1178m, 1153m, 1076s, 999s, 931w, 852w, 813w, 756m, 726s, 
684w, and 621s cm-1; HR-ESI-MS: m/z: 349.19106 ([M-ClO4-]+, calcd for C22H25N2O2+: 
349.19105). 
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8.2.7 Synthesis of (5S)-2,2,3-Trimethyl-5-(para-fluorobenzyl)-4-imidazolidinone (7)  
 
(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-(para-fluoro)benzyl-4-imidazolidinone (27)[122a] 
 
A solution of (S)-Boc-BMI (23) (570 mg, 2.22 mmol, 1.0 equiv.) in dry THF (3.00 mL) in a 
flame-dried Schlenck under an atmosphere of argon was cooled to –78 °C. LDA (2.0 N in 
THF/nheptane/ethylbenzene, 1.22 mL, 2.44 mmol, 1.1 equiv.) was added dropwise and the 
solution stirred for 30 min before 4-fluorobenzylbromide (420 mg, 2.22 mmol, 1.0 equiv.) in 
THF (1.00 mL) was added slowly. After 4 h, the reaction was quenched by addition of a sat. 
aqueous solution of NH4Cl (2 mL), diluted with water (3 mL) and extracted with CH2Cl2 (3 
x 5 mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo. 
Purification by CC (SiO2; CH/EtOAc 8:1) gave 27 as a white solid (667 mg, 82%). 
Rf = 0.49 (SiO2; hexane/EtOAc 2:1); M.p. = 126.8 °C decomp.; [α]D20: +26.8 (c = 0.91, 
CH3OH); 1H NMR (400 MHz, CDCl3): δ = 7.12 (2H, dd, J = 8.2, 5.8, H–C3'), 6.87 (2H, t, 
J = 8.7, H–C4'), 4.54 (1H, b, H–C2), 4.29 (1H, s, H–C5), 3.81 (1H, b, H–C1'), 3.15 (1H, dd, 
J = 14.1, 2.2, H–C1'), 2.78 (3H, b, H–C8), 1.49 (9H, s, H–C4''), and 0.91 (9H, s,  
H–C7) ppm; 13C NMR (101 MHz, CDCl3): δ = 171.4 (C4), 162.0 (d, 1JCF = 252.4, C5'), 
152.7 (C1''), 131.8 (C2´), 131.6 (2C, d, 3JCF = 3.1, C3'), 114.8 (2C, d, 2JCF = 20.9, C4'), 81.2 
(C3''), 81.2 (C2), 60.8 (C5), 41.0 (C6), 32.8 (C1'), 31.9 (C8), 28.4 (C4''), and 26.7 (C7) ppm; 
19F NMR (282 MHz, CDCl3): δ = –116.55 (1F, b, F–C5') ppm; IR (ATR):  = 2975w, 
2933w, 1694s, 1602w, 1512w, 1478w, 1457w, 1440w, 1400m, 1377s, 1364s, 1302m, 
1258m, 1236w, 1216m, 1179m, 1160m, 1116s, 1098w, 1934w, 1010w, 981w, 948w, 886m, 
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867w, 841w, 822w, 786m, 770m, 717m, and 705w cm-1; HR-ESI-MS: m/z (%): 387.2059 
([M–Na]+, calcd for C20H29FN2O3Na+: 387.2060). Analytical data in agreement with the 
literature.[122a] 
 
L-(para-Fluoro)-phenylalanine N-methyl amide (32) 
 
To a solution of 27 (575 mg, 1.58 mmol, 1.0 equiv.) in MeOH (15.0 mL) was added an 
aqueous solution of HCl (1 N, 15.0 mL) at RT and the mixture heated to reflux for 10 h. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N) and extracted with CH2Cl2 (3·20.0 mL). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo to give amide 32 as a white solid (290 mg, 
94%). 
M.p. = 133.7–134.5 °C; [α]D23: +28.1 (c = 1.04, CH3OH); 1H NMR (300 MHz, CDCl3): 
δ = 7.23 (1H, b, H–Namide), 7.16 (2H, dd, J = 8.6, 5.5, H–C3'), 6.98 (2H, t, J = 8.7, H–C4'), 
3.56 (1H, dd, J = 9.1, 4.1, H–C2), 3.20 (1H, dd, J = 13.8, 4.0, H–C1'), 2.79 (3H, d, J = 5.0, 
H–C3), 2.69 (1H, dd, J = 13.8, 9.1, H–C1'), and 1.32 (2H, b, H–Namine) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 174.7 (C1), 161.9 (d, 1JCF = 244.9, C5'), 133.7 (d, 4JCF = 3.3, C2'), 
130.8 (2C, d, 3JCF = 7.9, C3'), 115.6 (2C, d, 2JCF = 21.2, C4'), 56.5 (d, 5JCF = 0.7, C1'), 40.3 
(C2), and 25.9 (C3) ppm; 19F NMR (382 MHz, CDCl3): δ = –116.20 (1F, tt, 3JHF = 8.7, 
4JHF = 5.4, F–C4´) ppm; IR (ATR):  = 3375w, 3300m, 2943w, 1637s, 1600m, 1530m, 
1507s, 1443w, 1406m, 1339w, 1311w, 1272w, 1222s, 1154m, 1110m, 1093m, 1016w, 
983w, 927w, 884w, 867w, 816s, 797m, 751m, 710w, 693m, and 658w cm-1; HR-ESI-MS: 
m/z: 197.1085 ([M+H]+, calcd for C10H14FN2O+: 197.1085).  
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(5S)-2,2,3-Trimethyl-5-(para-fluorobenzyl)-4-imidazolidinone (7) 
 
To a solution of amide 32 (141 mg, 0.72 mmol, 1.0 equiv.) in MeOH (4.00 mL) were added 
aceton (0.40 mL, 5.33 mmol, 7.5 equiv.) and NEt3 (0.08 mL, 0.58 mmol, 0.8 equiv.) at RT 
under an atmosphere argon and the solution heated to reflux for 8 h. The reaction was 
allowed to come to RT and concentrated in vacuo to give imidazolidinone 7 as an orange 
sticky solid (172 mg, quant.).  
[α]D23: –44.0 (c = 0.50, CH3OH); 1H NMR (300 MHz, CDCl3): δ = 7.12 (2H, dd, J = 8.6, 
5.5, H–C3'), 6.89 (2H, t, J = 8.7, H–C4'), 3.68 (1H, dd, J = 6.7, 4.6, H–C5), 3.02 (1H, dd, 
J = 14.2, 4.4, H–C1'), 2.87 (1H, dd, J = 14.2, 6.8, H–C1'), 2.66 (3H, s, H–C7), 1.71 (1H, b, 
H–N), 1.19 (3H, s, H–C6), and 1.10 (3H, s, H–C6) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 173.1 (C4), 161.7 (d, 1JCF = 244.7, C5'), 132.9 (d, 4JCF = 3.2, C2'), 130.9 (2C, d, 
3JCF = 7.8, C3'), 115.2 (2C, d, 2JCF = 21.1, C4'), 75.5 (C2), 59.2 (C5), 36.4 (C1'), 27.2 (C6), 
25.2 (C6), and 25.1 (C7) ppm; 19F NMR (75 MHz, CDCl3): δ = –116.28 (1F, s, F–C4´) 
ppm; IR (ATR):  = 3315w, 2978w, 2927w, 1683s, 1602w, 1509s, 1426m, 1399s, 1220s, 
1158m, 1098w, 1017w, 824m, and 722w cm-1; HR-ESI-MS: m/z: 237.1398 ([M+H]+, calcd 
for C13H18FN2O+: 237.1398).  
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8.2.8 Syntheses of (5S)-2,2,3-Trimethyl-5-(2,4,6-trifluorobenzyl)-4-imidazolidinone 
(8) and (S)-5-(2',4',6'-Trifluorobenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-
phenylallylidene]-imidazolidin-1-ium salt (8a) 
 
(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-(2,4,6-trifluorobenzyl)-4-imidazolidinone (28) 
 
A solution of (S)-Boc-BMI (23) (570 mg, 2.22 mmol, 1.0 equiv.) in dry THF (3.00 mL) in a 
flame-dried Schlenck under an atmosphere of argon was cooled to –78 °C. LDA (2.0 N in 
THF/nheptane/ethylbenzene, 1.22 mL, 2.44 mmol, 1.1 equiv.) was added dropwise and the 
solution stirred for 30 min before 2,4,6-trifluorobenzylbromide (500 mg, 2.22 mmol, 
1.0 equiv.) in THF (1.00 mL) was added slowly. After 5 h, the reaction was quenched by 
addition of saturated aqueous solution of NH4Cl (2 mL), diluted with water (3 mL) and 
extracted with CH2Cl2 (3 · 5 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. Purification by CC (SiO2; CH/EtOAc 10:1) gave 28 as an orange oil 
(757 mg, 85%). 
Rf = 0.51 (SiO2; CH/EtOAc 2:1); [α]D23: –1.1 (c = 0.89, CH3OH);  1H NMR (300 MHz, 
CDCl3): δ = 6.62 (2H, t, J = 8.3, H–C4'), 4.99 (1H, s, H–C2), 4.22 (1H, d, J = 5.6, H–C5), 
3.79 (1H, dd, J = 13.9, 3.4, H–C1'), 2.93 (4H, s, H–C8, H–C1'), 1.49 (9H, s, H–C4''), and 
0.95 (9H, s, H–C7) ppm; 13C NMR (75 MHz, CDCl3): δ = 171.1 (C4), 161.5 (2C, ddd, 
1JCF = 248.4, 3JCF = 15.5, 3JCF = 14.7, C3'), 161.4 (dt, 1JCF = 247.4, 4JCF = 15.7, C5'), 152.9 
(b, C1''), 109.3 (t, 2JCF = 21.3, C2'), 99.7 (2C, ddd, 2JCF = 28.4, 2JCF = 25.4, 4JCF = 2.6, C4'), 
81.2 (C2), 80.6 (C3''), 57.1 (C5), 40.9 (C6), 31.8 (C1'), 28.2 (3C, C4''), 26.5 (3C, C7), and 
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23.9 (b, C8) ppm; 19F NMR (75 MHz, CDCl3): δ = –110.4 (2F, b, F–C3'), and –110.8 (b, F–
C5') ppm; IR (ATR):  = 3331w, 2976w, 2928w, 1682s, 1602w, 1508s, 1425m, 1398s, 
1368w, 1219s, 1158m, 1098m, 1016w, 922w, 823m, and 731m cm-1; HR-EI-MS: m/z : 
423.1867 ([M–Na]+, calculated for C20H27F3N2O3Na+: 423.1866).  
 
L-2,4,6-Trifluorophenylalanine N-methyl amide (33) 
 
To a solution of 28 (680 mg, 1.70 mmol, 1.0 equiv.) in MeOH (10.0 mL) was added an aq. 
solution of HCl (1 N, 10.0 mL) at RT and the mixture heated to reflux overnight. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N) and extracted with CH2Cl2 (3 · 35 mL). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo to give amide 33 as a white solid (355 mg, 90%). 
Rf = 0.56 (CH2Cl2/MeOH 10:1); M.p. = 50.7–52.1 °C; [α]D23: +30.3 (c = 0.95, CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 7.26 (1H, b, H–Namide), 6.65 (2H, dd, J = 8.7, 7.8, H–C4'), 
3.54 (1H, dd, J = 9.6, 4.3, H–C2), 3.29 (1H, dd, J = 14.1, 4.3, H–C1'), 2.81 (3H, d, J = 5.0, 
H–C3), 2.74 (1H, dd, J = 14.1, 9.7, H–C1'), and 1.42 (2H, bs, H–Namine) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 174.2 (C1), 161.9 (2C, ddd, 1JCF = 247.8, 3JCF = 14.7, 3JCF = 11.5, 
C3'), 161.6 (dt, 1JCF = 248.4, 3JCF = 15.7, H-C5'), 110.4 (td, 2JCF = 20.4, 4JCF = 4.6, C2'), 
101.3–99.6 (2C, m, C4'), 55.0 (C2), 28.0 (C1'), and 26.0 (C3) ppm; 19F NMR (282 MHz, 
CDCl3): δ = –109.84 (1F, tt, 3JFH = 22.6, 4JFF = 5.8, F–C5'), and –111.26 (2F, dd, 3JFH = 7.4, 
4JFF = 5.9, F–C3') ppm; IR (ATR):  = 3302w, 3077w, 2941w, 1625s, 1601s, 1538m, 
1493m, 1436m, 1412w, 1345w, 1305w, 1272w, 1224w, 1157w, 1138w, 1114s, 1021m, 
993m, 950w, 838m, 779w, 723w, 707w, and 659w cm-1; HR-ESI-MS: m/z: 233.0902 
([M+H]+, calcd for C10H12F3N2O+: 233.0896).  
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(5S)-2,2,3-Trimethyl-5-(2,4,6-trifluorobenzyl)-4-imidazolidinone (8) 
 
To a solution of amide 33 (320 mg, 1.38 mmol, 1.0 equiv.) in MeOH (8.00 mL) were added 
aceton (0.76 mL, 10.3 mmol, 7.5 equiv.) and NEt3 (0.15 mL, 1.10 mmol, 0.8 equiv.) at RT 
under an atmosphere argon and the solution heated to reflux overnight. The reaction was 
allowed to come to RT and concentrated in vacuo to give imidazolidinone 8 as yellow oil 
(682 mg, quant.).  
[α]D23: –32.2 (c = 0.48, CH3OH); 1H NMR (300 MHz, CDCl3): δ = 6.60 (2H, dd, J = 8.8, 7.7, 
H–C4'), 3.69 (1H, dd, J = 10.2, 4.1, H–C5), 3.22 (1H, dd, J = 14.1, 4.2, H–C1'), 2.75 (3H, s, 
H–C7), 2.68 (1H, dd, J = 14.1, 10.4, H–C1'), 1.74 (1H, b, H–N), 1.35 (3H, s, H–C6), and 
1.23 (3H, s, H–C6) ppm; 13C NMR (101 MHz, CDCl3): δ = 172.9 (C4), 161.7 (2C, ddd, 
1JCF = 247.7, 3JCF = 14.8, 3JCF = 11.6, C3'), 161.4 (dt, 1JCF = 248.0, 3JCF = 15.7, C5'), 110.3 
(td, 2JCF = 20.5, 4JCF = 4.7, C2'), 100.1 (2C, ddd, 2JCF = 28.7, 2JCF = 25.5, 4JCF = 2.1, C4'), 
75.7 (C2), 58.0 (C5), 27.6 (C6), 25.8 (C8), 25.3 (C6), and 25.3 (C7) ppm; 19F NMR 
(75 MHz, CDCl3): δ = –110.35 (1F, t, 3JFF = 5.7, F–C5'), and –111.45 (2F, d, 3JFF = 5.7,  
F–C3') ppm; IR (ATR):  = 3326w, 2976w, 1687s, 1641m, 1622m, 1605s, 1497m, 1440s, 
1400m, 1268w, 1167m, 1149w, 1116s, 1058m, 998m, 940w, 839m, and 737w cm-1;  
HR-ESI-MS: m/z: 273.1207 ([M+H]+, calcd for C13H16F3N2O+: 273.1209).  
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(S)-5-(2',4',6'-Trifluorobenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium perchlorate (8a ClO4-): 
 
To imidazolidinone 8 (43.6 mg, 0.16 mmol, 1.0 equiv.) in Et2O (0.2 mL) was added HClO4 
(60% in H2O, 26.8 mg, 0.16 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.4 mL) at RT and stirred 
for 10 min, before the sovent was evaporated in vacuo to give the off-white HClO4 salt as a 
solid. The solid was dissolved in MeOH (0.4 mL) and (E)-cinnamaldehyde (40.2 µL, 
0.32 mmol, 2.0 equiv.) was added at 35 °C and the yellow solution stirred for 1 h. The 
solvent was evaporated in vacuo. The residue was dissolved in a minimum amount of 
MeOH, the iminium salt was crashed out with Et2O and the supernatant solution taken off. 
This purification procedure was repeated two additional times to give 8a·ClO4- as a yellow 
solid. 
M.p. = 198.5 °C decomp.; [α]D20 = +122.5 (c = 0.83 in CH3CN); 1H NMR (600 MHz, 
CD3CN): δH = 8.87 (1H, dd, J = 10.7, 1.7, H–C1''), 8.20 (1H, d, J = 15.0, H–C3''), 7.83 (2H, 
dd, J = 8.2, 1.0, H–C5''), 7.73–7.69 (1H, m, H–C7''), 7.60 (2H, t, J = 7.9, H–C6''), 7.16 (1H, 
dd, J = 15.0, 10.7, H–C2''), 6.87 (2H, dd, J = 8.9, 7.9, H–C3'), 5.06 (1H, t, J = 6.0, H–C5), 
3.48 (1H, dd, J = 15.0, 7.6, H–C8), 3.42 (1H, dd, J = 15.1, 5.8, H–C8), 2.89 (3H, d, J = 0.5, 
H–C7), 1.82 (3H, s, H–C6anti), and 1.64 (3H, s, H–C6syn) ppm; 13C NMR (151 MHz, 
CD3CN, C1', C2' and C4' assigned in CFdec spectrum): δC = 168.7 (C1''), 166.6 (C3''), 
164.5 (C4), 163.6 (C4'), 162.9 (2C, C2'), 136.2 (C7''), 134.3 (C4''), 132.2 (2C, C5''), 130.8 
(2C, C6''), 118.1 (C2''), 108.2 (C1'), 101.7 (2C, dd, 2JCF = 31.2, 2JCF = 26.0, C3'), 86.8 (C2), 
61.9 (C5), 26.9 (C6syn), 26.9 (C6anti), 26.4 (C8), and 26.3 (C7) ppm; 19F NMR (564 MHz, 
CD3CN): δF = –108.7 (1F, tt, 2JHF = 9.0, 3JFF = 6.7, F–C4'), and –110.4 (2F, dd, 2JHF = 7.8, 
3JFF = 6.6, F–C2') ppm; IR (ATR):  = 3376br, 3071w, 2985w, 1705s, 1619s, 1604s, 1588s, 
1517m, 1442m, 1403m, 1392m, 1325w, 1276w, 1233w, 1198m, 1178m, 1153m, 1075s, 
998s, 931w, 852w, 813w, 756m, 684w, and 621s cm-1; HR-ESI-MS: m/z: 387.16776 ([M-
ClO4-]+, calcd for C22H22F3N2O+: 387.16787).   
ν~
8 Experimental Section 173 
8.2.9 Syntheses of (5S)-2,2,3-Trimethyl-5-(para-ntirobenzyl)-4-imidazolidinone (9) 
and 5-(4'-Nitrobenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium salt (9a) 
 
L-(para-Nitro)-phenylalanine N-methyl amide (18) 
 
To L-(para-nitro)-phenylalanine (14) (500 mg, 2.38 mmol, 1.0 equiv.) in EtOH (2.00 mL) 
was added thionyl chloride (0.40 mL, 5.47 mmol, 2.3 equiv.) over 5 min at 0 °C and the 
resulting solution was allowed to come to RT before it was heated to reflux for 1 d. The 
solution was allowed to come to RT and evaporated in vacuo to give the L-(para-nitro)-
phenylalanine methyl ester hydrochloride as a yellow solid. To the ester was added MeNH2 
(8 N in EtOH, 1.20 mL, 9.52 mmol, 4.0 equiv.) at RT and the solution stirred overnight. 
After evaporation in vacuo, a saturated aqueous solution of NaHCO3 (5 mL) was added and 
the aqueous layer extracted with CH2Cl2 (3 · 5 mL). The combined organic layers were dried 
over MgSO4, filtrated concentrated in vacuo to give amide 18 as a yellow solid (483 mg, 
91%), which was used without characterisation in the next step. 
1H NMR (300 MHz, CDCl3): δ = 8.18 (2H, d, J = 8.7, H–C4´), 7.39 (2H, d, J = 8.6, H–C3´), 
7.22 (1H, b, H–Namide), 3.66 (1H, dd, J = 8.7, 4.2, H–C2), 3.34 (1H, dd, J = 13.7, 4.2,  
H–C1´), 2.91 (1H, dd, J = 13.7, 8.7, H–C1´), 2.82 (3H, d, J = 5.0, H–C3), and 1.36 (2H, b, 
H–Namine) ppm. 
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(5S)-2,2,3-Trimethyl-5-(para-ntirobenzyl)-4-imidazolidinone (9) 
 
To a solution of amide 18 (450 mg, 2.02 mmol, 1 equiv.) in MeOH (10.0 mL) was added 
acetone (1.10 mL, 15.1 mmol, 7.5 equiv.) at RT under an atmosphere of argon and the 
yellow solution was heated to reflux for 8 h. The reaction was allowed to come to RT and 
concentrated in vacuo to give imidazolidinone 9 as a yellow oil (533 mg, quant.).   
[α]D23: –57.1 (c = 1.25, CH3OH); 1H NMR (400 MHz, CDCl3): δ = 8.13 (2H, d, J = 8.8, H–
C4'), 7.42 (2H, d, J = 8.9, H–C3'), 3.84 (1H, ddd, J = 7.7, 4.2, 0.8, H–C5), 3.25 (1H, dd, 
J = 14.1, 4.2, H–C1'), 2.96 (1H, dd, J = 14.1, 7.8, H–C1'), 2.76 (3H, d, J = 0.7, H–C7), 1.81 
(1H, b, H–Namine), 1.28 (3H, s, H–C6), and 1.21 (3H, s, H–C6) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 172.4 (C4), 146.8 (C5'), 145.8 (C2'), 130.4 (2C, C3'), 123.6 (2C, C4'), 75.7 
(C2), 59.1 (C5), 38.0 (C1'), 27.8 (C6), 25.5 (C6), and 25.2 (C7) ppm; IR (ATR): 
 = 3326w, 2976w, 1681s, 1601m, 1515s, 1427m, 1399m, 1368w, 1343s, 1265w, 1205w, 
1182w, 1148w, 1108w, 1086w, 1017w, 907w, 861w, 819w, 746w, and 700w cm-1; HR-ESI-
MS: m/z: 264.1345 ([M+H]+, calcd for C13H18N3O3+: 264.1343).  
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5-(4'-Nitrobenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium 
perchlorate (9a·ClO4-) 
 
To imidazolidinone 9 (21.1 mg, 0.08 mmol, 1 equiv.) was added perchloric acid (60% in 
H2O, 13.4 mg, 0.16 mmol, 1 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at RT and the resulting 
mixture stirred for 10 min before it was evaporated in vacuo to give the imidazolidinone salt. 
The salt was dissolved in MeOH (0.20 mL) and (E)-cinnamaldehyde (20.1 µL, 0.16 mmol, 
1 equiv.) was added and the yellow solution stirred overnight during which time the product 
precipitated as a yellow solid. Iminium salt 9a was filtered off, washed with Et2O and dried 
in vacuo.  
M.p. = 117.3 °C decomp.; [α]D23: +587.5 (c = 0.59, CH3CN); 1H NMR (400 MHz, CD3CN): 
δH = 8.82 (1H, dd, J = 10.7, 2.0, H–C1''), 8.24 (1H, d, J = 15.0, H–C3''), 8.13 (2H, d, J = 8.7, 
H–C3'), 7.92 (2H, d, J = 8.7, H–C5''), 7.72 (1H, t, J = 7.4, H–C7''), 761 (2H, t, J = 7.6,  
H–C6''), 7.36 (2H, d, J = 8.7, H–C2'), 7.28 (1H, dd, J = 15.0, 10.7, H–C2''), 5.28 (1H, bs, 
H–C5), 3.70 (1H, dd, J = 14.6, 5.9, H–C8), 3.57 (1H, dd, J = 14.7, 4.1, H–C8), 2.80 (3H, s, 
H–C7), 1.73 (3H, s, H–C6anti), and 0.99 (3H, s, H–C6syn) ppm; 13C NMR (101 MHz, 
CD3CN): δC = 168.7 (C1''), 167.4 (C3''), 164.8 (C4), 148.7 (C4'), 142.5 (C1'), 136.2 (C7''), 
134.3 (C4''), 132.6 (2C, C5''), 132.5 (2C, C2'), 130.7 (2C, C6''), 124.9 (2C, C3'), 118.1 
(C2''), 86.5 (C2), 64.3 (C5), 37.0 (C8), 27.4 (C6anti), 26.2 (C7), and 25.6 (C6syn) ppm; 
IR (ATR): = 3375w, 2978w, 1714m, 1672m, 1629w, 1603w, 1590w, 1520s, 1500s, 
1434w, 1419w, 1395m, 1345s, 1300w, 1201w, 1180w, 1109s, 1056s, 1035m, 1014w, 997s, 
971s, 946s, 893w, 857w, 822w, 799w, 757w, 743w, 696w, and 683w cm-1. 
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8.2.10 Syntheses of (5S)-2,2,3-Trimethyl-5-(pentafluorobenzyl)-4-imidazolidinone (10) 
and 5-Pentafluorobenzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium salt (10a) 
 
(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-(pentafluorobenzyl)-4-imidazolidinone (29)[122a] 
 
A solution of (S)-Boc-BMI (23) (128 mg, 0.50 mmol, 1.0 equiv.) in dry THF (0.70 mL) in a 
flame-dried Schlenck under an atmosphere of argon was cooled to –78 °C. LDA (0.28 mL, 
0.55 mmol, 1.1 equiv.) was added resulting in a dark red solution. After 30 min, 
pentafluorobenzylbromide (131 mg, 0.50 mmol, 1.0 equiv.) in dry THF (0.25 mL) was 
added slowly upon which the solution turned purple. The reaction was stirred at –78 °C for 
5 h and then quenched by addition of saturated aqueous solution of NH4Cl (2 mL) and 
extracted with CH2Cl2 (3 · 5 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. Purification by CC (SiO2; CH/EtOAc 8:1) gave 29 as an off-white 
solid (179 mg, 82%). 
Rf = 0.66 (SiO2; CH/EtOAc 2:1); M.p. = 65.9–69.6°C; [α]D23: –0.7 (c = 0.95, CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 4.99 (1H, bs, H–C2), 4.22 (1H, bs, H–C5), 3.89 (1H, dd, 
J = 13.9, 3.0, H–C1'), 2.95 (3H, s, H–C8), 2.91 (1H, bs, H–C1'), 1.48 (9H, s, H–C4''), and 
0.95 (9H, s, H–C7) ppm; 13C NMR (75 MHz, CDCl3): δ = 170.8 (C4), 152.8 (C1''), 145.6 
(2C, dm, 1JCF = 246.8, CAr), 137.2 (dm, 1JCF = 268.6, C5'), 137.0 (2C, dm, 1JCF = 205.2, CAr), 
111.1 (b, C2'), 81.8 (C2), 80.9 (C3''), 56.8 (C5), 41.1 (C6), 32.1 (C1'), 28.3 (3C, C4''), 26.6 
(3C, C7), and 24.7 (b, C8) ppm; 19F NMR (282 MHz, CDCl3): δ = –141.7 (2F, bs, F–C3'),  
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–157.3 (1F, bs, F–C5'), and –163.2 (2F, bs, F–C4') ppm; IR (ATR):  = 2973w, 2932w, 
1695s, 1658w, 1602w, 1511m, 1506m, 1478w, 1457w, 1400m, 1376s, 1364s, 1302m, 
1257m, 1216m, 1178m, 1160m, 1116s, 1098m, 1035w, 1010w, 980m, 948w, 934w, 912w, 
886m, 840w, 821w, 786m, 771m, and 717m cm-1; HR-ESI-MS: m/z: 459.1662 ([M+Na]+, 
calcd for C20H25F5N2O3Na+: 459.1678). Analytical data in agreement with the literature.[122a]  
 
L-Pentafluorophenylalanine N-methyl amide (34) 
 
To a solution of 29 (100 mg, 0.23 mmol, 1.0 equiv.) in MeOH (3.0 mL) was added an 
aqueous solution of HCl (1 N, 3.0 mL) at RT and the mixture heated to reflux for 11 h. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N) and extracted with CH2Cl2. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo to give amide 34 as a white solid (62 mg, quant.). 
M.p. = 98.4–99.3 °C; [α]D22 = –0.263 (c = 0.039 in CHCl3); 1H NMR (300 MHz, CDCl3): 
δ = 7.21 (1H, bs, H–Namide), 3.58 (1H, dd, J = 9.1, 4.9, H–C2), 3.37 (1H, dd, J = 14.1, 4.4, 
H–C1'), 2.91–2.74 (4H, m, H–C3, H–C1'), and 1.50 (2H, s, H–Namine) ppm; 13C NMR (75 
MHz, CDCl3): δ = 173.5 (C1), 145.6 (dm, 1JCF = 247.3, CAr), 139.8 (dm, 1JCF = 252.1, CAr), 
137.3 (dm, 1JCF = 250.5, CAr), 111.9 (td, 2JCF = 18.5, 3JCF = 3.7, C2'), 54.8 (C2), 28.5 (C1'), 
and 26.1 (C3) ppm; 19F NMR (377 MHz, CDCl3): δ = –142.4 (2F, dd, 3JFF = 22.6, 4JFF = 8.4, 
F–C3'), –156.0 (1F, t, 3JFF = 20.9, F–C5'), and –162.1 (2F, dt, 3JFF = 22.5, 4JFF = 8.4,  
F–C4') ppm; IR (ATR): = 3379w, 3330m, 3298w, 2953w, 2910w, 1649s, 1540m, 1520s, 
1500s, 1445m, 1423m, 1407m, 1298m, 1116s, 1098s, 1000s, 972s, 932s, 914s, 890m, 849m, 
805s, 735m, 710s, and 664m cm-1; HR-ESI-MS: m/z: 269.0718 ([M+H]+, calcd for 
C10H10F5N2O+: 269.0708).  
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(5S)-2,2,3-Trimethyl-5-(pentafluorobenzyl)-4-imidazolidinone (10) 
 
To a solution of amide 34 (181 mg, 0.68 mmol, 1.0 equiv.) in MeOH (4.0 mL) were added 
acetone (0.37 mL, 5.06 mmol, 7.5 equiv.) and NEt3 (0.08 mL, 0.54 mmol, 0.8 equiv.) at RT 
under an atmosphere argon and the solution heated to reflux for 9 h. The reaction was 
allowed to come to RT and concentrated in vacuo to give imidazolidinone 10 as an off-white 
solid (194 mg, 93%).  
M.p. = 73.0–75.3 °C; [α]D20 = –31.5 (c = 0.91 in CH3OH); 1H NMR (300 MHz, CDCl3): 
δ = 3.78 (1H, dd, J = 10.3, 4.6, H–C5), 3.31 (1H, d, J = 14.1, H–C1'), 2.86–2.75 (4H, m,  
H–C1', H–C7), 1.72 (2H, b, H–N), 1.40 (3H, s, H–C6), and 1.30 (3H, s, H–C6) ppm;  
13C NMR (101 MHz, CDCl3, racemic compound): δ = 172.3 (C4), 145.6 (2C, dm, 
1JCF = 245.6, CAr), 139.6 (dm, 1JCF = 245.0, C5'), 137.4 (2C, dm, 1JCF = 251.8, CAr), 111.9 
(td, 2JCF = 18.4 3JCF = 3.8, C2'), 76.0 (C2), 57.7 (C5), 28.0 (C6), 26.6 (C1'), 25.6 (C6), and 
25.4 (C7) ppm; 19F NMR (282 MHz, CDCl3): δ = (–142.3)–(–142.7) (2F, m, F-C3'), –157.2 
(1F, t, 3JFF = 20.8, F–C5'), and –163.0 (2F, td, 3JFF = 22.6, 4JFF = 8.3, F–C4') ppm; IR (ATR): 
 = 3318m, 2982w, 1676s, 1519s, 1499s, 1441m, 1404s, 1384m, 1371m, 1303w, 1279w, 
1202w, 1182m, 1156w, 1119s, 1099m, 1042m, 1012m, 977m, 964s, 937s, 885w, 795w, 
768w, 736w, and 681w cm-1; HR-EI-MS: m/z: 309.1018 ([M+H]+, calcd for C13H14F5N2O+: 
309.1021); elemental analysis (racemic compound) calcd (%) for C13H13F5N2O (308.2):  
C 50.65, H 4.25, N 9.09, F 30.82; found: C 50.74, H 4.43, N 8.87, F 31.06. 
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2,2,3-Trimethyl-5-(pentafluorobenzyl)-4-imidazolidinone hydrochloride (10·HCl) 
 
Racemic imidazolidinone 10 (30 mg, 97.0 µmol, 1.0 equiv.) was dissolved in HCl in MeOH 
(1.25 N, 0.31 mL) and stirred for 30 min at RT. The solvent was evaporated in vacuo to give 
10·HCl as a white solid. Crystals suitable for crystallographic analysis were obtained by 
vapor diffusion of a methanolic solution of the solid with Et2O. 
M.p. = 184.1–186.2 °C; 1H NMR (600 MHz, CD3OD): δ = 4.52 (1H, t, J = 7.3, H–C5), 3.55 
(1H, dd, J = 14.9, 6.8, H–C1'), 3.29 (1H, dd, J = 15.0, 7.1, H–C1'), 2.90 (3H, J = 0.5, H–C7), 
1.82 (3H, s, H–C6), and 1.64 (3H, s, H–C6) ppm; 13C NMR (151 MHz, CD3OD): δ = 166.8 
(C4), 147.0 (2C, dqd, 1JCF = 246.1, 3JCF = 8.0, 4JCF = 3.7, CAr), 142.1 (dm, 1JCF = 251.9, C5'), 
140.0 (2C, dm, 1JCF = 249.8, CAr), 110.7 (td, 2JCF = 18.1 3JCF = 3.5, C2'), 79.1 (C2), 56.4 
(C5), 25.7 (C7), 24.4 (C6), 22.6 (C1'), and 22.2 (C6) ppm; 19F NMR (282 MHz, CDCl3): 
δ = –143.33 (2F, m, F-C3'), –158.4 (1F, t, 3JFF = 20.0, F–C5'), and –165.1 (2F, m,  
F–C4') ppm; IR (ATR):  = 2935w, 2661w, 2512w, 2460w, 2400w, 1715s, 1662w, 1562w, 
1520m, 1506s, 1435m, 1418m, 1396m, 1355m, 1299w, 1271w, 1238w, 1197w, 1181w, 
1156m, 1127m, 1059s, 1003w, 988w, 970m, 954s, 919m, 847w, 780w, and 667w cm-1.  
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5-Pentafluorobenzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-
ium perchlorate (10a·ClO4-): 
 
To imidazolidinone 10 (24.7 mg, 0.08 mmol, 1.0 equiv.) in Et2O (0.10 mL) was added 
perchloric acid (60% in H2O, 11.5 mg, 0.08 mmol, 1 equiv.) in Et2O/EtOH (1:1, 0.2 mL) at 
RT and the resulting mixture stirred for 10 min before it was evaporated in vacuo to give the 
imidazolidinone salt. The salt was redissolved in MeOH (0.20 mL) and heated to 35 °C. (E)-
cinnamaldehyde (20.1 µL, 0.16 mmol, 2 equiv.) was added and the yellow solution stirred 
for 1 h. The solvent was removed in vacuo and the residue dissolved in a minimum amount 
of MeOH. From this solution the iminium salt 10a·ClO4-was crashed out as a yellow solid 
with Et2O and the supernatant solution taken off. Crystals suitable for X-ray crystallographic 
analysis were obtained from a solution in MeOH/CH3CN (2:1) by vapour diffusion with 
Et2O. 
M.p. = 185.1–186.3 °C; 1H NMR (600 MHz, CD3CN): δH = 8.87 (1H, dd, J = 10.7, 1.8,  
H–C1''), 8.24 (1H, d, J = 15.0, H–C3''), 7.89 (2H, dd, J = 8.2, 1.0, H–C5''), 7.76–7.71 (1H, 
m, H–C7''), 7.63 (2H, t, J = 7.9, H–C6''), 7.22 (1H, dd, J = 15.0, 10.7, H–C2''), 5.09–5.04 
(1H, m, H–C5), 3.54 (1H, dd, J = 15.0, 5.2, H–C8), 3.49 (1H, dd, J = 15.0, 8.3, H–C8), 2.90 
(3H, d, J = 0.5, H–C7), 1.83 (3H, s, H–C6anti), and 1.70 (3H, s, H–C6syn) ppm; 13C NMR 
(151 MHz, CD3CN, C1', C2', C3' and C4' not visible): δC = 168.8 (C1''), 167.2 (C3''), 164.1 
(C4), 136.5 (C7''), 134.2 (C4''), 132.3 (2C, C5''), 130.9 (2C, C6''), 117.9 (C2''), 86.8 (C2), 
61.1 (C5), 27.2 (C6syn), 26.8 (C6anti), 26.5 (C8), and 26.3 (C7) ppm; 19F NMR (564 MHz, 
CD3CN): δF = (–141.1)–(–141.2) (2F, m, F–C2'), –155.6 (1F, t, 2JFF = 20.1, F-C4'), and  
(–163.6)–(–163.7) (2F, m, F–C3') ppm; IR (ATR):  = 2997b, 1712s, 1661w, 1617m, 
1603m, 1588s, 1523m, 1506s, 1455m, 1434m, 1405m, 1396m, 1334w, 1277m, 1236w, 
1215w, 1181m, 1161m, 1125m, 1093s, 1074s, 1039s, 1012m, 1004m, 976m, 964m, 935m, 
865m, 823w, 765s, 700w, 685w, and 621m cm-1; HR-ESI-MS: m/z: 423.1484 ([M-ClO4-]+, 
calcd for C22H20F5N2O+: 423.1496).  
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1H NMR counterion-effect study of 10a·X in CD3CN at RT: 
5-Pentafluorobenzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-
ium hexafluoroantimonat (10a·SbF6-) 
 
1H NMR (400 MHz, CD3CN): δH = 8.85 (1H, dd, J = 10.7, 1.7, H–C1''), 8.22 (1H, d, J = 
15.0, H–C3''), 7.89 (2H, d, J = 7.3, H–C5''), 7.74 (1H, tt, J = 7.4, 1.2, H–C7''), 7.63 (2H, t, J 
= 7.6, H–C6''), 7.22 (1H, dd, J = 15.0, 10.7, H–C2''), 5.05 (1H, t, J = 6.3, H–C5), 3.54 (1H, 
dd, J = 15.2, 5.6, H–C8), 3.48 (1H, dd, J = 15.0, 8.2, H–C8), 2.90 (3H, s, H–C7), 1.82 (3H, 
s, H–C6anti), and 1.70 (3H, s, H–C6syn) ppm. 
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8.2.11 Syntheses of (S)-5-(1-Methylindol-3-ylmethyl)-2,2,3-trimethylimidazolidin-4-one 
and (S)-5-(1-Methylindol-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-
phenylallylidene]-imidazolidin-1-ium salt 
 
1-Methyl-L-tryptophan methyl ester  
 
To 1-methyl-L-tryptophan (500 mg, 2.29 mmol, 1.0 equiv.) in MeOH (1.86 mL, 45.8 mmol, 
20 equiv.) was added thionyl chloride (0.20 mL, 2.75 mmol, 1.2 equiv.) over 10 min at 0 °C 
and the resulting mixture was allowed to come to RT before it was heated to reflux 
overnight. The solution was allowed to come to RT and evaporated in vacuo to give  
1-methyl-L-tryptophan methyl ester hydrochloride as an off-white solid (615 mg, quant.).  
M.p. = 197.6–198.4 °C; [α]D23: +14.5 (c = 0.89, CH3OH); 1H NMR (300 MHz, CD3OD): 
δ = 7.54 (1H, dt, J = 7.9, 1.0, H–C5'), 7.39 (1H, dt, J = 8.3, 0.8, H–C8'), 7.21 (1H, ddd, 
J = 8.2, 7.1, 1.1, H–C7'), 7.14–7.07 (2H, m, H–C6', H–C2'), 4.32 (1H, dd, J = 7.3, 5.5, H–
C2), 3.80 (6H, s, H–C3, H–C10'), 3.45 (1H, ddd, J = 15.1, 5.5, 0.6, H–C4), and 3.36 (1H, dd, 
J = 9.6, 5.6, H–C4) ppm; 13C NMR (75 MHz, CD3OD): δ = 170.8 (C1), 138.8 (C9'), 129.9 
(C2'), 128.7 (C4'), 123.1 (C7'), 120.4 (C6'), 119.1 (C5'), 110.7 (C8'), 106.8 (C3'), 54.6 (C2), 
53.7 (C3), 32.9 (C10'), and 27.4 (C4) ppm; IR (ATR):  = 3009w, 2837m, 2637w, 2010w, 
1746s, 1613w, 1575w, 1542w, 1505m, 1474m, 1445m, 1377w, 1359w, 1327w, 1284w, 
1251w, 1228s, 1186w, 1159w, 1123w, 1074m, 1047w, 1011w, 9909w, 945w, 919w, 890w, 
864w, 833w, 739m, 727s, and 657w cm-1; HR-ESI-MS: m/z: 233.1283 ([M–Cl]+, calcd for 
C13H17N2O2+: 233.1285); analytical data in agreement with the literature.[185] 
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1-Methyl-L-tryptophan methyl amide (53) 
 
To 1-methyl-L-tryptophan methyl ester (584 mg, 2.17 mmol, 1.0 equiv.) was added MeNH2 
(8 N in EtOH, 1.10 mL, 8.70 mmol, 4.0 equiv.) at RT and the solution stirred overnight. 
After evaporation in vacuo, the crude product was dissolved in a saturated aqueous solution 
of NaHCO3 (20 mL) and CHCl3 (15 mL), the aqueous layer was extracted twice with CHCl3 
(2 · 15 mL), the combined organic layers were dried over MgSO4 and concentrated in vacuo 
to give amide 53 as a sticky oil (502 mg, quant.).  
[α]D23: +6.7 (c = 0.95, CH3OH); 1H NMR (300 MHz, CDCl3): δ = 7.67 (1H, dt, J = 7.9, 1.1, 
H–C5'), 7.31 (1H, dt, J = 8.2, 1.2, H–C8'), 7.23 (1H, dd, J = 8.2, 1.1, H–C7'), 7.12 (1H, ddd, 
J = 8.0, 6.8, 1.2, H–C6'), 6.92 (1H, s, H–C2'), 3.76 (3H, s, H–C10'), 3.70 (1H, dd, J = 8.9, 
4.1, H–C2), 3.38 (1H, ddd, J = 14.4, 4.1, 0.6, H–C4), 2.90 (1H, dd, J = 14.4, 9.0, H–C4), 
2.81 (3H, d, J = 5.0, H–C3), and 1.46 (2H, bs, H–Namine) ppm; 13C NMR (75 MHz, CD3OD): 
δ = 175.4 (C1), 137.2 (C9'), 128.1 (C4'), 127.9 (C2'), 121.9 (C7'), 119.2 (2C, C5', C6'), 110.3 
(C3'), 109.4 (C8'), 55.8 (C2), 32.8 (C10'), 30.7 (C3), and 25.9 (C4) ppm; IR (ATR): 
 = 3300w, 3052w, 2934w, 1652s, 1532m, 1471m, 1409w, 1375w, 1326m, 1250w, 1156w, 
1130w, 1012w, 909w, 846w, and 735s cm-1; HR-ESI-MS: m/z: 232.1445 ([M+H]+, calcd for 
C13H18N3O+: 232.1444). 
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(S)-5-(1-Methylindol-3-ylmethyl)-2,2,3-trimethylimidazolidin-4-one (35): 
 
To a solution of amide 53 (502 mg, 2.17 mmol, 1.0 equiv.) in MeOH (10.0 mL) was added 
acetone (1.20 mL, 16.3 mmol, 7.5 equiv.) and NEt3 (0.24 mL, 1.74 mmol, 0.8 equiv.) at RT 
under an atmosphere of argon and the yellow solution was heated to reflux overnight. The 
reaction was allowed to come to RT and concentrated in vacuo. Purification by CC (SiO2; 
CH2Cl2/MeOH/NH3 (25% in H2O) 20:1:0.2) gave imidazolidinone 35 as a yellow oil 
(484 mg, 82%). 
Rf = 0.46 (CH2Cl2/MeOH 10:1); [α]D23: –37.8 (c = 0.31, CH3OH); 1H NMR (600 MHz, 
CDCl3): δ = 7.64 (1H, dt, J = 7.8, 0.9, H–C4'), 7.27 (1H, dt, J = 8.2, 0.9, H–C7'), 7.21 (1H, 
ddd, J = 8.2, 7.0, 1.1, H–C6'), 7.10 (1H, ddd, J = 8.0, 7.0, 1.0, H–C5'), 6.95 (1H, s, H–C2'), 
3.82 (1H, ddd, J = 5.9, 4.7, 0.5, H–C5), 3.73 (3H, s, H–C10'), 3.32 (1H, ddd, J = 15.1, 4.6, 
0.7, H–C8), 3.17 (1H, ddd, J = 15.1, 6.1, 0.7, H–C8), 2.73 (3H, d, J = 0.6, H–C7), 1.25 (3H, 
s, H–C6), and 1.09 (3H, s, H–C6) ppm; 13C NMR (151 MHz, CDCl3): δ = 174.1 (C4), 136.9 
(C9'), 128.4 (C8'), 128.0 (C2'), 121.6 (C6'), 119.1 (C5'), 119.0 (C4'), 109.1 (C7'), 109.0 
(C3'), 75.4 (C2), 59.1 (C5), 32.7 (b, C10'), 27.0 (C6), 26.3 (C8), 25.2 (C7), and 25.1 
(C6) ppm; IR (ATR):  = 3295b, 2921w, 2239w, 1682s, 1615w, 1526w, 1472m, 1425m, 
1397m, 1379m, 1327w, 1253w, 1205w, 1150w, 1086w, 1013w, 921w, 799w, and 738s cm-1; 
HR-ESI-MS: m/z: 272.1763 ([M+H]+, calcd for C16H22N3O+: 272.1757). 
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(S)-5-(1-Methylindol-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium perchlorate (35a·ClO4-): 
 
To imidazolidinone 35 (43.4 mg, 0.16 mmol, 1.0 equiv.) in Et2O (0.2 mL) was added HClO4 
(60% in H2O, 26.8 mg, 0.16 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.4 mL) at RT and stirred 
for 10 min, before the solution was evaporated in vacuo to give the HClO4 salt as a solid. 
The solid was dissolved in MeOH (0.4 mL) and (E)-cinnamaldehyde (40.2 µL, 0.32 mmol, 
2.0 equiv.) was added at 35 °C and the solution stirred for 1 h. The solvent was evaporated 
in vacuo. The residue was dissolved in a minimum amount of MeOH, the iminium salt was 
crashed out with Et2O and the supernatant solution taken off. This purification procedure 
was repeated two additional times to give iminium salt 35a·ClO4- as a red solid.  
M.p. = 137.8 °C decomp.; [α]D20 = +195.3 (c = 0.43 in CD3CN); 1H NMR (600 MHz, 
CD3CN): δH = 8.67 (1H, d, J = 10.7, H–C1''), 7.94 (1H, d, J = 15.1, H–C3''), 7.66–7.62 (1H, 
m, H–C7''), 7.59 (1H, dt, J = 8.0, 0.9, H–C4'), 7.50 (2H, t, J = 7.8, H–C6''), 7.40 (2H, dd, 
J = 8.2, 1.0, H–C5''), 7.24–7.18 (2H, m, H–C6', H–C7'), 7.14 (1H, ddd, J = 8.0, 6.5, 1.5, H–
5'), 6.93 (1H, s, H–C2'), 6.68 (1H, dd, J = 15.0, 10.6, H–C2''), 5.08 (1H, t, J = 5.0, H–C5), 
3.81 (1H, dd, J = 15.5, 5.0, H–C8), 3.59 (3H, s, H–C10'), 3.43 (1H, dd, J = 17.8, 6.6, H–C8), 
2.78 (3H, d, J = 0.4, H–C7), 1.72 (3H, s, H–C6anti), and 1.14 (3H, s, H–C6syn) ppm; 
13C NMR (151 MHz, CD3CN): δC = 167.7 (C1''), 166.0 (C4), 164.6 (C3''), 138.1 (C9'), 
135.5 (C7''), 134.2 (C4''), 131.9 (2C, C5''), 130.8 (C2'), 130.6 (2C, C6''), 128.3 (C3'), 123.4 
(C8'), 120.6 (C5'), 119.6 (C4'), 118.5 (C2''), 111.0 (C7'), 107.0 (C3'), 86.5 (C2), 64.7 (C5), 
33.1 (C10'), 29.3 (C8), 27.3 (C6anti), 26.1 (C7), and 25.6 (C6syn) ppm; IR (ATR): 
 = 3058w, 2939w, 1712s, 1621m, 1604m, 1589s, 1474m, 1455m, 1429m, 1390m, 1324w, 
1282w, 1197m, 1180m, 1073s, 1011m, 999m, 932w, 743s, 686m, and 621s cm-1; HR-ESI-
MS: m/z: 386.22284 ([M-ClO4-]+, calcd for C25H28N3O+: 386.22324).   
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8.2.12 Synthesis of (5S)-2,2,3-Trimethyl-5-[4-(1H-pyrrol-1-yl)benzyl]imidazolidin-4-
one (40) 
 
(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-[4-(1H-pyrrol-1-yl)benzyl]-4-imidazolidinone 
(45) 
 
A solution of HMDS (0.42 mL, 2.03 mmol, 1.2 equiv.) in dry THF (1.50 mL) in a flame-
dried Schlenck under an atmosphere of argon was cooled to 0 °C. nBuLi (1.6 N in nhexane, 
1.27 mL, 2.03 mmol, 1.2 equiv.) was added dropwise and the solution stirred for 15 min 
before it was cooled to –78 °C. DMPU (0.61 mL, 5.08 mmol, 3.0 equiv.) and then (S)-Boc-
BMI (23) (429 mg, 1.69 mmol, 1.0 equiv.) in THF (1.50 mL) was added dropwise to the 
orange solution that turned darker upon addition. After 30 min, the reaction was diluted with 
THF (1.50 mL) and 1-[4-(Bromomethyl)phenyl]-1H-pyrrole (400 mg, 1.69 mmol, 1.0 
equiv.) was added in small portions over 2 min. The resulting suspension was gradually 
warmed to –30 °C over 7 h. The reaction was quenched by addition of a saturated aqueous 
solution of NaHCO3 and extracted three times with CH2Cl2. The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. Purification by CC (SiO2; CH/EtOAc 
5:1) gave 45 as a white solid (440 mg, 63%). 
Rf = 0.76 (CH/EtOAc 1:1); M.p. = 137.0–138.4 °C; [α]D20: +57.3 (c = 0.94, CH3OH); 1H 
NMR (600 MHz, CDCl3): δ = 7.22 (4H, bs, H–C3', H–C4'), 7.06 (2H, t, J = 2.2, H–C8'), 
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6.33 (2H, t, J = 2.2, H–C7'), 4.58 (1H, bs, H–C2), 4.32 (1H, bs, H–C5), 3.86 (1H, bs, H–
C1'), 3.21 (1H, dd, J = 14.0, 2.2, H–C1'), 2.81 (3H, bs, H–C8), 1.50 (9H, s, H–C4''), and 0.93 
(9H, s, H–C7); 13C NMR (151 MHz, CDCl3): δ = 171.4 (C4), 152.8 (C1''), 139.4 (C5'), 133.4 
(C2'), 131.4 (2C, C3'), 119.8 (2C, C4'), 119.2 (2C, C7'), 110.4 (2C, C8'), 81.2 (C3''), 81.2 
(C2), 60.8 (C5), 41.0 (C6), 33.2 (C1'), 32.0 (C8), 28.4 (3C, C4''), and 26.7 (3C, C7) ppm; IR 
(ATR): = 2970w, 2932w, 1691s, 1612w, 1522m, 1482w, 1458w, 1437w, 1405w, 1378s, 
1362m, 1327m, 1299m, 1254m, 1180m, 1163m, 1118m, 1071m, 1024w, 984w, 944w, 
923w, 884w, 867w, 847w, 832w, 792w, 766w, and 722s cm-1; HR-ESI-MS: m/z: 412.2604 
([M+H]+, calcd for C24H34N3O3+: 412.2595). 
 
L-4-(1H-pyrrol-1-yl)phenylalanine N-methyl amide (47) 
 
To a solution of 45 (339 mg, 0.82 mmol, 1.0 equiv.) in MeOH (7.5 mL) was added an 
aqueous solution of HCl (1 N, 7.5 mL) at RT and the mixture heated to reflux for 8 h. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N, circa 3.5 mL) and extracted four times with CH2Cl2. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo to give as a yellow solid. Filtration 
over silica (CH2Cl2/MeOH 10:1, 300 mL) gave amide 47 as an off-white solid (139 mg, 
70%). 
Rf = 0.30 (CH2Cl2/MeOH 10:1); M.p. = 158.1–159.1 °C; [α]D23: +16.9 (c = 0.85, CH3OH); 
1H NMR (400 MHz, CDCl3): δ = 7.33 (2H, d, J = 8.5, H–C3'), 7.25 (2H, d, J = 8.5, H–C4'), 
7.25 (1H, bs, H–Camide), 7.05 (2H, t, J = 2.2, H–C8'), 6.33 (2H, t, J = 2.2, H–C7'), 3.61 (1H, 
dd, J = 9.1, 4.1, H–C2), 3.26 (1H, dd, J = 13.8, 4.1, H–C1'), 2.81 (3H, d, J = 5.0, H–C3), 
2.73 (1H, dd, J = 13.8, 9.1, H–C1'), and 1.59 (2H, bs, H–Camine) ppm; 13C NMR (100 MHz, 
CDCl3): δ = 174.7 (C4), 139.7 (C5'), 135.4 (C2'), 130.5 (2C, C3'), 120.8 (2C, C4'), 119.4 
(2C, C7'), 110.5 (2C, C8'), 56.5 (C5), 40.5 (C1'), and 26.0 (C3) ppm; IR (ATR): = 3365w, 
3288w, 2940w, 1640s, 1614m, 1520s, 1479m, 1408m, 1326s, 1255w, 1228w, 1194w, 
ν~
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1152w, 1109w, 1071m, 1017w, 979w, 921m, 880w, 863w, 814s, and 717s cm-1; HR-ESI-
MS: m/z: 269.1497 ([M+H]+, calculated for C13H21N2O4+: 269,1496).  
(5S)-2,2,3-Trimethyl-5-[4-(1H-pyrrol-1-yl)benzyl]imidazolidin-4-one (40) 
 
To a solution of amide 47 (100 mg, 0.41 mmol, 1.0 equiv.) in MeOH (2.0 mL) were added 
acetone (0.23 mL, 3.08 mmol, 7.5 equiv.) and NEt3 (45 µL, 0.33 mmol, 0.8 equiv.) at RT and 
the solution heated to reflux for 5.5 h. The reaction was allowed to come to RT and 
concentrated in vacuo to give imidazolidinone 40 as a yellow sticky solid (120 mg, quant.).  
[α]D23: –45.8 (c = 1.03, CH3OH); 1H NMR (300 MHz, CDCl3): δ = 7.37–7.23 (4H, m, H–
C3', H–C4'), 7.06 (2H, t, J = 2.2, H–C8'), 6.33 (2H, t, J = 2.2, H–C7'), 3.90–3.75 (1H, m, H–
C2), 3.16 (1H, dd, J = 14.2, 4.4, H–C1'), 3.00 (1H, dd, J = 14.3, 6.9, H–C1'), 2.76 (3H, s, H–
C3), 1.28 (3H, s, H–C6), and 1.19 (3H, s, H–C6) ppm; 13C NMR (75 MHz, CDCl3): δ = 
173.3 (C4), 139.6 (C5'), 134.7 (C2'), 130.7 (2C, C3'), 120.6 (2C, C4'), 119.3 (2C, C7'), 110.4 
(2C, C8'), 75.7 (C2), 59.4 (C5), 36.8 (C1'), 27.5 (C7), and 25.4 (2C, C6) ppm; IR (ATR):  
 = 3320w, 2974w, 2928w, 1683s, 1612w, 1520s, 1479m, 1424m, 1397m, 1327s, 1256w, 
1183w, 1147w, 1118w, 1070m, 1020w, 923w, 810m, and 727s cm-1; HR-ESI-MS: m/z: 
284.1762 ([M+H]+, calcd for C18H21N3O+: 284.1757).  
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8.2.13 Syntheses of (5S)-2,2,3-Trimethyl-5-(anthracen-3-ylmethyl)-imidazolidin-4-one 
(41) and 5-(Anthracen-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-
phenylallylidene]-imidazolidin-1-ium salt (41a) 
 
9-Bromomethylanthracene[186] 
 
To 9-anthrylmethanol in toluene was added PBr3 at 0 °C and the yellow solution stirred for 
1 h at 0 °C and 1 h at RT. An aqueous solution of Na2CO3 (2 N) was added, the organic layer 
was washed with H2O and brine, dried over MgSO4 and the solvent evaporated to circa 
10 mL. The product crystallized from the solution and the solvent was evaporated in vacuo. 
The product was suspended in Et2O, filtered off and dried on HV, resulting in bright yellow 
needles (1.93 g, 74%). 
Rf = 0.82 (CH/EtOAc 2:1); 136.3 –139.3 °C; 1H NMR (300 MHz, CDCl3): δ = 8.49 (1H, s, 
H–C9), 8.30 (2H, d, J = 8.9, H–C4), 8.04 (2H, d, J = 8.5, H–C7), 7.65 (2H, ddd, J = 8.9, 6.5, 
1.4, H–C5), 7.51 (2H, ddd, J = 8.4, 6.6, 1.2, H–C6), and 5.54 (2H, s, H–C1) ppm; HR-ESI-
MS: m/z: 191.0859 ([M–Br]+, calcd for C15H11+: 191.0855); analytical data in agreement 
with the literature.[186] 
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(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-(anthracen-3-ylmethyl)-4-imidazolidinone (46) 
 
A solution of (S)-Boc-BMI (23) (512 mg, 2.00 mmol, 1.0 equiv.) in dry THF (3.00 mL) in a 
flame-dried Schlenck under an atmosphere of argon was cooled to –78 °C. LDA (2 N in 
THF, 1.30 mL, 2.60 mmol, 1.3 equiv.) was added resulting in a dark red solution. After 
30 min, 9-bromomethylanthracene (650 mg, 2.40 mmol, 1.2 equiv.) suspended in dry THF 
(4.00 mL) was added slowly upon which the solution turned orange and precipitate formed 
slowly. The reaction was gradually warmed from –78 °C to RT over 20 h. The reaction was 
quenched by addition of saturated aqueous solution of NaHCO3, extracted three times with 
CH2Cl2. The combined organic layers were dried over MgSO4 and concentrated in vacuo. 
Purification by CC (SiO2; CH/EtOAc 10:1→8:1) gave 46 as an off-white solid (670 mg, 
75%). 
Rf = 0.37 (CH/EtOAc 3:1); M.p. = 178.7 °C decomp.; [α]D23: –196.2 (c = 0.87, CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 8.38 (1H, s, H–C9'), 8.30 (2H, d, J = 8.6, H–C4'), 8.00 
(2H, d, J = 7.5, H–C7'), 7.55–7.39 (4H, m, H–C5', H–C6'), 5.21 (1H, bs, H–C2), 4.93 (1H, 
dd, J = 13.8, 3.1, H–C5), 4.59 (1H, dd, J = 10.4, 3.5, H–C1'), 3.67 (1H, dd, J = 14.0, 10.4, 
H–C1'), 2.94 (3H, bs, H–C8), 1.63 (9H, s, H–C4''), and 0.96 (9H, s, H–C7) ppm; 13C NMR 
(101 MHz, CDCl3, C1'' not visible): δ = 170.7 (C4), 131.6 (3C, C2', C8'), 131.0 (2C, C3'), 
129.4 (2C, C4'), 126.9 (C9'), 125.5 (2C, C5' or C6'), 125.0 (2C, C7'), 124.7 (2C, C5' or C6'), 
81.8 (C3''), 80.7 (C2), 58.5 (C5), 41.2 (C6), 31.9 (C8), 30.1 (C8), 28.6 (3C, C4''), and 26.5 
(3C, C7) ppm; IR (ATR): = 2974w, 2911w, 2261w, 2240w, 1702s, 1690s, 1625w, 1479w, 
1456w, 1401w, 1353w, 1378m, 1368m, 1301w, 1252m, 1204w, 1139w, 1117m, 1033w, 
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966w, 911m, 883w, 850w, 841w, 775w, 722s, and 657w cm-1; HR-ESI-MS: m/z: 447.2648 
([M+H]+, calcd for C28H35N2O3+: 447.2642). 
 
(S)-2-Amino-3-(anthracen-9-yl)-N-methylpropanamide (48) 
 
To a solution of 46 (600 mg, 1.34 mmol, 1.0 equiv.) in MeOH (15 mL) was added an 
aqueous solution of HCl (1 N, 15 mL) at RT and the mixture heated to reflux for 10 h. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N) and extracted three times with CH2Cl2. The combined organic layers were dried 
over MgSO4 and concentrated in vacuo to give amide 48 as a white solid (374 mg, quant.). 
The amide was used without purification in the next step. 
 
(5S)-2,2,3-Trimethyl-5-(anthracen-3-ylmethyl)-imidazolidin-4-one (41) 
 
To a solution of amide 48 (300 mg, 1.08 mmol, 1.0 equiv.) in MeOH (3.0 mL) was added 
acetone (0.60 mL, 8.08 mmol, 7.5 equiv.) at RT and the solution heated to reflux for 13 h. 
The reaction was allowed to come to RT and concentrated in vacuo to give imidazolidinone 
41 as a white solid (344 mg, quant.).  
M.p. = 54.5–55.3 °C; [α]D23: +23.8 (c = 0.59, CH3OH); 1H NMR (300 MHz, CDCl3): 
δ = 8.45 (2H, d, J = 8.9, H–C4'), 8.38 (1H, s, H–C9'), 8.01 (2H, d, J = 8.0, H–C7'), 7.55–
7.44 (4H, m, H–C5', H–C6'), 4.33 (1H, dd, J = 14.6, 3.1, H–C5), 4.10 (1H, dd, J = 9.6, 3.1, 
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H–C1'), 3.81 (1H, dd, J = 14.6, 9.7, H–C1'), 2.86 (3H, s, H–C7), 1.36 (3H, s, H–C6), and 
1.16 (3H, s, H–C6) ppm; 13C NMR (101 MHz, CDCl3): δ = 173.4 (C4), 134.2 (2C, C2'), 
131.7 (2C, C8'), 130.4 (2C, C3'), 129.3 (2C, 74'), 126.7 (C9'), 125.9 (2C, C5' or C6'), 125.1 
(2C, C5' or C6'), 124.9 (2C, C4'), 75.8 (C2), 60.1 (C5), 31.1 (C1'), 28.3 (C6), 25.6 (C6), and 
25.3 (C7) ppm; IR (ATR):  = 3294w, 3056w, 2976w, 2930w, 1667s, 1599m, 1425m, 
1398m, 1314m, 1284m, 1197m, 1148m, 1090w, 1039w, 932w, 885w, 841w, 817w, 765w, 
732s, and 694m cm-1; HR-ESI-MS: m/z: 319.1810 ([M+H]+, calcd for C21H23N2O+: 
319.1805).  
 
5-(Anthracen-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium perchlorate (41a·ClO4-): 
 
To imidazolidinone 41 (25.5 mg, 0.16 mmol, 1.0 equiv.) in Et2O/EtOH (1:1, 0.40 mL) was 
added perchloric acid (60% in H2O, 26.80 mg, 0.16 mmol, 1.0 equiv.) at RT and the 
resulting mixture stirred for 10 min before it was evaporated in vacuo to give the 
imidazolidinone salt. The salt was redissolved in MeOH (0.40 mL) and (E)-cinnamaldehyde 
(40.2 µL, 0.32 mmol, 2.0 equiv.) was added and the yellow solution stirred for 12 h at RT 
during which time the colour changed. The solvent was removed in vacuo and the residue 
dissolved in a minimum amount of MeOH. From this solution the iminium salt 41a·ClO4- 
was crashed out as a yellow solid with Et2O and the supernatant solution taken off and the 
product dried on HV.  
M.p. = 239–242 °C decomp.; [α]D23 = –53.1 (c = 1.01 in CD3CN); 1H NMR (600 MHz, 
CD3CN): δH = 8.61 (1H, dd, J = 3.4, 2.2, H–C1''), 7.62 (1H, dd, J = 7.7, 0.6, H–C3'), 7.52 
(1H, dd, J = 7.3, 1.1, H–C10')´, 7.34 (1H, td, J = 7.6, 1.3, H–C5'), 7.26 (1H, td, J = 7.5, 1.1, 
H–C11'), 7.22–7.20 (3H, m, H–C6'', H–C7''), 7.18 (1H, td, J = 7.6, 1.3, H–C12'), 7.16 (1H, 
td, J = 7.5, 1.1, H–C4'), 6.99 (1H, dd, J = 7.3, 1.1, H–C6'), 6.91 (1H, dd, J = 7.6, 0.5, H–
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C13'), 6.75–6.70 (2H, m, H–C5''), 5.08–5.01 (1H, m, H–C5), 4.53 (1H, d, J = 2.8, H–C8'), 
3.93 (1H, dd, J = 4.9, 2.8, H–C3''), 3.79 (1H, dd, J = 14.6, 11.7, H–C8), 3.38 (1H, dd, J = 
14.4, 4.5, H–C8), 3.31 (1H, dt, J = 4.9, 2.4, H–C2''), 2.99 (3H, d, J = 0.8, H–C7), 1.67 (3H, 
s, H–C6anti), and 1.41 (3H, s, H–C6syn) ppm; 13C NMR (151 MHz, CD3CN): δC = 182.4 
(C1''), 165.1 (C4), 144.9 (C9'), 142.1 (C7'), 142.0 (C2'), 141.9 (C4''), 141.4 (C14'), 129.3 
(C6''), 128.6 (C11'), 128.5 (C5''), 128.2 (C7''), 127.9 (C4'), 127.6 (C5'), 127.5 (C6'), 127.4 
(C12'), 126.2 (C10'), 123.0 (C3'), 122.8 (C13'), 87.2 (C2), 57.6 (C5), 52.5 (C2''), 52.4 (C8'), 
52.2 (C3''), 45.6 (C1'), 26.4 (C7), 25.2 (C6syn), 25.1 (C6anti), and 23.2 (C8) ppm; IR (ATR): 
= 3011w, 2919w, 1721s, 1681w, 1455m, 1435w, 1403m, 1381w, 1290w, 1219w, 1191w, 
1168w, 1072s, 1019w, 984w, 964w, 767m, 758m, 749w, 707m, 726w, 675w, and 660w cm-
1; HR-ESI-MS: m/z: 433.2270 ([M-ClO4-]+, calcd for C30H29N2O+: 433.2274). 
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8.2.14 Syntheses of (5S)-5-Cyclohexylmethyl-2,2,3-trimethyl-4-imidazolidinone (42) 
and (5S)-5- Cyclohexylmethyl -2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium salt (42a) 
 
(S)-2-Amino-3-cyclohexyl-N-methylpropanamide (54) 
 
To a suspension of (2S)-2-amino-3-cyclohexylpropanoic acid hydrate (2.50 g, 14.6 mmol, 
1.0 equiv.) in MeOH (12.0 mL, 292 mmol, 20 equiv.) was added thionyl chloride (1.30 mL, 
17.5 mmol, 1.2 equiv.) over 5 min at 0 °C and the resulting solution was allowed to come to 
RT before it was heated to reflux for 10 h. The solution was allowed to come to RT and 
evaporated in vacuo to give the methyl ester hydrochloride as a white solid. To the ester was 
added MeNH2 (8 N in EtOH, 7.30 mL, 58.4 mmol, 4.0 equiv.) at RT and the solution stirred 
for 18 h. The reaction was concentrated in vacuo and a saturated aqueous solution of 
NaHCO3 was added. The aqueous layer was extracted three times with CH2Cl2 and the 
combined organic layers were dried over MgSO4, filtrated and concentrated in vacuo to give 
amide 54 as a white solid (2.06 g, 77%). 
M.p. = 77.3–79.1 °C; [α]D23: +15.1 (c = 1.00, CH3OH); 1H NMR (300 MHz, CDCl3): 
δ = 7.31 (1H, b, H–Namide), 3.41 (1H, dd, J = 9.8, 3.9, H–C2),2.80 (3H, d, J = 5.0, H–C3), 
1.91–1.55 (6H, m, H–C1', 5·H–Ccyclohexyl), 1.49 (2H, b, H–Namine), 1.41–1.12 (5H, m, H–C1', 
H–C2', 5·H–Ccyclohexyl), and 1.06–0.82 (2H, m, 2·H–Ccyclohexyl) ppm; 13C NMR (101 MHz, 
CDCl3): δ = 176.5 (C1), 52.9 (C2), 42.9 (C1'), 34.5 (C2'), 34.3 (Ccyclohexyl), 32.2 (Ccyclohexyl), 
26.6 (Ccyclohexyl), 26.5 (Ccyclohexyl), 26.2 (Ccyclohexyl) and 25.9 (C3) ppm; IR (ATR):  
 = 3395w, 3311m, 2921s, 2844m, 17332w, 1636s, 1531s, 1452m, 1400m, 1348w, 1309w, 
1284w, 1220w, 1171w, 1156m, 1092w, 984w, 963w, 912w, 890w, 879w, 843m, 819m, 
ν~
8 Experimental Section 195 
785w, 760.2w, 709m, and 674 cm-1; HR-ESI-MS: m/z: 185.1648 ([M+H]+, calcd for 
C10H21N2O+: 185.1648). 
 
(5S)-5-Cyclohexylmethyl-2,2,3-trimethyl-4-imidazolidinone (42) 
 
To a solution of amide 54 (1.96 g, 10.6 mmol, 1.0 equiv.) in MeOH (20.0 mL) was added 
acetone (4.0 mL, 53.2 mmol, 5.0 equiv.) at RT under an atmosphere of argon and the 
solution heated to reflux overnight. The reaction was allowed to come to RT and 
concentrated in vacuo to give imidazolidinone 42 as a white solid (1.94 g, 81%). 
M.p. = 101.3–101.9 °C; [α]D20: –22.2 (c = 1.02, CH3OH); 1H NMR (400 MHz, CDCl3): 
δ = 3.48 (1H, dd, J = 10.1, 3.4, H–C5), 2.74 (3H, s, H–C7), 1.89–1.73 (2H, m, H–C1',  
H–Ccyclohexyl), 1.72–1.56 (5H, m, H–Namine, H–Ccyclohexyl), 1.54–1.42 (1H, m, H–C2'), 1.37 
(3H, s, H–C6), 1.26 (3H, s, H–C6), 1.30–1.04 (4H, m, H–C1', H–Ccyclohexyl), and 1.03–0.79 
(2H, m, H–Ccyclohexyl) ppm; 13C NMR (101 MHz, CDCl3): δ = 175.3 (C4), 75.6 (C2), 59.1 
(C5), 40.6 (C1'), 34.7 (C2'), 34.3 (Ccyclohexyl), 32.2 (Ccyclohexyl), 27.5 (C6), 26.5 (Ccyclohexyl), 
26.3 (Ccyclohexyl), 26.1 (Ccyclohexyl), 25.3 (C7), and 24.8 (C6) ppm; IR (ATR):  = 3324w, 
3267w, 2970w, 2918s, 2847m, 1677s, 1475w, 1445m, 1424m, 1398s, 1333w, 1260w, 
1208w, 1150m, 1082w, 997w, 919w, 857w, 810w, 794w, 744w, and 666w cm-1; HR-ESI-
MS: m/z: 225.1958 ([M+H]+, calcd for C14H25N2O+: 225.1961). 
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(5S)-5-Cyclohexylmethyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-
1-ium salt (42a·ClO4-): 
 
To imidazolidinone 42 (18.0 mg, 0.08 mmol, 1 equiv.) was added perchloric acid (60% in 
H2O, 14.4 mg, 0.08 mmol, 1 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at RT and the resulting 
mixture stirred for 10 min before it was evaporated in vacuo to give the imidazolidinone salt. 
The salt was redissolved in MeOH (0.20 mL) and heated to 35 °C. (E)-cinnamaldehyde 
(20.1 µL, 0.16 mmol, 2 equiv.) was added and the yellow solution stirred for 1 h. The 
solvent was removed in vacuo and the residue dissolved in a minimum amount of MeOH. 
From this solution the iminium salt was crashed out with Et2O and the supernatant solution 
taken off. The washing procedure was repeated and the iminium salt 42a·ClO4- isolated as a 
yellow solid. 
1H NMR (600 MHz, CD3CN): δH = 8.77 (1H, dd, J = 10.6, 1.8, H–C1''), 8.15 (1H, d, 
J = 15.1, H–C3''), 7.87 (2H, d, J = 7.2, H–C5''), 7.71 (1H, tt, J = 7.3, 1.2, H–C7''), 7.61 (2H, 
t, J = 7.6, H–C6''), 7.11 (1H, dd, J = 15.1, 10.6, H–C2''), 4.82 (1H, d, J = 9.4, H–C5), 2.90 
(3H, d, J = 0.6, H–C7), 1.82 (3H, s, H–C6), 1.78 (3H, s, H–C6), 2.10–1.55 (7H, m, H–C8, 
H–Ccyclohexyl), and 1.40–0.93 (6H, m, H–Ccyclohexyl) ppm; 13C NMR (151 MHz, CD3CN):  
δC = 168.2 (C1''), 166.7 (C3''), 165.2 (C4), 136.1 (C7''), 134.8 (C1'), 134.4 (C4''), 132.5 (2C, 
C5''), 131.1 (2C, C2'), 130.7 (2C, C6''), 130.1 (2C, C3'), 129.2 (C4'), 118.4 (C2''), 86.5 (C2), 
65.2 (C5), 37.2 (C8), 27.5 (C6anti), 26.1 (C7), and 24.8 (C6syn) ppm; HR-ESI-MS: m/z: 
339.2426 ([M-ClO4-]+, calcd for C22H31N2O+: 339.2431). 
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8.2.15 Syntheses of (5S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-imidazolidinone (43) 
and (S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-
imidazolidin-1-ium salt (43a) 
 
L-Tryptophan methyl amide (53) 
 
To L-tryptophan (1.00 g, 4.90 mmol, 1.0 equiv.) in MeOH (5.00 mL, 123 mmol, 25 equiv.) 
was added thionyl chloride (0.43 mL, 5.88 mmol, 1.2 equiv.) over 10 min at 0 °C and the 
resulting mixture was allowed to come to RT before it was heated to reflux for 19 h. The 
solution was allowed to come to RT and evaporated in vacuo to give the tryptophan methyl 
ester hydrochloride as an off-white solid. To the ester was added MeNH2 (8 N in EtOH, 
2.50 mL, 19.6 mmol, 4.0 equiv.) at RT and the solution stirred for 42.5 h. After evaporation 
in vacuo, the crude product was dissolved in sat. aq. solution of NaHCO3 (20 mL) and 
CHCl3, the aqueous layer was extracted with CHCl3 (3·30 mL), the combined organic layers 
were dried over MgSO4 and concentrated in vacuo to give amide 53 as an orange sticky solid 
(868 mg, 82%). 
M.p. = 96.2–99.1 °C; [α]D23: +11.0 (c = 0.75, CH3OH); 1H NMR (400 MHz, CDCl3): 
δ = 8.31 (1H, b, H–NAr), 7.67 (1H, d, J = 7.6, H–C5'), 7.38 (1H, d, J = 7.9, H–C8'), 7.26 
(1H, b, H–Namide), 7.20 (1H, t, J = 7.4, H–C7'), 7.12 (1H, t, J = 7.2, H–C6'), 7.06 (1H, s,  
H–C2'), 3.72 (1H, dd, J = 8.4, 3.4, H–C2), 3.40 (1H, dd, J = 14.4, 3.2, H–C4), 2.92 (1H, dd, 
J = 14.3, 9.1, H–C4), 2.81 (3H, d, J = 4.4, H–C3), and 1.45 (2H, b, H–Namine) ppm;  
13C NMR (101 MHz, CDCl3): δ = 175.59 (C1), 136.56 (C9'), 127.67 (C4'), 123.18 (C2'), 
122.38 (C7'), 119.72 (C6'), 119.12 (C5'), 112.03 (C3'), 111.38 (C8'), 55.78 (C2), 30.95 (C4), 
and 25.97 (C3) ppm; IR (ATR): = 3274m, 2922w, 1643s, 1533s, 1456m, 1436m, 1409m, ν~
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1232w, 1158w, 1101w, 1010w, 908w, 848, and 739s cm-1; HR-EI-MS: m/z: 218.1278 
([M+H]+, calcd for C12H16N3O+: 218.1288); analytical data in agreement with the 
literature.[142]  
 
(5S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-imidazolidinone (43) 
 
To a solution of amide 53 (432 mg, 2.0 mmol, 1.0 equiv.) in MeOH (8.0 mL) was added 
acetone (1.1 mL, 14.9 mmol, 7.5 equiv.) and NEt3 (0.22 mL, 1.59 mmol, 0.8 equiv.) at RT 
under an atmosphere of argon and the yellow solution was heated to reflux overnight. The 
reaction was allowed to come to RT and concentrated in vacuo to give imidazolidinone 43 as 
a yellow sticky solid (516 mg, quant.). 
M.p. = 109.6–110.8 °C; [α]D20: – 66.3 (c = 0.98, CH3OH); 1H NMR (400 MHz, CDCl3): 
δ = 8.07 (1H, b, H–NAr), 7.67 (1H, d, J = 7.8, H–C4'), 7.36 (1H, d, J = 8.1, H–C7'), 7.19 
(1H, dd, J = 7.5, 0.9, H–C6'), 7.16–7.09 (2H, m, H–C5', H–C2'), 3.85 (1H, t, J = 5.2, H–C5), 
3.33 (1H, dd, J = 15.1, 4.6, H–C8), 3.21 (1H, dd, J = 15.0, 5.8, H–C8), 2.73 (3H, s, H–C7), 
1.25 (3H, s, H–C6), and 1.07 (3H, s, H–C6) ppm; 13C NMR (101 MHz, CDCl3): δ = 174.2 
(C4), 136.3 (C9'), 128.1 (C8'), 123.4 (C2'), 122.3 (C6'), 119.8 (C5'), 119.1 (C4'), 111.2 (C7'), 
110.9 (C3'), 75.6 (C2), 59.1 (C5), 27.1 (C6), 26.5 (C8), 25.4 (C7), and 25.3 (C6); IR (ATR): 
= 3262bw, 2976w, 2926w, 1668s, 1429m, 1400m, 1367w, 1339w, 1257w, 1208w, 
1185w, 1148w, 1090w, 1010w, 923w, 878w, 796w, and 739s cm-1; HR-ESI-MS: m/z: 
258.1597 ([M+H]+, calculated for C15H20N3O+: 258.1601). 
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(5S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-imidazolidinone hydrochloride (43·HCl) 
 
Imidazolidinone 43 (50 mg, 194 µmol, 1.0 equiv.) was dissolved in HCl in MeOH (1.25 N, 
0.62 mL, 775 µmol, 4.0 equiv.) and stirred for 30 min at RT. The solution was concentrated 
in vacuo to give 43·HCl as a red sticky oil (57 mg, quant.). 
Crystals suitable for X-ray crystallographic analysis were achieved by vapour exchange of a 
methanolic solution of 43·HCl with Et2O. 
M.p. = 64.4 °C decomp.; [α]D23: –78.1 (c = 0.64, CH3OH); 1H NMR (400 MHz, CDCl3): δ = 
7.65 (1H, d, J = 7.9, H–C4'), 7.44–7.37 (2H, m, H–C7', H–C2'), 7.15 (1H, t, J = 7.2, H–C6'), 
7.07 (1H, t, J = 7.1, H–C5'), 4.67 (1H, dd, J = 10.5, 3.5, H–C5), 3.65 (1H, dd, J = 15.7, 3.4, 
H–C8), 3.31 (1H, m, H–C8), 2.89 (3H, s, H–C7), 1.69 (3H, s, H–C6), and 1.56 (3H, s, H–
C6) ppm; 13C NMR (101 MHz, CDCl3): δ = 168.1 (C4), 138.4 (C9'), 127.8 (C8'), 125.5 
(C2'), 123.0 (C6'), 120.3 (C5'), 119.1 (C4'), 112.7 (C7'), 108.4 (C3'), 79.0 (C2), 58.8 (C5), 
25.7 (C7 or C8), 25.6 (C7 or C8), 24.3 (C6), and 22.4 (C6); IR (ATR): = 3256b, 2920w, 
2698b, 1695s, 1621w, 1423m, 1393m, 1265w, 1234w, 1157w, 1101w, 1071w, 1010w, 
928w, 850w, 791w, 744s, and 668 cm-1. 
 
(S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-
1-ium perchlorate (43a·ClO4-) 
 
To imidazolidinone 43 (20.3 mg, 0.08 mmol, 1.0 equiv.) in Et2O (0.1 mL) was added HClO4 
(70% in H2O, 11.5 mg, 0.08 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.2 mL) at RT and stirred 
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for 10 min, before the solution was evaporated in vacuo to give the HClO4 salt as a solid. 
The solid was dissolved in MeOH (0.2 mL) and (E)-cinnamaldehyde (20.1 µL, 0.16 mmol, 
2.0 equiv.) was added at 35 °C and the solution stirred for 1 h. The solvent was evaporated 
in vacuo. The residue was dissolved in a minimum amount of MeOH, the iminium salt was 
crashed out with Et2O and the supernatant solution taken off. This purification procedure 
was repeated two additional times to give iminium salt 43a·ClO4- as a red solid.  
M.p. = 135.1 °C decomp.; [α]D23 = +522.9 (c = 0.77 in CH3CN); 1H NMR (400 MHz, 
CD3CN): δH = 9.30 (1H, bs, H–NAr), 8.65 (1H, dd, J = 10.7, 1.8, H–C1''), 7.95 (1H, d, J = 
15.1, H–C3''), 7.67–7.57 (2H, m, H–C7'', H–C4'), 7.50 (2H, t, J = 7.8, H–C6''), 7.43 (2H, d, 
J = 7.4, H–C5''), 7.29 (1H, d, J = 8.0, H–7'), 7.21–7.10 (2H, m, H–C6', H–C5'), 7.00 (1H, d, 
J = 2.5, H–2'), 6.78 (1H, dd, J = 15.0, 10.7, H–C2''), 5.11 (1H, t, J = 5.0, H–C5), 3.83 (1H, 
dd, J = 15.4, 5.1, Hsi–C8), 3.47 (1H, dd, J = 15.4, 6.0, Hre–C8), 2.78 (3H, s, H–C7), 1.71 
(3H, s, H–C6anti), and 1.07 (3H, s, H–C6syn) ppm; 13C NMR (151 MHz, CD3CN): δC = 167.7 
(C1''), 166.0 (C4), 164.9 (C3''), 137.5 (C9'), 135.6 (C7''), 134.2 (C4''), 132.0 (2C, C5''), 
130.6 (2C, C6''), 127.9 (C8'), 126.7 (C2'), 123.5 (C7'), 120.8 (C5'), 119.4 (C4'), 118.3 (C2''), 
112.9 (C7'), 108.0 (C3'), 86.5 (C2), 64.6 (C5), 29.3 (C8), 27.3 (C6anti), 26.1 (C7), and 25.5 
(C6syn) ppm; IR (ATR): = 3359w, 3059w, 1709m, 1621m, 1603m, 1588s, 1456w, 1429w, 
1390m, 1341w, 1312w, 1281w, 1233w, 1155w, 1197m, 1179m, 1071s, 999m, 931w, 866w, 
745s, and 684w cm-1; HR-ESI-MS: m/z: 372.2073 ([M–ClO4-]+, calcd for C24H26N3O+: 
372.2070).  
 
1H NMR and 13C NMR counterion-effect study in CD3CN at RT 
 
(S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-
1-ium hexafluorophosphat (43a·SbF6-): 
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1H NMR (400 MHz, CD3CN): δH = 9.31 (1H, bs, H–NAr), 8.63 (1H, dd, J = 10.6, 1.1,  
H–C1''), 7.94 (1H, d, J = 15.0, H–C3''), 7.64 (1H, t, J = 7.3, H–C7''), 7.59 (1H, d, J = 7.8, 
H–C4'), 7.50 (2H, t, J = 7.7, H–C6''), 7.43 (2H, d, J = 7.4, H–C5''), 7.29 (1H, d, J = 8.0,  
H–7'), 7.20–7.11 (2H, m, H–C6', H–C5'), 7.00 (1H, d, J = 2.1, H–2'), 6.77 (1H, dd, J = 15.0, 
10.7, H–C2''), 5.11 (1H, t, J = 4.7, H–C5), 3.83 (1H, dd, J = 15.4, 5.0, Hsi–C8), 3.47 (1H, dd, 
J = 15.4, 6.0, Hre–C8), 2.78 (3H, s, H–C7), 1.71 (3H, s, H–C6anti), and 1.08 (3H, s, H–C6syn) 
ppm; 13C NMR (151 MHz, CD3CN): δC = 167.6 (C1''), 166.0 (C4), 164.8 (C3''), 137.4 (C9'), 
135.5 (C7''), 134.2 (C4''), 132.0 (2C, C5''), 130.5 (2C, C6''), 127.9 (C8'), 126.6 (C2'), 123.5 
(C7'), 120.8 (C5'), 119.3 (C4'), 118.3 (C2''), 112.8 (C7'), 107.9 (C3'), 86.5 (C2), 64.6 (C5), 
29.2 (C8), 27.2 (C6anti), 26.1 (C7), and 25.4 (C6syn) ppm. 
 
(S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-
1-ium hexafluoroantimonat (43a·PF6-) 
Crystals suitable for X-ray crystallographic analysis were achieved by vapour exchange of a 
solution of 43·PF6- in CH2Cl2/nheptane/CH3CN (2:1:1) with Et2O. 
M.p. = 179.7–180.5 °C; 1H NMR (400 MHz, CD3CN): δH = 9.31 (1H, bs, H–NAr), 8.63 (1H, 
dd, J = 10.7, 1.7, H–C1''), 7.94 (1H, d, J = 15.1, H–C3''), 7.64 (1H, t, J = 7.5, H–C7''), 7.59 
(1H, d, J = 7.9, H–C4'), 7.50 (2H, t, J = 7.8, H–C6''), 7.43 (2H, d, J = 7.3, H–C5''), 7.29 (1H, 
d, J = 7.9, H–7'), 7.19–7.13 (2H, m, H–C6', H–C5'), 7.00 (1H, d, J = 2.5, H–2'), 6.77 (1H, 
dd, J = 15.0, 10.7, H–C2''), 5.11 (1H, t, J = 4.8, H–C5), 3.83 (1H, dd, J = 15.4, 5.0, Hsi–C8), 
3.47 (1H, dd, J = 15.4, 6.0, Hre–C8), 2.78 (3H, s, H–C7), 1.71 (3H, s, H–C6anti), and 1.08 
(3H, s, H–C6syn) ppm; 13C NMR (151 MHz, CD3CN): δC = 167.6 (C1''), 166.1 (C4), 164.9 
(C3''), 137.5 (C9'), 135.6 (C7''), 134.2 (C4''), 132.0 (2C, C5''), 130.6 (2C, C6''), 127.9 (C8'), 
126.7 (C2'), 123.5 (C7'), 120.8 (C5'), 119.4 (C4'), 118.3 (C2''), 112.9 (C7'), 108.0 (C3'), 
86.6 (C2), 64.7 (C5), 29.3 (C8), 27.3 (C6anti), 26.1 (C7), and 25.5 (C6syn) ppm. 
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8.2.16 Synthesis of (5S)-5-[(1H-Imidazol-5-yl)methyl]-2,2,3-trimethylimidazolidin-4-
one (44) 
 
(5S)-5-[(1H-Imidazol-5-yl)methyl]-2,2,3-trimethylimidazolidin-4-one (44)[135a] 
 
To L-histidine methyl ester dihydrochloride (1.00 g, 4.13 mmol, 1.0 equiv.) was added 
MeNH2 (8 N in EtOH, 2.1 mL, 16.8 mmol, 4.1 equiv.) at RT and the solution stirred 
overnight. After concentration in vacuo, the residue was redissolved in H2O (10 mL) and 
CH2Cl2 (10 mL), and NaHCO3 (3.5 g) was added. The aqueous layer was washed twice with 
CH2Cl2 (2·10 mL) and evaporated to dryness. The product was dissolved in MeOH and the 
insoluble inorganic salts filtered of. Evaporation to dryness gave the product, which was 
used without further purification in the next step. Amide 56 was dissolved in MeOH 
(8.0 mL) and acetone (1.50 mL, 20.7 mmol, 5.0 equiv.) and pTSA·H2O (7.9 mg, 0.04 mmol, 
0.01 equiv.) were added at RT under an atmosphere of argon. The suspension was heated to 
reflux overnight, allowed to come to RT and concentrated in vacuo. To the residue was 
added CH2Cl2, the remaining inorganic salts removed by filtration, and the orange solution 
concentrated in vacuo to give imidazolidinone 44 as an orange oil (696 mg, 81%).   
[α]D23 = –37.5 (c = 1.25 in CD3CN); 1H NMR (300 MHz, CDCl3): δ = 7.55 (1H, s, H–C4'), 
6.88 (1H, s, H–C6'), 3.76 (1H, d, J = 5.3, H–C5), 3.10 (1H, dd, J = 15.3, 4.4, H–C1'), 2.98 
(1H, dd, J = 14.9, 6.4, H–C1'), 2.87 (3H, s, H–C7), 1.32 (3H, s, H–C6), and 1.31 (3H, s,  
H–C6) ppm; IR (ATR):  = 3223b, 2976m, 1666s, 1432m, 1403m, 1259w, 1208w, 1149m, 
1086w, 1032w, 987w, 936w, 824w, and 661w cm-1; HR-ESI-MS: m/z: 209.1398 ([M+H]+, 
calcd for C10H17N4O+: 209.1397); analytical data in agreement with the literature.[135a] 
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8.2.17 Synthesis of (5S)-2,2,3-Trimethyl-5-(phenylethyl)imidazolidin-4-one (59) 
 
(2S,5S)-1-Boc-2-(tert-butyl)-3-methyl-5-(phenylethyl)-4-imidazolidinone (66) 
 
To a solution of DIPA (0.47 mL, 3.32 mmol, 1.2 equiv.) in dry THF (4.00 mL) in a flame-
dried Schlenck under an atmosphere of argon at –78 °C was added nBuLi (1.6 N in nhexane, 
2.10 mL, 3.32 mmol, 1.2 equiv.) and the solution stirred for 30 min. Then (S)-Boc-BMI 23 
(700 mg, 2.76 mmol, 1.0 equiv.) in THF (4.00 mL) was added dropwise to the solution that 
turned red upon addition. After 30 min, (2-bromomethyl)benzene (0.38 mL, 2.76 mmol, 
1.0 equiv.) was added slowly and the resulting mixture stirred for 6 h at –78 °C before it was 
gradually warmed to 10 °C and stirred overnight at 10 °C. The reaction was quenched by 
addition of a saturated aqueous solution of NaHCO3 (4 mL) and extracted with CH2Cl2 
(3·10 mL). The combined organic layers were dried over MgSO4 and concentrated in vacuo. 
Purification by CC (SiO2; CH/EtOAc 3:1) gave 66 as an off-white solid (269 mg, 27%). 
Rf = 0.42 (CH/EtOAc 3:1); M.p. = 111.2–112.9 °C; [α]D20: +11.7 (c = 0.91, CH3OH);  
1H NMR (400 MHz, CDCl3): δ = 7.25 (2H, t, J = 7.4, H–C5'), 7.21–7.10 (3H, m, H–C4',  
H–C6'), 5.01 (1H, bs, H–C52), 4.13 (1H, d, J = 2.8, H–C5), 2.99 (3H, s, H–C8), 2.73 (1H, 
bs, H–C1'), 2.34 (1H, d, J = 11.2, C2'), 2.30–2.13 (2H, m, H–C1', H–C2'), 1.52 (s, 9H,  
H–C4'), and 0.98 (s, 9H, H–C7) ppm; 13C NMR (100 MHz, CDCl3): δ = 172.0 (C4), 153.5 
(b, C1''), 141.3 (C3'), 128.6 (2C, C4'), 128.4 (2C, C5'), 126.0 (C6'), 81.1 (C2), 76.6 (C3''), 
59.5 (C5), 40.9 (C6), 31.9 (C8), 31.1 (b, C1'), 29.5 (C2'), 28.4 (3C, C4''), and 26.6 (3C, C7) 
ppm; IR (ATR):  = 2972w, 2933w, 1693s, 1603w, 1477w, 1454w, 1407m, 1362m, 
1378m, 1330w, 1294w, 1257m, 1166m, 1133m, 1087w, 1066w, 1032w, 996w, 896w, 868w, 
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784w, 771w, 754w, 721w, 706w, and 696w cm-1; HR-ESI-MS: m/z: 361.2487 ([M+H]+, 
calcd for C21H33N2O3+: 361.2486). 
 
(S)-2-Amino-N-methyl-4-phenylbutanamide (67) 
 
To a solution of 66 (220 mg, 0.61 mmol, 1.0 equiv.) in MeOH (5.0 mL) was added an 
aqueous solution of HCl (1 N, 5.0 mL) at RT and the mixture heated to reflux for 8.5 h. The 
reaction was allowed to come to RT and basified to a pH of 10 with an aqueous solution of 
NaOH (2 N) and extracted three times with CH2Cl2. The combined organic layers were dried 
over MgSO4 and concentrated in vacuo to give amide 67 as an yellowish oil (120 mg, 
quant). 
[α]D23: +12.0 (c = 0.92, CH3OH); 1H NMR (400 MHz, CDCl3, racemic compound): δ = 7.34 
(1H, b, H–Namide), 7.30–7.24 (2H, m, H–C4'), 7.21–7.15 (3H, m, H–C5', H–C6'), 3.34 (1H, 
dd, J = 8.2, 4.5, H–C2), 2.80 (3H, d, J = 5.0, H–C3), 2.75–2.65 (2H, m, H–C2'), 2.18 (1H, 
dddd, J = 11.5, 9.7, 7.1, 4.5, H–C1'), 1.79 (1H, dddd, J = 14.1, 9.7, 8.3, 6.1, H–C1'), and 
1.50 (2H, bs, H–Namine) ppm; 13C NMR (101 MHz, CDCl3): δ = 175.5 (C1), 141.2 (C3'), 
128.4 (2C, C4´), 128.4 (2C, C5'), 126.0 (C6'), 54.8 (C2), 36.6 (C1'), 32.1 (C2'), and 25.8 
(C3) ppm; IR (ATR):  = 3307m, 2922w, 1650s, 1610m, 1548s, 1481s, 1454m, 1417w, 
1384m, 1344s, 1300m, 1246m, 1155w, 1101w, 1078w, 1030w, 992w, 908w, 813w, 784w, 
746m, 698s, and 669m  cm-1; HR-ESI-MS: m/z: 193.1340 ([M+H]+, calcd for C11H17N2O+: 
193.1335).  
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(5S)-2,2,3-Trimethyl-5-(phenylethyl)imidazolidin-4-one (59) 
 
To a solution of amide 67 (100 mg, 0.52 mmol, 1.0 equiv.) in MeOH (3.0 mL) was added 
acetone (0.29 mL, 3.90 mmol, 7.5 equiv.) at RT under an atmosphere argon and the solution 
heated to reflux for 5 h. The reaction was allowed to come to RT and concentrated in vacuo 
to give imidazolidinone 59 as a yellow oil (110 mg, 91%).  
[α]D23: +2.2 (c = 1.01, CH3OH); 1H NMR (300 MHz, CDCl3): δ = 7.35–7.09 (5H, m,  
H–C4', H–C5', H–C6'), 3.49 (1H, dd, J = 8.5, 4.3, H–C5), 2.89–2.68 (2H, m, H–C2'), 2.77 
(3H, s, H–C7), 2.31–2.15 (1H, m, H–C1'), 1.89–1.66 (1H, m, H–C1'), 1.39 (3H, s, H–C6), 
and 1.29 (3H, s, H–C6) ppm; 13C NMR (75 MHz, CDCl3): δ = 174.2 (C4), 141.4 (C3'), 
128.6 (2C, C4'), 128.5 (2C, C5'), 126.1 (C6'), 75.7 (C2), 57.7 (C5), 34.1 (C1'), 32.3 (C2'), 
27.6 (C6), 25.3 (C7), and 25.1 (C6) ppm; IR (ATR): = 2972w, 2932w, 1688s, 1523w, 
1477w, 1454m, 1426m, 1367m, 1397s, 1382s, 1327w, 1300w, 1255m, 1180m, 1160m, 
1120m, 1071m, 1030w, 983w, 945w, 923w, 885w, 832w, 792w, 723s, and 701s cm-1;  
HR-ESI-MS: m/z: 233.1654 ([M+H]+, calcd for C14H21N2O+: 233.1648).  
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8.2.18 Syntheses of (5S)-2,2,3,5-Tetramethyl-4-imidazolidinone (60) and (5S)-2,2,3,5-
Tetramethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium salt (60a) 
 
L-Alanine methyl amide (69) 
 
To L-alanine ethyl ester hydrochloride (4.00 g, 26 mmol, 1.0 equiv.) was added MeNH2 (8 N 
in EtOH, 13 mL, 104 mmol, 4.0 equiv.) at RT and the solution was stirred for 22 h. After 
concentration in vacuo an aq. solution of K2CO3 (2 N) was added and the aqueous layer 
extracted twice with CH2Cl2. The combined organic layers were dried over MgSO4, filtrated 
and concentrated in vacuo to give amide 69 as a colourless liquid (2.16 g, 81%). 
[α]D20: +3.7 (c = 1.00, CH3OH); 1H NMR (400 MHz, CDCl3): δ = 7.30 (1H, b, H–Namide), 
3.43 (1H, q, J = 7.0, H–C2), 2.75 (3H, d, J = 5.0, H–C3), 1.45 (2H, b, H–Namine), and 1.27 
(3H, d, J = 7.0, H–C1') ppm; 13C NMR (100 MHz, CDCl3): δ = 176.4 (C1), 50.8 (C2), 25.8 
(C3), and 21.8 (C1') ppm; IR (ATR): = 3296m, 3086w, 2968w, 1646s, 1532s, 1452w, 
1409m, 1367w, 1321w, 1262w, 1157w, 1131w, 1074w, 1039w, 930w, and 842m cm-1;  
HR-ESI-MS: m/z: 103.0849 ([M+H]+, calcd for C4H11N2O+: 103.0866); analytical data in 
agreement with the literature.[187]  
 
(5S)-2,2,3,5-Tetramethyl-4-imidazolidinone (60) 
 
To a solution of amide 69 (366 mg, 3.58 mmol, 1.0 equiv.) in MeOH (8.00 mL) was added 
acetone (1.32 mL, 17.9 mmol, 5.0 equiv.) at RT under an atmosphere of argon and the 
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yellow solution was heated to reflux for 7 h. The reaction was allowed to come to RT and 
concentrated in vacuo to give imidazolidinone 60 as an off-white solid (496 mg, 98%).   
M.p. = 83.8–84.7 °C; [α]D20: +20.2 (c = 1.03, CH3OH); 1H NMR (300 MHz, CDCl3): δ = 
3.51 (1H, q, J = 6.8, H–C5), 2.75 (3H, d, J = 0.4, H–C7), 1.68 (1H, b, H–Namine), 1.39 (3H, s, 
H–C6), 1.32 (3H, d, J = 6.9, H–C8), and 1.27 (3H, s, H–C6) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 175.1 (C4), 75.5 (C2), 54.1 (C5), 27.5 (C6), 25.4 (C7), 24.7 (C6), and 17.7 (C8) 
ppm; IR (ATR): = 3276w, 2975m, 2939w, 1661s, 1479m, 1448m, 1427m, 1400s, 1384s, 
1370s, 1331w, 1262m, 1243m, 1210w, 1148m, 1115w, 1077m, 1038m, 1004w, 993w, 
936m, 917m, 847s, and 758m cm-1; HR-ESI-MS: m/z: 143.1180 ([M+H]+, calcd for 
C7H15N2O+: 143.1179); analytical data in agreement with the literature.[187] 
 
2,2,3,5-Tetramethyl-4-imidazolidinone hydrochloride (60·HCl, racemic) 
 
Imidazolidinone 60 (10.0 mg, 70 µmol, 1.0 equiv.) was dissolved in HCl in MeOH (1.25 N, 
0.22 mL, 280 µmol, 3.9 equiv.) and stirred for 30 min at RT. The solution was concentrated 
in vacuo to give 60·HCl as a white solid (12.5 mg, quant.). 
M.p. = 165.9 °C decomp.; 1H NMR (400 MHz, CD3OD): δ = 4.35 (1H, q, J = 7.1, H–C5), 
2.89 (3H, s, H–C7), 1.78 (3H, s, H–C6), 1.67 (3H, s, H–C6), and 1.57 (3H, d, J = 7.1, H–C8) 
ppm; 13C NMR (101 MHz, CD3OD): δ = 168.8 (C4), 78.6 (C2), 53.9 (C5), 25.6 (C7), 24.7 
(C6), 22.6 (C6), and 13.9 (C8) ppm; IR (ATR): = 2925m, 2790w, 2701m, 2494m, 2414w, 
2066w, 1720s, 1593m, 1472m, 1444m, 1423s,1395s, 1373s, 1307m, 1335w, 1267w, 1215w, 
1196w, 1160w, 1098w, 1082w, 1037m, 957w, 935w, 745w, and 668w cm-1; analytical data 
in agreement with the literature.[49] 
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(5S)-2,2,3,5-Tetramethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium 
perchlorate (60a·ClO4-) 
 
To imidazolidinone 60 (22.7 mg, 0.16 mmol, 1 equiv.) in Et2O (0.20 mL) was added 
perchloric acid (60% in H2O, 26.8 mg, 0.16 mmol, 1 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at 
RT and the resulting mixture stirred for 15 min before it was evaporated in vacuo to give the 
imidazolidinone salt. The salt was redissolved in MeOH (0.40 mL) and heated to 35 °C.  
(E)-cinnamaldehyde (40.2 µL, 0.32 mmol, 2 equiv.) was added and the solution stirred for 
1 h. The solvent was removed in vacuo and the residue dissolved in a minimum amount of 
MeOH. From this solution the iminium salt was crashed out with Et2O and the supernatant 
solution taken off. The washing procedure was repeated and the iminium salt 60a·ClO4- 
isolated as a yellow solid (28.3 mg, 50%). 
M.p. = 105.7–107.2 °C; [α]D20.5: –14.2 (c = 0.49, CH3CN); 1H NMR (600 MHz, CD3CN): 
δ = 8.80 (1H, dd, J = 10.6, 1.8, H–C1''), 8.18 (1H, d, J = 15.1, H–C3''), 7.93 (2H, dd, 
J = 8.4, 1.0, H–C5''), 7.69 (1H, t, J = 7.4, H–C7''), 7.60 (2H, t, J = 7.8, H–C6''), 7.30 (1H, 
ddd, J = 15.1, 10.6, 0.6, H–C2''), 4.88 (1H, q, J = 7.1, H–C5), 2.92 (3H, d, J = 0.5,  
H–C7),1.83 (1H, s, H–C6), 1.80 (3H, s, H–C6), and 1.70 (3H, d, J = 7.2, H–C8) ppm; 
13C NMR (151 MHz, CD3CN): δ = 167.4 (C1''), 166.5 (C4), 165.9 (C3''), 135.8 (C7''), 134.5 
(C4''), 132.2 (2C, C5''), 130.7 (2C, C6''), 118.2 (C2''), 86.3 (C2), 59.5 (C5), 27.8 (C6), 26.4 
(C6), 26.2 (C7), and 18.9 (C8) ppm; IR (ATR): = 3492b, 2975b, 1710s, 1621m, 1604m, 
1590s, 1575m, 1474w, 1455w, 1429w, 1391m, 1324w, 1282w, 1197w, 1180w, 1074s, 
1012m, 999m, 932w, 876w, 866w, 744s, 686w, and 621s cm-1; HR-ESI-MS: m/z: 257.16572 
([M-ClO4-]+, calcd for C16H21N2O+: 257.16484); analytical data in agreement with the 
literature.[49] 
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1H NMR counterion-dependence comparison in CD3CN at RT 
2,2,3,5-Tetramethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium 
hexafluoridoantimonate (60a·SbF6-, racemic) 
 
1H NMR (300 MHz, CD3CN): δH = 8.76 (1H, dd, J = 10.6, 1.8, H–C1''), 8.14 (1H, d, 
J = 15.1, H–C3''), 7.97–7.88 (2H, m, H–C5''), 7.75–7.66 (1H, m, H–C7''), 7.64–7.55 (2H, m, 
H–C6''), 7.29 (1H, dd, J = 15.1, 10.6, H–C2''), 4.86 (1H, qd, J = 7.3, 1.7, H–C5), 2.92 (3H, 
d, J = 0.6, H–C7),1.82 (1H, s, H–C6), 1.80 (3H, s, H–C6), and 1.69 (3H, d, J = 7.2, H–C8) 
ppm. 
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8.2.19 Syntheses of (5S)-5-Benzhydryl-2,2,3-trimethyl-4-imidazolidinone (61) and (5S)-
5-Benzhydryl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-
ium salt (61a) 
 
L-Diphenylalanine methyl amide (71) 
 
To a suspension of L-diphenylalanine (250 mg, 1.04 mmol, 1.0 equiv.) in MeOH (0.84 mL, 
20.7 mmol, 20 equiv.) was added thionyl chloride (0.09 mL, 1.24 mmol, 1.2 equiv.) over 
5 min at 0 °C and the resulting solution was allowed to come to RT before it was heated to 
reflux for 8 h. The solution was allowed to come to RT and evaporated in vacuo to give the 
L-diphenylalanine methyl ester hydrochloride as a white solid. To the ester was added 
MeNH2 (8 N in EtOH, 0.52 mL, 1.04 mmol, 4.0 equiv.) at RT and the solution stirred for 
18 h. The reaction was concentrated in vacuo and a saturated aqueous solution of NaHCO3 
was added. The aqueous layer was extracted three times with CH2Cl2. The combined organic 
layers were dried over MgSO4, filtrated and concentrated in vacuo to give amide 71 as a 
yellow oil (229 mg, 87%). 
[α]D23: +71.6 (c = 0.32, CH3OH); 1H NMR (300 MHz, CDCl3): δ = 7.28–7.10 (10H, m,  
H–C3', H–C4', H–C5'), 6.47 (1H, bs, H–Namide), 4.51 (1H, d, J = 6.2, H–C2), 4.03 (1H, b,  
H–C1'), 2.56 (3H, d, J = 4.8, H–C3), and 1.67 (2H, b, H–Namine) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 174.0 (C1), 141.8 (C2'), 140.2 (C2'), 129.3 (CAr), 128.8 (CAr), 128.8 (CAr), 128.6 
(CAr), 128.6 (CAr), 128.5 (CAr), 128.2 (CAr), 128.1 (CAr), 127.0 (C5'), 126.7 (C5'), 59.2 (C1'), 
54.9 (C2), and 25.9 (C3) ppm; IR (ATR): = 3296w, 3060w, 3028w, 2941w, 1736w, 
1652m, 1599w, 1539m, 1494m, 1450m, 1410w, 1277w, 1157w, 1080w, 1031w, 1002w, 
856w, 747m, and 697s cm-1; HR-ESI-MS: m/z: 255.1506 ([M+H]+, calcd for C16H19N2O+: 
255.1492). 
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(5S)-5-Benzhydryl-2,2,3-trimethyl-4-imidazolidinone (61) 
 
To a solution of amide 71 (200 mg, 0.79 mmol, 1 equiv.) in MeOH (2.00 mL) was added 
acetone (0.29 mL, 3.93 mmol, 5.0 equiv.) at RT under an atmosphere of argon and the 
solution was heated to reflux for 6 h. The reaction was allowed to come to RT and 
concentrated in vacuo. Purification by CC (SiO2; CH/EtOAc 8:1→5:1) gave imidazolidinone 
61 as a white solid (121 mg, 52%).  
Rf = 0.13 (CH/EtOAc 3:1); M.p. = 106.8–108.8 °C; [α]D23: –107.8 (c = 1.30, CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 7.49 (2H, d, J = 7.3, H–CAr), 7.40–7.14 (6H, m, H–CAr), 
7.12–7.02 (2H, m, H–CAr), 5.02 (1H, d, J = 1.2, H–C8), 4.16 (1H, d, J = 1.3, H–C8), 2.71 
(3H, s, H–C7), 1.75 (1H, b, H–Namine), 1.28 (3H, s, H–C6), and 0.87 (3H, s, H–C6) ppm; 
13C NMR (75 MHz, CDCl3): δ = 173.3 (C4), 142.2 (C1'), 139.8 (C1'), 129.8 (CAr), 129.0 
(CAr), 128.9 (CAr), 128.9 (CAr), 128.6 (CAr), 128.3 (CAr), 127.1 (CAr), 126.9 (CAr), 126.7 
(CAr), 75.9 (C2), 62.2 (C5), 50.6 (C8), 26.6 (C6), 25.7 (C6), and 25.5 (C7) ppm; IR (ATR): 
= 3337w, 3028w, 2976w, 1734m, 1674m, 1600w, 1494m, 1450m, 1435w, 1403m, 
1382w, 1367w, 1271w, 1184m, 1091w, 1030w, 1002w, 950w, 845w, 789w, 764m, 746m, 
and 703s cm-1; HR-ESI-MS: m/z: 295.1807 ([M+H]+, calcd for C19H23N2O+: 295.1805). 
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(5S)-5-Benzhydryl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-ium 
perchlorate (61a·ClO4-) 
 
To imidazolidinone 61 (23.6 mg, 0.08 mmol, 1.0 equiv.) was added perchloric acid (60% in 
H2O, 13.4 mg, 0.08 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at RT and the resulting 
mixture stirred for 15 min before it was evaporated in vacuo to give the imidazolidinone salt. 
The salt was redissolved in MeOH (0.20 mL) and heated to 35 °C. (E)-cinnamaldehyde 
(20.1 µL, 0.16 mmol, 2.0 equiv.) was added and the brown solution stirred for 1 h. The 
solvent was removed in vacuo and the residue dissolved in a minimum amount of MeOH. 
From this solution the iminium salt 61a·ClO4- was crushed out with Et2O and the 
supernatant solution taken off. The washing procedure was repeated and the iminium salt 
contaminated with starting material 61 (circa 3:1 product:SM) was isolated as a brown solid. 
1H NMR (300 MHz, CD3CN): δH = 8.75 (1H, d, J = 10.9, H–C1''), 8.08 (1H, d, J = 15.1, H–
C3''), 7.78 (2H, d, J = 7.0, H–C5''), 7.74–7.27 (12H, m, H–CAr), 7.20 (1H, t, H–C7''), 7.05 
(1H, dd, J = 14.9, 10.7, H–C2''), 5.73 (1H, d, J = 5.8, H–C5), 4.81 (1H, d, J = 5.9, H–C8), 
2.77 (3H, s, H–C7), 1.75 (3H, s, H–C6anti), and 1.18 (3H, s, H–C6syn) ppm; HR-ESI-MS: 
m/z: 409.2266 ([M-ClO4-]+, calcd for C28H29N2O+: 409.2274). 
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8.2.20 Attempted Syntheses of (5S)-5-Trityl-2,2,3-trimethyl-4-imidazolidinone (62) 
 
2-tert-Butyl-3-methyl-2,3-dihydroimidazol-4-one-N-oxide (74)[138] 
 
To a solution of MTO (26 mg, 0.11 mmol, 0.05 equiv.) and UHP (1.00 g, 10.6 mmol, 
5 equiv.) in MeOH (3 mL) at 0 °C under an atmosphere of argon was added imidazolidinone 
19 (333 mg, 2.13 mmol, 1.0 equiv.) in MeOH (7.0 mL) over 10 min. The solution was 
slowly warmed to RT and stirred for 24 h. After concentration in vacuo, the product was 
taken up in CH2Cl2, the remaining white solid was filtered of and the filtrate washed with a 
saturated aqueous solution of NaHCO3. The organic layer was dried over MgSO4 and 
concentrated in vacuo to give the product at a white solid (253 mg, 70%).  
1H NMR (300 MHz, CDCl3): δ = 7.05 (1H, s, H–C5), 4.63 (1H, s, H–C2), 3.04 (3H, s,  
H–C8), and 1.08 (9H, s, H–C9) ppm; 13C NMR (75 MHz, CDCl3): δ = 165.9 (C4), 126.4 
(C5), 94.7 (C2), 37.5 (C6), 32.2 (C8), and 25.4 (3C, C7) ppm. Analytical data in agreement 
with the literature.[138] 
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tButyl (S)-4-(hydroxydiphenylmethyl)-2,2-dimethyloxazolidine-3-carboxylate (75)[188] 
 
A flame dried flask under argon was charged with Mg swarfs (94 mg, 3.86 mmol, 2.5 equiv.) 
and I2 (0.4 mg). THF (2 mL) and PhBr (135 µL, 1.29 mmol, 0.83 equiv.) and the reaction 
initiated with the heat gun. PhBr (270 µL, 2.58 mmol, 1.67 equiv.) was added over 10 min. 
After complete addition, the reaction was stirred for another 15 min, before it was cooled to 
0 °C, and 76 (400 mg, 1.54 mmol, 1.0 equiv.) in dry THF (1 mL) was added over 5 min. The 
reaction was warmed to RT and stirred for 6 h during which time it turned from yellow to 
red. A saturated aqueous solution of NH4Cl was added and the mixture was extracted three 
times with Et2O. The combined organic layers were dried over MgSO4 and concentrated in 
vacuo to give a brown liquid. Purification by CC (SiO2; CH/EtOAc 8:1) gave the product as 
a white foam (521 mg, 88%). The product was observed to be unstable and decompose to the 
ring-opened product (2:3 product/opened product after 1 d).   
Rf = 0.63 (CH/EtOAc 3:1) 1H NMR (300 MHz, CDCl3): δ = 7.54–7.47 (2H, m, H–CAr), 
7.37–7.18 (8H, m, H–CAr), 4.96 (1H, dd, J = 7.0, 1.8, H–C2), 4.11 (1H, dd, J = 9.9, 7.1, H–
C3), 4.01 (1H, dd, J = 9.9, 1.8, H–C3), 1.42 (9H, s, H–C4''), and 1.35 (6H, b, H–C7) ppm; 
HR-ESI-MS: m/z: 406.1993 ([M+Na]+, calcd for C23H29NO4Na+: 406.1989). Analytical data 
in agreement with the literature.[188] 
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8.2.21 Synthesis of (S)-5-Benzyl-3-methylimidazolidin-4-one (78) 
 
(S)-5-Benzyl-3-methylimidazolidin-4-one (78) 
 
To a solution of amide 15 (220 mg, 1.23 mmol, 1.0 equiv.) in toluene (4.0 mL) was added 
formaldehyde (37% in H2O, 0.25 mL, 3.09 mmol, 2.5 equiv.) and the flask equipped with a 
Dean-Stark trap. The solution was heated to reflux overnight. The solvent was removed in 
vacuo to give imidazolidinone 78 as an orange solid (235 mg, quant.).   
M.p. = 65.3–65.8 °C; [α]D23: –71.2 (c = 0.52, CH3OH); 1H NMR (300 MHz, CDCl3): 
δ = 7.32–7.27 (5H, m, H–CAr), 4.67 (1H, d, J = 15.2, H–C2), 4.37 (1H, d, J = 15.4, H–C2), 
3.80 (1H, dd, J = 9.0, 5.5, H–C5), 3.38 (1H, dd, J = 14.7, 5.5, H–C7), 2.94 (3H, s, H–C6), 
and 2.92 (1H, dd, J = 14.8, 8.9, H–C7) ppm; 13C NMR (75 MHz, CDCl3): δ = 174.6 (C4), 
139.6 (C1'), 129.2 (2C, CAr), 128.4 (2C, CAr), 126.3 (C5'), 82.6 (C5), 64.5 (C2), 37.2 (C7), 
and 34.7 (C6) ppm; IR (ATR):  = 3321w, 2934w, 1634s, 1496w, 1453m, 1397w, 1358m, 
1306w, 1228w, 1144w, 1064m, 1030w, 992m, 954w, 875w, 814w, 725s, and 697s cm-1; 
HR-ESI-MS: m/z: 415.2099 ([(M)2+NaC]+, calcd for C23H28N4O2Na+: 415.2104).  
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8.2.22 Synthesis of (S)-7-Benzyl-5-methyl-2-oxa-5,8-diazaspiro[3.4]octan-6-one (79) 
 
(S)-7-Benzyl-5-methyl-2-oxa-5,8-diazaspiro[3.4]octan-6-one (79) 
 
To a solution of amide 15 (1.00 g, 5.61 mmol, 1.0 equiv.) in C2H4Cl2 (30 mL) was added 
oxetane-3-one (0.33 mL, 5.61 mmol, 1.0 equiv.) and DIPEA (0.77 mL, 4.49 mmol, 0.8 
equiv.) and the solution heated to 60 °C for 15 h. The solvent was removed in vacuo and 
purification by CC (SiO2; CH2Cl2/MeOH 20:1) gave imidazolidinone 79 as a yellow solid 
(1.09 g, 84%). 
M.p. = 143.6–144.3 °C; [α]D20: –8.7 (c = 1.00, CH3OH); 1H NMR (300 MHz, CDCl3): 
δ = 7.37–7.26 (3H, m, H–C4', H–C5'), 7.19–7.11 (2H, m, H–C3'), 6.79 (1H, bs, H–Namine), 
5.15 (2H, t, J = 2.8, H–C4), 4.81 (1H, dt, J = 13.0, 2.4, H–C2), 3.71–3.54 (2H, m, H–C2,  
H–C7), 3.39 (1H, dd, J = 13.2, 2.7, H–C1'), 2.87 (3H, d, J = 5.0, H–C9), and 2.73 (1H, dd, 
J = 13.2, 10.6, H–C1') ppm; 13C NMR (75 MHz, CDCl3): δ = 171.8 (C6), 167.8 (C1), 137.9 
(C2'), 129.8 (2C, C3'), 128.7 (2C, C4'), 127.0 (C5'), 84.0 (C4), 82.4 (C2), 68.2 (C7), 40.5 
(C1'), and 25.9 (C9) ppm; IR (ATR):  = 3300m, 3028w, 2931w, 1754w, 1651s, 1533m, 
1496m, 1454m, 1410m, 1157w, 972w, 848w, 748m, and 702s cm-1; HR-ESI-MS: m/z: 
233.1284 ([M+H]+, calcd for C13H17N2O2+: 233.1285).  
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8.2.23 Syntheses of (2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.4]nonan-3-one (80) and 
(2S)-2-Benzyl-1-methyl-1,4-diaza-1-[(E)-3-phenylallylidene]-spiro[4.4]nonan-3-
one salt (80a) 
 
(2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.4]nonan-3-one (80)[140] 
 
To a solution of 15 (1.00 g, 5.61 mmol, 1.0 equiv.) in MeOH (12.0 mL) was added 
cyclopentanone (2.48 mL, 28.1 mmol, 5.0 equiv.) and NEt3 (0.62 mL, 4.49 mmol, 
0.8 equiv.) at RT under an atmosphere of argon and the yellow solution was heated to reflux 
overnight. The reaction was allowed to come to RT and concentrated in vacuo. Purification 
by CC (SiO2; CH2Cl2/MeOH/NH3 (25% in H2O) 20:1:0.1) gave 80 as a yellow oil (1.36 g, 
99%).   
Rf = 0.64 (CH2Cl2/MeOH 10:1); [α]D20: –57.7 (c = 1.05, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ = 7.33–7.26 (2H, m, H–C4'), 7.26–7.18 (3H, m, H–C3', and H–C5'), 3.77 (1H, dd, 
J = 6.8, 4.4, H–C2), 3.12 (1H, dd, J = 14.0, 4.4, H–C1'), 2.99 (1H, dd, J = 14.0, 6.7, H–C1'), 
2.75 (3H, s, H–C10), 1.69–1.40 (8H, m, H–C6, H–C7, H–C8, H–C9, H–Namine), and 0.95 
(1H, d, J = 12.4, H–C9 or H–C6) ppm; 13C NMR (101 MHz, CD3OD): δ = 174.1 (C3), 137.3 
(C2'), 129.6 (2C, C3'), 128.6 (2C, C4'), 126.8 (C5'), 85.8 (C5), 59.5 (C2), 36.9 (C9), 36.9 
(C1'), 34.7 (C6), 25.5 (C10), 23.9 (C7 or C8), and 23.9 (C7 or C8) ppm; IR (ATR):  
 = 3306bw, 2955m, 1682s, 1496w, 1425m, 1401m, 1332w, 1260w, 1095m, 1030w, 806w, 
748m, and 701m cm-1; HR-ESI-MS: m/z: 245.1657 ([M+H]+, calcd for C15H21N2O+: 
245.1648); analytical data in agreement with the literature.[140] 
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(2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.4]nonan-3-one hydrochloride (80·HCl)  
 
Imidazolidinone 80 (7.9 mg, 32 µmol, 1.0 equiv.) was dissolved in HCl in MeOH (1.25 N, 
0.2 mL, 250 µmol, 7.8 equiv.) and stirred for 30 min at RT. The solution was concentrated in 
vacuo to give 80·HCl as a white solid (9.0 mg, quant.). 
Crystals suitable for X-ray crystallographic analysis were achieved by vapour exchange of a 
methanolic solution of 80·HCl with Et2O. 
1H NMR (400 MHz, CD3OD): δ = 7.46–7.37 (4H, m, H–C3', H–C4'), 7.32 (1H, t, J = 6.9, 
H–C5'), 4.60 (1H, dd, J = 10.3, 3.6, H–C2), 3.52 (1H, dd, J = 15.1, 3.4, H–C1'), 3.07 (1H, 
dd, J = 15.2, 10.3, H–C1'), 2.93 (3H, s, H–C10), 2.40–2.33 (1H, m, H–C9 or H–C6), 2.19–
1.95 (3H, m, H–C9, H–C6), and 1.94–1.73 (4H, m, H–C7, H–C8) ppm; 13C NMR (101 
MHz, CD3OD): δ = 167.9 (C3), 136.5 (C2'), 130.3 (2C, C4'), 130.2 (2C, C3'), 128.8 (C5'), 
88.4 (C5), 60.0 (C2), 35.2 (C9), 35.1 (C1´), 33.4 (C6), 26.0 (C10), 25.2 (C7 or C8), and 24.8 
(C7 or C8) ppm. 
 
(2S)-2-Benzyl-1-methyl-1,4-diaza-1-[(E)-3-phenylallylidene]-spiro[4.4]nonan-3-one 
hexafluorophosphate (80a·PF6-): 
 
To imidazolidinone 80 (25.0 mg, 0.10 mmol, 1.0 equiv.) in EtOH (0.3 mL) was added 
hexafluorophosphoric acid (60% in H2O, 25.0 mg, 0.10 mmol, 1.0 equiv.) at RT and the 
resulting mixture stirred for 10 min before it was evaporated in vacuo to give the 
imidazolidinone salt. The residue was dissolved in EtOH (0.5 mL) and (E)-cinnamaldehyde 
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(29.0 µL, 0.23 mmol, 1 equiv.) was added. The red solution was stirred overnight at RT 
during which time a white solid crushed out. The solid was filtered of and dried in vacuo to 
give the iminium salt 80a·PF6- as a yellow solid.  
M.p. = 136.1 °C decomp.; [α]D23 = +466.5 (c = 0.65 in CH3CN); 1H NMR (400 MHz, 
CD3CN): δH = 8.53 (1H, dd, J = 10.7, 1.8, H–C1''), 8.21 (1H, d, J = 15.0, H–C3''), 7.91 (2H, 
d, J = 7.3, H–C5''), 7.72 (1H, t, J = 7.4, H–C7''), 7.62 (2H, t, J = 7.6, H–C6''), 7.41–7.21 (4H, 
m, H–C4', H–C5', H–C2''), 7.08 (2H, d, J = 6.2, H–C3'), 5.17 (1H, bs, H–C2), 3.53 (1H, dd, 
J = 14.6, 5.7, H–C1´), 3.45 (1H, dd, J = 14.6, 3.6, H–C1´), 2.79 (3H, s, H–C10), 2.36 (1H, 
dt, J = 16.4, 8.4, H–C6 or H–C9), 2.15 (1H, dt, J = 16.1, 6.9, H–C6 or H–C9), 1.92–1.83 
(2H, m, H–C7 or H–C8), 1.75 (1H, tt, J = 14.7, 7.4, H–C7 or H–C8), 1.64 (1H, tt, J = 16.1, 
8.1, H–C7 or H–C8), and 1.14 (2H, t, J = 7.5, H–C6 or H–C9) ppm; 13C NMR (101 MHz, 
CD3CN): δC = 167.4 (C1''), 166.5 (C3''), 165.2 (C3), 136.1 (C7''), 134.6 (C2'), 134.4 (C4''), 
132.4 (2C, C5''), 131.1 (2C, C3'), 130.7 (2C, C6''), 130.1 (2C, C4'), 129.2 (C5'), 118.5 (C2''), 
95.7 (C5), 65.5 (C2), 41.2 (C6 or C9), 39.6 (C6 or C9), 37.3 (C1'), 26.8 (C7 or C8), 26.7 (C7 
or C8) and 26.1 (C10) ppm; IR (ATR): = 2977w, 1695s, 1627w, 1590m, 1512w, 1479w, 
1457w, 1440w, 1400m, 1377m, 1364m, 1337w, 1302m, 1258w, 1234w, 1216w, 1197m, 
1180s, 1160m, 1116m, 1099m, 1034w, 1014w, 982w, 948w, 886w, 868w, 842s, 822s, 
786m, and 771m cm-1; HR-ESI-MS: m/z: 359.2112 ([M–PF6-]+, calcd for C22H25N2O+: 
359.2118); analytical data in agreement with the literature.[53] 
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8.2.24 Synthesis of (2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.5]decan-3-one (81) 
 
(2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.5]decan-3-one (81)[140] 
 
To a solution of amide 15 (1.00 g, 5.61 mmol, 1 equiv.) in MeOH (12.0 mL) was added 
cyclohexanone (2.90 mL, 28.1 mmol, 5.0 equiv.) and NEt3 (0.62 mL, 4.49 mmol, 0.8 equiv.) 
at RT under an atmosphere of argon and the yellow solution was heated to reflux overnight. 
The reaction was allowed to come to RT and concentrated in vacuo. Purification by CC 
(SiO2; CH2Cl2/MeOH/NH3 (25% in H2O) 20:1:0.1) gave imidazolidinone 81 as an orange oil 
(1.43 g, 98%). 
Rf = 0.48 (CH2Cl2/MeOH 10:1); [α]D20: –56.5 (c = 1.05, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ = 7.32–7.27 (2H, m, H–C4'), 7.26–7.11 (3H, m, H–C3', H–C5'), 3.76 (1H, dd, 
J = 6.8, 4.5, H–C2), 3.11 (1H, dd, J = 14.1, 4.4, H–C1'), 2.99 (1H, dd, J = 14.1, 6.8, H–C1'), 
2.74 (3H, s, H–C11), 1.74–1.38 (9H, m, H–C6, H–C7, H–C8, H–C9, H–C10, H–Namine), 
1.13–0.98 (1H, m, H–C8), and 0.94 (1H, d, J = 12.3, H–C6 or H–C10) ppm; 13C NMR 
(101 MHz, CD3OD): δ = 173.7 (C3), 137.7 (C2'), 129.8 (2C, C3'), 128.6 (2C, C4'), 126.8 
(C5'), 77.4 (C5), 59.3 (C2), 38.0 (C1'), 36.5 (C6 or C10), 33.8 (C6 or C10), 25.4 (C11), 25.0 
(C8), 22.7 (C7 or C9), and 22.2 (C7 or C9) ppm; IR (ATR): = 3329bw, 2929m, 2856w, 
1682s, 1496w, 1425m, 1403m, 1347w, 1242w, 1097m, 1075m, 907w, 805w, 744m, and 
700m cm-1; HR-ESI-MS: m/z: 259.1807 ([M+H]+, calcd for C16H23N2O+: 259.1805); 
analytical data in agreement with the literature.[140]  
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(2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.5]decan-3-one hydrochloride (81·HCl) 
 
81 (8.4 mg, 32 µmol, 1.0 equiv.) was dissolved in HCl in MeOH (1.25 N, 0.2 mL, 250 µmol, 
7.8 equiv.) and stirred for 30 min at RT. The solution was concentrated in vacuo to give 
81·HCl as a white solid (9.6 mg, quant.). 
Crystals suitable for X-ray crystallographic analysis were achieved by vapour exchange of a 
methanolic solution of 81·HCl with Et2O. 
M.p. = 158.3 °C decomp.; [α]D20: –35.9 (c = 0.48, CH3OH); 1H NMR (400 MHz, CD3OD): δ 
= 7.43 (2H, d, J = 7.1, H–C3'), 7.37 (2H, t, J = 7.3, H–C4'), 7.31 (1H, t, J = 7.1, H–C5'), 4.61 
(1H, dd, J = 7.3, 5.4, H–C2), 3.44 (1H, dd, J = 15.1, 5.2, H–C1'), 3.19 (1H, dd, J = 15.1, 7.5, 
H–C1'), 2.91 (3H, s, H–C11), 2.07 (1H, td, J = 13.8, 4.1, H–C7 or H–C9), 1.96 (1H, dd, J = 
11.9, 4.5, H–C8), 1.91–1.81 (2H, m, H–C7 or H–C9), 1.78–1.65 (3H, m, H–C6, H–C10, and 
H–C7 or H–C9), 1.50 (1H, dd, J = 27.0, 13.5, H–C6 or H–C10), and 1.34 (1H, t, J = 13.0, 
H–C6 or H–C10) ppm; 13C NMR (101 MHz, CD3OD): δ = 167.8 (C3), 136.5 (C2'), 130.6 
(2C, C3'), 130.0 (2C, C4'), 128.7 (C5'), 82.0 (C5), 60.0 (C2), 35.6 (C1'), 33.4 (C7 or C9), 
31.2 (C8), 26.4 (C11), 24.4 (C6 or C10), 22.5 (C7 or C9) and 24.8 (C6 or C10) ppm; IR 
(ATR): = 2915m, 2869w, 2599w, 2171w, 2003w, 1717s, 1665w, 1605w, 1574w, 1443w, 
1457m, 1421m, 1398m, 1378m, 1362m, 1259w, 1244w, 1170w, 1113w, 1090m, 1033w, 
954w, 914w, 895w, 752s, 703s, and 677m cm-1. 
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(2S)-2-Benzyl-1-methyl-1,4-diaza-1-[(E)-3-phenylallylidene]-spiro[4.4]nonan-3-one 
hexafluorophosphate (81a·PF6-) 
 
To 81 (26.4 mg, 0.10 mmol, 1.0 equiv.) in EtOH (0.3 mL) was added hexafluorophosphoric 
acid (60% in H2O, 25.0 mg, 0.10 mmol, 1.0 equiv.) at RT and the resulting mixture stirred 
for 10 min before it was evaporated in vacuo to give the imidazolidinone salt. The residue 
was dissolved in EtOH (0.5 mL) and (E)-cinnamaldehyde (29.0 µL, 0.23 mmol, 1 equiv.) 
was added. The red solution was stirred overnight at RT and evaporated to dryness. The 
solvent was removed in vacuo and the residue dissolved in a minimum amount of MeOH. 
From this solution the iminium salt was crashed out with Et2O and the supernatant solution 
taken off. This purification procedure was repeated two additional times to give a mixture of 
81a·PF6-, 81a, and (E)-cinnamaldehyde (1:1.4:0.06) as a white solid which could not be 
separated.  
1H NMR (400 MHz, CD3CN, 81a·PF6-): δ = 8.82 (1H, dd, J = 10.6, 1.8, H–C1''), 8.24 (1H, 
d, J = 15.0, H–C3''), 7.87 (2H, d, J = 7.2, H–C5''), 7.75–7.69 (1H, m, H–C7''), 7.61 (2H, t, 
J = 7.6, H–C6''), 7.35–7.29 (3H, m, H–C4', H–C5'), 7.17 (1H, dd, J = 15.0, 10.6, H–C2''), 
7.11 (2H, d, J = 6.8, H–C3'), 5.18 (1H, t, J = 4.3, H–C2), 3.57 (1H, dd, J = 14.7, 5.7,  
H–C1´), 3.43 (1H, dd, J = 14.5, 4.9, H–C1´), 2.96 (3H, s, H–C11), 2.25–2.14 (1H, m, H–C6 
or H–C10), 2.05–1.97 (1H, m, H–C6 or H–C10), 1.90–1.20 (6H, m, H–C7, H–C8 and  
H–C9), 1.19–1.10 (1H, m, H–C6 or H–C10), and 0.94–0.88 (1H, m, H–C6 or H–C10) ppm; 
13C NMR (101 MHz, CD3CN): δ = 168.1 (C1''), 167.0 (C3''), 165.9 (C3), 136.1 (C7''), 136.1 
(C2'), 134.4 (C4''), 132.4 (2C, C5''), 131.1 (2C, C3'), 130.7 (2C, C6''), 130.1 (2C, C4'), 129.2 
(C5'), 118.5 (C2''), 87.3 (C5), 65.3 (C2), 37.8 (C1'), 36.4 and 34.7 (C6 and C10), 28.2 (C11), 
23.4, 23.1, and 21.9 (C7, C8, and C9) ppm. 
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8.2.25 Syntheses of 2nd Generation Catalysts 82-87[142] 
 
The 2nd generation MacMillan catalysts were prepared following the procedure reported by 
Tomkinson and co-workers.[142] 
 
(2S,5S)-5-Benzyl-2-tert-butyl-3-methyl-4-imidazolidinone (82) and (2R,5S)-5-Benzyl-2-
tert-butyl-3-methyl-4-imidazolidinone (83) 
 
To amide 15 (2.00 g, 11.2 mmol, 1.00 equiv.) and pivaldehyde (1.93 g, 22.4 mmol, 
2.00 equiv.) in CHCl3 (100 mL) under an atmosphere of argon was added Yb(OTf)3 (70 mg, 
0.11 mmol, 0.01 equiv.) and the resulting mixture heated to reflux for 8 h. The reaction was 
allowed to come to RT and the two diastereomers separated by CC (SiO2; CH/EtOAc 2:1). 
The trans-diastereomer elutes from the column prior to the cis-diastereomer. 
(2S,5S)-5-Benzyl-2-tert-butyl-3-methyl-4-imidazolidinone (82): yellow oil (314 mg, 11%). 
Rf = 0.32 (CH/EtOAc 1:1); M.p. = 69.5–73.0 °C; [α]D23: –34.6 (c = 0.85, CH3OH); 1H NMR 
(300 MHz, CDCl3): δ = 7.39–7.15 (5H, m, H–CAr), 4.06 (1H, d, J = 1.4, H–C2), 3.76–3.64 
(1H, m, H–C5), 3.15 (1H, dd, J = 13.7, 4.0, H–C9), 3.00–2.89 (1H, m, H–C9), 2.91 (3H, s, 
H–C8), and 0.83 (9H, s, H–C7) ppm; IR (ATR):  = 3368w, 3355w, 2961w, 1674s, 1495w, 
1472w, 1453w, 1419w, 1393m, 1360w, 1340w, 1261w, 1205w, 1106m, 1078w, 1052w, 
1028w, 1009w, 974w, 946w, 913w, 891w, 827w, 793w, 764w, 755m, 737m, 710m, and 
699m cm-1; HR-ESI-MS: m/z: 515.3356 ([2M+Na]+, calcd for C30H44N4O2Na+: 515.3356). 
Analytical data in agreement with the literature.[142] 
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(2R,5S)-5-Benzyl-2-tert-butyl-3-methyl-4-imidazolidinone (83): off-white solid (1.60 g, 
58%). 
Rf = 0.39 (CH/EtOAc 1:1); M.p. = 69.5–73.0 °C; [α]D23: –55.6 (c = 1.00, CH3OH); 1H NMR 
(300 MHz, CDCl3): δ = 7.33–7.20 (5H, m, H–CAr), 3.89–3.82 (1H, m, H–C5), 3.80 (1H, d, 
J = 1.8, H–C2), 3.11 (1H, dd, J = 14.1, 4.2, H–C9), 2.89 (1H, dd, J = 14.0, 7.1, H–C9), 2.89 
(3H, d, J = 0.5, H–C8), 1.88 (1H, b, H–Namine)and 0.90 (9H, s, H–C7) ppm; IR (ATR):  
 = 2956w, 1677s, 1603w, 1456m, 1431m, 1396m, 1355w, 1330w, 1307w, 1283w, 1260w, 
1204w, 1160w, 1102m, 1025w, 902w, 848w, 755m, 735m, and 701s cm-1; HR-ESI-MS: m/z: 
515.3357 ([2M+Na]+, calcd for C30H44N4O2Na+: 515.3356). Analytical data in agreement 
with the literature.[142] 
 
(2S,5S)-5-(3,4,5-Trimethoxybenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (84) and 
(2R,5S)-5-(3,4,5-Trimethoxybenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (85) 
 
To amide 30 (600 mg, 2.24 mmol, 1.0 equiv.) and pivaldehyde (385 mg, 4.47 mmol, 
2.0 equiv.) in CHCl3 (25 mL) under an atmosphere of argon was added Yb(OTf)3 (136 mg, 
0.22 mmol, 0.1 equiv.) and the resulting mixture heated to reflux for 8 h. The reaction was 
allowed to come to RT and the two diastereomers separated by CC (SiO2; CH/EtOAc 
1:1→1:2). The trans-diastereomer elutes from the column prior to the cis-diastereomer. 
(2S,5S)-5-(3,4,5-Trimethoxybenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (84): yellow 
oil (248 mg, 33%). 
Rf = 0.19 (CH/EtOAc 1:1); [α]D23: –16.8 (c = 1.00, CH3OH); 1H NMR (300 MHz, CDCl3): 
δ = 6.47 (2H, s, H–C2'), 4.05 (1H, d, J = 1.4, H–C2), 3.80 (6H, s, H–C5'), 3.77 (3H, s,  
H–C6'), 3.65 (1H, t, J = 5.5, H–C5), 3.08–2.91 (2H, m, H–C9), 2.89 (3H, s, H–C8), and 0.82 
(9H, s, H–C7) ppm; 13C NMR (101 MHz, CDCl3): δ = 175.3 (C4), 153.4 (2C, C3'), 136.9 
(C4'), 133.4 (C1'), 106.6 (2C, C2'), 82.4 (C2), 60.9 (C6'), 59.4 (C5), 56.2 (C5'), 38.3 (C9), 
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35.0 (C6), 30.8 (C8), and 25.4 (3C, C7) ppm; IR (ATR):  = 3363w, 2956w, 2838w, 
1692m, 1589m, 1506w, 1456m, 1421m, 1396w, 1325w, 1238m, 1185w, 1123s, 1008w, 
898w, 781w, 743w, and 675w cm-1; HR-ESI-MS: m/z: 695.3990 ([2M+Na]+, calcd for 
C36H56N4O8Na+: 695.3990). 
(2R,5S)-5-(3,4,5-Trimethoxybenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (85): off-white 
solid (307 mg, 41%). 
Rf = 0.10 (CH/EtOAc 1:1); M.p. = 84.9–88.5 °C; [α]D23: –42.2 (c = 1.07, CH3OH); 1H NMR 
(300 MHz, CDCl3): δ = 6.46 (2H, s, H–C2'), 3.82 (6H, s, H–C5'), 3.85–3.75 (5H, m, H–C2, 
H–C5, H–C6'), 2.99 (1H, dd, J = 14.0, 4.5, H–C9), 2.92 (1H, dd, J = 14.1, 6.3, H–C9), 2.90 
(3H, s, H–C8), 1.87 (1H, b, H–Namine) and 0.91 (9H, s, H–C7) ppm; 13C NMR (101 MHz, 
CDCl3): δ = 175.4 (C4), 153.3 (2C, C3'), 136.8 (C4'), 133.0 (C1'), 106.4 (2C, C2'), 83.6 
(C2), 61.0 (C6'), 59.7 (C5), 56.2 (C5'), 38.4 (C9), 37.9 (C6), 31.6 (C8), and 25.8 (3C, 
C7) ppm; IR (ATR):  = 3320w, 2941w, 2877w, 1682s, 1593m, 1507m, 1453s, 1426s, 
1400m, 1390m, 1357w, 1328m, 1314w, 1282w, 1233s, 1208w, 1181w, 1117s, 1105s, 
1049w, 1006m, 978m, 910w, 853w, 809s, 780w, 755w, 729m, 679w, and 656m cm-1;  
HR-ESI-MS: m/z: 359.1945 ([M+Na]+, calcd for C18H28N2O4Na+: 359.1941). 
 
(2S,5S)-5-(Pentafluorobenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (86) and 
(2R,5S)-5-(Pentafluorobenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (87) 
 
To amide 34 (500 mg, 1.86 mmol, 1.0 equiv.) and pivaldehyde (321 mg, 3.73 mmol, 
2.0 equiv.) in CHCl3 (20 mL) under an atmosphere of argon was added Yb(OTf)3 (115 mg, 
0.19 mmol, 0.1 equiv.) and the resulting mixture heated to reflux for 8 h. The reaction was 
allowed to come to RT and the two diastereomers separated by CC (SiO2; CH/EtOAc 
8:1→3:1). The trans-diastereomer elutes from the column prior to the cis-diastereomer. 
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(2S,5S)-5-(Pentafluorobenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (86): off-white solid 
(309 mg, 49%). 
Rf = 0.38 (CH/EtOAc 1:1); M.p. = 79.0–85.8 °C; [α]D23 = –21.8 (c = 1.518 in CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 4.13 (1H, d, J = 1.3,H–C2 ), 3.83 (1H, dd, J = 9.2, 4.7,  
H–C5), 3.21 (1H, dd, J = 13.8, 4.5, H–C9), 2.93 (3H, s, H–C8), 2.88 (1H, dd, J = 13.9, 9.1, 
H–C9), 2.03 (1H, b, H–Namine), and 0.92 (9H, s, H–C7) ppm; 13C NMR (151 MHz, CDCl3): 
δ = 173.4 (C4), 145.6 (2C, dm, 1JCF = 244.9, CAr), 140.1 (dm, 1JCF = 252.0, C4'), 137.6 (2C, 
dm, 1JCF = 250.4, CAr), 112.0 (t, 2JCF = 17.5, C1'), 82.4 (C2), 57.1 (C5), 35.6 (C6), 30.9 (C8), 
and 25.3 (C7) ppm; 19F NMR (282 MHz, CDCl3): δ = –141.8 (2F, dd, 3JFF = 20.8, 4JFF = 8.0, 
F–C3'), –156.8 (1F, t, 3JFF = 20.9, F–C5'), and –162.8 (2F, td, 3JFF = 22.2, 4JFF = 8.3,  
F–C4') ppm; IR (ATR):  = 3375w, 2976w, 1729w, 1673s, 1520m, 1499s, 1435w, 1422w, 
1396m, 1347w, 1300w, 1259w, 1202w, 1121m, 1110m, 1056w, 1034w, 995m, 971m, 946m, 
893w, 850w, 799w, 763w, 743w, 719w and 667w cm-1; HR-EI-MS: m/z: 359.1152 
([M+Na]+, calcd for C15H17F5N2ONa+: 359.1153). 
Crystals suitable for X-ray crystallographic analysis were achieved by vapour exchange of a 
methanolic solution of the hydrochloride salt 80·HCl with Et2O. 
 
(2R,5S)-5-(Pentafluorobenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone (87): off-white solid 
(186 mg, 30%). 
Rf = 0.51 (CH/EtOAc 1:1); M.p. = 52.8–55.2 °C; [α]D23 = –21.2 (c = 1.14 in CH3OH); 
1H NMR (300 MHz, CDCl3): δ = 4.09 (1H, d, J = 1.7,H–C2 ), 3.83 (1H, dd, J = 9.2, 4.8,  
H–C5), 3.27–3.13 (1H, m, H–C9), 2.96 (3H, s, H–C8), 2.77 (1H, dd, J = 13.7, 9.2, H–C9), 
and 0.93 (9H, s, H–C7) ppm; 13C NMR (151 MHz, CDCl3): δ = 174.2 (C4), 145.7 (2C, dm, 
1JCF = 246.7, CAr), 140.1 (dm, 1JCF = 252.4, C4'), 137.6 (2C, dm, 1JCF = 250.6, CAr), 111.8 
(td, 2JCF = 18.0, 3JCF = 3.1, C1'), 83.4 (C2), 57.6 (C5), 37.5 (C6), 31.5 (C8), and 25.7 
(C7) ppm; 19F NMR (282 MHz, CDCl3): δ = (–142.3)–(–142.6) (2F, m, F-C3'), –156.8 (1F, 
t, 3JFF = 20.9, F–C5'), and (–162.6)–(–162.8) (2F, m, F–C4') ppm; IR (ATR):  = 3353w, 
2971w, 2872w, 1683s, 1519m, 1499s, 1444w, 1418w, 1401m, 1366w, 1344w, 1305w, 
1258w, 1205w, 1121m, 1075w, 1040m, 985m, 954m, 939m, 884w, 855w, 792w, 753w, and 
737w cm-1; HR-EI-MS: m/z: 695.2417 ([2M+Na]+, calcd for C30H34F10N4O2Na+: 695.2414). 
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8.2.26 1H NMR Study of Iminium Salts 92-95 and 98 
(5S)-5-Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-(para-chlorophenylallylidene]-
imidazolidin-1-ium perchlorate (92·ClO4-): 
 
To imidazolidinone 1 (17.5 mg, 0.08 mmol, 1.0 equiv.) was added perchloric acid (60% in 
H2O, 13.4 mg, 0.08 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at RT and the resulting 
mixture stirred for 30 min before it was evaporated in vacuo to give the imidazolidinone salt. 
The salt was redissolved in MeOH (0.20 mL) and heated to 35 °C. (E)-(para-
chloro)cinnamaldehyde (26.7 mg, 0.16 mmol, 2.0 equiv.) was added and the orange solution 
stirred for 1 h during which time the solution turned red. The solvent was removed in vacuo 
and the residue dissolved in a minimum amount of MeOH. From this solution the iminium 
salt was crashed out with Et2O and the supernatant solution taken off. The washing 
procedure was repeated and the iminium salt isolated as a yellow solid.  
Crystals suitable for X-ray crystallographic analysis were achieved by vapour exchange of a 
methanolic solution of 92· ClO4- with Et2O. 
M.p. = 123.5–125.6 °C; [α]D23: +561.9 (c = 0.70, CH3CN); 1H NMR (300 MHz, CD3CN): 
δH = 8.73 (1H, dd, J = 10.6, 1.9, H–C1''), 8.13 (1H, d, J = 15.1, H–C3''), 7.89 (2H, d, J = 8.6, 
H–C5''), 7.63 (2H, d, J =8.6, H–C6''), 7.41–7.37 (1H, m, H–C4'), 7.32–7.26 (3H, m, H–C3', 
H–C2''), 7.09 (2H, dd, J = 7.7, 1.7, H–C2'), 5.19 (1H, s, H–C5), 3.57 (1H, dd, J = 14.6, 5.6, 
H–C8), 3.46 (1H, dd, J = 14.6, 3.8, H–C8), 2.78 (3H, d, J = 0.7, H–C7), 1.69 (3H, s, H–
C6anti), and 0.80 (3H, s, H–C6syn) ppm; IR (ATR):  =  2985w, 1699m, 1619m, 1603m, 
1581m, 1489w, 1427w, 1402w, 1333w, 1311w, 1274w, 1238w, 1199w, 1177w, 1154w, 
1076s, 1023w, 1011m, 963w, 928w, 867w, 816w, 747w, 705w, and 671w cm-1; HR-EI-MS: 
m/z: 367.1567 ([M–ClO4-]+, calcd for C22H24ClN2O+: 367.1572). 
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(5S)-5-Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-(para-fluorophenylallylidene]-
imidazolidin-1-ium perchlorate (93·ClO4-): 
 
To imidazolidinone 1 (17.5 mg, 0.08 mmol, 1.0 equiv.) was added perchloric acid (60% in 
H2O, 13.4 mg, 0.08 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at RT and the resulting 
mixture stirred for 30 min before it was evaporated in vacuo to give the imidazolidinone salt. 
The salt was redissolved in MeOH (0.20 mL) and heated to 35 °C. (E)-(para-
fluoro)cinnamaldehyde (22.4 mg, 0.16 mmol, 2.0 equiv.) was added and the solution stirred 
for 1 h. The solvent was removed in vacuo and the residue dissolved in a minimum amount 
of MeOH. From this solution the iminium salt was crashed out with Et2O and the 
supernatant solution taken off. The washing procedure was repeated and the iminium salt 
isolated as an orange solid. 
M.p. = 71.2–73.0 ; [α]D23: +462.7 (c = 0.30, CH3CN); 1H NMR (300 MHz, CD3CN): 
δH = 8.70 (1H, dd, J = 10.7, 1.8, H–C1''), 8.14 (1H, d, J = 15.0, H–C3''), 7.98 (2H, dd, 
J = 8.8, 5.5, H–C5''), 7.42–7.26 (5H, m, H–C3', H–C4', H–C6''), 7.22 (1H, dd, J = 15.0, 
10.7, H–C2''), 7.09 (2H, dd, J = 7.7, 1.9, H–C2'), 5.18 (1H, b, H–C5), 3.57 (1H, dd, J = 14.7, 
5.6, H–C8), 3.47 (1H, dd, J = 10.8, 4.0, H–C8), 2.78 (3H, s, H–C7), 1.69 (3H, s, H–C6anti), 
and 0.79 (3H, s, H–C6syn) ppm; 19F NMR (282 MHz, CD3CN) = –102.9 (1F, tt, 3JHF = 8.8, 
4JHF = 5.6); IR (ATR):  = 3076w, 1705m, 1625m, 1610m, 1583s, 1508w, 1434w, 1392m, 
1404m, 1310w, 1281w, 1226m, 1197m, 1158m, 1076s, 1009m, 931w, 831m, 776w, 
747m,and 703m cm-1; HR-EI-MS: m/z: 351.1870 ([M–ClO4-]+, calcd for C22H24FN2O+: 
351.1867). 
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(5S)-5-Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-(para-methoxyphenylallylidene]-
imidazolidin-1-ium perchlorate (94·ClO4-): 
 
To imidazolidinone 1 (17.5 mg, 0.08 mmol, 1.0 equiv.) was added perchloric acid (60% in 
H2O, 13.4 mg, 0.08 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at RT and the resulting 
mixture stirred for 30 min before it was evaporated in vacuo to give the imidazolidinone salt. 
The salt was redissolved in MeOH (0.20 mL) and heated to 35 °C. (E)-(para-
methoxy)cinnamaldehyde (26.0 mg, 0.16 mmol, 2.0 equiv.) was added and the solution 
stirred for 1 h. The solvent was removed in vacuo and the residue dissolved in a minimum 
amount of MeOH. From this solution the iminium salt was crashed out with Et2O and the 
supernatant solution taken off. The washing procedure was repeated and the iminium salt 
isolated as a dark red solid. 
M.p. = 111.5 °C decomp.; [α]D23: +672.6 (c = 0.34, CH3CN); 1H NMR (400 MHz, CD3CN): 
δH = 8.57 (1H, dd, J = 10.9, 1.8, H–C1''), 8.09 (1H, d, J = 14.7, H–C3''), 7.93 (2H, d, J = 8.9, 
H–C5''), 7.34–7.25 (3H, m, H–C3', H–C4'), 7.21–7.12 (3H, m, H–C2'', H–C6''), 7.11–7.05 
(2H, m, H–C2'), 5.11 (1H, b, H–C5), 3.95 (3H, s, H–C8''), 3.57 (1H, dd, J = 14.6, 5.7, H–
C8), 3.47–3.41 (1H, m, H–C8), 2.77 (3H, s, H–C7), 1.65 (3H, s, H–C6anti), and 0.73 (3H, s, 
H–C6syn) ppm; 13C NMR (101 MHz, CD3CN): δC = 167.1 (C7''), 166.6 (C1''), 166.5 (C3''), 
165.5 (C4), 116.5 (2C, C6''), 115.6 (C2''), 85.8 (C2), 64.7 (C5), 56.9 (C8''), 36.8 (C8), 27.5 
(C6anti), 26.0 (C7), and 24.7 (C6syn) ppm; IR (ATR):  = 2938w, 1710m, 1626w, 1562s, 
1511m, 1436w, 1402m, 1312w, 1265m, 1240m, 1207w, 1166s, 1075s, 1013s, 934w, 831m, 
746w, and 702w cm-1; HR-ESI-MS: m/z: 363.2069 ([M-ClO4-]+, calcd for C23H27N2O2+: 
363.2067). 
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(5S)-5-Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-(para-dimethylaminophenylallylidene]-
imidazolidin-1-ium perchlorate (95·ClO4-): 
 
To imidazolidinone 1 (17.5 mg, 0.08 mmol, 1.0 equiv.) was added perchloric acid (60% in 
H2O, 13.4 mg, 0.08 mmol, 1.0 equiv.) in EtOH/Et2O (1:1, 0.40 mL) at RT and the resulting 
mixture stirred for 30 min before it was evaporated in vacuo to give the imidazolidinone salt. 
The salt was redissolved in MeOH (0.20 mL) and heated to 35 °C. (E)-(para-
dimethylamino)cinnamaldehyde (28.0 mg, 0.16 mmol, 2.0 equiv.) was added and the red 
solution stirred for 1 h. The solvent was removed in vacuo and the residue dissolved in a 
minimum amount of MeOH. From this solution the iminium salt was crashed out with Et2O 
and the supernatant solution taken off. The washing procedure was repeated and the iminium 
salt isolated as a dark green solid. 
M.p. = 136.5 °C; [α]D23: +1168.7 (c = 0.12, CH3CN); 1H NMR (300 MHz, CD3CN): 
δH = 8.21 (1H, dd, J = 11.4, 1.3, H–C1''), 7.90 (1H, d, J = 14.0, H–C3''), 7.80 (2H, b, H–
C6''), 7.29–7.27 (3H, m, H–CAr), 7.15–7.03 (2H, m, H–CAr), 6.92–6.83 (3H, m, H–C2'', H–
CAr), 4.94 (1H, s, H–C5), 3.56 (1H, dd, J = 14.4, 5.7, H–C8), 3.36 (1H, dd, J = 14.5, 2.8, H–
C8), 3.21 (6H, s, H–C8''), 2.73 (3H, s, H–C7), 1.58 (3H, s, H–C6anti), and 0.64 (3H, s, H–
C6syn) ppm; 13C NMR (75 MHz, CD3CN): δC = 165.0 (C4), 163.9 (C1''), 160.1 (C3''), 155.9 
(C7''), 134.3 (C1'), 129.8 (2C, CAr), 128.4 (2C, CAr), 127.4 (CAr), 121.5 (CAr), 112.4 (2C, b 
C6''), 108.8 (C2''), 82.7 (C2), 62.2 (C5), 39.5 (C8''), 34.7 (C8), 26.2 (C6anti), 24.4 (C7), and 
23.3 (C6syn) ppm; IR (ATR):  = 2938w, 1706m, 1627w, 1587m, 1551m, 1439w, 1379m, 
1313w, 1227w, 1158m, 1074s, 1008m, 933m, 872w, 819w, 746w, 725w, and 702w cm-1; 
HR-ESI-MS: m/z: 376.2381 ([M-ClO4-]+, calcd for C24H30N3O+: 376.2381). 
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(5S)-2,2,3,5-tetramethyl-4-oxo-1-[(E)-3-(para-dimethylaminophenylallylidene]-
imidazolidin-1-ium perchlorate (96·ClO4-): 
To imidazolidinone 1 (100 mg, 0.70 mmol, 1.0 equiv.) was added perchloric acid (60% in 
H2O, 118 mg, 0.70 mmol, 1.0 equiv.) in MeOH (2.00 mL) at RT and the resulting mixture 
stirred for 30 min before (E)-(para-dimethylamino)cinnamaldehyde (136 mg, 0.77 mmol, 
1.1 equiv.) was added and the red solution stirred overnight. The solvent was removed in 
vacuo and the residue dissolved in a minimum amount of MeOH. From this solution the 
iminium salt was crashed out with Et2O and the supernatant solution taken off. The washing 
procedure was repeated and the iminium salt isolated as a red/purple solid. 
M.p. = 193.0 °C decomp.; [α]D23: +2731.2 (c = 0.46, CH3CN); 1H NMR (600 MHz, 
CD3CN): δH = 8.29 (1H, dd, J = 11.3, 1.5, H–C1'), 7.86 (1H, d, J = 14.1, H–C3'), 7.77 (2H, 
b, H–C5'), 6.85 (2H, d, J = 9.4, H–C6'), 6.78 (1H, dd, J = 14.1, 11.3, H–C2'), 4.62 (1H, q, 
J = 7.1, H–C5), 3.18 (6H, s, H–C8'), 2.88 (3H, d, J = 0.6, H–C7), 1.73 (3H, s, H–C6), 1.70 
(3H, s, H–C6), and 1.61 (3H, d, J = 7.0, H–C8) ppm; 13C NMR (151 MHz, CD3CN, C5' not 
visible): δC = 167.7 (C4), 164.9 (C3'), 161.1 (C1'), 157.1 (C7'), 122.6 (C4'), 113.7 (2C, C6'), 
109.8 (2C, C2'), 84.0 (C2), 57.8 (C5), 40.8 (2C, C8'), 27.7 (C6), 26.4 (C6), 25.9 (C7), and 
18.1 (C8) ppm; IR (ATR):  = 2921w, 1716m, 1625w, 1549s, 1526s, 1486w, 1444w, 
1411w, 1378s, 1307m, 1243m, 1151s, 1076s, 1008m, 972m, 939m, 856w, 821m, 723m and 
695w cm-1; HR-ESI-MS: m/z: 300.2076 ([M-ClO4-]+, calcd for C18H26N3O+: 300.2070). 
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8.3 General Procedures for Catalysis Screening 
8.3.1 General Procedure for the Conjugate Addition of 1-Methyl-1H-pyrrole (38) and 
(E)-cinnamaldehyde (2) to give 3-(1-Methyl-1H-pyrrol-2-yl)-3-phenylpropan-1-
ol (39) 
To the corresponding imidazolidinone catalyst (33.0 µmol, 0.2 equiv.) was added TFA 
(3.76 mg, 33.0 µmol, 0.2 equiv.) in THF (0.33 mL) and H2O (0.05 mL) and the solution was 
stirred for 5 min at the given temperature before (E)-cinnamaldehyde was added (63 µL, 
0.50 mmol, 3.0 equiv.). After an additional 30 min, 1-methyl-1H-pyrrole (15 µL, 0.17 mmol, 
1.0 equiv.) was added and the yellow solution stirred for the given time, after which 
complete conversion of the starting material was observed by TLC. EtOH (0.5 mL) and 
NaBH4 (19.0 mg, 0.50 mmol, 3.0 equiv.) were added (and the mixture warmed to RT). The 
reduction was quenched with aqueous saturated NaHCO3 after 30 min and extracted three 
times with CH2Cl2. The combined organic layers were dried over MgSO4 and evaporated in 
vacuo. The crude product 39 was purified by column chromatography (CH/EtOAc 4:1). The 
enantioselectivities were determined by chiral HPLC on a Chiracel OJ-H column, using  
n-hexane/i-PrOH 85:15 as eluent (1.0 mL/min). Retention times of the two enantiomers are: 
11.30 min (R) and 18.31 min (S). 
Rf = 0.58 (CH/EtOAc 1:1); 1H NMR (300 MHz, CDCl3): δ = 7.33–7.23 (2H, m, H–C6), 
7.23–7.09 (3H, m, H–C5, H–C7), 6.53 (1H, t, J = 2.3, H–C5'), 6.19–6.14 (1H, m, H–C3'), 
6.14–6.07 (1H, m, H–C4'), 4.12 (1H, t, J = 7.5, H–C3), 3.75–3.56 (2H, m, H–C1), 3.30 (3H, 
s, H–C6'), 2.34 (1H, dq, J = 13.4, 7.1, H–C2), 2.10 (1H, ddt, J = 14.0, 8.5, 5.7, H–C2), and 
1.45 (1H, b, H–O) ppm; 13C NMR (75 MHz, CDCl3): δ = 143.6 (C4), 135.0 (C2'), 128.7 (2C, 
C6), 128.0 (2C, C5), 126.5 (C7), 122.0 (C5'), 106.4 (C4'), 105.8 (C3'), 60.8 (C1), 39.6 (C2), 
39.1 (C6'), and 34.0 (C3) ppm; HR-ESI-MS: m/z: 238.1208 ([M+Na]+, calcd for 
C14H17NONa+: 238.1202); analytical data in agreement with the literature.[112b] 
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8.3.2 General Procedure for the Conjugate Addition of 1-Methyl-1H-indole (96) and 
(E)-cinnamaldehyde (2) to give 3-(1-Methyl-1H-indole-3-yl)-3-phenylpropan-1-
ol (97) 
To the corresponding imidazolidinone catalyst (33.0 µmol, 0.2 equiv.) was added TFA 
(3.76 mg, 33.0 µmol, 0.2 equiv.) in CH2Cl2 (0.28 mL) and i-PrOH (0.05 mL) and the 
solution was stirred for 5 min at the given temperature before (E)-cinnamaldehyde (2) was 
added (63 µL, 0.50 mmol, 3.0 equiv.). After an additional 30 min, 1-methyl-1H-indole (96) 
(15 µL, 0.17 mmol, 1.0 equiv.) was added and the yellow solution stirred for the given time, 
after which complete conversion of the starting material was observed by TLC. EtOH 
(0.5 mL) and NaBH4 (19.0 mg, 0.50 mmol, 3.0 equiv.) were added (and the mixture warmed 
to RT). The reduction was quenched with aqueous saturated NaHCO3 after 30 min and 
extracted three times with CH2Cl2. The combined organic layers were dried over MgSO4 and 
evaporated in vacuo. The crude product 97 was purified by column chromatography 
(CH/EtOAc 5:1). The enantioselectivities were determined by chiral HPLC on a Reprosil 
Chiral-OM column, using n-hexane/i-PrOH 85:15 as eluent (1.0 mL/min). Retention times 
of the two enantiomers are: 15.45 min (R) and 20.97 min (S). 
Rf = 0.17 (CH/EtOAc 3:1); 1H NMR (300 MHz, CDCl3): δ = 7.39 (1H, d, J = 7.8, H–C5’), 
7.28–7.16 (5H, m, H–C5, H–C6, H–C7), 7.14–7.05 (2H, m, H–C7', H–C8'), 6.94 (1H, t, 
J = 7.8, H–C6'), 6.82 (1H, s, H–C2'), 4.31 (1H, t, J = 7.8, H–C3), 3.67 (3H, s, H–C10'), 3.59 
(2H, td, J = 6.4, 2.2, H–C1), 2.48–2.30 (1H, m, H–C2), 2.27–2.13 (1H, m, H–C2), and 1.46 
(1H, s, H–O) ppm; HR-ESI-MS: m/z: 288.1361 ([M+Na]+, calcd for C18H19NONa+: 
288.1359); analytical data in agreement with the literature.[52] 
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8.3.3 General Procedure for the Heterogeneous Hydrogenation Reactions of 
Ketopantolactone (KPL), Methylbenzoylformate (MBF) and 
Trifluoroacetophenone (TFAP)  
 
The catalyst Pt/Al2O3 was pre-reduced (purge 10 min with He, change to H2-flow, heat to 
400 °C, keep at 400 °C for 1 h, let come to RT). The reaction vessel was charged with the 
pre-reduced Pt/Al2O3 (50 mg) and the solvent (5 mL), an atmosphere of H2 was created and 
the mixture stirred for 1 h before the modifier (1 mM) and the substrate (0.2 M) in the 
solvent (5 mL) were added and the reaction stirred for the given time. Analysis (conversion 
and enantioselectivity) was performed using chiral GC (CP-Chirasil-Dex CB, 25 m length, 
0.25 mm internal diameter, 0.25 µm film thickness). 
GC details for the analysis of KPL hydrogenations: Temperature program: Start at 80 °C, 
increased to 140 °C at 10 °C min–1, increased to 180 °C at 20 °C min–1 , held for 2 min. 
Retention times and elution temperatures: KPL (5.84 min, 138.4 °C), (S)-PL (7.38 min, 
167.6 °C), and (R)-PL (7.51 min, 170.2 °C). 
GC details for the analysis of MBF hydrogenations: Temperature program: Start at 120 °C, 
increased to 180 °C at 20 °C min–1, held for 2 min. Retention times and elution temperatures: 
MBF (6.09 min, 145.5 °C), (R)-MM (7.38 min, 155.2 °C), and (S)-MM (7.51, 155.7 °C). 
GC details for the analysis of TFAP hydrogenations: Temperature program: Start at 120 °C, 
held for 1 min, increased to 130 °C at 1 °C min–1, held for 1 min, increased to 140 °C at 
10 °C min–1, held for 1 min, increased to 150 °C at 1 °C min–1, held for 1 min, increased to 
180 °C at 40 °C min–1. Retention times and elution temperatures: TFAP (1.75 min, 120.8 
°C), (S)-PTFE (10.7 min, 130.0 °C), and (R)-PTFE (11.1 min, 130.1 °C). 
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8.4 X-Ray Crystallographic Data 
2,2,3-Trimethyl-5-(3,4,5-trimethoxybenzyl)-4-imidazolidinone hydrochloride (3·HCl) 
C16H25ClN2O4, M = 344.83; monoclinic; space group P121/n1; 
a = 13.994(3) Å, b = 6.9573(14) Å, c = 19.006(4) Å; 
α = 90°, β = 106.868(7)°, γ = 90°; 
V = 1770.8(6) Å3; Z = 4; T = 100(2) K; 
reflections collected: 13330, independent reflections: 3657; 
Rint = 0.1118, R1 = 0.0557, wR2 = 0.0893.  
 
(5S)-2,2,3-Trimethyl-5-(2,4,6-trifluorobenzyl)-4-imidazolidinone hydrochloride (8·HCl) 
C13H16ClF3N2O, M = 308.73; monoclinic; space group P21; 
a = 10.9270(7) Å, b = 5.8988(4) Å, c = 11.8970(7) Å; 
α = 90°, β = 113.156(5)°, γ = 90°; 
V = 705.06(8) Å3; Z = 2; T = 223(2) K; 
reflections collected: 4468, independent reflections: 2184; 
Rint = 0.041, R1 = 0.0449, wR2 = 0.1248, Flack parameter = –0.02(2).  
 
(5S)-2,2,3-Trimethyl-5-(para-nitrobenzyl)-4-imidazolidinone hydrochloride (9·HCl) 
C13H18ClN3O3, M = 299.75; monoclinic; space group P21; 
a = 5.9962(3) Å, b = 11.9908(10) Å, c = 20.1033(6) Å; 
α = 90°, β = 95.649(5)°, γ = 90°; 
V = 1438.39(15) Å3; Z = 4; T = 223(2) K; 
reflections collected: 10131, independent reflections: 4024; 
Rint = 0.079, R1 = 0.0656, wR2 = 0.1676, Flack parameter = 0.03(3).  
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2,2,3-Trimethyl-5-(pentafluorobenzyl)-4-imidazolidinone hydrochloride (10·HCl) 
C13H15ClF5N2O, M = 344.71; monoclinic; space group P121/c1; 
a = 11.0689(5) Å, b = 11.9396(4) Å, c = 11.0229(5) Å; 
α = 90°, β = 108.3820(10)°, γ = 90°; 
V = 1382.44(10) Å3; Z = 4; T = 100(2) K; 
reflections collected: 10797, independent reflections: 3184; 
Rint = 0.0216, R1 = 0.0295, wR2 = 0.0813.  
 
5-(4'-Hydroxybenzyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-
ium perchlorate (6a·ClO4-) 
C24H28ClN3O6, M = 489.94; monoclinic; space group P121/c1; 
a = 8.8543(16) Å, b = 23.147(5) Å, c = 12.154(3) Å; 
α = 90°, β = 109.935(6)°, γ = 90°; 
V = 2341.7(9) Å3; Z = 4; T = 100(2) K; 
reflections collected: 20623, independent reflections: 5372; 
Rint = 0.1022, R1 = 0.0586, wR2 = 0.1087.  
 
5-Pentafluorobenzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-
ium perchlorate (10a·ClO4-) 
C22H20ClF5N2O5, M = 521.85; monoclinic; space group P121/c1; 
a = 7.0387(7) Å, b = 18.0680(19) Å, c = 17.673(2) Å; 
α = 90°, β = 95.013(5)°, γ = 90°; 
V = 2239.0(4) Å3; Z = 4; T = 100(2) K; 
reflections collected: 23237, independent reflections: 5183; 
Rint = 0.0600, R1 = 0.0869, wR2 = 0.0963.  
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(5S)-5-Cyclohexylmethyl-2,2,3-trimethyl-4-imidazolidinone hydrochloride (42·HCl) 
C13H25ClN2O, M = 260.80; orthorombic; space group P212121; 
a = 6.9301(1) Å, b = 10.2438(1) Å, c = 20.7565(1) Å; 
α = 90°, β = 90°, γ = 90°; 
V = 1473.52(3) Å3; Z = 4; T = 223(2) K; 
reflections collected: 5853, independent reflections: 2447; 
Rint = 0.054, R1 = 0.0480, wR2 = 0.1102, Flack parameter = –0.02(3).  
 
(5S)-5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-imidazolidinone hydroperchlorate  
(43·HClO4) 
C15H20ClN3O5, M = 357.79; orthorhombic; space group Pna21; 
a = 11.8766(4) Å, b = 11.5769(5) Å, c = 12.4657(5) Å; 
α = 90°, β = 90°, γ = 90°; 
V = 1713.96(12) Å3; Z = 4; T = 100(2) K; 
reflections collected: 26282, independent reflections: 3950; 
Rint = 0.0291, R1 = 0.0390, wR2 = 0.1003, Flack parameter = 0.0(1).  
 
(5S)-5-[(1H-Imidazol-5-yl)methyl]-2,2,3-trimethyl-4-imidazolidinone dihydrochloride 
(44·2HCl) 
C11H22Cl2N4O2, M = 313.23; monoclinic; space group P1211; 
a = 7.4452(4) Å, b = 7.3042(3) Å, c = 14.5434(7) Å; 
α = 90°, β = 101.326(2)°, γ = 90°; 
V = 775.49(6) Å3; Z = 2; T = 100(2) K; 
reflections collected: 7370, independent reflections: 3122; 
Rint = 0.0396, R1 = 0.0376, wR2 = 0.0652, Flack parameter = –0.0(1).  
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5-(Indol-3-ylmethyl)-2,2,3-trimethyl-4-oxo-1-[(E)-3-phenylallylidene]-imidazolidin-1-
ium perchlorate (43a·PF6-) 
C24H26F6N3OP, M = 517.45; monoclinic; space group P121/n1; 
a = 9.2146(4) Å, b = 22.4643(10) Å, c = 11.9453(5) Å; 
α = 90°, β = 109.230(2)°, γ = 90°; 
V = 2334.71(17) Å3; Z = 4; T = 100(2) K; 
reflections collected: 37211, independent reflections: 5352; 
Rint = 0.0421, R1 = 0.0389, wR2 = 0.1053.  
 
2,2,3,5-Tetramethyl-4-imidazolidinone hydrochloride (60·HCl) 
C7H15ClN2O, M = 178.66; monoclinic; space group C2/c; 
a = 21.2327(6) Å, b = 6.8342(5) Å, c = 14.6064(8) Å; 
α = 90°, β = 115.692(3)°, γ = 90°; 
V = 1909.97(18) Å3; Z = 8; T = 223(2) K; 
reflections collected: 10318, independent reflections: 1636; 
Rint = 0.043, R1 = 0.0359, wR2 = 0.1023. 
 
(2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.4]nonan-3-one hydrochloride (80·HCl) 
C15.25H21.5Cl1.5N2O, M = 302.02; monoclinic; space group P1211; 
a = 14.9864(3) Å, b = 6.9196(2) Å, c = 31.2073(7) Å; 
α = 90°, β = 100.410(2)°, γ = 90°; 
V = 3182.93(13) Å3; Z = 8; T = 100(2) K; 
reflections collected: 12021, independent reflections: 6300; 
Rint = 0.0320, R1 = 0.0392, wR2 = 0.0932, Flack parameter = 0.0(0). 
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(2S)-2-Benzyl-4-methyl-1,4-diaza-spiro[4.5]decan-3-one hydrochloride (81·HCl) 
C16H23ClN2O, M = 294.81; monoclinic; space group P1211; 
a = 10.7535(4) Å, b = 6.7205(2) Å, c = 10.9429(4) Å; 
α = 90°, β = 102.4400(10)°, γ = 90°; 
V = 772.26(5) Å3; Z = 2; T = 100(2) K; 
reflections collected: 11633, independent reflections: 3461; 
Rint = 0.0223, R1 = 0.0277, wR2 = 0.0756, Flack parameter = 0.0(0). 
 
(2S,5S)-5-(Pentafluorobenzyl)-2-tert-butyl-3-methyl-4-imidazolidinone hydrochloride 
(86·HCl) 
C15H18ClF5N2O, M = 372.76; orthorombic; space group P212121; 
a = 6.9225(2) Å, b = 22.0213(9) Å, c = 23.4008(9) Å; 
α = 90°, β = 90°, γ = 90°; 
V = 3567.30(2) Å3; Z = 8; T = 223(2) K; 
reflections collected: 21684, independent reflections: 5504; 
Rint = 0.080, R1 = 0.0472, wR2 = 0.1010, Flack parameter = –0.01(2). 
 
(5S)-5-Benzyl-2,2,3-trimethyl-4-oxo-1-[(E)-3-(para-chlorophenylallylidene]-
imidazolidin-1-ium perchlorate (92·ClO4-) 
C22H24Cl2N2O5, M = 467.33; triclinic; space group P1; 
a = 9.3902(1) Å, b = 11.1396(1) Å, c = 13.2246(1) Å; 
α = 68.627(1)°, β = 84.585(1)°, γ = 85.411(1)°; 
V = 1280.90(2) Å3; Z = 2; T = 223(2) K; 
reflections collected: 15552, independent reflections: 6344; 
Rint = 0.036, R1 = 0.0888, wR2 = 0.2455, Flack parameter = 0.042(18). 
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01/2007–09/2010 Student president 
09/2009–12/2009 Tutor for Inorganic Chemistry I for chemistry students 
01/2009–06/2009 Tutor for Chemistry for engineering students 
Tutor for Organic Chemistry II for pharmacy students 
12/2008–06/2009 Head of the event committee of the chemistry student association 
06/2007–12/2009 Member of several committees concerning university policy 
12/2007–12/2008 Editor-in-chief of the magazine for chemistry students 
 
Social Activities outside University: 
Jan. 2nd to 5th 2014 Organization of the annual workshop of the “Friends of the Chemistry-Olympiad“ 
Since 08/2009 Designer of the annual magazine of the “Friends of the Chemistry-Olympiad“ 
Since 01/2007 Member of the advisory board of the “Friends of the Chemistry-Olympiad“ 
01/2009–01/2013 Cash auditor of the “Friends of the Chemistry-Olympiad“ 
02/2005–03/2006 Responsible for internal affairs of the association of school students in Mainz 
2003–2006 Tutoring of high school students 
 
Competitions, Awards and Honours: 
12/2013 Recipient of EU grant CALIPSO to study conformational diversity using free electron 
laser FELIX in Nijmegen  
07/2013 Syngenta poster prize at the ESOC 2013  
07/2013 Invited participation at the Nobel Laureate Meeting on Chemistry in Lindau 
05/2013 1st place poster prize at the MSCEC 2013 
2006 GDCh-Award (German chemical society) for the best chemistry student of the 
graduating year level at the Rabanus-Maurus Gymnasium 
2004–2006  Participation in the Chemistry Olympiad (twice) 
2003 First in Class Award in Chemistry at Kavanagh College, New Zealand 
2001/2002 Participation in a state chemistry competition for junior high school 
2001 Participation in the national history competition (Geschichtswettbewerb des 
Bundespräsidenten); Ranking: 3rd prize  
 
